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Abstract 
Objectives 
Missing data represent a source of bias in randomized clinical trials (RCTs). This thesis 
focuses on pragmatic RCTs with missing continuous outcome data and evaluates the use 
and appropriateness of current methods of analysis. 
Methods 
This thesis consists of three parts. First, a systematic review examined practices relating 
to missing data in published RCTs. Second, a simulation study compared the 
performance of various methods for handling missing data in a number of plausible trial 
scenarios. Finally, an empirical evaluation of two pragmatic RCTs investigated the use of 
a reminder process to inform whether missingness is likely to be non-ignorable.  
Results 
The majority of 91 trials in the systematic review adopted a form of single imputation, such 
as last observation carried forward (LOCF) for dealing with missing data. Mixed-effects 
model for repeated measures (MMRM) and/or multiple imputation (MI) were limited to 
eight trials. Sensitivity analyses were infrequently and inappropriately used, and 
insufficiently reported. 
In the simulation study, LOCF yielded biased estimates of treatment effect in most 
scenarios, irrespective of missing data mechanisms. All methods, except LOCF, yielded 
unbiased estimates for scenarios of equal dropout rate and same direction of dropout in 
both treatment groups. MMRM and MI were more robust to bias than complete-case and 
LOCF-based analyses. 
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In the empirical study, the evaluation using reminder responses indicated the possibility of 
biased MMRM estimation in one trial and unbiased MMRM estimation in the other. 
Conclusion 
CCA and LOCF-based analysis should be disregarded in favour of methods such as 
MMRM and MI-based analysis. The proposed reminder approach can be used to assess 
the robustness of the missing at random (MAR) assumption by checking expected 
consistency in MAR-based estimates. If the results deviate, then analyses incorporating a 
range of plausible missing not at random assumptions are advisable, at least as sensitivity 
tests for the evaluation of treatment effect.  
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Chapter 1: Introduction 
1.1 The present study: research issues 
Randomized clinical trials (RCTs) play a vital role in assessing the efficacy and 
effectiveness of new interventions compared to a standard or control intervention. An 
intention-to-treat (ITT) strategy – whereby an analysis should be performed by including 
all study participants in the groups to which they were randomized, regardless of any 
departures from the original assigned group – serves to preserve the benefits of 
randomization, which is intended to ensure that differences in outcome observed between 
treatment groups are solely the result of the treatments, and to reduce the risk of selection 
bias. A true ITT analysis requires baseline and outcome measurements on all randomized 
patients. In practice, no matter how well designed and implemented a study, missing data 
are almost inevitable – particularly in pragmatic trials. Different degrees of data 
incompleteness in these trials can occur as measurements may be available only at 
baseline or may be missed for one or several follow-up time-points. In general there are 
three potential problems that arise from missing data; loss of efficiency, complication in 
data handling and analysis, and bias due to differences between the observed and 
unobserved data. Despite extensive literature on methods of handling missing data, it 
appears that many RCTs continue to be based on inappropriate statistical methods when 
dealing with missing data (Hollis & Campbell, 1999; Wood et al., 2004; Baron et al., 2005; 
Gravel et al., 2007; Fielding et al., 2008). 
This thesis focused on RCTs with missing continuous outcome data, which are prone to 
dropouts due to their longitudinal nature. A particular focus is on pragmatic trials of 
musculoskeletal disorders in primary care (though much of the theory and findings relate 
more generally to other RCTs). Principally, the work aims to align current 
recommendations to the methods of analysis being used in practice, and evaluate the 
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appropriateness of current methods of analysis in respect of the validity in estimation of 
the true between-group treatment effect conditional on missing data. In order to meet the 
overall aim, the following objectives were identified. 
i. To provide a general overview of the statistical methods to deal with missing data 
ii. To investigate any divergence among researchers on acceptance of these 
methods for analysing missing data 
iii. To review current practices being used in the analysis of RCTs in the presence of 
missing data 
iv. To evaluate the impact of various missing data handling methods for the analysis 
of continuous outcomes in longitudinal clinical trials under various plausible 
conditions in a comprehensive manner using simulation studies 
v. To propose and investigate how reminder responses – data that are retrieved by 
sending reminders to the initial non-responders – can be utilized to infer the nature 
of missing data and help inform appropriate analysis of the RCT dataset in order to 
reduce potential bias in treatment effect estimation 
vi. To collectively appraise the various findings and provide recommendations on how 
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1.2 Outline of thesis  
Chapter 2: Background 
Chapter two provides an initial background to the issues associated with missing data and 
a summary of the current missing data literature. In particular, the review focuses on key 
issues relating to missing continuous outcome data and methods of handling missing data 
currently in use in longitudinal clinical trials. The methods include listwise deletion, single 
imputation (e.g. last observation carried forward method [LOCF]), multiple imputation (MI), 
and a maximum likelihood based approach (e.g. mixed-effects model for repeated 
measures [MMRM]) that can use all available data without imputation. This chapter 
discusses the advantages and disadvantages of these missing data methods based on a 
review of previous simulation studies that compared these methods. The chapter also 
discusses the limitation of these simulation studies and rationalizes the requirement for 
further study. 
Chapter 3: Systematic review 
In this chapter, I present a systematic review that examines current practice relating to ITT 
analysis and methods to handle missing data in published trials. Specifically, the review 
has the following objectives: 
 To describe the extent of adherence to random allocation;  
 To describe the extent of reported dropout; 
 To summarize the frequency in use of different analytical methods used to handle 
missing data;  
 To assess the use of sensitivity analyses used to assess the robustness of the 
primary analysis results to various missing data assumptions.  
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In this study, the review focuses on RCTs reported in five leading medical journals that 
mainly focus on research in musculoskeletal conditions. 
Chapters 4–6: Simulation study 
Chapter four details the methodology of a simulation study that investigates the 
performance of various methods for handling missing data in a longitudinal clinical trial 
with continuous outcome data, across a number of different scenarios. The methods 
include listwise deletion, LOCF, MI, and MMRM. The simulation study has the following 
objectives: 
 To assess the relative performance of the missing data methods with respect to 
bias and accuracy of the estimate of treatment effect under various scenarios; 
 To assess the relative performance of the missing data methods with respect to 
the coverage of confidence interval of the estimate of treatment effect at the 
nominal alpha level of 0.05 under various scenarios; 
 To assess the relative performance of the missing data methods with respect to 
conditional loss of statistical power to detect the true treatment effect under various 
scenarios (given nominal power of 90%); 
 To assess whether an increment in sample size in proportion to an expected 
dropout rate helps to achieve the required statistical power when using these 
missing data methods; 
 To assess whether including the baseline measure as part of the response vector 
in an MMRM model has an advantage over including it as a covariate. 
Chapters five and six present the simulation study results. 
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Chapter 7: Re-analysis of real incomplete longitudinal RCT datasets 
Chapter seven presents the re-analysis of two pragmatic clinical trials that included a 
reminder process for non-responders. Here, I propose an approach that utilizes the 
reminder process as a proxy for missingness to assess the impact of missing data on the 
estimation of treatment effect, and the likely missing data mechanism. 
Chapter 8: Discussion and conclusion 
Chapter eight concludes with a detailed discussion and interpretation around the findings 
from all the chapters. I finish by providing a summary of my recommendations on how to 
deal with missing data in RCTs, and some thoughts on further research in this area. 
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Chapter 2: Background 
2.1 Introduction 
This chapter focuses on key issues relating to missing continuous outcome data and 
methods of handling the missing data currently in use in longitudinal clinical trials. This 
chapter also discusses the advantages and disadvantages of these missing data methods 
based on a review of available simulation studies that compared these methods. The 
chapter further discusses the limitation of these simulation studies and then conclude by 
identifying the need for a further study to compare these missing data techniques. Before 
describing the different missing data techniques, the definition and underlying theory of 
missing data are also presented. 
2.2 The problem of missing data in clinical trials 
Randomized clinical trials (RCTs) play a vital role in assessing the efficacy and 
effectiveness of new interventions compared to a standard or control intervention. 
Randomization in a clinical trial is intended to generate comparable groups of patients in 
terms of known and, more importantly, unknown factors that could be associated with the 
outcome of interest at the onset of the trial. That is, the method ensures at least 
theoretically, that both observed and unobserved baseline differences between the 
interventions are attributable to chance. After accounting for chance variations, the 
remaining differences can be attributed reliably to the interventions so long as other 
sources of bias have been eliminated. To provide an unbiased comparison of estimates of 
treatment effects, randomization alone is not sufficient and it is also important to obtain 
outcome measurements on all randomized patients. Therefore, the principal advantage of 
randomization is threatened when some outcome measurements are missing. As trials 
with missing data may not retain the balance of randomization, the basis for statistical 
inference is lost (Wright & Sim, 2003; Lewis & Machin, 1993) and there is no longer a 
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statistical rationale to guarantee lack of bias for the estimation of the parameter and its 
associated confidence interval – even if the study is assumed to be free of other risks of 
bias, such as non-masked evaluation. 
The intention-to-treat (ITT) principle is widely recommended as the primary design and 
analysis strategy for clinical trials (Frangakis & Rubin, 1999; Feinman, 2009); this is 
mandatory for any confirmatory trial (Committee for Proprietary Medical Products, 2001; 
Food and Drug Administration, 2008). An ITT analysis is a pragmatic approach that may 
help to avoid bias in estimation of treatment effect occasioned by any study protocol 
violation after randomization, such as dropout of subjects, which may affect the baseline 
equivalence established by randomization (Schwartz & Lellouch, 2009). An ITT analysis 
corresponds to analysing groups exactly as randomized. Strictly, an ITT analysis should 
include all randomized subjects, regardless of their adherence with the eligibility criteria, 
the treatment they actually received, and subsequent withdrawal or loss to follow-up from 
treatment or deviation from the study protocol (Fisher et al., 1990). Accordingly, an ITT 
analysis includes all randomized subjects according to randomized treatment assignment. 
It ignores protocol deviations, non-compliance, withdrawal and anything that happens 
after randomization (Heritier et al., 2003; Kruse et al., 2002). An ITT analysis is generally 
explained as “once randomized, always analysed” (Wertz, 1993). Hollis and Campbell 
(1999) point out two purposes of an ITT approach: firstly, it maintains treatment groups 
that are similar apart from random variation, and secondly, it allows for non-compliance 
and deviations from policy by investigators. Thus, an ITT analysis reflects the practical 
clinical scenario. Therefore, an ITT analysis is most suitable for pragmatic trials, which 
measure the effectiveness of treatments in everyday practice (Hollis & Campbell, 1999). 
It has been reported that investigators often refer to ITT to describe the analysis of all 
available subjects as randomized without considering the issue of missing data (Gravel et 
al., 2007). It is pointed out in the CONSORT (CONsolidated Standards Of Reporting 
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Trials) statement that a strict ITT analysis is often hard to achieve for two main reasons: (i) 
missing outcomes for some participants and (ii) non-adherence to the treatment protocol 
(Moher et al., 2010). Therefore, compliance with the ITT principle would necessitate 
complete follow-up of all randomized subjects for study outcomes and retention of 
randomized allocation grouping regardless of deviation from treatment protocol. Exclusion 
of participants, possibly in a non-random or informative way, raises great concerns about 
the validity of the study. Many reviews of RCTs concede that the ITT approach is often 
inadequately described and applied (Schulz et al., 1996; Hollis & Campbell, 1999; Kruse 
et al., 2002; Gravel et al., 2007) – the deviation from the true ITT was mostly linked in 
these reviews with missing data (Chapter 3). The International Conference on 
Harmonisation (ICH) guideline (Food and Drug Administration, 1997) states: “no analysis 
should be considered complete unless the potential biases arising from these specific 
exclusions, or any others, are addressed.” 
RCTs are generally longitudinal in nature – such that the outcome of interest is measured 
at more than one occasion – with a common schedule of measurements for all 
participants, but with a small number of measurement occasions. In a review of trial 
reports published between July and December 2001 in four major general medicine 
journals (BMJ, JAMA, Lancet and New England Journal of Medicine), among the 71 trial 
reports that were examined, 37 (52%) of them were with multiple follow-up assessments 
(Wood et al., 2004). Even though outcome data are observed in a longitudinal fashion, the 
primary focus of RCTs is often a specific time of measurement, usually the last – called 
the primary endpoint. The aim of these trials is usually limited to comparing the effect of 
two or more treatments at this specific time-point – i.e., estimating treatment effect at the 
primary endpoint (Verbeke & Molenberghs, 2005). Importantly, many musculoskeletal 
conditions (MSCs) necessitate long-term trials because they are chronic conditions, and 
this consequently results in a high number of patients being discontinued from the trial 
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prior to the primary endpoint (Kim, 2011; Moore et al., 2008); however, there is often at 
least one post-baseline assessment among these missing follow-ups. 
Missing data, a common problem and a potential source of bias in research, involves 
information that is missing for some variable(s) and/or for some unit(s) of observation 
(Allison, 2001). In this thesis, missing data are defined as the absence of some value(s) 
on an outcome variable. Missing data also occur in the covariates but that is not the focus 
of this thesis. In practice, no matter how well designed and implemented, there will almost 
always be some missing data (Crutzen et al., 2013). Within RCTs, outcome data can be 
missing due to several reasons (Little & Rubin, 2002). For example, in a trial (Baerwald et 
al., 2010) with a 24% (191/810) dropout rate, reasons for the dropouts included lack of 
efficacy (n=63), adverse events (n=55), withdrawn consent (n=39), violation of eligibility 
criteria (n=18), loss to follow-up (n=7), and other unspecified reasons (n=9). A positive 
outcome, such as symptom relief, recovery, or cure, may also lead to discontinuation from 
a trial (National Research Council, 2010). Reasons for the dropouts are extremely 
important and should be collected, since they can be used to justify the assumptions of 
statistical analysis. Moore et al. (2008) examined participants’ discontinuation in clinical 
trials based on 21 trial datasets in MSCs (osteoarthritis, rheumatoid arthritis, chronic low-
back pain and ankylosing spondylitis) and reported that lack of efficacy or intolerable 
adverse events, or both, were the major reasons for discontinuation in those trials. 
The validity and interpretability of findings from RCTs can be substantially reduced by 
missing data (Little & Rubin, 2002; Molenberghs & Kenward, 2007; European Medicines 
Agency, 2010; National Research Council, 2010; Fleming, 2011). In an RCT, as 
mentioned earlier, the advantages of randomization are jeopardized when the trial has 
missing data. To prevent selection bias in a clinical trial, it is important to adopt an ITT 
strategy, which requires all randomized patients to be included and analysed as 
randomized. However, the presence of missing data in a trial creates many challenges in 
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the selection of an ITT sample. The impact of missing data in a study is difficult to assess 
and is related to the question of what would hypothetically have been observed if no 
patient had withdrawn from the study. In general, there are three potential problems 
associated with the presence of missing data: loss of efficiency, bias in estimate of true 
parameters, and complication in data handling analysis (Horton & Lipsitz, 2001).  
Loss of efficiency is an unavoidable consequence of missing data. Trials with missing data 
will be underpowered because fewer participants have completed than was originally 
planned; that is, the trial no longer has enough participants to demonstrate the same level 
of clinically important differences as statistically significant (Little & Rubin, 2002; 
Molenberghs & Kenward, 2007).  
Another implication is that ignoring the presence of missing outcome data may lead to 
biased estimates, and thereby misleading inferences about treatment effects 
(Molenberghs & Kenward, 2007). A major concern is that being lost to follow-up could be 
related to a patient’s responses to the treatment. Participants who do not complete a trial 
of a new treatment, for example, may be: those who improved the most, and do not see 
the necessity of continuing; those who improved the least, and see no reason to continue 
to comply with the treatment that is not working for them; or those who may have decided 
to discontinue owing to the occurrence of adverse effects. If the majority of dropouts are 
those who improved, then this will serve to make the interventions appear less effective 
than they actually are. Conversely, if most of the people dropped out because the new 
treatment was ineffective, this will, paradoxically, make the intervention look better, 
because many of the non-responders are no longer in that arm of the study. In view of the 
fact that missing data usually occur for reasons outside of the control of the investigators, 
and may be related to the outcome measurement of interest, the subsequent data 
analysis is extremely complicated.  
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As noted previously, no analysis should be treated as appropriate unless potential biases 
due to missing data are appropriatly addressed. To address this issue either imputation of 
values or modelling for missing data is generally required (European Medicines Agency, 
2010), which rely heavily on untestable assumptions about the missing data – the wrong 
assumptions lead to biased estimates of treatment effect and standard errors. Since the 
potential impact of missing data depends primarily on missing data assumptions, it is 
important to investigate the processes (i.e. missing data mechanism) leading to missing 
data (Rubin, 1976; Little & Rubin, 2002). 
2.3 Missing data: theoretical framework 
To understand how best to deal with missing data, the first step is to determine the nature 
of the missing data and their possible implications for statistical inferences (National 
Research Council, 2010). The validity of any statistical analyses of incomplete data 
depends critically on causes of missing data. Since observed data cannot themselves 
explain definitely what might be the reasons for the missing data, it is necessary to make 
assumptions about the missing data mechanism. Therefore, statistical inferences on 
incomplete data rely on the subjective, untestable assumption about the distribution of 
missing data. Little and Rubin (1987; 2002) described a general missing data taxonomy, 
which includes a useful hierarchy of missing data mechanisms based on possible causal 
relationships between missing data and observed data in a study. Further discussions 
around this taxonomy for missingness in longitudinal data are available (Little, 1995; 
Schafer & Graham, 2002). A detailed review of this taxonomy is followed by an 
introduction of the repeated measures data structure.  
Let                  refer to a vector of repeated measurements of an outcome variable 
  on   occasions, and   as design variables that represent treatment indicators and 
baseline covariates. For simplicity, it is assumed that   is fully observed. To distinguish 
between observed and missing data, let                  denote the indicator of 
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whether   is missing, where         if observation at the  
th time for the  th subject is 
missing. 
2.3.1 Missing data patterns 
In longitudinal studies, missed visits and/or study dropouts resulting in missing response 
data may occur. A missed visit occurs when a participant misses a clinic visit or fails to 
respond to a questionnaire meant for a particular follow-up visit during a follow-up 
schedule, whereas a dropout occurs when a participant discontinues from the study at any 
time during the study period and thus fails to provide outcome data thereafter. In trials with 
repeated follow-ups, participants who miss a study visit are often lost thereafter (National 
Research Council, 2010). 
A dataset with a series of measurements on an outcome variable                  is 
said to have a monotone missing pattern when an event that a measurement    is missing 
for an individual implies that all subsequent measurements       , are missing for that 
individual. That is, under a monotone missing data pattern, the reason for missing data in 
a longitudinal trial is solely through study dropouts. Figure 2.1 shows a representation of 
monotone and non-monotone missing data patterns. A dataset with an arbitrary missing 
pattern is one with a monotone and non-monotone (i.e. intermittent) missing pattern; the 
missing data are due to both missed visits and study dropouts. 
Monotone missing patterns Non-monotone missing patterns 
ID Y1 Y2 Y3 Y4 
1 o o o o 
2 o o o m 
3 o o m m 
4 o m m m 
 
ID Y1 Y2 Y3 Y4 
1 o o o o 
2 o m o m 
3 o o m o 
4 o m m o 
 
‘o’ – observed; ‘m’ – missing 
 
Figure 2.1: Missing data patterns 
 
 Chapter 2                                              13 
2.3.2 Missing data mechanism 
To understand the potential impact and how best to deal with missing data it is important 
to consider the process (i.e. mechanism) leading to the missingness. A general taxonomy 
for missing data, which is common in the statistical literature (Rubin, 1976; Little & Rubin, 
1987; 2002; Little, 1995; Schafer & Graham, 2002; National Research Council, 2010), 
distinguishes between missing data that are missing completely at random (MCAR), 
missing at random (MAR), and missing not at random (MNAR). The classification is based 
on the dependence of missingness on observed and/or unobserved data. The missing 
data mechanism can be represented in terms of conditional distribution           for the 
missing data indicators given the values of the study variables that were intended to be 
collected. 
Missing data are MCAR if missingness is independent of observed and unobserved data 
(i.e., missingness does not depend on values of the variables   and  ). That is, 
               . This is the most desirable, but an unlikely scenario in trials with missing 
data. An example of such a scenario occurs when a participant discontinues a trial due to 
change of location during the course of the trial for reasons unrelated to the trial and/or 
disease of interest (e.g. job transfer). DeSouza et al. (2009) point out that missed visits 
are often not study-related, and thus the missing data are MCAR. 
The second classification, which is more realistic than MCAR, is MAR. This mechanism 
requires that missingness is dependent on observed responses and/or covariates (      ), 
but independent of unobserved responses (    ). That is,                         . This 
type of missingness may be referred to as outcome-dependent MAR and/or covariate-
dependent MAR, as the case may be (DeSouza et al., 2009). In longitudinal studies, MAR 
is plausible as dropouts are more likely to be related to previous responses (DeSouza et 
al., 2009). For example, if participants withdraw from a chronic pain trial once their pain 
intensity exceeds a certain threshold, then the missing data are MAR. The plausibility of 
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the MAR assumption can be improved by considering auxiliary variables that are 
predictive of whether the outcome variables are missing and predictive of the values of the 
missing variables (National Research Council, 2010).  
MAR will fail to hold if missingness is dependent on unobserved data after accounting for 
available observed data. In that situation, the missingness is said to be MNAR. That is, 
                             . For example, if a participant feels better on his or her 
clinical condition after a visit and decides not to show up for the next scheduled visit, then 
the missing data are MNAR. Consequently, in longitudinal studies, future values of 
outcome variables for those who drop out cannot be reliably predicted based on data 
collected prior to dropping out if MNAR holds. 
The implication of MCAR is that a missing data mechanism need not to be incorporated 
into an inference model, and a valid analysis is possible with observed data alone. For 
MAR, the missing data mechanism can be considered ignorable after including correlates 
of missingness in an inference model. For MNAR, on the other hand, the missing data 
mechanism is non-ignorable and needs to be incorporated into an analysis to make a 
valid inference. Importantly, a particular missing data mechanism is not in itself always 
ignorable or non-ignorable, depending on the statistical model. That is, if a statistical 
model fails to incorporate correlates of missingness, then a missing data mechanism 
cannot be considered as ignorable. Therefore, it is important to obtain additional variables 
that explain missingness and include these variables into the statistical model. As 
discussed here, missing data mechanisms play an important role in determining 
appropriate formal statistical analyses of data with missing values; however, it is difficult to 
distinguish the mechanisms in practice. In fact, on the basis of the observed data alone, it 
is impossible to identify the underlying missing data mechanism with certainty (Fielding et 
al., 2009). 
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2.3.3 Identification of the missing data mechanism  
Few methods have been proposed to test for MCAR as a preliminary screening tool (Little, 
1988; Diggle, 1989; Ridout, 1991; Fairclough, 2002). The purpose of these methods is not 
to explicitly detect violations of MAR, but violations of MCAR by identifying dependence 
on observed data. For example, Fairclough (2002) describes a logistic regression 
approach to conﬁrm that a dropout process in repeated measurement data depends on 
observed data. A significant association between the dropouts and the observed data 
serves to rule out the possibility of MCAR. 
Since there are valid analysis methods available for MAR data and not for MNAR data, 
the important consideration is the distinction between MAR and MNAR rather than 
between MCAR and MAR. To distinguish between MAR and MNAR, one must examine 
the relationship between missingness and unobserved data. Although it is impossible to 
determine the relationship empirically, a method has been proposed to evaluate the 
possibility of MNAR through a comparison of immediate responders who responded 
without any reminders and reminder responders who responded after sending reminders. 
By treating reminder responses as missing, Fielding et al. (2009) outlined an extension of 
Fairclough’s logistic regression approach to determine whether the mechanism behind the 
reminder data are MNAR rather than MCAR or MAR. A significant difference in current 
scores between immediate and reminder responders after adjusting for the covariates that 
are predictors of reminder responses constitutes evidence of possible MNAR data. 
However, this evaluation excludes cases with actual missing responses. 
2.4 Methods for handling incomplete continuous data 
Several statistical procedures exist for handling missing data. These procedures can 
generally be divided into three broad categories: procedures based on listwise deletion; 
imputation-based procedures; and model-based procedures. Procedures based on 
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listwise deletion simply discard cases with missing values and analyse only those cases 
with complete data on all variables included in an analysis model. Analysis of covariance 
(ANCOVA), which is the most commonly used analysis method to estimate treatment 
effect in an RCT setting (Chapter 3), leads to listwise deletion of cases with missing data 
unless the missing values are imputed. In imputation-based procedures, missing values 
are replaced with particular values, which are determined by a specific procedure, in order 
to secure a complete dataset for analysis. As Little and Rubin (2002) explain, the purpose 
of imputation is to preserve important data characteristics, such as mean and variance, of 
the whole dataset but not to predict the true values of the missing data. From that 
perspective, a method that can replace missing values with multiple plausible values has 
been proposed (Rubin, 1978). Lastly, model-based procedures allow available data – not 
leading to listwise deletion – without imputation of missing values. 
2.4.1 Description of candidate approaches to analysing longitudinal RCT data 
with missing values 
2.4.1.1 ANCOVA without imputation of missing values 
In an RCT, a transient benefit shown early in the trial might not persist through to the end 
of the trial and therefore it is necessary to demonstrate a sustained improvement at the 
primary endpoint. Although outcome data are commonly measured at more than one 
follow-up in trials, the aim of these trials is therefore usually limited to comparing the effect 
of two or more treatments at a specific time-point (Verbeke & Molenberghs, 2005). Unless 
it is important to know how study participants have reached the study endpoint, a simple 
comparison of the treatment groups at the primary endpoint is often recommended and 
adequate to demonstrate the treatment effect, if any (European Medicines Agency, 2006; 
Verbeke & Molenberghs, 2005). In case of continuous outcomes, a standard ANCOVA 
model, with baseline values of the outcome as the covariate, would be sufficient for such a 
comparison if outcome data are available on all participants (Van Breukelen, 2006; 
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Egbewale et al., 2014). Alternative methods such as analysis of variance and change-
score analysis are not recommended because these analysis methods are subject to bias 
and are less precise than ANCOVA in relation to pretest-posttest correlation and the 
direction of baseline imbalance (Egbewale et al., 2014). 
ANCOVA utilizes baseline and observed covariates as predictor variables in an analysis 
model, with the follow-up outcome at the primary endpoint as the outcome variable. For 
subject           and repeated observations at visit           (primary endpoint) per 
subject, the ANCOVA model is 
                          
where 
    : outcome measurement at the primary endpoint for the  
th subject 
    : outcome measurement at baseline for the  
th subject 
   : intercept 
   : effect of baseline measurement (   ) 
   : effect size at the primary endpoint 
   : treatment group for subject   
   : assumed to be independently distributed from a univariate normal distribution 
When employing ANCOVA, only subjects with complete observations on all the variables 
of interest are included in the model. This kind of approach is referred as complete-case 
analysis (CCA) in missing data literature. In this method, cases with missing data on any 
variable of interest are dropped from the analysis (i.e., listwise deletion of subjects with 
missing data). For example, Hewlett et al. (2011) investigated the effect of group 
cognitive-behavioural therapy compared to the control intervention on fatigue impact 
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among people with rheumatoid arthritis. The primary outcome – fatigue impact visual 
analogue scale – was measured at baseline, week 6, week 10 and week 18 (primary 
endpoint), and the study failed to measure the outcome on 33% (42/127) of participants at 
the primary endpoint. The primary analysis using ANCOVA removed those 42 participants 
irrespective of whether the outcome data were observed at earlier times. That is, the study 
analysed only a subset of participants. This generally does not provide a valid estimator of 
an ITT estimate (National Research Council, 2010). CCA requires the assumption that 
missing data are a random subset of the population of interest (Little & Rubin, 2002). 
Accordingly, if the missing data are MCAR, the sub-sample will be a random sample of 
the original sample, and the results of CCA will be unbiased but inefficient because of an 
inflated standard error if missingness is appreciable (Little & Rubin, 2002). However, if the 
missing data are MAR or MNAR, the analysis using CCA may not be valid as the reduced 
sample may no longer be representative of the population of interest, giving rise to biased 
estimates. In spite of these limitations, listwise deletion is still popular among researchers 
(Chapter 3) and is the default option with many statistical methods in major statistical 
software packages. 
2.4.1.2 ANCOVA with single imputation of missing values 
Single imputation methods replace each missing data point with a single value in order to 
produce a complete dataset to which standard statistical methods, such as ANCOVA, can 
be applied without discarding subjects with missing observations. That is, these methods 
treat imputed values as real values, and hence do not account for the uncertainty around 
the missing values. Therefore, the variance of estimates is likely to be too small, leading 
to underestimation of standard error. Further, these methods may produce biased 
estimates depending on how far the imputed value differed from the true value, which is 
unknown in real data. Hence, inferences based on the filled-in data can be distorted if the 
assumptions underlying the imputation method are invalid. Commonly, the imputation of 
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missing observations is based on the observed values. Several ad hoc strategies to 
perform single imputations – such as last observation carried forward (LOCF), mean 
imputation and regression imputation – are common in practice (Chapter 3). 
Imputing by LOCF is a common single imputation method for repeated measures. In this 
method, a missing outcome value is replaced with the most recently available value of that 
outcome variable. LOCF therefore makes a strong assumption that there is no change in 
outcome for a participant after dropout. The rationale of this approach is that it is fairly 
conservative, as this approach likely underestimates the degree of change in an outcome 
over time (Streiner, 2008). However, this may not necessarily be the case in estimating a 
treatment effect (i.e. between-group difference in change) in trials, since imbalance 
between treatment groups in underestimation of degree of change in the outcome may 
overestimate the treatment effect. For example, if many participants who are expected to 
do worse over time discontinue a study treatment, or many of those who are expected to 
do well over time discontinue a control treatment, the benefit of the study treatment is 
more likely to be overestimated than the control with the LOCF method. 
Some researchers contend that LOCF makes an MCAR assumption. For example, 
Mallinckrodt et al. (2008) state “when assessing LOCF mean change via analysis of 
variance (ANOVA), the key assumptions are that missing data arise from an MCAR 
mechanism and that for subjects with missing endpoint observations, their responses at 
the endpoint would have been the same as their last observed values”. However, the 
assumption of no change in outcome after drop out may not be valid under MCAR or MAR 
(National Research Council, 2010). As mentioned earlier, the MAR assumption is that the 
predictive distribution of an outcome variable at time   (  ) conditional on design variable   
and observed data             is the same for both observed and missing   . However, 
LOCF assumes that the predicted value of missing    is      with probability one and the 
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assumption may not hold with observed    (i.e. the probability may not be one for the 
observed data). That is, in general LOCF makes an MNAR assumption. 
2.4.1.3 ANCOVA with multiple imputation 
Multiple imputation (MI) is designed to substitute each missing value with a range of 
plausible values based on observed information in order to reflect the uncertainty 
associated with imputation of missing values (Rubin, 1978; 1987; 1996; Schafer, 1997; 
Little & Rubin, 2002; Molenberghs & Kenward, 2007; Carpenter & Kenward, 2013). For 
example, in a study with two observations (age and pain intensity) on each participant, 
suppose that age is completely observed and pain intensity is incomplete. The basic idea 
is to use the association between age and pain intensity from the complete data to fill the 
missing pain intensity score with multiple plausible values. These multiple values are a 
random draw from the posterior predictive distribution of missing values based on a 
statistical model explaining the association between the variables. The imputation is 
based on an implicit and untestable assumption that the association between age and 
pain intensity is the same for those participants who provided complete data and those 
who do not. That is, MI requires the MAR assumption. 
The MI procedure involves three stages (Rubin, 1987): imputation, analysis and pooling. 
Initially, it is required to specify a statistical model (referred to as an imputation model) to 
explain the relationship between observed data and missing data. The posterior 
distribution for the estimated parameters of the model is used to simulate the parameters 
of the posterior predictive distribution of the missing data from which m predicted values 
are drawn. This creates m completed datasets. In the second stage, one fits a statistical 
model (referred to as analysis model), e.g. ANCOVA model, to each completed dataset, 
and generates parameter estimates  ̂   ̂     ̂  and associated variance. Finally, these 
estimates and variances are combined into a summary inference about  , using Rubin’s 
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rule (1987). The MI estimate is the average of the estimates from the   datasets, and the 
variance of the estimate is 
   (
   
 
)    
where   is the average of the variances from the m datasets and   is the between-
sample variance of the estimates over the m datasets. 
Methods for MI of multivariate missing data include three broad approaches (Molenberghs 
& Kenward, 2007): (i) sequential MI for data with monotone missingness; (ii) joint 
modelling (JM) approach, which assumes that all variables in the imputation model jointly 
follow a multivariate normal distribution; and (iii) full conditional specification (FCS) 
approach (which is referred to as multiple imputation by chained equation [MICE]), which 
does not rely on the multivariate normality assumption. If the missing data pattern is 
monotone, regression imputation can be performed sequentially, starting with the variable 
having least missing values; this approach uses noniterative techniques for simulating 
from the posterior predictive distribution of missing data. The imputation method based on 
a multivariate normal regression uses an iterative Markov chain Monte Carlo (MCMC) 
technique to simulate from the posterior predictive distribution of missing data. The MICE 
method uses a Gibbs-like algorithm to obtain imputed values. If the missingness 
mechanism is non-monotone, both JM and FCS approaches are generally preferred and 
provide similar results in a standard regression analysis involving a mixture of continuous 
and categorical variables (Lee & Carlin, 2010).  
2.4.1.3.1 Selecting variables for an imputation model 
As mentioned earlier, MI requires two statistical models: an imputation model, which is 
used to impute missing values and a substantive analysis model, which is used to analyse 
the imputed data. Choice of imputation model for the MI can have a pronounced effect on 
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the outcome of the data analysis (Spratt et al., 2010). Ideally, an imputation model should 
include all variables that are in the substantive analysis model and should reflect the 
structure of the subsequent analysis (Kenward & Carpenter, 2007; Sterne et al., 2009; 
Carpenter & Kenward, 2013) – which is referred to as a restrictive modelling strategy 
(Collins et al., 2001). Further, it is possible to incorporate auxiliary variables that are not 
part of the analysis model into the imputation model in order to make MAR more plausible 
and, therefore, to increase efficiency and reduce bias (Collins et al., 2001; Spratt et al., 
2010) – which is referred to as an inclusive modelling strategy (Collins et al., 2001). White 
et al. (2011b) pointed out that one should include in an imputation model all variables that 
predict the incomplete variables in an analysis model and/or predict whether the 
observations on the incomplete variables are missing. 
2.4.1.3.2 Selecting the number of imputations 
The amount of missing data should be considered when deciding the number of 
imputations, say m, in the MI method. Rubin (1987) previously demonstrated the relative 
efficiency of a finite-m estimator as 
   ̅  
   ̅  





, where   is the fraction of missing 
information for an outcome measure to be analysed. Using this formula, table 2.1 shows 
the relative efficiencies with different   and fractions of missing information. 




Rate of missing data ( ) 
0.1 0.3 0.5 0.7 0.9 
1 91 77 67 59 53 
3 97 91 86 81 77 
5 99 94 91 88 85 
10 99 97 95 93 92 
  100 100 100 100 100 
 Chapter 2                                              23 
Following Rubin’s calculation of relative efficiency, many researchers have advocated a 
small number of imputations as adequate to yield excellent results. For example, Schafer 
and Olsen (1998) suggested only 2–5 imputations, and Schafer (1999) further 
emphasised that no more than ten imputations are usually required. However, these 
suggestions have been recently critiqued. Graham et al. (2007) and Spratt et al. (2010) 
observed that, with the small number of imputations, variability due to the imputation 
procedure was substantial enough to affect inferences, and recommend that many more 
imputations should be performed than previously considered adequate. In favour of this 
recommendation, White et al. (2011b) proposed a rule of thumb, which states that the 
number of imputations should at least be equal to the percentage of incomplete cases.  
2.4.1.4  Model-based methods: direct maximum likelihood estimation 
Maximum likelihood (ML) refers to a method of estimating the parameters of a statistical 
model. ML estimates, which maximize the likelihood function of sample data, are 
asymptotically unbiased if the model has been specified correctly (Little & Rubin, 2002). 
When data is incomplete, direct likelihood based methods (also referred to as full-
information ML [FIML] methods) can use all available data, instead of deleting 
observations with missing values, for analysis without explicit imputation of missing data, 
and assume that the missing data mechanism is either MCAR or MAR (Little & Rubin, 
2002). The joint likelihood for the observed data yobs and the missing data indicator  is: 
                                              
                                            
                                        if MAR 
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Thus, if the parameters   and   are distinct, then   can be estimated by maximizing the 
observed data likelihood  (yobs; θ) alone, independent of the model for . Therefore, when 
the missingness mechanism is MCAR or MAR, specification of a missingness model is 
unnecessary and inferences are based on the likelihood function given the observed data 
only (DeSouza et al., 2009). In addition to the MAR assumption, FIML methods require a 
large sample size and need to meet the multivariate normality assumption for the 
variables used in a model (Little & Rubin, 2002). 
2.4.1.4.1 Mixed-effects models (Random-effects models)  
For longitudinal data, mixed-effects models provide a parsimonious way to specify a 
multivariate distribution. Linear mixed models are an extension of linear regression 
models allowing for inclusion of random-effects to account for within-subject dependency 
in the longitudinal measurements (Laird & Ware, 1982). Specification of mixed-effects 
models requires: (i) a model for the mean structure of the longitudinal data, which usually 
depends on covariates, design matrix for time, treatment group and patient specific 
random-effects; (ii) an assumption on the distribution of the random-effects; and (iii) 
specification of an additional correlation matrix in the longitudinal measurements (Wong et 
al., 2011). The model can be specified as 
                , 
where 
    is the    x 1 vector of responses for subject  , and    is the number of 
measurements for subject   (         
    is a known    x   covariate matrix of  
th subject for ﬁxed eﬀects   
    is a known    x   covariate matrix of  
th subject for random eﬀects    
   is a   x 1 vector of unknown population parameters 
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    is a   x 1 vector of unknown subject effects (random-effects) distributed as 
        
    is a    x 1 vector of random residuals distributed independently as          
    and    are independent 
In matrix notation,   = (
   
   
   
) and   = (
    
   
    
) represent the variance-
covariance matrices of   and   respectively. Therefore, the variance-covariance matrix for 
the vector of outcomes for all subject visits   is specified as: 
                                                     
2.4.1.4.2 Mixed-effects model for repeated measures using categorical time 
effects (MMRM) 
Likelihood-based, mixed-effects models offer a general framework to extend the standard 
ANCOVA for repeated measures data in a clinical trial to provide the direct estimates and 
statistical test for treatment group differences at the primary endpoint, which is typically of 
direct interest for regulatory decision-making, while incorporating available data for 
participants who dropped out early (Mallinckrodt et al., 2001a). In many longitudinal RCT 
settings, the repeated measures are balanced in the sense that outcomes are assessed at 
the same time interval over a limited number of visits for all participants. This allows a 
“saturated” mixed-effects model to be specified by including a full treatment group by 
measurement time interaction for outcome means combined with an unstructured within-
subject error variance-covariance matrix1 (Beunckens et al., 2005). The model is often 
                                               
1
An unstructured within-subject error variance-covariance matrix is recommended unless the 
underlying (“true”) structure is known (Mallinckrodt et al., 2004) 
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referred to as MMRM (Mallinckrodt et al., 2001a; 2003). MMRM is a particular 
parameterization of the mixed linear model, often with no random-effects,2 and with time 
of assessments considered as a factor variable and group-by-time effect as an 
unstructured interaction effect, instead of considering the group-by-time effect as the 
slope difference of the treatment groups over time (Mallinckrodt et al., 2001a; 2003). That 
is an MMRM model does not make any assumptions about the shape of the response 
profile over time. Since there is no random-effect specified (i.e.   and   are zero), the 
variance-covariance matrix for the vector of outcomes for all subject visits   becomes: 
              
2.4.1.4.3 Strategies to model baseline responses 
Various strategies on how to handle baseline responses in an MMRM analysis are 
discussed in the literature (Liang & Zeger, 2000; Fitzmaurice et al., 2004; Liu et al., 2009; 
Kenward et al., 2010; Dinh & Yang, 2011). Among those, two strategies are generally 
recommended in RCT settings, where detecting treatment effect at a particular time-point 
is the major consideration (Fitzmaurice et al., 2004; Dinh & Yang, 2011). They are:  
 Consider the baseline responses as a covariate in the analysis of follow-up i.
responses, allowing different regression slopes by specifying a ‘baseline-by-time’ 
interaction term into the MMRM model. 
 Retain the baseline responses as part of the outcome vector and assume mean ii.
responses at baseline are equal between the groups in the MMRM model. This 
approach sometimes referred as constrained longitudinal data analysis (cLDA). 
                                               
2
The specification of the random part ‘|| id:’ with Stata mixed procedure statement is not to 
introduce random-effects at the subject level, but to group the repeated measurements as a 
“blocking factor”, where data from separate subjects are uncorrelated and data within each are 
correlated; where variable id is a unique identifier of subjects. 
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The additional restrictions in both strategies provide an adjustment for the observed 
baseline difference in estimating the treatment effects. In practice, it is quite common that 
some participants may miss either baseline assessment or entire follow-up assessments. 
The systematic review of trials in chapter 3 reports that there are instances of randomized 
participants who discontinued the trial and failed to provide outcome responses after 
baseline visits; thus these trials failed to perform a true ITT analysis. The model with 
baseline as an outcome (i.e. cLDA) provides a framework for including all randomized 
participants in the analysis who have baseline or follow-up assessments. Whereas the 
usual MMRM model with baseline as a covariate includes only those individuals who have 
baseline response and at least one follow-up assessment. These methods give identical 
point estimates and very similar SEs when the baseline is complete (Liang & Zeger, 2000; 
Kenward et al., 2010; Dinh & Yang, 2011). In contrast, Fitzmaurice et al. (2004) and Liu et 
al. (2009) favour treating baseline values as an outcome, and Liu et al. (2009) found that 
retaining baseline as a covariate could result in slightly greater loss of efficiency compared 
to the other approach. However, Kenward et al. (2010) argue that Liu et al.’s (2009) 
conclusion is flawed because of failure to use restricted ML instead of ML estimation and 
a correction for finite sample bias (for example, the Kenward–Roger adjustment in SAS 
proc mixed). They further commented that the loss of efficiency was accompanied by a 
gain in confidence interval (CI) coverage. 
2.4.2 Choice of approach to handling missing data: existing literature on 
comparisons of the approaches 
Missing values in a clinical trial data lead to concern and confusion in identifying the full 
dataset according to an ITT approach, making data analyses more complex and 
challenging. Though a number of approaches are discussed in the literature to deal with 
missing values in a clinical trial none of them can be regarded as a universal approach 
because each trial has its own design and measurement characteristics. As discussed 
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earlier in this chapter, the above discussed approaches to deal with missing outcome data 
were developed under certain missing data assumptions. That is, methods leading to 
listwise deletion assume MCAR; LOCF assumes outcome remains constant after dropout 
of a participant; MI and MMRM assume MAR. Identification of the underlying missing data 
mechanism is important in order to carry out appropriate formal analyses of data with 
missing values. However, it is impossible to identify this mechanism with certainty based 
on the observed data alone (Fielding et al., 2009). Therefore, to aid the selection of an 
appropriate approach that best deals with missing data, the relative performance of 
missing data techniques needs to be considered under various clinical trial scenarios. The 
guideline for confirmatory clinical trials (European Medicines Agency, 2010) specifies that 
the primary analysis of clinical trial datasets can only be accepted if the analysis is 
considered to be reasonably free from biases that favour the experimental treatment, and 
if it can be verified that the variability of the estimated treatment effect is not 
underestimated to an important extent. 
Collins et al. (2001) claim that both MI and direct likelihood based approaches tend to 
yield very similar estimates when both analyses are implemented in a similar manner (i.e. 
imputation model is similar to likelihood-based model). However, little research has been 
done in comparing the performance of MMRM and MI in controlling the type 1 error rate 
and statistical power in hypothesis testing of treatment effect. Barnes et al. (2008) 
performed a simulation study to evaluate the type 1 error rate in baseline observation 
carried forward (BOCF), LOCF, MMRM and MI where no differences existed between 
treatment groups in mean change to endpoint. Their study was designed to mimic several 
clinical trial data characteristics with high differential dropout rates between study groups 
(high dropout rates in a placebo-controlled group [25% vs 33%; 25% vs 40%] and vice 
versa) under an MNAR mechanism. The study found that both MMRM and MI 
outperformed BOCF and LOCF in most scenarios. However, the study reported a slightly 
larger average standard error from MI compared with MMRM, thus resulting in a wider CI 
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with MI. A wider CI controls type 1 error conservatively under a null hypothesis, and fails 
to provide adequate statistical power under an alternative hypothesis. Barnes et al. (2008) 
argue that the larger standard error may be associated with the low number of imputations 
(   ) they used with MI.  
Siddiqui (2011) reported a similar finding that supports MMRM as a better choice against 
MI, even under MAR dependent on observed outcome data. Siddiqui (2011) performed a 
simulation study to assess the relative performances of MMRM, MI (JM approach), and MI 
(sequential approach) in controlling type 1 error and statistical power. Their study 
considered two correlation matrices (strong and moderate) along with high differential 
dropout rates (placebo: 30% vs new treatment: 40%) between study groups to simulate 
datasets under a MAR mechanism dependent on observed outcome data. The study used 
a relatively high number of imputations (    ) compared to that in Barnes et al. (2008). 
In this simulation study, both MI procedures yielded very similar results in all scenarios. 
When the null hypothesis was true, MMRM and MI analyses estimated the null effect, but 
MI was too conservative in controlling type 1 error. On the other hand, when there was a 
true difference between study groups, MI analysis underestimated the true difference, and 
it produced a larger standard error of the estimate. The combined effect was substantially 
lower statistical power with MI analysis in comparison to the corresponding power with 
MMRM analysis. The bias in the estimate raises concern over the simulation study 
implementation since both MMRM and MI were developed under an MAR mechanism, 
and these analyses are expected to produce unbiased estimates. Additionally, the 
substantial difference in statistical power between the MMRM and MI analyses in this 
study may be partially explained by the lower number of imputations, against the recent 
suggestion by White (2011b), and estimation using ANCOVA instead of MMRM after MI. 
However, this explanation needs to be verified through an extensive simulation study. 
Peters et al. (2012) did a simulation study to assess the added value of MI of missing 
outcome values in longitudinal RCT datasets (overall dropout rate ranged 10%–60%) 
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analysed with linear mixed-effects (LME) models, and found no additional benefit for doing 
so. Although the study questioned the advantage of MI in analysing missing repeated 
outcome measurements, the comparison of the findings to Siddiqui (2011) is limited due 
to several factors. Importantly, the dropouts were generated under an MAR assumption 
dependent on a fixed covariate (age at recruitment). Additionally, the study was a 
comparison of LME analyses with and without MI, and the estimand was the difference in 
rate of change (slope) between study groups instead of between-group difference in 
treatment effect at an endpoint.  
Like Barnes et al. (2008), Olsen et al. (2012) performed a simulation study under MNAR 
scenarios to compare CCA, LOCF, MMRM and MI (JM and sequential approaches; 
    ) in terms of bias, type 1 error, and power. Deletion of outcome values at follow-up 
visits was implemented – in a similar manner reported by Baron et al. (2008) – dependent 
on the rate of change from the previous visit to the current visit. This deletion criterion led 
to two scenarios: (i) nearly the same dropout rate in both groups (31% with true null 
hypothesis and 34% with true alternative hypothesis); (ii) slightly differential dropout rate 
between the groups (placebo: 36% vs new treatment: 31% with true null hypothesis; 34% 
vs 29% with true alternative hypothesis). Interestingly, all but the MI (JM) approach 
retained the type 1 error rate within an acceptable range3 in nearly all scenarios 
considered in the study. Slightly larger type 1 error rate with CCA had been reported 
under the differential dropout scenario. Importantly, MI (JM) was too conservative in 
controlling type 1 error. With an alternative hypothesis, their study found notable 
differences in bias and power between equal and differential dropout scenarios; bias and 
loss of power were minimal with CCA, MMRM and MI (sequential) under the equal 
dropout scenario. In all but the MI (JM) method, the observed power was higher than 80% 
                                               
3
 Burton et al. (2006): acceptable range 3.6%–6.4% was determined based on 1000 receptions in 
the simulation study. 
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in all scenarios with the high dropout rate against the observed power of 96% with the 
original dataset having no missing data; for MMRM, it was higher than 90% with the high 
dropout. Olsen et al. (2012) argue that the poor performance of MI (JM) was due to the 
exclusion of a variable indicating randomized treatment group from the imputation model. 
Lyass (2010) recommends the inclusion of randomized treatment group as a covariate in 
the imputation model to maintain type 1 error and power of the subsequent statistical test 
comparing treatment effect.  
The simulation study by Olsen et al. (2012) reported a higher power along with a slightly 
lower CI coverage when MMRM was used instead of ANCOVA, irrespective of whether MI 
(sequential) was being used or not. Their study also reported similar estimates of 
treatment effect, type I error rate and statistical power from MMRM or ANCOVA, 
irrespective of MI (sequential) being used or not. That is, this study did not find any 
marked benefit of employing MI of missing repeated measurements in an RCT dataset 
prior to analysing with MMRM or ANCOVA. However, the results that suggested no 
substantial differences in estimate of bias, power and CI coverage between CCA and MI 
ANCOVA under MNAR scenarios of a high dropout rate is a matter of concern. In 
summary, these findings favoured an MMRM analysis of available data without any kind of 
imputations under the scenarios considered in their study. However, this summary 
contrasts markedly with the findings of a simulation study by Baron et al. (2008), which 
had been implemented with similar dropout criteria but lower differential dropout between 
groups (placebo: 20% vs new treatment: 11%). Baron et al. (2008) supported MI (JM; 
m=5) against other approaches (listwise deletion, LOCF and LME) used in this study in 
respect of good control over type 1 error rate, power and bias. Further, in this simulation 
study, MI (JM) substantially outperformed both CCA and LME. Since their study used 
ANOVA and LME modelling as the analysis model instead of ANCOVA and MMRM, and it 
failed to retain the nominal CI coverage of 95% for the estimates from the original data 
having no missing values even with 1000 replications in the simulation, a direct 
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comparison with Olsen et al. (2012) may not be ideal. Additionally, a higher number of 
follow-up visits (6 visits), in comparison with Baron et al. (2008) (3 visits), may contribute 
to favouring longitudinal data modelling in Olsen et al. (2012), but the lower dropout rate in 
Baron et al. (2008) cannot be ignored. 
Another important finding from Olsen et al.’s (2012) simulation study was that CCA, 
MMRM, and MI (sequential) could estimate the true treatment effect in the original data 
without missing values when the dropout rate was equal between the groups. With equal 
dropout rate between the groups, these methods could also retain the CI coverage in the 
acceptable range4 and the loss of power in a minimal level. Recently, Bell et al. (2013) 
demonstrated that equal dropout does not guarantee unbiased estimates of treatment 
effect through a simple simulation study, which compared CCA, LOCF and MMRM under 
different missing data mechanisms with a high overall dropout rate. 
In the above simulation studies, by ignoring the limitations discussed, either MMRM or MI 
was the superior approach to deal with missing outcome data in longitudinal clinical trials 
in comparison with CCA and single imputation approaches. In addition, several simulation 
studies have addressed the impact of missing data and compared methods of handling 
missing outcome data in longitudinal clinical trials (Mallinckrodt et al., 2001b; 2001a; 2004; 
Lane, 2008; Siddiqui et al., 2009; DeSouza et al., 2009). The first three studies 
(Mallinckrodt et al., 2001b; 2001a; 2004) had been performed to compare MMRM (but not 
adjusted for baseline observations) against LOCF ANOVA, and aimed to understand how 
robust these approaches are to violations of the MAR assumption. Mallinckrodt et al. 
(2001b) evaluated these approaches in a range of deletion criteria, and found that the 
MMRM provided adequate control of type 1 error rate even in the most extreme scenarios 
                                               
4
   Burton et al. (2006): acceptable range 93.6%–96.4% was determined based on 1000 receptions 
in the simulation study. 
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(i.e., scenarios with high dropout rates (>30%) and a strong MNAR mechanism). In 
contrast, type 1 error rates from LOCF ANOVA were inflated severely in most scenarios 
due to an increased bias – a similar observation was later made by Barnes et al. (2008). 
In a simulation study with high differential dropout rates between treatment groups 
(placebo: 60% versus new treatment: 30%), Mallinckrodt et al. (2001a) observed that the 
average estimates of treatment effect from the MMRM model did not substantially deviate 
from the true value, and the standard error and CI accurately reflected the true uncertainty 
of the estimates. On the other hand, LOCF ANOVA produced biased estimates – 
markedly underestimating the difference in treatment effect when both treatment groups in 
their simulation study were effective and overestimating the difference when one of the 
treatments was ineffective. In another simulation study that evaluated the effect of within-
subject error correlation structure, Mallinckrodt et al. (2004) reported that specifying an 
unstructured matrix for use in MMRM, regardless of the true correlation structure, yielded 
superior control over type 1 error, bias and CI coverage than LOCF in every scenario. The 
previous work by Lane (2008) and Siddiqui et al. (2009) supports MMRM against LOCF 
ANCOVA in respect of good control over bias in the estimate of treatment effect and CI 
coverage in all missing data mechanisms. However, unlike the studies by Mallinckrodt et 
al. (2001b; 2001a; 2004), they reported that both methods were affected by serious 
misinterpretation due to biased estimates of treatment effect and coverage in MNAR data. 
Unlike the other studies mentioned in this paragraph, DeSouza et al. (2009) compared the 
performance of CCA, LOCF and MMRM through simulated datasets with relatively smaller 
overall dropout rates (10%, 15% and 30%). Their study evaluated a number of dropout 
patterns under an MAR dropout mechanism, and reported that MMRM performed 
consistently well – in terms of controlling bias – compared to the other methods across the 
dropout rates and dropout patterns; however, the loss of power was substantial in all 
these methods. 
 Chapter 2                                              34 
2.4.3 Sample size calculation in anticipation of dropouts 
Sample size calculations are essential in the proper design of an RCT. Particularly 
important in relation to missing data is how to account for loss of power due to dropouts in 
hypothesis tests or CIs; however, this issue has not been studied extensively (Little et al., 
2012). The most intuitive strategy would be to multiply by some factor the number of 
subjects determined under an assumption of no dropout. For example, if an anticipated 
dropout rate is   (         ), then the multiplication factor would be        –    . The 
inflation of sample size is based on an assumption that the extent of loss in nominal power 
is proportional to the amount of missing data. However, this assumption is not necessarily 
true, and it is important to take into account the effect of any imputation methods that will 
be used in the analysis.  
A few of the previous simulation studies (Mallinckrodt et al., 2001a; Baron et al., 2008; 
Lane, 2008; DeSouza et al., 2009; Siddiqui, 2011; Olsen et al., 2012) compared various 
missing data handling approaches in terms of statistical power, and found that all the 
approaches influenced the expected power irrespective of biased or unbiased estimates 
of treatment effects from these approaches. As evident from the previous simulation 
studies, the achieved power of a study given an analysis method is influenced by the 
amount and direction of bias – the bias in estimate leads to artificial inflation (due to 
substantial overestimation of treatment effect) or reduction of power. Additionally, even 
methods that provide unbiased estimates of treatment effect may not protect against loss 
of power. However, it is unclear whether the loss of power is a matter of concern with an 
inflated sample size, which is calculated using the naïve approach to account for the loss 
of power due to attrition. These simulation studies used an unrealistic sample size (due to 
random selection of sample size) that yielded substantially higher or lower power in the 
absence/presence of missing data than the routinely used desired power of 80% or 90% 
in real practice. As was pointed out in the previous section, three studies – Mallinckrodt et 
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al. (2001a); Baron et al. (2008); Olsen et al. (2012) – limited their exploration to an MNAR 
mechanism. Siddiqui (2011) did the exploration under an MAR mechanism but reported 
biased estimates of treatment effect with MI. Lane (2008) and DeSouza et al. (2009) did 
not consider MI in their simulation studies. Further, none of these studies explored the 
impact of different sample size or different level of dropout rate to understand its effects 
on statistical power. Therefore, the findings from these simulation studies might have 
limited generalizability in real practice. It remains unclear how the extent and distribution 
of missing data actually influences the power in longitudinal clinical trials, and whether the 
naïve approach is helpful to attain the desired power in the missing data scenarios. 
Lu at al. (2008; 2009) have proposed a modified multiplication factor to increase the 
number of subjects determined under an assumption of no dropout where the estimation 
of treatment effect at an endpoint is based on an MMRM model. The approach requires 
complete specification of correlation matrix and dropout rate by treatment group over time. 
However, in practice there is often only limited data at the design stage of RCTs. 
Therefore, the use of this approach is limited by the extensive computational requirements 
and pre-specification of more information on parameters. 
2.5 Guidance on prevention and handling of missing data in RCTs 
Several sets of guidelines and recommendations on prevention and handling of missing 
data in RCTs have been published in order to promote best practice, and to maintain 
standards on study design, study conduct, data analysis and reporting (Mallinckrodt et al., 
2008; European Medicines Agency, 2010; National Research Council, 2010; Little et al., 
2012; Dziura et al., 2013; Li et al., 2014). Li et al. (2014) conducted a systematic review 
on regulatory guidelines containing recommendations relevant to the prevention and 
handling of missing data in clinical studies, including RCTs. The review concludes with 
three important points for consideration. First, the single best approach is to take 
appropriate measures at the design stage to prevent the occurrence of missing data, as 
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there is no single method to solve the problem of missing data. Second, trialists should 
use valid statistical methods that properly reflect all the sources of uncertainty in respect 
of the missing data. Third, details of missing data should be reported thoroughly and 
transparently to allow readers to judge the validity of the findings.  
With particular reference to RCTs, two documents – “The prevention and treatment of 
missing data in clinical trials” by U.S. National Research Council (NRC) panel (2010) and 
“Guideline on missing data in confirmatory clinical trials” by European Medicines Agency 
(EMA) (2010) – provide extensive coverage of the missing data problem. The NRC report 
provides 18 recommendations to address missing data in clinical trials through careful trial 
design, conduct and analysis. Recommendations 9–15 specifically provide important 
direction towards the analysis of missing data. The EMA guideline provides advice on how 
missing data in confirmatory clinical trials should be addressed and reported, and on 
regulatory acceptability of these approaches. Unlike the NRC report, this guideline covers 
only general recommendations on acceptable frameworks for handling missing data in a 
regulatory setting. This guideline discourages the use of CCA as a primary analysis. 
However, the guideline does not completely agree with the NRC report on the use of 
LOCF or BOCF; these approaches can be acceptable if they can be shown to be 
conservative. This guideline also supports the use of either MI or mixed models as the 
primary analysis, and concludes by indicating the importance of sensitivity analyses that 
make different assumptions to assess the robustness of trial findings. 
2.6 Rationale of the thesis 
As detailed in section 2.4.2, there have only been a small number of simulation studies 
evaluating the performance of statistical methods in the presence of missing data in 
respect of treatment effect in RCTs. Of these, some compared the performance of MMRM 
and MI in respect of bias, CI coverage and statistical power, while the remaining studies 
reported comparisons between MMRM and LOCF-based analysis or CCA. None of the 
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previous simulation studies favoured either CCA or LOCF under an MAR or MNAR 
mechanism; however, the findings on MMRM and MI substantially varied across these 
studies. The studies largely had a narrow real-life clinical scope and limited applicability. 
Hence, due to the lack of wider generalizability of these previous studies, a 
comprehensive simulation study is planned to examine the relative performance of 
missing data handling strategies on a number of possible and credible clinical trial 
scenarios in order to provide a broader and practically more accessible picture of the 
impact of missing outcome data on the estimation of treatment effect in an RCT.  
The efficiency and accuracy of estimates from statistical methods depend on how close 
mechanisms truly generating the missing data are to the underlying statistical 
assumptions of the methods used. In practice, the missing data mechanisms are not 
strictly identifiable from incomplete data, so the desired “fit” in terms of assessing whether 
a method properly aligns to a mechanism of missingness is difficult to ascertain. As 
pointed out in section 2.3.3, although some methods have been proposed for the 
identification of missing data mechanism, their purpose is generally to detect violations of 
the MCAR assumption by identifying dependence of missingness on observed data, but 
not to confirm either MAR or MNAR assumption. Since it is not possible to guarantee a 
particular missing data mechanism on an incomplete dataset, it is important to assess the 
sensitivity of primary analysis results to departure from a missing data mechanism that 
was assumed in the analysis. Importantly, MNAR-based analyses require stringent 
assumptions about missing data and are rarely reported in practice (details will be 
discussed in chapter 3).  The NRC report on the prevention and treatment of missing data 
in clinical trials (National Research Council, 2010) highlights the need for sensitivity 
analyses to confirm the primary analysis findings; however, the report also acknowledges 
the lack of guidelines on the selection of sensitivity analyses and interpretation of their 
findings, and lack of software packages to implement such analyses. Due to such 
difficulties associated with the sensitivity analyses, in this thesis I propose a simple 
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approach using the responses obtained after a number of failed attempts to verify the 
ignorability of the missing data that is assumed by the primary analysis and hence the 
unbiasedness of the estimate of treatment effect. The results from the proposed approach 
will be a “sign-post” to decide whether it is important or not to proceed to carry out 
sensitivity analyses that assess the robustness of the original estimates to deviation from 
the ignorable assumption relating to the mechanism for missingness. 
2.7 Conclusion 
RCTs are the gold standard for evaluating the direct causal relationship between 
intervention and outcome, as randomization equalizes known and unknown 
characteristics between intervention groups. Since the presence of missing data may 
affect the balance achieved through randomization, RCTs may fail to recognize the 
underlying causal relationship. Further, an analysis of incomplete data may be less 
efficient and leads to biased estimation of treatment effect. Despite efforts to minimize 
missing data, the problem will inevitably still occur in RCTs. Any analysis of incomplete 
data requires unverifiable assumptions about the nature of the missing data, and validity 
of inferences from these analyses depends on the correctness of these assumptions. 
Since, it is not possible to exactly verify the correctness of the missing data assumption 
based on observed data alone, it is important to assess the robustness on the inferences 
to a variety of scenarios in RCT settings. 
In this chapter, I have discussed four methods to deal with incomplete longitudinal 
continuous outcome data: two frequently used ones – standard ANCOVA and LOCF 
ANCOVA – and two frequently recommended ones – MI ANCOVA and MMRM. As 
discussed earlier, a few simulation studies have been performed in respect of a limited 
number of scenarios – especially those featuring a high overall dropout rate – to evaluate 
the performance of these methods. Due to the limitations of these studies and their 
contrasting findings discussed earlier, a comprehensive simulation study is required to 
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evaluate these methods. The need for further research has been advocated in the NRC 
report (National Research Council, 2010). The areas in need of further research include: 
(i) the effect of missing data on the power of clinical trials, (ii) how to set useful target rates 
and acceptable rates of missing data in clinical trials, and (iii) the robustness of missing 
data methods to violations of its assumptions.  
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Chapter 3: Systematic review 
3.1 Introduction 
In this chapter, an attempt is made to review current practices in analyses of randomized 
clinical trial (RCT) data in the presence of protocol violations (e.g. inclusion of ineligible 
patients, treatment crossover) and missing data. Here, the review focuses on RCTs 
reported in five leading medical journals that mainly publish studies of musculoskeletal 
conditions (MSCs). Trials on MSCs differ from those in other areas, due to several 
characteristics that may influence the trials and lead to missing outcome data in many 
situations. The review seeks to cover current issues and practices related to statistical 
analyses of RCT data centred on handling of missing outcome data, with specific 
reference to trials in MSCs. The objectives of this review are listed in detail in section 3.3. 
3.2 Background 
Intention-to-treat (ITT) analysis is the preferred method of analysis for RCTs with a 
superiority design. The ITT principle states that an analysis should be performed by 
including all study participants in the groups to which they were randomized, regardless of 
any departures from the original assigned group (Chan et al., 2013). This principle helps 
to preserve the benefits of randomization, which is intended to ensure that differences in 
outcome observed between the groups are solely the result of the treatment (Montori & 
Guyatt, 2001; Heritier et al., 2003), and to reduce the risk of selection bias (Altman, 2009; 
Fleming, 2011). In an ideal setting, all subjects enrolled in an RCT would follow the study 
protocol and complete their allocated treatment as detailed therein, and thus contribute 
data that were complete in all respects (Lewis & Machin, 1993). However, this is rarely 
achieved in practice – particularly under pragmatic trial conditions. Moreover, to provide 
an unbiased estimate of treatment effect, randomization alone is not sufficient and it is 
also important to obtain complete data on all randomized subjects (Lachin, 2000). Some 
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authors, however, describe an analysis as ITT without regard to this requirement to 
include data for all randomized participants in the analysis (Higgins & Altman, 2011). In 
this review, an approach that deviates from a full ITT analysis in this way – by retaining 
treatment group membership as per random allocation but excluding participants with no 
follow-up data – was referred as a partial ITT analysis. The term “modified ITT” has 
frequently been used to describe this approach (Higgins & Altman, 2011), but this term 
has been criticized for being ambiguous and lacking clarity regarding the exclusion of data 
(Ioannidis et al., 2004; Abraha & Montedori, 2010). 
Due to a perceived misuse of the term “ITT” (Ioannidis et al., 2004; Abraha & Montedori, 
2010; Schulz et al., 2010), item 16 in the 2010 CONSORT statement was updated to 
include a more explicit request for group-wise details on the number of participants 
included in each analysis and whether the analysis was by randomized groups (Schulz et 
al., 2010). Non-ITT analyses such as an ‘as-treated’ (AT) analysis, which groups 
participants according to treatment received rather than according to randomization, and a 
‘per-protocol’ (PP) analysis, which omits participants who do not follow the study protocol, 
are not protected by randomization and thus may be affected by an imbalance in baseline 
variables (McNamee, 2009). 
In practice, no matter how well designed and implemented a study, missing data are 
almost inevitable (Crutzen et al., 2013). In an RCT, missing data are more prevalent in 
outcome variables than in covariates, since data on covariates are usually collected at the 
time of enrolment. Different degrees of data incompleteness in these trials can occur as 
measurements may be available only at baseline or may be missed for one or several 
follow-up time-points. Incomplete outcome data in trials can lead to potential problems 
such as loss of efficiency due to reduced sample size and bias in the estimate of 
treatment effect due to differences between the observed and unobserved data (Horton & 
Lipsitz, 2001). For example, if missing data on an outcome are ignored and an analysis is 
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based only on the observed data, and these data are disproportionately from patients who 
are doing well in a new treatment arm and from patients who are doing poorly in the 
control arm, then the estimate of treatment effect could be overestimated. In addition, the 
benefits of randomization may be compromised; any statistical inferences, therefore, rely 
on additional assumptions. Further, a full dataset requires either imputation of missing 
values or modelling of unobserved data (European Medicines Agency, 2010).  
Any analysis of RCTs with incomplete data is based on specific assumptions on the 
missing data mechanism, as detailed in chapter 2, such as missing completely at random 
(MCAR), missing at random (MAR), or missing not at random (MNAR) (Rubin, 1976; Little 
& Rubin, 2002). For a valid analysis of RCTs with incomplete data, a transparent and 
plausible assumption on the mechanism of missing data is important (Little & Rubin, 
2002). Since impacts of missing data on inferences of an RCT are difficult to assess and 
are closely associated with the question of what would have happened if all participants 
had completed that trial, it is important to try to gather information on the missing data, 
including the reason for its being missing, to make a justifiable assumption about the 
missing data. 
As trials with missing data may not retain the balance of randomization, the basis for 
statistical inference is lost (Wright & Sim, 2003; Lewis & Machin, 1993) and there is no 
longer a statistical rationale to guarantee lack of bias for the estimation of the parameter 
and its associated confidence interval – even if the study is assumed to be free of other 
risks of bias, such as non-masked evaluation. Identification of the underlying missing data 
mechanism is important in order to carry out appropriate formal analyses of data with 
missing values; however, it is impossible to identify this mechanism with certainty based 
on the observed data alone (Fielding et al., 2009). Missing data should therefore be 
considered at the design, conduct and analysis stages of a trial (Molenberghs & Kenward, 
2007; National Research Council, 2010; White et al., 2011). First, trialists should attempt 
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to minimize missing data in the first instance by following up all randomized subjects, even 
if they withdraw from an allocated intervention. Second, analysts should perform a primary 
analysis with a plausible assumption on the mechanism of missing data. Third, sensitivity 
analyses should explore the robustness of the results to a range of alternative plausible 
assumptions regarding missingness. 
A few studies (Hollis & Campbell, 1999; Kruse et al., 2002; Wood et al., 2004; Gravel et 
al., 2007; Fielding et al., 2008) have examined practices regarding the use of the ITT 
principle and/or reporting and handling of missing data in RCTs published in general 
medical journals. Additionally, two studies have assessed the quality and application in 
RCTs in MSCs (Baron et al., 2005; Henschke et al., 2012). Baron et al. (2005) examined 
the proper use of the ITT approach and rate of missing data in 81 reports of superiority 
RCTs assessing structural outcomes in rheumatic diseases published between 1994 and 
2003 in 10 general and 21 speciality journals. Henschke et al. (2012) evaluated trend over 
time (1980–2008) in quality of RCTs (n=157) of interventions for chronic low-back pain. 
The study was not limited to an evaluation of the use of ITT and the rate of missing data; 
in addition, several other study design characteristics associated with risk of bias were 
also considered. All these studies found many instances in which analyses were poorly 
defined and noted variation in practice regarding the ITT principle and the handling of 
missing data. 
Hollis and Campbell (1999) examined 249 reports of RCTs published in 1997 in four 
medical journals (BMJ, JAMA, Lancet and New England Journal of Medicine) and 
reported that 48% of the reports claimed to perform an analysis according to ‘ITT 
strategy’, but conceded that the ITT analysis was not clearly described and applied in 
many instances. Kruse et al. (2002) evaluated a sample of 100 RCTs, published in 1999, 
that used the word ‘intention-to-treat’ or ‘intent-to-treat’ in their abstract. They reported that 
only 42% of the trials included all randomized subjects in their primary endpoint analysis. 
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In another study, Gravel et al. (2007) evaluated 403 reports of RCTs published in 2002 in 
ten medical journals and reported that 62% of the trials analysed their primary outcome on 
an ITT basis. However the reviewers found that only 39% of the identified trials actually 
analysed all subjects as randomized. The study also reported that 60% of the trials had at 
least some missing data and most of these trials (59%) excluded subjects with missing 
data from the primary analysis.  
Wood et al. (2004) examined 71 trial reports published between July and December 2001 
in BMJ, JAMA, Lancet and New England Journal of Medicine and reported that almost 
89% had missing outcome data. Importantly, the review reported that outcomes were 
missing for more than 10% of participants in about half of the reviewed trials. The review 
further reported that 18% of the trials had more than 20% missing outcomes, and 
complete-case analysis was the most common approach in the primary analysis. Similar 
findings were observed in another review of the use of imputation methods to deal with 
missing quality of life outcomes in 61 RCTs published during 2005 and 2006 in the same 
medical journals (Fielding et al., 2008). 
3.2.1 RCTs in MSCs  
The number of RCTs on interventions for MSCs has increased steadily over the past 
decades (Koes et al., 2005; Henschke et al., 2012). Many RCTs in MSCs differ from the 
archetypal clinical trials that use placebo-controlled, double-blind methods (Akai, 2010). It 
is, for example, often difficult to utilize double-blind methods in pragmatic trials of clinical 
interventions for these conditions. For example, in a trial with comparison of standard 
treatment and standard treatment plus cognitive-behavioural training among patients with 
rheumatoid arthritis, imposing a double-blind method is not practical; only an open-label 
trial, where patients know about their treatment, is usually possible in such circumstances. 
In this situation, perceptions of disadvantages of one treatment over another may 
influence the patient’s decision to continue in the trial. Additionally, the aims of treatment 
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for MSCs are mainly to reduce the burden of diseases and disability, and to improve 
health-related quality of life. Accordingly, the outcome measures are mostly related to 
participants’ well-being or functional ability of the patients, not the quantification of 
biochemical or other laboratory data. Finally, owing to their chronic nature, many MSCs 
necessitate long-term trials, which are prone to loss to follow-up. Each of these features 
may predispose to missing values. 
3.2.2 ITT analysis and missing outcome data in trials in MSCs 
Baron et al. (2005) reviewed superiority trials published between 1994 and 2003 that 
assessed outcomes in rheumatic diseases (n = 81) and reported that a full ITT analysis – 
an analysis includes all randomized subjects in the analysis as randomized – was not 
applied in most (93%) of the identified trials. The researchers additionally examined the 
rate of missing data and found that about two-thirds of 63 reports in which missing data 
information had been reported had >10% participants with missing outcome data and 
approximately one-third had >20%. However, only a quarter of the reports reported 
statistical methods for handling the missing data. 
Henschke et al. (2012) reported a study that examined the trend over time (1980–2008) in 
quality – based on study design characteristics associated with the risk of bias – of RCTs 
(n = 157) of interventions for chronic low-back pain. This evaluation was based on 11 
criteria described by Koes et al. (2005), of which two (9 and 11) are closely linked to the 
ITT principle. Criterion 9 is fulfilled if the percentage of withdrawals and dropouts does not 
exceed 20% for short-term follow-up and 30% for long-term follow-up, and such dropouts 
must be described with reasons; more than one-third of the RCTs failed to fulfil the 
criterion most years during the study period. Criterion 11 is fulfilled if all randomized 
patients are analysed in the group they were allocated to by randomization for the primary 
effect measurement, minus missing values, irrespective of non-compliance and co-
interventions; fewer than 60% of the RCTs fulfilled this criterion. Clearly the percentages 
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will fall further when considering both criteria 9 and 11 – which aligns with the strict 
definition of ITT whereby analysis extends to all individuals randomized whether data is 
lost or not.  
3.2.3 Handling of missing outcome data in trials in MSCs 
Baron et al. (2005) further investigated how missing data were handled in the reviewed 
trials, and reported that, after complete-case analysis, last observation carried forward 
(LOCF) was the most common method used to handle the missing data. The researchers 
also found that analysis methods that better address bias through missing data were 
limited to a very small fraction of the trials; one trial used mixed-effect statistical modelling. 
Since then, there have been several guidelines issued on prevention and treatment of 
missing data in RCTs (Food and Drug Administration, 2008; European Medicines Agency, 
2010; National Research Council, 2010). No studies have been reported recently to 
assess the improvement in quality of reporting and handling of missing data in RCTs on 
MSCs.  
3.3 Objectives  
As mentioned in the background section, trials in MSCs are generally pragmatic in nature 
and hence issues of key relevance to the ITT principle, specifically adherence and 
compliance to treatment regimen and dropout through withdrawal and loss to follow-up, 
are prominent in this field, and possibly so to a greater extent than in other areas of 
clinical research. This study sought to examine the reporting of clinical trials in the 
musculoskeletal field in terms of the ITT principle and analysis issues relating to missing 
data.  
Specifically, this study had the following objectives:  
 To describe the extent of reported dropout;  i.
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 To evaluate the extent of deviation from an ITT principle, and resulting loss to ii.
analysis in respect of the primary analysis; 
 To evaluate the analytical methods used for handling the missing follow-up data in iii.
the main analysis; 
 To evaluate the use of the sensitivity analyses performed to assess the robustness iv.
of inferences from the primary analysis to a range of alternative plausible missing 
data assumptions. 
3.4 Methods 
3.4.1 Selection of studies 
3.4.1.1 Journal selection 
Five journals (Annals of the Rheumatic Diseases, Arthritis & Rheumatism, Journal of 
Rheumatology, Pain and Rheumatology) were non-randomly selected as sources of RCTs 
in the areas of MSCs. The impact factors of journals (Thomson Reuters, 2011) were taken 
into consideration when the selection was performed. The impact factor of the selected 
journals ranged from 3.551 (Journal of Rheumatology) to 9.082 (Annals of the Rheumatic 
Diseases). The impact factor was taken in to account for two main reasons. Firstly, a high 
impact factor can be an indicator of higher methodological quality – a manuscript of a trial 
with weak methodological quality is less likely to be published in a journal that has a high 
impact factor than a manuscript of a trial with strong methodological quality (Lee et al., 
2002). This argument is supported by a review of 469 RCTs published in 2007 in core 
clinical journals where trials published in higher impact journals had higher methodological 
quality compared with those published in lower impact journals in their reported design, 
conduct, and analysis (Bala et al., 2013). Secondly, acceptability of a published article – 
an article published in a journal that has a high impact factor is more likely to influence 
clinical practice and is more likely to be cited in future publications (Akl et al., 2009).  
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3.4.1.2 Eligibility criteria 
The eligibility criteria were based on those used by Egbewale (2012). Only parallel-arm 
individually RCTs were included in this study. This restriction was imposed mainly 
because other trials like crossover trials and cluster RCTs follow a different design, 
analysis, and reporting strategy; moreover, the objectives of the thesis were centred on 
parallel-arm individually randomized clinical trials. More specifically, establishing the true 
ITT principle in the analysis of data is more troublesome in cluster RCTs than in 
individually RCTs because the strategy must be applied at the level of both the cluster and 
the individual, and because of challenging issues surrounding the recruitment process in 
cluster RCTs. Crossover trials depend on the absence of dropout and randomization is 
only in relation to the order of treatment assignment. So the issues are different in relation 
to application of the ITT analysis in these trials. 
Primary reports of all such phase III clinical trials published in the aforementioned five 
journals over a two-year period were considered, but restricted to those reporting the 
primary outcome measure of the trial. 
Additional exclusion criteria were: 
 Pilot/feasibility studies, as these mainly aim to demonstrate the feasibility and/or i.
affordability of subsequently conducting a large similar study, rather than to detect 
a true between-group difference with sufficient power. 
 Trials with a number of subjects randomized less than 50, as the small sample ii.
size could impose limitations on the possible methods of analysis. 
 Publications based on an interim analysis (i.e. where the primary analysis was iii.
centred on an outcome measured at a time-point earlier than the designated 
primary endpoint). 
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 Extended follow-up studies (those that only considered outcomes beyond the iv.
primary endpoint). 
 Studies with survival outcomes, as standard survival models take into account lost v.
to follow-up through non-informative censoring. 
 Publications based on multiple trials.  vi.
3.4.1.3 Search strategy 
A search was performed for all reports of RCTs published between 1st January 2010 and 
31st December 2011 in these five journals. The advanced search option was used in each 
journal website with keywords ‘clinical trial’, ‘randomization’, ‘randomisation’, ‘randomized’, 
‘randomised’, ‘randomly’, or ‘random’ in the titles or abstracts to identify relevant citations. 
This search strategy produced 405 relevant citations: 120 from Annals of the Rheumatic 
Diseases, 64 from Arthritis & Rheumatism, 70 from Journal of Rheumatology, 86 from 
Pain, and 65 from Rheumatology. 
3.4.1.4 Selection and review process 
Figure 3.1 illustrates the selection procedure and indicates the reasons for exclusions. An 
initial screening of titles, abstracts and keywords of all retrieved reports was performed to 
identify potentially relevant publications based on the eligibility criteria. The first screening 
resulted in exclusion of 206 reports. A copy of the full report of each selected publication 
was then accessed and screened. A further 108 reports were excluded during this second 
screening process. In total, 314 reports were excluded based on the eligibility criteria. Any 
additional tables and results relating to the trials referred to in the 91 reports finally 
selected for the review were obtained from the respective journal website. A list of the 
selected reports is provided in appendix 1. 
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Figure 3.1: Identification of randomized trials from January 2010 to December 2011 
 
 
3.4.2 Data extraction and management 
A draft data extraction form was developed based on the CONSORT 2010 Statement 
(Schulz et al., 2010), the guideline on the prevention and treatment of missing data in 
clinical trials (National Research Council, 2010), and a research paper on the flow of 
participants in a randomized trial (Hopewell et al., 2011). The form was discussed with the 
supervisory team, and modified further until there was agreement on items and their 
operational definitions. 
Data extraction mainly centred on the primary outcome (variable) at the primary endpoint 
(time). The primary outcome was identified from the definition given in the report (e.g. in 
the study objectives) or from the details on the sample size calculation. If more than one 
120 Ann Rheum Dis
64 Arthritis Rheum 80 Reviews and analysis of multiple trials
70 J Rheumatol 46 Non-randomized studies
86 Pain 20 Secondary publications/reports of extended follow-up trials
65 Rheumatology 20 Editorials/letters
15 Phase I and II studies
10 Studies with sample size less than 50
6 Cross-over trials
4 Pilot/feasibility studies
3 Economic evaluation studies
2 Non-human studies
67 Ann Rheum Dis
36 Arthritis Rheum 34 Secondary publications/reports of extended follow-up trials
30 J Rheumatol 18 Non-randomized studies
47 Pain 14 Studies with sample size less than 50
19 Rheumatology 11 Reviews and analysis of multiple trials
9 Phase I and II studies
8 Cross-over trials
6 Pilot/feasibility studies
5 Studies with survival outcome
2 Non-human studies
1 Economic evaluation studies
405 Citations:
206 Excluded based on review of title, abstract & keywords:
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primary outcome was reported, the first one listed was used. If, in the case of multiple 
follow-ups, the primary endpoint was not explicitly identified, it was taken to be the final 
measurement. The decision on the choice of the primary endpoint has been taken 
because MSCs are commonly long-standing, and the aim is usually to address long-term 
pain and functional difficulties. Further, a primary analysis was defined as the analysis of 
the primary outcome at the primary endpoint. 
Data were extracted, using the proforma (Appendix 2), from each of the 91 eligible trial 
reports. Information was obtained on basic characteristics of the trials, participants’ 
exclusions and withdrawals, methods used to handle the missing outcome data, statistical 
analyses performed, and sensitivity analyses performed. 
Specifically, reports were scrutinized for: number of centres involved, number of arms 
involved, details on primary outcome variable (including the type of variable used for 
measurement and analysis; sometimes a continuous primary outcome is categorized for 
the purpose of a primary analysis), number of follow-up visits after baseline visit, and 
details on sample size (including calculated sample size and whether adjustment for 
attrition in the calculation was done). When the information on sample size calculation 
was not given in an article, the details were obtained from a previously published paper on 
the same trial if available. In addition, data were extracted on number of subjects 
randomized, allocated to each group, receiving the allocated intervention, not receiving 
the allocated intervention, completing the primary outcome measure at the primary 
endpoint, and included in the primary analysis. Apart from the numbers, information was 
also collected on the reasons for not completing the primary outcome assessment at the 
primary endpoint and for exclusion of participants from the primary analysis. In addition, 
the method used, if any, to deal with missing data was identified. Information was also 
gathered on handling of treatment crossover, or other protocol violations (e.g. subjects 
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may not have followed the treatment procedure properly or may have taken other 
medication along with their assigned treatment). 
3.4.2.1 Calculation of dropout rate 
Dropouts were subjects who did not complete the primary outcome assessment at the 
primary endpoint, whereas completers were those who completed the assessment. 
Dropouts include individuals lost to follow-up (through non-response) and those not 
followed up due to study protocol violations such as ineligibility or treatment crossover. 
Dropout rate was calculated as the difference between the number randomized and the 
number remaining in the trial (completers) at the primary endpoint, divided by the number 
randomized. In trials with repeated follow-ups, the dropouts were classified as either “early 
dropouts”, defined as subjects who did not complete any follow-up assessment, or “late 
dropouts”, defined as those who completed at least one follow-up assessment prior to 
dropping out. The early and late dropout rates were calculated based on the number of 
subjects randomized. 
3.4.2.2 Classification of analysis strategies 
The analysis strategy used in the reviewed reports was categorized as: full ITT (FITT) 
analysis, partial ITT (PITT) analysis, complete-case analysis (CCA), PP analysis, or AT 
analysis. The definition of each category is given in table 3.1. FITT is an analysis of data 
as randomized, and includes data on all randomized subjects through either imputation or 
modelling of any missing data. PITT denotes an analysis restricted to a subset of the full 
ITT sample where the sub-sample excludes early dropouts (in trials with repeated follow-
ups). The purpose of this classification is to highlight the exclusion of early dropouts from 
the primary analysis. In trials with a single follow-up, the exclusions lead to a CCA as 
there is no scope for further follow-up data. White et al. (2012) argue that including all 
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randomized subjects in an analysis of an outcome with missing data is insufficient; 
suggesting one should also consider an appropriate method to handle the missing data. 
 
Table 3.1: Classification of analysis strategy used in trial reports 
Statistical analysis strategy Explanation 
Full ITT (FITT) analysis All randomized subjects included in the analysis and 
analysed as randomized. 
Partial ITT (PITT) analysis 
 
Analysis includes all randomized subjects except those 
who did not provide any follow-up data on the primary 
outcome in trials with repeated follow-ups. 
Complete-case analysis 
(CCA) 
Analysis includes only those randomized subjects who 
completed the primary outcome measurement at the 
primary endpoint. i.e., this analysis excludes subjects 
with missing data at the primary endpoint. 
As-treated (AT) analysis All subjects analysed as treated, regardless of the 
treatment to which they were assigned. 
Per-protocol (PP) analysis Analysis includes subjects who completed the trial in 




3.4.2.3 Definition of loss to analysis 
The exclusion of randomized subjects from the primary analysis was referred to as ‘loss to 
analysis’ (Deo et al., 2011) and was calculated as the difference in the number 
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randomized and the number included in the primary analysis. Deviation from the FITT 
analysis generally results in loss to analysis. The reason for loss to analysis can be either 
loss of participants in the analysis with lack of measured or imputed outcome, or exclusion 
of participants with a measured outcome because of certain reasons (e.g. non-adherence 
to treatment protocol), or both. For example, in PP analysis, loss to analysis includes 
completers who were excluded for reasons of protocol violation in addition to dropouts, 
whereas in a PITT analysis, it includes only early dropouts.  
 
3.4.2.4 Classification of methods to handle missing data 
The method used, if any, to deal with missing data was classified as:  
 Methods that lead to listwise deletion of subjects with missing data, and moment-i.
based methods, such as generalized estimating equations (GEE). 
 Single imputation methods, such as baseline observation carried forward (BOCF), ii.
last observation carried forward (LOCF), worst observation carried forward 
(WOCF), non-responder (i.e. treatment failure) imputation (NRI), regression 
method or linear extrapolation method. In NRI, dropouts are assumed to be non-
responders regardless of their prior response status at the time of dropout, where 
an outcome is analysed on a dichotomous or categorical scale. 
 Multiple imputation (MI) – a method to overcome certain limitations (e.g. risk of iii.
underestimating the variance of treatment effect) of single imputations. 
 Statistical models that can include all randomized subjects without imputation of iv.
missing values. For example, full-information maximum likelihood (FIML) based 
methods, such as mixed-effects model for repeated measures (MMRM). 
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3.4.2.5 Data accuracy 
To ensure accuracy, the process of data extraction was repeated after several months, 
blind to the outcome of the initial data extraction. Any discrepancies were reconciled 
through a third review of corresponding reports. Another reviewer (RO) then 
independently verified the corrected data against a random selection of 20 reports (22%), 
and identified discrepancies in less than 1% of total data points. These discrepancies in 
the data extraction were resolved by discussion.  
3.5 Results 
3.5.1 Characteristics of included trials 
A description of the 91 trials included in the review is presented in table 3.2. More than 
half (57%) were multicentre trials. Three-quarters were two-arm studies, while 10% had 
more than three study arms. Even though 72 trials had a numerical primary outcome 
measure, 13 of them categorized this continuous outcome measure; for example, one of 
the included trials (Russell et al., 2011) defined favourable/clinically-improved outcome as 
30% reduction in pain visual analogue scale score from baseline to the end of the 
treatment period. In 80 (88%) trials, there was assessment of the primary outcome at two 
or more follow-ups; hence, at least one intermediate outcome measurement was available 
before the assessment at the primary endpoint. 
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Table 3.2: Description of the selected trials (n=91) 
Description of the trials No. of trials (%) 
Journal  
 Annals of Rheumatic Diseases (IF: 9.082) 31 (34.1) 
 Arthritis & Rheumatism (IF: 8.435) 16 (17.6) 
 Journal of Rheumatology (IF: 3.551) 11 (12.1) 
 Pain (IF: 5.355) 27 (29.6) 
 Rheumatology (IF: 4.171) 6 (6.6) 
Year of publication  
 2010 38 (41.8) 
 2011 53 (58.2) 
Multicentre trials  
            Yes 52 (57.1) 
Number of subjects per trial
1
   
 <100 36 (39.6) 
 100–499 41 (45.0) 
 500 and above 14 (15.4) 
Number of arms per trial  
            2 67 (73.6) 
            3 15 (16.5) 
            >3 9 (9.9) 
Type of primary outcome measure  
 Categorical  19 (20.9) 
 Numerical
2
 72 (79.1) 
Number of follow-up assessments  
 Single 11 (12.1) 
  Repeated 80 (87.9) 
IF – Impact factor; 
1
Number of subjects randomized; 
2
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Nineteen (21%) trials did not present any formal sample size calculation (Table 3.3). 
Among the 72 trials that detailed the sample size calculation, only 28 (39%) made 
adjustment for attrition. In 18/72 (25%) trials, the number of subjects randomized was less 
than the calculated sample size (the shortfall ranged from 1% to 53%; median 5%). The 
number of subjects randomized in the identified trials ranged from 51 to 1025, with a 
median of 140. The number of subjects remaining in the trials at the primary endpoint 
ranged from 32 to 786, with a median of 107 subjects. The number of subjects included in 
the primary analysis ranged from 32 to 1025, with a median of 115. 
Table 3.3: Size of the trial 
Details 
No. of trials 
reporting 
the details 
Number of subjects 
Median (IQR) Min – Max 
Calculated sample size 72
a
 136 (74–366) 38–1025 
Number of subjects randomized 91 140 (76–306) 51–1025 
Number of subjects completed the trial 90
b
 107 (66–247) 32–786 
Number of subjects included in the primary 
analysis 
91 115 (71–261) 32–1025 
a
In 28 trials this included an adjustment for attrition;
 b
It was clear from the remaining one article that 




All but one trial reported the number or proportion of subjects with missing data at the 
primary endpoint. In the one exception it was clear from the report that there were missing 
values at the primary endpoint. However, arm-specific details were not clearly reported in 
12 trials. Figure 3.2 displays the percentage of trials with various levels of dropouts. 
Eighty-six trials (95%) had some subjects with missing outcome data at the primary 
endpoint. The median dropout rate was 12% (IQR 7% to 24%; range 0% to 51%). Fifty-
four (60%) trials had more than 10% dropouts and 29 (32%) had more than 20% dropouts 
based on number of subjects randomized. 
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The number above each bar indicates the number of trials; *One trial did not report the dropout rate 
 
Figure 3.2: The distribution of the 90 trials based on the percentage of dropouts 
 
 
The distribution of the dropout rates by number of follow-ups is shown in figure 3.3. 
Among 11 trials with a single follow-up, 10 (91%) trials reported dropouts (median [IQR] 
dropout rate of 9% [6%, 12%]). Among 80 trials with repeated follow-ups, 39 (49%) trials 
reported early dropouts (median [IQR] dropout rate of 3% [1%, 9%]), and 75 (94%) trials 
reported late dropouts (median [IQR] dropout rate of 10% [6%, 21%]).  
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*One trial did not report the dropout rate; +indicates median dropout rate 
 





The bold dashed line indicates line of perfect equality, and the upper and lower dashed lines 
indicate +/- 5% from perfect equality 
 
Figure 3.4: Dropout rate at the primary endpoint between arms (n=61) 
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Figure 3.4 displays the pattern of dropout rates between arms as a scatter plot. Among 67 
trials with two arms, four trials had no dropout, 28 (42%) trials had nearly equal dropout 
rates between the arms (the difference in dropout rates between arms was less than 5%), 
15 (22%) had higher dropout rate in the new treatment arm, 14 (21%) had higher dropout 
rate in the placebo/standard treatment arm, and the remaining six trials did not report the 
arm-specific dropout details.  
3.5.3 Analysis strategy and loss to analysis 
Table 3.4 indicates the analysis strategy followed in the primary analysis of the trials. FITT 
analysis was performed in 34 (37%) trials; in four trials (one with a single follow-up and 
three with repeated follow-ups), there were no missing outcome data at the primary 
endpoint and in the remaining 30 trials (one with a single follow-up and 29 with repeated 
follow-ups), all randomized subjects were included in the analysis through either 
imputation of missing values or an analysis that accommodates missing data.  
In 24 (26%) trials (seven with a single follow-up and 17 with repeated follow-ups), only 
completers were included in the analysis. In detail, all dropouts were excluded from nearly 
two-thirds of trials with a single follow-up (median [IQR] loss to analysis of 10% [8%, 
15%]) and one-fifth of trials with repeated follow-ups (median [IQR] loss to analysis of 8% 
[6%, 17%]).  
Among 10 trials that reported deviations from allocated treatment (i.e. crossover of 
treatment) after randomization, one trial (Rubbert-Roth et al., 2010) performed the primary 
analysis on an AT basis. Protocol violations were reported in 22 trials, and four of them 
(two each with a single follow-up and repeated follow-ups) followed a PP strategy as the 
primary analysis. 
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Table 3.4: Analysis strategy followed in the primary analysis. Data are counts (%) 
Analysis strategy 
Trials with single 
follow-up 
Trials with repeated 
follow-ups 
Total 
Intention-to-treat (ITT) 2 (18.2) 60 (75.0) 62 (68.1) 
       Full ITT 2 (18.2) 32 (40.0) 34 (37.4) 
       Partial ITT n/a 28 (35.0) 28 (30.7) 
Complete-case analysis 7 (63.6) 17 (21.3) 24 (26.4) 
As-treated analysis  0 (0.0) 1 (1.2) 1 (1.1) 
Per-protocol analysis 2 (18.2) 2 (2.5) 4 (4.4) 
Total 11 (100.0) 80 (100.0) 91 (100.0) 
 n/a: not applicable 
 
 
In another 28 (35%) of the 80 trials with repeated follow-ups, a PITT analysis was 
performed (excluding early dropouts). Among these trials, median [IQR] dropout rate was 
21% [11%, 30%] and median loss to analysis was 2% [1%, 6%]. The terms ‘ITT’ and 
‘modified ITT’ were used interchangeably across these trials to denote the analysis 
strategy. As noted in table 3.5, nine trials failed to give a clear description of the analysis 
strategy that was followed in the trial report. Various descriptions were used to define the 
analysis strategy among the remaining 19 trials (Table 3.5). The descriptions varied in 
relation to several reasons for the exclusions from the analysis; patients were ineligible 
because they were mistakenly randomized, patients did not start the intervention or did 
not complete the entire course, patients did not provide a baseline assessment, or 
patients did not complete any post-baseline assessment. 
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Table 3.5: Description on analysis strategy provided in the 28 trial reports with classification ‘partial ITT’ 







Not defined 9 1%–20% Atchia et al., 2011; Beaudreuil et al., 2011; Brien et al., 2011; 
Christiansen et al., 2010; Keefe et al., 2011; Machold et al., 
2010; Oldenmenger et al., 2011; Schmidt et al., 2011; Zangi et 
al., 2011 
All randomly assigned patients who received at least 
one dose of study medication 
10 0.5%–7% Bliddal et al., 2011; Emery et al., 2010; Furie et al., 2011; 
Griffiths et al., 2010; Jones et al., 2010; Katz et al., 2011; 
Molsberger et al., 2010; Pauer et al., 2011; Strand et al., 2011; 
Taylor et al., 2011 
All randomly assigned patients who received at least 
one dose of study medication, and had a baseline as 
well as at least one post-baseline values for the 
primary outcome 
5 0.5%–14% Baranauskaite et al., 2011; Branco et al., 2010; Tak et al., 
2011; Kim et al., 2011; Seibold et al., 2010 
All randomly assigned patients with at least one 
efficacy assessment after randomization 
2 2% & 16% Kravitz et al., 2011; Navarro-Sarabia et al., 2011 
All randomly assigned patients who met the inclusion 
criteria and were followed up 
1 12% Alavi et al., 2011 
All randomly assigned patients who met the study 
eligibility criteria, received at least one dose of study 
medication, and had a baseline as well as at least 
one post-baseline values for the primary endpoint 
1 3% Tanaka et al., 2011 
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3.5.4 Handling of dropouts: imputation strategy 
Among the ten trials with a single follow-up that reported dropouts, nine excluded the 
dropouts from analysis, while the remaining one trial employed BOCF in the analysis. 
Among the 39 trials with repeated follow-ups that reported early dropouts, 36 (92%) 
excluded those dropouts from the analysis (28 followed PITT, 7 followed CC, and one 
followed AT analysis), and the remaining three each employed BOCF, MI or MMRM to 
handle the missing outcome data. 
Table 3.6 shows the methods used to handle the missing values occurring after at least 
one follow-up assessment among the trials with repeated follow-ups. Among the 75 trials 
with late dropouts, 26 (35%) trials did not use any kind of imputation, 44 (59%) trials 
performed some sort of single imputation, two (3%) trials performed MI to replace missing 
values, and the remaining three trials did not provide the relevant details. Among the trials 
that did not use any imputation approaches (n=26), eight trials used analysis methods that 
made full use of all available data (MMRM in six and GEE in two) and the remaining 18 
trials excluded the dropouts from the primary analysis without considering the availability 
of the outcome data measured at an earlier follow-up time. It can be seen that LOCF was 
the most frequently used imputation approach, used in 23 (31%) trials. The BOCF 
approach was followed in another four trials. In 12 (16%) trials, subjects with missing 
values were dealt with through non-responder imputation; in two of these trials, the 
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Table 3.6: Methods used to handle late dropouts, who had completed at least one 
follow-up assessment. Data are counts (%) 
Method used in primary analysis 
Percentage of late dropouts 
>0–10% >10–20% >20% Total 
No imputation     
     Excluded 10 (29.5) 6 (33.3) 2 (9.1) 18 (24.0) 
     MMRM 2 (5.9) 1 (5.6) 3 (13.6) 6 (8.0) 
     GEE 1 (2.9)  1 (4.6) 2 (2.7) 
Single Imputation:     
      LOCF
1
 7 (20.6) 7 (38.8) 8 (36.3) 23 (30.7) 
      NRI 7 (20.6) 2 (11.1) 3 (13.6) 12 (16.0) 
      BOCF 1 (2.9)  3 (13.6) 4 (5.3) 
      Regression imputation 1 (2.9) 1 (5.6)  2 (2.7) 
      LOCF + NRI
2
  1 (5.6)  1 (1.3) 
      LOCF + WOCF
3
   1 (4.6) 1 (1.3) 
      Linear extrapolation 1 (2.9)   1 (1.3) 
Multiple imputation 2 (5.9)   2 (2.7) 
No details 2 (5.9)  1 (4.6) 3 (4.0) 
Total 34 (100) 18 (100) 22 (100) 75 (100) 
MMRM – mixed model for repeated measures; GEE – generalized estimating equations; LOCF – 
last observation carried forward; NRI – non-responder imputation; BOCF – baseline observation 
carried forward; WOCF – worst observation carried forward; 
1
dropout rate was not reported in one 
trial; 
2
trial in which subjects dropping out were treated as non-responder when dropout due to 
adverse events or lack of effectiveness, otherwise imputed with LOCF; 
3
trial imputed with WOCF 
when dropout due to adverse events or inefficacy, otherwise imputed with LOCF 
 
 
Figure 3.5 depicts the approaches to missing data followed in 40 (50%) longitudinal 
studies with more than 10% late dropouts. Importantly, subjects with missing outcomes 
were completely excluded from eight (20%) trials; in the remaining 32 trials, 15 used 
LOCF to accommodate subjects with missing outcome data. Further, MMRM was 
employed only in four (10%) trials, and MI was not performed in any of these trials. 
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Figure 3.5: Handling of missing data in trials with >10% late dropouts (n=40; detail 
was not reported in one trial) 
 
 
3.5.5 Sensitivity analysis and cautionary notes on missing data 
Eighteen (21%) out of 86 trials with missing outcome values at the primary endpoint 
reported a sensitivity analysis to assess the robustness of inferences from the primary 
analysis to a range of alternative plausible assumptions regarding missing data (Table 
3.7). The sensitivity analyses were performed in trials with relatively high proportions of 
missing data (median 24%; IQR 17%, 33%). Either exclusion of subjects with missing data 
(i.e. listwise deletion) or a single imputation method was the designated sensitivity 
analysis. Very few trials (6/18; 33%) presented the results of their sensitivity analysis, 
while the others just reported that a sensitivity analysis had been performed and indicated 
that the findings from the primary analysis were supported by those of the sensitivity 
analysis. 
We further reviewed all 54 trial reports with 10% or more missing data to determine how 
the authors addressed the uncertainty due to missing data in their interpretation of results. 























Missing data handling approch 
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the uncertainty around their findings due to the missing data, apart from a few instances in 
which dropout was briefly identified as a limitation of the study. 









Verstappen et al. 268 5.6 CCA Treated as responder, NRI 
Genevay et al. 61 6.6 LOCF with 
MMRM 
BOCF 
Beaudreuil et al. 70 11.4 MI CCA 
Gabay et al. 162 14.2 LOCF Linear interpolation 
Lumley et al. 88 17.0 CCA Latent growth curve 
modelling 
Ginzler et al. 370 17.3 LOCF CCA 
Kravitz et al. 307 18.9 MMRM MI with MMRM 
Branco et al. 884 21.6 LOCF BOCF 
Machold et al. 389 22.1 LOCF Treated as a responder 
Turner et al. 191 25.7 CCA MI 
Keefe et al. 116 27.6 MMRM Pattern-mixture models, CCA 
Arnold et al. 1025 30.1 BOCF CCA, LOCF, MMRM 
Furie et al. 826 30.3 Non-responder LOCF, CCA 
Griffiths et al. 90 32.2 LOCF CCA 
Thorn et al. 83 34.9 MI with MMRM MMRM 
Russell et al. 548 39.1 BOCF LOCF 
Bliddal et al. 96 41.7 BOCF with 
MMRM 
CCA 
Hewlett et al. 168 50.6 CCA MI 
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3.6 Discussion 
3.6.1 Overall summary  
This review of recently published trial reports in five major musculoskeletal journals 
illustrates current practice relating to the ITT principle and the handling of missing 
outcome data in the primary analysis of RCTs for these clinical conditions. Missing 
outcome data were of concern in most of the reviewed trials; nevertheless 68% trials in 
this review analysed all randomized subjects who had at least one follow-up assessment. 
In particular, a FITT (with emphasis on endpoint analysis of all randomized subjects) was 
performed in 37% and a PITT (based on analysis of randomized subjects excluding 
individuals displaying early dropout in trials with repeated follow-ups) was performed in 
another 31%. However, since most trials failed to use appropriate statistical methods to 
account for missing data, it is likely that descriptive estimates and hence, the inference on 
treatment effect were biased, given that missing data are likely to differ from reported 
data. 
This review noted inconsistency in reporting baseline differences of participants when loss 
to analysis is substantial; several trials evaluated the differences in baseline 
characteristics between arms based on number of subjects randomized rather than on 
number analysed despite a discrepancy between these numbers. This oversight fails to 
locate (and hence may fail to adjust for) any imbalance in the baseline characteristics 
between arms in the analysis dataset. Further, most trials failed to justify the assumption 
made during the analysis. Almost no trials considered the possibility of MNAR; moreover, 
many of the trials failed to adopt a method that is valid under the MAR assumption, which 
is a recommended neutral starting point in many settings (Molenberghs & Kenward, 2007; 
National Research Council, 2010; White et al., 2011). Importantly, sometimes the applied 
method (e.g. LOCF) may not even be valid under MCAR (European Medicines Agency, 
2010; National Research Council, 2010). Some researchers – e.g. Navarro-Sarabia et al. 
 Chapter 3              68 
(2011) – used LOCF with an expectation that this approach can provide a conservative 
estimate of treatment effect; but this may not be true in some situations (European 
Medicines Agency, 2010). A similar finding was observed in sensitivity analyses as well. 
The findings of this study are comparable with previous studies (Hollis & Campbell, 1999; 
Kruse et al., 2002; Wood et al., 2004; Gravel et al., 2007) that reviewed trials published in 
general medical journals. It is a concern that progress has not been made in reducing the 
large proportion of trials that are inappropriately analysed, and which therefore may be 
prone to erroneous estimates and conclusions. 
3.6.2 Quality of reporting 
When compared to trials in the previous studies (Hollis & Campbell, 1999; Wood et al., 
2004; Baron et al., 2005; Gravel et al., 2007), the overall reporting quality of the trials in 
this review was higher. Most of the trials in this review followed the CONSORT statement 
(Moher et al., 2001; 2010) in reporting the trial results. The 2010 CONSORT flow diagram 
demands detailed information on arm-wise progress through various phases of an RCT. It 
explicitly requires reporting of arm-wise numbers of subjects: assessed for eligibility; 
declining to participate (with reasons); randomized; allocated to intervention; not receiving 
the allocated intervention (with reasons); lost to follow-up (with reasons); discontinued the 
intervention (with reasons); and excluded from the analysis (with reasons). In this review, 
five trial reports failed to provide the flow diagram. Another seven trials failed to report 
arm-wise detail on number of subjects randomized, but provided the number of eligible 
subjects who had started the intervention. This clearly limited the scope for calculating 
arm-wise dropout rate, and for assessing the association of assigned interventions with 
exclusions due to ineligibility and failure to start the allocated intervention. 
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3.6.3 Importance of collecting data on all randomized subjects 
As Lavori et al. (2008) specified, it is important to take careful steps to minimize missing 
data in the trial design and data collection. It helps to reduce the need to use unverifiable 
assumptions about the missing data and thus minimize problems in inferential analyses, 
especially those that flow from misspecification of missing data assumptions in the 
analysis. Trialists should give greater attention to missing data that may be influenced by 
unobserved data. For example, study participants may wish to miss a hospital visit for 
outcome assessment when such a visit may be either difficult for those who are too ill or 
unnecessary for those who are feeling well. Researchers may prefer a home visit instead 
of requesting the participants to make a hospital visit. Another important point is to gather 
information on the reasons for missing data and on patient characteristics that can predict 
it. This is highlighted in the National Academy of Science (NAS) report (National Research 
Council, 2010), which contains recommendations regarding the prevention and treatment 
of missing data in clinical trials. Recommendations 3–5 specifically suggest obtaining 
more information on post-withdrawal data (Table 3.8). The additional information may help 
to justify an ignorable missing data and allows adjustment for bias in treatment effect 
through appropriate methods of analysis. Additionally, trialists should consider the 
availability of secondary sources to obtain outcome data information when there is data 
missing from the primary source. For example, information on outcome data was collected 
from general practice notes in one trial (Verstappen et al., 2010): data on disease-
modifying antirheumatic drug use were obtained from GPs on 23 patients who 
discontinued the study and did not want to attend for further assessments. The accuracy 
of the data from a secondary source may be questioned; however, a trade-off between the 
accuracy and having missing data is required. 
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Table 3.8: Recommendations 3–5 of the NAS report on missing data 
# Recommendations 
3 Trial sponsors should continue to collect information on key outcomes on 
participants who discontinue their protocol-specified intervention in the course of the 
study, except in those cases for which a compelling cost-benefit analysis argues 
otherwise, and this information should be recorded and used in the analysis. 
4 The trial design team should consider whether participants who discontinue the 
protocol intervention should have access to and be encouraged to use specific 
alternative treatments. Such treatments should be specified in the study protocol. 
5 Data collection and information about all relevant treatments and key covariates 
should be recorded for all initial study participants, whether or not participants 
received the intervention specified in the protocol. 
 
 
3.6.4 Power calculation in anticipation of dropouts 
In the review, we found that one-fifth of trials failed to report a formal sample size 
calculation, contrary to the requirements of the CONSORT statement (Moher et al., 2010). 
This is important because specification of a primary outcome variable and primary 
endpoint guards against changing the planned outcome and placing undue emphasis on 
an outcome that was not the original primary outcome. Additionally, these calculations 
alert readers to potential problems like loss of power due to problems with participant 
recruitment and retention in RCTs. Most of the RCTs in this review did not meet their 
sample size targets. Specifically, 25% (18/72) of trials reporting a sample size calculation 
failed to achieve adequate numbers at randomization and 62/72 did not meet the target 
set for the primary endpoint. 
 Chapter 3              71 
As found in this review, trials often fail to recognize the importance of adjustment for 
attrition in sample size calculations in order to retain sufficient statistical power to detect a 
true treatment effect. Only a limited number of trials in the review (28/72) reported a kind 
of adjustment for anticipated dropout rate – inflating sample size in proportion to the 
dropout rate. In a quarter of the trials in the review (18/72), the number of subjects 
randomized was less than the calculated sample size. These findings raise many 
fundamental questions, such as: (i) Why did a large proportion of trials fail to perform 
and/or report the adjustment for attrition?; (ii) Do those methods not leading to listwise 
deletion protect against loss of power?; (iii) Does inflating sample size protect against the 
loss of statistical power due to attrition? A detailed discussion around these issues will be 
carried out in chapter 6. 
3.6.5 Dropout rate 
Dropout was not limited to a small proportion of trials. Almost 95% of trials in this review 
reported dropouts, which ranged from 1% to 51% of randomized subjects. The average 
dropout rate was a little over 10%. Compared to previous studies (Wood et al., 2004; 
Baron et al., 2005), which reviewed RCTs published nearly a decade ago, the present 
study did not observe any major change in the level of missing data. As seen in figure 3.6, 
Wood et al. (2004) reported that more than a half of reports had a dropout rate >10% and 
19% had >20%. In Baron et al.’s (2005) study, 69% of 63 reports that clearly provided a 
missing data proportion had a dropout rate >10% and 29% had >20%. The amount of 
dropouts in this study may vary if one considers those reports (n = 18) that did not report 
the rate of missing data. The higher percentage is perhaps attributable to the inclusion 
criteria of that study, as it did not distinguish reports that were based on the primary 
outcome variable from those that were not. Usually, secondary outcome variables are less 
focused and more prone to missing outcomes in RCTs (Hopewell et al., 2013). Indeed, 
the present study also identified that a high proportion (60%) of trials had more than 10% 
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dropouts and 31% had >20%. The high proportion of trials with a significant number of 
dropouts is concerning. 
 
     n = number of trials reviewed 
 
Figure 3.6: Comparison of reviews in relation to percentage of trials with various 
levels of dropout rates 
 
 
The benefits of randomization in RCTs may be threatened if not all randomized 
participants are included in the analysis. Exclusion of participants without any follow-up 
outcome was the most common approach among the trials in this review. Such excluded 
participants, as expected, were more prevalent in trials with a single follow-up compared 
to trials with repeated follow-ups. Trialists should therefore consider collecting interim 
measures of the outcome, which may increase the number of subjects with at least some 
outcome data, and makes an MAR assumption more plausible (Wood et al., 2004). Still, 
nearly half of trials with repeated follow-ups in this review reported early dropout after 
randomization; nearly a quarter of them had >10%. Reasons for such dropouts varied 
across trials: intervention not received/completed, absence of baseline assessment, 






















Dropout rate >10–20% 
n = 70 
n = 63 
n = 90 
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were the major reason for early dropouts. A small proportion was due to practitioners’ 
decisions such as exclusion of randomized subjects who were subsequently identified as 
not eligible. In most situations, it was rather unclear how the assigned intervention 
influenced the dropouts.  
Late dropouts in trials limit the inferences from those trials; the inferences depend on 
unverifiable assumptions about the missing data. Ninety-four percent of trials with 
repeated follow-ups had reported late dropouts; more than one-half of them had >10% 
late dropouts and a quarter had >20%. Unlike early dropouts, the late dropouts can be 
included in an analysis effectively and make the MAR assumption more plausible, since 
interim measures of outcome are available on the late dropouts. Reasons for the dropouts 
are extremely important and should be collected, since they can be used to justify the 
analysis assumptions. Trials in this review frequently reported the reasons for the late 
dropouts, but mostly failed to justify the assumptions made to impute the missing data 
based on these reasons. Subjects who dropped out for different reasons were handled 
differently in the analysis in a few trials, but this approach still may not be appropriate. For 
example, in one trial (Baerwald et al., 2010) with a late dropout rate of 24% (191/810), 
reasons for dropouts included lack of efficacy (n=63), adverse events (n=55), withdrawn 
consent (n=39), violation of eligibility criteria (n=18), lost to follow-up (n=7), and other 
unspecified reasons (n=9). The primary analysis of reduction in pain score imputed 
missing values using either the WOCF if data were missing due to a withdrawal 
attributable to a treatment related adverse event, or the LOCF if the data were missing for 
any other reason. The implicit assumption of zero reduction in pain score from the point of 
discontinuation may not be appropriate in many situations. Subjects who discontinued due 
to lack of efficacy are more likely to return to their baseline score and BOCF may be more 
sensible. In the same way, subjects’ withdrawal of consent is more likely to be associated 
with adverse events or difficulty in complying with study interventions (Gabriel & Mercado, 
2011), and hence LOCF may not be appropriate in these situations. 
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3.6.6 Analysis strategy 
In accordance with the ITT principle, most trials in the review analysed the data by the 
groups to which subjects were randomized regardless of the intervention received. 
However, many of these trials failed to measure outcome data on all randomized subjects 
and/or include all the subjects in the primary analysis. Consequently, only one-third of 
trials performed a FITT approach for the primary analysis. The proportion is comparable 
with that reported by Kruse et al. (2002) and Gravel et al. (2007); these studies examined 
the quality of RCTs published in general medical journals in 1999 and 2002, respectively. 
However, the proportion is higher than that reported by Baron et al. (2005). The lower 
proportion noted by Baron et al. (2005) may reflect changes in practice since 1994–2003, 
or may be due to their focus on trials with a particular outcome measure (structural 
outcomes in rheumatic diseases) without regard to whether or not it was a primary 
outcome. In many RCTs, secondary outcomes are less focused and less rigorously 
measured, analysed or reported (Hopewell et al., 2013), and this may explain the lower 
proportion of FITT analyses in Baron et al.’s (2005) study. An increasing number of 
guidelines (CONSORT 2001; CONSORT 2010; Food and Drug Administration, 2008) and 
endorsement of these guidelines by journals have improved the quality of reporting of 
RCTs (Turner et al., 2012), and hence may have improved the use of the ITT principle. 
Early dropouts are one of the major challenges to performing a FITT analysis. The subset 
of the FITT sample (called the PITT sample) was the analysis choice in more than one-
third of the reviewed trials with repeated follow-ups. It was clear from the CONSORT flow 
chart in the trial reports that none of the excluded subjects completed any post-baseline 
assessment; therefore, these trials were included in the PITT category in terms of early 
dropouts. It is worth noting that the descriptions on the PITT strategy (Table 3.5) did not 
include reasons for early dropout of subjects, but only indicated reasons for the exclusion 
from the analysis in many situations. For example, in table 3.5, the descriptions relating to 
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initiation of treatment, baseline assessment or post-baseline assessment did not provide 
reasons for the missing data in a trial – whether the missing outcome data resulted from 
withdrawals from the trial due to protocol violation or from loss to follow-up. Additionally, 
several previous studies have reported that PITT was inconsistently defined and the 
description did not reflect the actual analysis strategy followed (Baron et al., 2005; Gravel 
et al., 2007; Abraha & Montedori, 2010; Alshurafa et al., 2012). For example, in one trial in 
this review (Daniels et al., 2011) it was unclear why the authors defined the analysis 
sample based on a PITT description; all randomly assigned patients received at least one 
dose of study medication and had at least one post-baseline follow-up for the primary 
outcome (where no subject was excluded from the analysis) – indicating a FITT sample. 
Therefore the descriptions provided in trial reports need to be interpreted cautiously. 
Late dropouts are also a challenge to a FITT analysis. A quarter of trials with late dropouts 
excluded them from the primary analysis (i.e. a CCA was adopted). In a pragmatic setting, 
exclusion of participants in a trial may limit interpretation of findings and therefore a FITT 
is recommended (Chan et al., 2013; Heritier et al., 2003), but it is clear that most trials in 
this review chose instead to exclude participants who had dropped out, whether late or 
early. Conceptually, if the principle of analysed-as-randomized is disturbed in any way, 
and for whatever reason, the chance of an imbalance in group comparison increases. At 
worst, early dropout may be an indication of selective 'exclusion'. Such exclusions of 
dropouts with no follow-up data may be reasonable if we can assume that the process of 
exclusion is protected against biased selection of an outcome or a data-driven preference 
for a particular analysis. Such protection is afforded when the criteria for exclusion of 
participants from the analysis are pre-specified in the protocol, and are not based on 
information related either to treatment allocation or to events or outcomes that occurred 
after randomization (Heritier et al., 2003). However, such exclusions should be limited in 
order to avoid selection bias (Heritier et al., 2003). Ideally, such decisions should also be 
made by a blind or independent observer. 
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3.6.7 Baseline comparison 
Exclusion of randomized subjects can affect the baseline balance between arms achieved 
through randomization. Comparison of baseline variables between arms for those who 
were included in the analysis indicates how loss to analysis affects the randomization 
balance. Baseline-adjusted analyses are essential to control selection bias when 
imbalance exists; however, this may not remove bias due to the exclusions. In this review, 
it was noted that the baseline comparison was mostly performed on the FITT sample 
rather than the analysis sample for trials where some loss to analysis was reported. 
Twenty out of 34 and 11 out of 19 trials failed to report the baseline comparison based on 
the subjects included in the primary analysis when the loss to analysis was more than 5% 
and 10%, respectively. These trials may have failed to diagnose any imbalance between 
the intervention arms and hence not adjust for this potential bias in the analysis. For 
example, in a two-arm trial with 27% dropouts (original sample size = 158; 79 vs. 79), 
Fritsche et al. (2010) reported baseline comparison between two intervention arms for 
those initiated interventions (PITT sample, n=150; 79 vs. 71); the primary analysis did not 
adjust for potential contrast in baseline variables for those analysed (CCA sample, n=115; 
60 vs. 55). This approach may sometimes be justified, as the proportion of dropouts here 
was similar across arms; however, an equal dropout rate between arms does not 
necessarily ensure a baseline balance between arms in a CCA sample as in an ITT 
sample. Their baseline comparison failed to observe any significant difference in baseline 
variables between the two study groups. The authors also reported a dropout analysis, in 
which comparisons of baseline variables between completers and dropouts were 
performed, but this was done without considering arm-wise stratification, which would 
need to be carried out to assess systematic imbalance in dropouts between study groups. 
The dropout analysis does not help to detect whether dropouts affect the randomization 
balance; however, it can be useful in assessing the plausibility of the MCAR assumption 
(Little, 1988). In this review, 10 trials reported a dropout analysis and most used this to 
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reasonably justify that dropouts did not affect the randomization balance. Many authors in 
this review highlighted equality in dropout rate between arms, possibly indicating a 
general view that equal dropout rate between arms would not lead to a biased estimate of 
treatment effect. However, bias is a function of both the frequency of and the reasons for 
the missing values in each arm (Wright & Sim, 2003). 
3.6.8 Handling missing data 
White et al. (2012) argue that including all randomized subjects in an analysis of an 
outcome with missing data is not enough; one should consider an appropriate method to 
handle the missing data. As mentioned in the background section, the validity of such an 
analysis depends on the correctness of assumptions made about missing data, which 
cannot be completely verified in most trials. Hence, trialists should attempt to justify the 
assumption based on the observed data. Although most of the reviewed trials reported the 
method used to handle the missing data, many of them failed to justify its adoption. 
There are a few options available to account for early dropouts if baseline data are 
available, but few of them are generally valid (Wood et al., 2004) – particularly methods 
that are simple and involve a single imputation. Almost all of the trials reviewed excluded 
the early dropouts because of absence of an outcome assessment. The missing primary 
outcome values were imputed using BOCF in two trials and MI in one trial. MMRM was 
performed in one trial through considering the baseline as an outcome. 
As regards late dropouts, these were improperly handled in many trials. A CCA includes 
only those subjects with complete data on the variables included in the analysis. In trials 
with repeated follow-ups, standard statistical methods, such as ANCOVA, exclude 
dropouts and does not consider availability of measurements at interim visits. These 
methods are likely to provide a biased result, unless the mechanism is MCAR, inefficient 
estimates, that is, estimates that have wide confidence intervals through lack of precision, 
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and loss of statistical power (Molenberghs & Kenward, 2007). More than a quarter of trials 
with repeated follow-ups excluded the late dropouts from the primary analysis. The 
proportion is lower than that reported by Wood et al (2004), in which nearly half of trials 
with longitudinal measurements used a CCA as the primary analysis. Additionally, the 
preference for a CCA was higher in trials with lower dropout rates compared to trials with 
a dropout rate greater than 20%. However, it is unclear whether the researchers 
erroneously believed that exclusions do not lead to a biased inefficient estimate of 
treatment effect in trials with lower dropout rates. 
There are several single imputation strategies common in the practice of RCTs (Little & 
Rubin, 2002). Unlike CCA, single imputation methods do not exclude subjects with 
missing outcome assessment and aim to create a full dataset, which can then be 
analysed using the standard statistical methods by considering it as a real dataset. These 
methods are generally not recommended because they fail to account adequately for the 
uncertainty in the data and may produce biased estimates (Molenberghs & Kenward, 
2007). Sixty percent (44/75) of trials with repeated follow-ups in the review used some sort 
of single imputation to replace the missing values. The findings of these trials are doubtful, 
as many of these methods are not valid even under MCAR (detailed in chapter 2). 
In particular, the LOCF approach makes a very strong assumption, which is unlikely to be 
true, that the value of an outcome remains constant after dropout. This was the most 
frequently used imputation method in the review. In a retrospective analysis of 
randomized antidepressant efficacy trials published during 1965–2004, Woolley et al. 
(2009) found that the percentage of RCTs using the LOCF method had increased over 
time. Additionally, in a review of reports published in ‘Arthritis and Rheumatism’ in 2005, 
Kim (2006) reported that LOCF was the most commonly used approach to handle missing 
data. The present review also yielded a similar finding: the approach was used in nearly a 
third of the trials with late dropouts, and was more prevalent in trials with a dropout rate 
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greater than 10%. The assumption of zero change after dropout is not justifiable in most 
trials, especially in trials comparing a new treatment against a standard treatment that is 
already proven effective. Given advances in methods that require less restrictive 
assumptions than LOCF and recommendations against using LOCF (Molenberghs & 
Kenward, 2007; Lane, 2008; National Research Council, 2010), the preference for this 
method is a major concern. 
A substantial proportion of trials used imputations that require extreme assumptions; for 
example, the assumption that dropouts are ‘non-responders’ or have no change from 
baseline, without considering whether the subject was responding to treatment at the time 
of dropout. The review identified that a substantial proportion of trials used these kinds of 
imputations to replace the missing values. In 16% (12/75) of trials with late dropouts, the 
dropouts were simply classified as failure where the primary outcome was analysed on a 
dichotomous scale (“success or failure”). Additionally, in another four trials with late 
dropouts, the missing outcome data were replaced by baseline data where the primary 
outcome was analysed on a continuous scale. These imputations can sometimes provide 
useful bounds on the effect of the missing data, but this rarely produces an unbiased 
estimate of treatment effect. Additionally a few trials replaced missing values through a 
regression or linear extrapolation based imputation. Though these are based on the MAR 
assumption, use of a single imputation generally underestimates the standard error 
(Molenberghs & Kenward, 2007). 
MI has recently received substantial attention in the literature as it helps to overcome the 
limitations of single imputations for handling incomplete data in RCTs (Sterne et al., 
2009). The MI technique uses several stochastic imputations to incorporate the 
uncertainty surrounding missing values and it gives valid standard errors under MAR. A 
review of trials published during 2005–2009 in four general medicine journals (BMJ, 
JAMA, Lancet and New England Journal of Medicine) found a substantial increase in MI 
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use and reported that 9% of the trials published in 2009 used MI in some way (Mackinnon, 
2010). Despite the evidence of increasing use of MI in the analysis of RCTs, only two 
trials in this review (Beaudreuil et al., 2011; Thorn et al., 2011) performed MI-based 
analyses and reported the results. Another three trials claimed to have done MI in some 
way as a sensitivity analysis, but no details or results were reported. Moreover, trials that 
performed MI failed to report the procedure adequately. Sterne et al. (2009) suggest 
guidelines for reporting analyses based on MI to prevent potential pitfalls with its 
application and to aid interpretation of its results. The guidelines specifically endorse the 
reporting (at least as online supplements) of details of the imputation modelling including: 
details of the software used; key settings for the imputation modelling; number of 
imputations performed; list of variables included in the imputation procedure; how the 
variables were handled; and importantly plausibility of MAR assumption based on the 
variables included in the imputation model.  
Analysis methods that make use of available data on all time-points were limited to a 
small proportion of reviewed trials. FIML-based models can use all available longitudinal 
data without a need either to delete or to impute measurements. A FIML method such as 
MMRM is valid when the dropout mechanism is ignorable (Laird & Ware, 1982). Only 8% 
(6/75) of trials with late dropouts used MMRM to analyse the longitudinal outcome data 
without any imputation. Additionally, MMRM was performed after imputation of missing 
values using LOCF in two trials (Genevay et al., 2010; Fary et al., 2011), BOCF in one 
trial (Bliddal et al., 2011), and MI in another one (Thorn et al., 2011). The use of 
imputations such as LOCF and BOCF undermine the benefits of MMRM and the results 
may not be valid under MAR. Moreover, the use of MI prior to performing the MMRM is 
not necessary, as there is no obvious gain from doing so (Twisk et al., 2013). 
Semi-parametric regression-based methods such as GEE can also use all available data. 
However, a standard GEE method is valid only under an MCAR assumption (Liang & 
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Zeger, 1986). In this study, two trials with late dropouts performed the standard GEE. 
Weighted GEE, in which weight is assigned at the subject level and calculated as the 
inverse of the probability for dropping out at the observed time of dropout, or MI-based 
GEE, in which MI is used before performing GEE, is preferred over a standard GEE 
because these methods can provide a valid estimate of treatment effect under MAR 
(Birhanu et al., 2011). No trials in this study presented results based on these methods. 
3.6.9 Sensitivity analysis 
Many researchers have agreed that analysis based on an MAR assumption is a 
reasonable starting point in many RCTs (Molenberghs & Kenward, 2007; National 
Research Council, 2010; White et al., 2011). Further, since there is no established set of 
tools to evaluate and distinguish one missing data mechanism from another, one should 
always be open to the possibility that the data are MNAR. Therefore, it is important to 
evaluate the sensitivity of the results and overall conclusions of a trial to possible 
departures from the MAR assumption by assuming a range of MNAR mechanisms. There 
is no established guideline or method in this matter as this is an active area of research 
(National Research Council, 2010). However, there are recommendations to explore the 
robustness of key inferences to possible departures from the expected missing data 
mechanism (Molenberghs & Kenward, 2007; National Research Council, 2010). The 
present study found that sensitivity analyses are infrequently and inappropriately used, 
and insufficiently reported. In the present era of the internet, authors have choices to 
publish sufficient details through online supplements if there is restriction in the main body 
of reports. It is unfortunate that many trials that performed a sensitivity analysis used the 
CCA or single imputation methods as the preferred approach in the sensitivity analysis. 
The use of CCA can be justified if additional exploration of the results under MAR and 
MNAR are performed. However, this was not the situation in these trials. 
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3.7 Limitations and generalizability 
The review was restricted to trials published in a sample of high-impact factor speciality 
journals. The small number of journals evaluated may lower the generalization of the 
findings. However, the journals were from different publishers; the expectation is that 
journals from same publishers may have similar reviewing criteria. The selected journals 
were high-impact factor journals, which should bias the results towards a better 
methodology and reporting; hence, it is expected that the statistics reported here around 
appropriate use of methodology for ITT evaluation will be overstated rather than 
understated. Thus, the finding here that the minority of RCTs are performing a full ITT 
analysis (as per recommendation) is likely to be conservative; the application of this ‘gold 
standard’ evaluation method across all pragmatic trials published in MSCs may be less 
frequent (particularly in respect of publications within speciality journals in this clinical 
area). Appreciably, the largest priority publications in any clinical area are likely to be 
published in the highest impact generic journals such as Lancet and BMJ; these 
publications, though few in number, reflect the pinnacle of research in any area of clinical 
research and are likely to have greater methodological quality as they undergo more 
extensive reviewer scrutiny. Nonetheless, the focus here on speciality journals likely 
embraces the major portion of published RCTs in the area of MSCs. 
3.8 Conclusion 
It is important to take careful steps to minimize missing data in trial design and data 
collection. However, the occurrence of missing outcome data is not avoidable in the 
majority of trials. Thus, handling missing data is a major challenge when analysing trial 
data. Simple methods such as exclusion of subjects with missing data and LOCF were the 
frequently adopted approaches in handling the missing data, despite the availability of 
advanced methods and sophisticated software programmes to deal with the missing data 
more appropriately. Further, most of the trials failed to report a sensitivity analysis that 
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aimed to assess the impact on results and inferences if the assumption made on the 
missing data mechanism was wrong, i.e. by examining the robustness of the primary 
result to a range of plausible missing data assumptions. Since trials with a high proportion 
of missing data are highly sensitive to deviation from simple assumptions like MCAR, and 
the assumptions cannot be fully justified from the data, reporting of sensitivity analysis is 
crucial in these trials. 
The systematic review raises concerns over the findings because of lack of / inappropriate 
use of the ITT principle, particularly in relation to missing data handling methods. The 
review highlights a need to conduct further evaluation and comparison of the frequently 
used methods such as CCA and LOCF with relatively efficient methods such as MMRM 
and MI. Of particular relevance to this PhD is to understand the merit of the different 
approaches in respect of key statistical parameters concerned with bias, precision and 
statistical testing. The goal of the following chapters of the thesis is to perform a 
comparative evaluation and present findings in a simple and clear way within a clinically 
meaningful context that makes it accessible to non-specialists without compromising the 
theoretical framework on which it is based.  
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Chapter 4: Simulation study: an overview of design 
4.1 Introduction 
As detailed in chapter 1, the primary objective of the thesis is to examine the relative 
performance of four missing data handling approaches – complete-case analysis (CCA), 
last observation carried forward (LOCF), mixed-effects model for repeated measures 
(MMRM) and multiple imputation (MI) methods – when analysing incomplete longitudinal 
clinical trial data with continuous outcome observations in relation to: spread of data, 
correlation between repeated measurements, trajectory pattern, sample size, dropout 
rate, and missing data mechanism. To meet the objective, four simulation studies were 
performed, and detailed below: 
Study 1: This simulation study aimed to understand whether changes in data variability 
and correlation between repeated measurements affect overall accuracy of the 
missing data handling approaches. 
Study 2: This simulation study aimed to understand whether changes in trajectory pattern 
over a study period and size of treatment effect at the endpoint affect the overall 
accuracy of the missing data handling approaches. 
Study 3: This simulation study aimed to understand whether an increment in sample size 
in proportion to an expected dropout rate helps to achieve the required 
statistical power when using the missing data handling approaches. 
Study 4: This simulation study aimed to compare two strategies for handling baseline data 
in MMRM analysis. These strategies are: (i) the baseline and post-
randomization values are modelled as outcome variables and assume the 
baseline mean responses for the treatment groups are equal; and (ii) the 
baseline values are used as a covariate in the analysis of post-randomization 
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values, allowing different regression slopes. These strategies were detailed in 
chapter 2 (section 2.4.2). 
This chapter presents detailed aspects of the design of these simulation studies. 
4.2 Background 
A Monte Carlo simulation – a numerical technique for conducting experiments on a 
computer – has a vital role in evaluating statistical methods. Within such a simulation 
study, a computer draws random samples with replacement from a population with known 
population parameters. The goal of any statistical method should be to make statistically 
valid inferences about population parameters from a random sample. A statistical method 
is recommended for practical use only if it provides results that are representative of the 
population parameters. Such recommendations are usually based on evaluation of 
statistical methods through theoretical proof and/or simulation studies (simulation being 
particularly relevant in cases where theoretical explanation is difficult or impossible to 
ascertain). Simulation studies can also be used to compare the performance of two or 
more procedures for addressing the same problem. 
The evaluation of statistical methods using empirical data is limited by unknown 
population parameters: it is not possible to form valid judgements on missing values 
based on available empirical data. Hence, a legitimate comparison of missing data 
approaches cannot be performed using empirical data. In general, these simulation 
studies help to answer the following questions: (i) how do estimates of population 
parameters deviate from true values under various missing data scenarios? and (ii) how 
different are the results obtained when different missing data approaches are used? 
A simulation study to evaluate missing data methods is performed by drawing multiple 
random samples of the same size from a realistic population with known parameters. 
Missing values are imposed on these random samples according to some plausible 
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missing data properties, such as missing data rate, pattern and mechanism. Parameters 
are estimated on these samples with imposed missing data, and these are compared with 
the true population parameters. 
The design of each simulation study listed above varied somewhat depending on what 
was needed to address the question posed. A detailed description of the simulation 
procedure applied is provided below. 
4.3 Simulation procedure 
Simulations were performed using Stata version 12.0 (StataCorp, 2011). The syntax used 
for simulations are listed in appendix 3. A schematic diagram in figure 4.1 summarizes the 
main steps involved in the simulation methodology. The details are discussed below. 
4.3.1 Step 1: Generating complete datasets 
For simplicity, only the case of two-arm individually randomized clinical trials with equal 
number of subjects per arm was considered. Characteristics of the simulated data were 
similar to those of a (typical) large, phase 3, randomized clinical trial, where the primary 
outcome was measured at four time-points (baseline visit [visit 0] and three post-baseline 
visits [visit 1, visit 2 and visit 3]), and compared the effectiveness of two treatments 
(control group and experimental group) at the primary endpoint (visit 3), in the context of 
musculoskeletal conditions. The simulated outcome variable Y represents pain intensity, 
measured on a 0–100 numeric rating scale. A high score indicates greater severity of pain, 
and reduction of score over time therefore indicates an improvement in pain. 
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Figure 4.1: Schematic diagram to show the simulation procedures 
 
 
In the simulation study, 1000 datasets (i.e. 1000 iterations) were generated under a 
multivariate normal assumption with a given mean vector and an unstructured covariance 
matrix. The properties of the selected mean vector and covariance structure are described 
below. The large number of iterations was used to obtain a robust estimate of the 
population parameters; the 1000 datasets obtained on a single trial scenario were meant 
to give an accurate view of the population distribution in respect of the specific trial 
scenario. Independence of the simulated datasets within a scenario was achieved by the 
use of a Monte Carlo simulation approach. Burton et al. (2006) point out that these 
generated datasets should also be completely independent for the different scenarios 
Parameters considered
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considered. Different starting seeds were specified in the Stata simulation programme5 to 
generate the independent complete datasets for each set of parameters considered with 
the multivariate normal distribution (Burton et al., 2006). 
4.3.1.1 Choices of mean vector (means trajectory) 
Four different sets of means trajectories with three treatment effect sizes relating to 
difference in mean pain score at the primary endpoint were assumed (Figure 4.2). 
Trajectory 1 assumed both treatments improved over time. However, the treatment group 
improved more and thus resulted in a treatment benefit over time (size of the treatment 
effect at the endpoint was assumed to be −9.0). This trajectory and the size of the 
treatment effect were chosen to mimic a typical (but hypothetical) scenario in trials of 
musculoskeletal disorders in primary care. This scenario was considered for all 








                                               
5
 The Stata command used to simulate datasets is “simulate, rep(1000) seed(#): command”; where 
seed(#) sets the random-number seed. 
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Trajectory 1 with treatment effect = −9.0 
Visit 0 1 2 3 
Control 53 50 46 40 




Trajectory 2 with treatment effect = −9.0 
Visit 0 1 2 3 
Control 53 45 48 32 





Trajectory 3 with treatment effect = 0.0 
Visit 0 1 2 3 
Control 53 50 46 40 




Trajectory 4 with treatment effect = −18.0 
Visit 0 1 2 3 
Control 53 50 53 48 
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In addition, three more trajectory patterns – trajectories 2–4 – were also considered to 
address the objective of study 2 (i.e. to assess the impact of trajectory pattern and size of 
treatment effect on inferences from the missing data handling approaches). Trajectory 2 
assumed a similar treatment effect (−9.0) at the primary endpoint as in trajectory 1; 
however, the control group showed better improvement during the initial visit (visit 1) than 
the experimental group. Trajectory 3 assumed both treatments improved equally well, and 
reflected the null hypothesis that there was no difference between treatments at the 
primary endpoint (i.e. size of the treatment effect at this endpoint is zero). Trajectory 4 
assumed the experimental group improved quickly but then showed little change over 
time; however, there was minor improvement in the control group and a treatment effect of 
−18.0 at the primary endpoint was assumed in favour of the experimental group. 
4.3.1.2 Choices of unstructured covariance matrix 
The extent of correlation between repeated measurements may vary widely across 
different RCTs. Similarly, the degree of data variability is likely to differ considerably 
across studies. Such differences are likely to arise from a variety of factors such as the 
type of outcome being measured. Hence, it is important to consider a range of covariance 
matrices to reflect the possible variation in data across studies. I used six covariance 
matrices – one in each scenario: weak correlation with low SD (WL), moderate SD (WM) 
and high SD (WH); strong correlation with low SD (SL), moderate SD (SM) and high SD 
(SH). The correlation and SD matrices are listed in table 4.1. The defined variance-
covariance matrices were based on, and similar in structure to, reported publications that 
were included in the systematic review in chapter 3. In keeping with the variance-
covariance patterns observed in the systematic review, the assumed covariance matrices 
exhibit parameters that reflect the variance of the outcome variable increasing across time 
and the correlation diminishing as the time-lag increases. 
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Table 4.1: Correlation and SD matrices for simulation scenarios 
Correlation matrices 
1. Weak 2. Strong 
t0 t1 t2 t3
t0 1
t1 0.45 1
t2 0.39 0.41 1
t3 0.30 0.34 0.40 1  




0.54 0.59 0.66 1  
 
Standard deviation (SD) matrices 


















4.3.1.3 Sample size calculation 
In general, sample size calculation was carried out based on an ANCOVA model – which 
may considerably reduce the number of subjects required for an RCT in comparison with 
the calculation based on t-test. The extent of reduction in the overall sample size is 
directly associated with the amount of correlation between baseline and endpoint data 
(Borm et al., 2007). Given the true treatment effect of −9.0 at the endpoint and various 
covariance patterns, the number of subjects per group required to detect the true 
difference with 90% power and 5% type 1 error rate is given in table 4.2. However, for 
simulations in study 2 – effect of trajectory patterns and the size of treatment effect – a 
fixed sample size of 60 per group across the trajectories was used in simulations. 
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Table 4.2: Calculated sample size under various covariance patterns 
True treatment effect 
Correlation between 
baseline and endpoint 
SD at endpoint 
Sample size per 
group 
−9.0 Weak Low 37 
  Moderate 75 
  High 168 
 Strong Low 30 
  Moderate 60 
  High 130 
 
 
One commonly used approach to account for loss of power due to dropouts in hypothesis 
tests or confidence intervals is to inflate the sample size in proportion to the anticipated 
dropout rate. Hence, to evaluate the effect of the ad hoc approach used for the sample 
size calculation, simulation study 3 was performed using trajectory 1 and the WM 
covariance matrix with sample size provided in table 4.3. In this simulation study, datasets 
with a sample size not inflated for expected dropout rate – as used with other simulation 
studies – were compared against datasets with a sample size inflated for dropouts. The 
study was replicated under four scenarios: combinations of dropout rates (10% and 30%) 
and desired statistical power (80% and 90%) in the absence of dropouts. This simulation 
study is intended to illustrate how an increase in sample size protects against the loss of 
power due to dropouts. 
Table 4.3: Sample size used for study 3 – effect of sample size 
# Dropout rate 
Inflated for 
dropouts 
Sample size per group
1
 
80% power in the 
absence of dropouts 
90% power in the 
absence of dropouts 
1 10% No 57 75 
2 Yes 63 84 
3 30% No 57 75 
4 Yes 81 108 
1
For a given WM covariance matrix 
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4.3.2 Step 2: Generating missing data 
From the complete datasets, incomplete datasets were created by using some pre-
specified deletion criteria. In all datasets, baseline measurements were complete for all 
subjects. In most longitudinal RCTs, the majority of missing data are caused by subjects 
discontinuing the trial prior to the primary endpoint. In such cases, the resulting missing 
data have a monotone pattern, meaning that once a subject has a missing observation for 
some visit, data will be missing for all subsequent visits. Typically, however, in practice 
there will be some small amount of non-monotone missing data (when subjects skip 
intermediate visits but returns for evaluations at subsequent visits). However, in an 
endpoint analysis, the major concern is whether the outcome has been observed at the 
primary endpoint. Hence, for simplicity, only a monotone missing data pattern was 
considered for the simulation studies. The monotone missing data pattern was imposed 
according to predefined dropout rates at each visit and in respect of a variety of assumed 
dropout mechanisms. 
4.3.2.1 Choices of dropout rates 
I considered a series of overall dropout rates with equal and unequal dropout rate 
between study groups. The selection was generally based on findings of the systematic 
review in chapter 3; the review identified that around 60% of studies had more than 10% 
and 15% had more than 30% dropouts at their primary endpoint. The percentages of 
missing data imposed on the simulation studies are summarized in table 4.4. The baseline 
(visit 0) measurement was assumed to be always observable; however, situations where 
some subjects had no post-baseline data were considered. All the studies were mainly 
centred on 10% and 30% dropout rate; however, MNAR situations were further explored 
with 20%, 40%, and 50% dropout rates. The use of a range of dropout rates – low to high 
– helps to assess the impact that level of dropout rates, whether equal or unequal 
between study groups, has on estimation of treatment effect. 
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rates (EQ)  
Higher dropout in 
experimental group (HE)  
Higher dropout in 
control group (HC) 
t0 t1 t2 t3 
 
t0 t1 t2 t3 
 
t0 t1 t2 t3 
10% Control 0 2 6 10 
 
0 2 4 6 
 
0 4 8 14 
 
Experimental 0 2 6 10 
 
0 4 8 14 
 
0 2 4 6 
20% Control 0 4 10 20 
 
0 4 8 14 
 
0 8 16 26 
 
Experimental 0 4 10 20 
 
0 8 16 26 
 
0 4 8 14 
30% Control 0 10 20 30 
 
0 5 15 20 
 
0 10 25 40 
 
Experimental 0 10 20 30 
 
0 10 25 40 
 
0 5 15 20 
40% Control 0 10 20 40 
 
0 10 20 30 
 
0 15 30 50 
 
Experimental 0 10 20 40 
 
0 15 30 50 
 
0 10 20 30 
50% Control 0 10 25 50 
 
0 10 25 40 
 
0 15 30 60 
 
Experimental 0 10 25 50 
 
0 15 30 60 
 
0 10 25 40 
 
 
4.3.2.2 Dropout mechanism 
Dropout rates, as listed in table 4.4, were imposed based on various dropout 
mechanisms: missing completely at random (MCAR); missing at random dependent on 
baseline data (MAR-B; where an observation that triggered a dropout was a baseline 
observation) or last observed outcome value (MAR-L; where an observation that triggered 
a dropout was a last observed value); and missing not at random (MNAR; where an 
observation that triggered a dropout was the observation itself). The MAR and MNAR 
dropout mechanisms were implemented under two quite contrasting situations to fully 
understand the robustness of the results under the considered missing data handling 
approaches. The observations at a time-point that triggered dropouts were a random 
selection within upper or lower  th percentile (where   = dropout rate at the endpoint plus 
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20%) of the observations at that time-point, depending on the following situations6. In the 
first situation, the dropouts were constrained to be in the same direction in both of the 
treatment groups whereby the same reasons for dropout generally applied across the 
groups. In this situation, subjects who had performed poorly (subjects with high values) 
were randomly dropped from both the control and the experimental group. In the second 
situation, the dropouts were in opposite directions across the groups in the sense that 
the reason for dropout was allowed to differ between the groups. In this situation, subjects 
who had performed poorly in the control group and well in the experimental group were 
randomly dropped. Admittedly, these situations are deliberately quite extreme since the 
interest is in evaluating possible large-scale impact and deviation in treatment response 
through differential and skewed dropout mechanisms. These situations were chosen to 
provide a more telling picture of what happens under various missing data situations, 
since one cannot predict what would have been the situation in a real incomplete dataset. 
Detailed descriptions of the dropout mechanisms are given below. 
4.3.2.2.1 MCAR 
In the MCAR dataset, all missing outcome values were selected randomly from the 
complete dataset. 
4.3.2.2.2 MAR-B1 
In the first MAR dataset (MAR-B1), absences at different time-points were selected in 
each group randomly from a subpopulation for which baseline values were higher than  th 
percentile of the baseline variable; where   is equal to: 100 – (dropout rate + 20%). In this 
                                               
6
 A similar strategy of implementing dropout rates based on a cut-off value was reported in a few 
publications (Hedeker & Gibbons, 2006; Enders & Gottschall, 2011) 
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dropout mechanism, a random sub-sample of subjects with higher baseline values was 
dropped from both the control and experimental groups.  
4.3.2.2.3 MAR-B2 
In the second MAR dataset (MAR-B2), absences at different time-points were selected 
randomly from a subpopulation for which baseline values were higher than the  th 
percentile of the baseline variable in the control group and lower than the  th percentile of 
the baseline variable in the experimental group; where   is equal to dropout rate plus 
20%. In this dropout mechanism, a random sub-sample of subjects with high baseline 
values from the control group and another random sub-sample of subjects with low 
baseline values from the experimental group were dropped.  
4.3.2.2.4 MAR-L1 
In the third MAR dataset (MAR-L1), absences at different time-points ( ) were selected in 
each group randomly from a subpopulation for which values of the outcome variable   
measured at time  -  were higher than the  th percentile of   at time    . In this dropout 
mechanism, a random sub-sample of subjects with high last observed outcome values 
were dropped out from both the control and the experimental groups.  
4.3.2.2.5 MAR-L2 
In the fourth MAR dataset (MAR-L2), absences at different time-points were selected 
randomly from a subpopulation for which values of the outcome variable   measured at 
time     were higher than the  th percentile of   at time     in the control group and 
lower than the  th percentile of   at time     in the experimental group. In this dropout 
mechanism, subjects with high last observed outcome values were randomly dropped 
from the control group and subjects with the low values from the experimental group. 
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4.3.2.2.6 MNAR-1 
Regarding MNAR, two datasets were created based on deletion restrictions. In the first 
MNAR dataset (MNAR-1), absences at different time-points were selected in each group 
randomly from a subpopulation for which values of the outcome variable   measured at 
time   were higher than the  th percentile of   at that time-point. Here the eliminated 
observations represent a random sub-sample of high values for the outcome variable at 
that particular time-point in both the control and experimental groups.  
4.3.2.2.7 MNAR-2 
In the second MNAR dataset (MNAR-2), observations were eliminated for subjects with 
high values in the control group and subjects with low values in the experimental group. In 
this dropout mechanism, absences at different time-points were selected randomly from a 
subpopulation for which values of the outcome variable   measured at a time   was higher 
than the  th percentile of   at that time-point in the control group and lower than the  th 
percentile of   at that time-point in the experimental group. 
4.3.3 Step 3: Imputation and analysis methods 
As detailed in chapter 1, the objective of the thesis is to compare the missing outcome 
data handling approaches in longitudinal trials, and the following approaches were 
considered:  
 CCA, where no imputation was performed and the data were analysed using i.
ANCOVA7 with the outcome at the endpoint as a response variable and baseline 
                                               
7
 The Stata command used to estimate the treatment effect at the endpoint is: regress y3 i.group 
baseline, where y3 is the outcome at the primary endpoint. 
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score as a covariate. This method excludes subjects with missing data (i.e. listwise 
deletion).  
 MMRM8 with baseline score as a covariate, in which no imputation was performed. ii.
The baseline-as-covariate model included baseline-by-time interactions to allow for 
different regression slopes. Kenward et al. (2010) recommend restricted maximum 
likelihood (REML) estimation in conjunction with the MMRM model. The within-
subject error was modelled using an unstructured variance-covariance pattern. 
 LOCF-based ANCOVA analysis, where missing outcome values were replaced by iii.
the last observed value and then analysed using an ANCOVA model. 
 Multiple imputation, as implemented in Stata (mi command)9, was used to create iv.
multiple, say  , complete datasets from the simulated missing data. These   
complete datasets were analysed independently using an ANCOVA model. 
Estimates of parameters of interest were averaged across the m copies to give a 
single estimate. Standard errors were computed according to the “Rubin rules” 
(Rubin, 1987) to incorporate additional uncertainty due to the missing data. These 
steps were performed using the Stata mi estimate10 command. As a rule of thumb, 
Bodner et al. (2008) and White et al. (2011b) suggested the number of 
                                               
8
 The Stata command used to estimate the treatment effect at the endpoint is: xtmixed y 
i.time##c.baseline i.rand1 i.rand2 i.rand3 if time>0 || id:, reml nocons res(uns, t(time)); where 
rand1, rand2, and rand3 are the interaction terms defined as (group==1)*(time==1), 
(group==1)*(time==2), and (group==1)*(time==3) respectively. The term ‘reml’ indicates the usage 
of restricted maximum likelihood method for the estimation of parameters; the term ‘nocons’ used 
to suppress random intercept term from the random-effects equation; and the term ‘uns’ used to 
specify the unstructured covariance structure. 
 
9
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imputations,  , should parallel the percentage of subjects with missing data. For 
example, with 30% dropout rate,   should be 30. 
In the study 4, I compared a variant of MMRM (by considering the baseline as an 
outcome11, in which baseline data was included as part of the outcome variable and the 
baseline mean responses for the treatment groups were assumed to be equal) with the 
approach given in (ii), whereby baseline data was considered a covariate. Both models 
were evaluated using the Stata xtmixed command where adjustment for small samples 
[e.g. Kenward-Roger correction (Kenward & Roger, 1997) in SAS proc mixed] is not 
implemented. However, a comparison of these models with and without the Kenwrad-
Roger correction using SAS proc mixed was performed. 
4.4 Measures of performance 
Quantities used to assess the performance of various missing data strategies were bias, 
accuracy, coverage probability, width of confidence interval, and statistical power. Details 
of these measures are presented below.  
4.4.1 Bias  
Bias is defined as the difference between the average value of estimated treatment effects 
over the simulation repetitions and the true parameter for treatment effect (i.e. raw bias = 
true parameter − average estimate of the parameter). Negative bias indicates 
underestimation of treatment effect and positive bias indicates overestimation of treatment 
effect. The raw bias, percentage bias (bias as a percentage of the true parameter) and 
standardized bias (bias as a percentage of SD of the parameter) are recommended 
assessments of bias (Burton et al., 2006). However, the raw bias was reported because 
                                               
11
 xtmixed y i.time i.rand1 i.rand2 i.rand3 || id:, reml nocons res(uns, t(time)) 
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the main objectives of the thesis includes the effect of size of the true parameter (study 2), 
where percentage bias would not be an appropriate measure, and the effect of size of the 
uncertainty in parameter estimates (study 1), where standardized bias would not be an 
appropriate measure of bias. 
4.4.2 Overall accuracy of the estimate 
Bias and variance of an estimate are often combined into a single measure called mean 
squared error (MSE) as a measure of overall accuracy of the estimate (Burton et al., 
2006). It is the average of squared difference between the estimated treatment effects ( ̂) 
and the true parameter (β) over repeated samples. MSE is equal to the sum of the 
variance and the squared bias of the estimated treatment effect. For easier interpretation, 
the square root of the MSE – root-mean-square error (RMSE) – is reported, to place it on 
the same scale as the parameter (Collins et al., 2001). 
4.4.3 Coverage of confidence interval 
The actual coverage of the nominal 95% CI of the estimated treatment effect is the 
proportion of time that nominal intervals contain the true treatment effect across all 
simulation replications. Since the 95% CI aims to contain the true treatment effect with a 
probability of 0.95, actual coverage should be approximately equal to the nominal 
coverage of 95% if the missing data strategy works well. A coverage larger than 95% 
indicates too wide (imprecise) CIs whereas a coverage smaller than 95% indicates too 
narrow (too precise) CIs. Over-coverage suggests the results are too conservative, as 
more simulations will fail to find a significant result when there is a true treatment effect, 
thus leading to loss of statistical power with too many type II errors (Burton et al., 2006). In 
contrast, under-coverage is unacceptable as it indicates over-confidence in the estimates, 
since more simulations will incorrectly detect a significant result, which leads to larger than 
expected type I errors (Burton et al., 2006). Burton et al. (2006) suggest that an observed 
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coverage falling inside the interval 93.6%—96.4%12 is considered to be an acceptable 
coverage of the nominal 95% CI. If the coverage is accurate, the probability of type I error 
(wrongly rejecting a true null hypothesis) will also be accurate (Burton et al., 2006; Collins 
et al., 2001).  
4.4.4 Average width of confidence interval 
Subject to correct coverage, a confidence interval of an estimate of a treatment effect 
should be narrow, because a shorter interval will reduce the probability of type II error 
(failure to accept a true alternative hypothesis). Therefore, if one method has a similar or 
higher coverage probability than another, but yields substantially narrower CIs, then it 
should be preferred (Collins et al., 2001).  
Average width of CI   ∑
   
   
 
    
      ̂
 
 
   ,   is the number of repetitions
13 
4.4.5 Statistical power 
The empirical power is calculated as the proportion of simulation samples in which the null 
hypothesis of no effect is rejected at the 5% two-tailed nominal significance level when the 
alternative hypothesis is true (Burton et al., 2006). As noted in section 4.3.1.3, simulations 
under study 1 were planned to have a 90% nominal statistical power to detect the true 
treatment effect in the absence of missing data, while study 3 aimed to determine the size 
of the sample required to achieve 90% empirical power in the presence of missing data. 
Note that study 2, which aimed to understand the effect of the size of the treatment effect 
                                               
12
 SE of the nominal coverage probability ( ), SE( )=√       ⁄ ; where   is the number of 
repetitions. 
13
 xtmixed command in Stata does not compute   ; it assumes  -distribution instead of  -
distribution. 
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and trajectory pattern, does not report the empirical power since the scenarios under this 
study were a mixture of true null and true alternative hypotheses. 
4.5 Summary of simulation scenarios 
Under study 1, 252 scenarios were evaluated for a given mean vector, as summarized in 
table 4.5: 
Table 4.5: Simulation scenarios under study 1 

















 Equal between 
groups (EQ) 
 High in 
experimental 
group (HE) 














*Additional explorations with 20%, 40%, and 50% dropout rates under MNAR were performed; 
†
MAR dependent on baseline value; 
‡
MAR dependent on last observed value; 
#
not valid for MCAR. 
 
 
Under study 2, 84 scenarios were evaluated for a given moderate SD and strong 
correlation, as summarized in table 4.6: 
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Table 4.6: Simulation scenarios under study 2 








 Trajectory 1 with true 
treatment effect of −9.0 at 
the endpoint 
 Trajectory 2 with true 
treatment effect of −9.0 at 
the endpoint 
 Trajectory 3 with true null 
effect at the endpoint 
 Trajectory 4 with true 
treatment effect of −18.0 
at the endpoint 
 30%  Equal between 
groups (EQ) 
 High in 
experimental 
group (HE) 















MAR dependent on baseline value; 
‡
MAR dependent on last observed value; *not valid for MCAR. 
 
Under study 3, 168 scenarios were evaluated for a given mean vector, moderate SD and 
weak correlation, as summarized in table 4.7: 
Table 4.7: Simulation scenarios under study 3 










 Not adjusted for 
dropout 






 Equal between 
groups (EQ) 
 High in 
experimental 
group (HE) 















MAR dependent on baseline value; 
‡
MAR dependent on last observed value; *not valid for MCAR. 
 
 
Under study 4, 42 scenarios were evaluated for a given mean vector, moderate SD and 
strong correlation, as summarized in table 4.8: 
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Table 4.8: Simulation scenarios under study 4 








 Baseline as part of an 
outcome vector 
 Baseline as a covariate 
 30%  Equal between 
groups (EQ) 
 High in 
experimental 
group (HE) 















MAR dependent on baseline value; 
‡
MAR dependent on last observed value; *not valid for MCAR. 
 
4.6 Discussion and conclusion 
To address the objectives of the thesis, four simulation studies were planned, and 546 
scenarios were explored. Among the four simulation studies, the first three were focused 
on the comparison of performance of CCA, LOCF, MMRM and MI in relation to 
missingness properties (i.e. overall dropout rate, dropout rate between groups, dropout 
mechanism, and direction of dropouts) along with complete data characteristics (i.e. 
correlation between repeated measurements and data variability, means trajectory, and 
sample size). The remaining simulation was used to assess the robustness of estimates in 
respect of different approaches to analysis in MMRM. Little and Rubin (2002) point out 
that the degree of bias and imprecision depends on the extent to which complete and 
incomplete cases differ and on the parameters of interest, in addition to the proportion of 
missing data and the type of missing data mechanism. As noted in the literature review 
(Chapter 2, section 2.4.2), most previously reported simulation studies that compared 
missing data approaches did not explore the impact of factors other than the proportion of 
missing data and the missing data mechanism. In the present simulation study, I 
additionally considered the effect of deviation in mean trajectory, data variability, 
correlation between repeated measurements, dropout rate between groups (equal vs. 
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unequal), and direction of dropouts. In fact, apart from information on sample size, the 
overall dropout rate and dropout rate between groups, other information on the data 
(actual estimates of correlation, SD, and mean; dropout mechanism; direction of dropouts) 
are unknown when some missing data is present. However, the present simulation 
provides an expected range of deviation around the true parameters, nominal coverage 
probability and nominal power under the studied missing data approaches. 
For the purpose of these simulation studies, focus is limited to analysis of a single 
continuous variable measured over time with monotone missingness. In RCTs, outcome 
data are usually measured at more than one follow-up; however, the aim of these trials is 
usually limited to comparing the effect of two or more treatments at a specific time-point 
(Verbeke & Molenberghs, 2005). Unless it is important to know how study participants 
have reached the study endpoint, a simple comparison of the treatment groups at the 
primary endpoint is often recommended and adequate to demonstrate the treatment 
effect, if any (European Medicines Agency, 2006; Verbeke & Molenberghs, 2005). As 
noted in the systematic review, nearly 90% of trials measured outcome in a longitudinal 
fashion; all of them limited the assessment of the treatment effect to the primary endpoint. 
Therefore, the simulation study was restricted to the endpoint analysis and did not assess 
the growth factor. 
The trajectory profiles, which were considered in this simulation, represent a situation 
where reduction in baseline score indicates an improvement; hence, a negative sign in 
treatment effect indicates that reduction in score was greater in the experimental group 
than in the control group. The reason for this choice is that most outcomes in 
musculoskeletal trials (and therefore of interest within the Arthritis Research UK Centre) 
are such that a treatment effect implies decrease in baseline score. For example, pain 
scales, depression/anxiety scales, disability scales are usually scored so that low scores 
(often 0) denote no pain, no depression/anxiety, or no disability, whereas the highest 
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scores denote maximum pain, highest depression/anxiety or most severe disability. 
Hence, patients present with high scores (denoting increased severity of the condition) 
and the goal of the treatment is to lower the score. In bias estimation of treatment effect, 
based on the trajectory patterns considered, a negative bias therefore denotes an 
underestimation of the treatment effect and a positive bias denotes an overestimation of 
the treatment effect.  
A range of summary statistics were considered for the simulation parameters – means, 
SDs, and correlation between repeated measurements – to understand the impact of 
these parameters (in study 1 and 2) on bias and loss of precision under the studied 
missing data approaches. In particular, study 1 evaluates the impact of SD and correlation 
on bias and loss of precision in the presence of missing data. A ‘moderate SD’ was 
chosen in order to ensure a moderate effect size (~0.5 with a treatment effect of −9.0) at 
the primary endpoint; thereafter, a weak and a high SD were defined in relation to the 
moderate SD. Additionally, two plausible correlation structures for association between 
repeated measurements (strong and weak) were considered – and have been used in a 
previous study by Siddiqui et al. (2009). Study 2 was planned in order to evaluate the 
effect of mean trajectories with the same treatment effect at the primary endpoint 
(trajectories 1 and 2 with treatment effect −9.0) and the effect of mean trajectories with 
different treatment effect at the endpoint (trajectories 1, 3 and 4 with treatment effects 
−9.0, 0 [no effect] and −18.0 respectively). 
In practice, there is no way to ascertain missing values with certainty. Thus, it is 
necessary to make assumptions, which are often unverifiable in an incomplete data, about 
the missingness. It is crucial, therefore, to assess the performance of methods to deal with 
missing data in relation to a variety of scenarios – especially under quite contrasting 
scenarios – in order to understand the robustness of the results under the missing data 
handling approaches to the extreme situations and to aid interpretation of findings from an 
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incomplete dataset. In this simulation study, monotone missing data were generated with 
pre-specified dropout rates with equal and unequal dropout rate between groups – one 
with a higher dropout rate in the experimental group and another with a higher dropout 
rate in the control group – under the four missing data mechanisms: MCAR, MAR-B, 
MAR-L and MNAR. The difference between complete and incomplete data becomes 
substantial when the missing data mechanism changes from MCAR towards MNAR. 
Further, the MAR and MNAR dropout mechanisms were implemented under two quite 
contrasting scenarios. In the first scenario, dropouts were in the same direction in both 
study groups – dropouts were a random sub-sample of subjects who did poorly at 
baseline, at the last follow-up and the time at which they were dropped out under MAR-
B1, MAR-L1 and MNAR-1 respectively. In the second scenario, dropouts were in opposite 
directions between study groups – dropouts were a random sub-sample of subjects who 
did poorly in the control group and those who did well in the experimental group at 
baseline, at the last follow-up and the time at which they were dropped out under MAR-
B2, MAR-L2 and MNAR-2 respectively. Further scenarios contrasting to the scenarios 
listed above – (i) dropouts were subjects who did well in both study groups; (ii) subjects 
who did well in the control group and those who did poorly in the experimental group – 
were also explored and detailed in appendix 4 (Tables 1 and 2). The dropout scenarios 
were constructed so as to evaluate the direction and magnitude of the performance 
indicators – bias, coverage and power – of the missing data handling methods 
considered. 
In an endpoint analysis, an important consideration is whether an outcome was measured 
at baseline and the primary endpoint. As detailed in chapter 2, a standard ANCOVA does 
not take into account the intermediate outcome measurements, and an MMRM model (to 
estimate the treatment effect at the endpoint) is less likely to be influenced by the 
intermediate outcome when the number of intermediate outcome assessments is small 
and when the outcome is measured at the endpoint. Simulated datasets with intermittent 
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missing values could have been used without altering the main point because either a 
standard ANCOVA (with no imputation of missing values), LOCF imputation, MI, or an 
MMRM model (with no imputation of missing values) was specified in order to assess 
treatment effect at the primary endpoint. Further, the motivation for the dropout setting is 
that monotone patterns are easier to address compared to arbitrary patterns of missing 
data; the computations needed to handle them are less cumbersome, and mechanisms 
producing them are easier to conceptualize and model. Dropout is often the dominant type 
of missingness in longitudinal studies, which partially explains why so many articles 
concerning dropout have recently appeared in statistics and biostatistics journals. 
The relative performance of the methods – CCA, MMRM, LOCF and MI – was assessed 
in each scenario using performance indicators: (a) raw bias in estimate of treatment effect; 
(b) root-mean-square error; (c) coverage probability of 95% CI; (d) average width of the 
95% CI; and (e) statistical power. Study 1 results are presented in chapter 5; the results of 
the remaining studies (study 2–4) are presented in chapter 6. 
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Chapter 5: Simulation study - findings 1 
5.1 Introduction 
This chapter presents the results of the simulation study 1 (detailed in chapter 4) that was 
designed to examine the relative performance of four missing data handling approaches – 
complete-case analysis (CCA), last observation carried forward (LOCF), mixed-effects model 
for repeated measures (MMRM) and multiple imputation (MI) methods – when analysing 
incomplete longitudinal randomized clinical trial (RCT) data under four missing data 
mechanisms: missing completely at random (MCAR), missingness dependent on baseline 
value (MAR-B), missingness dependent on last observed value (MAR-L), and missing not at 
random (MNAR). Analysis of covariance (ANCOVA) was used in conjunction with CCA, 
LOCF and MI; a baseline-as-covariate model was specified with MMRM. The comparison 
was in respect of various levels of experimental conditions typical of an RCT: levels of data 
variability, levels of correlation between repeated assessments, levels of dropouts, equal and 
unequal dropout rate between groups, and missing data mechanisms. As stated in the 
introduction chapter, the goal of this simulation study is to answer the following research 
questions: 
 Within and across the missing data handling approaches, does the accuracy (in terms i.
of bias and precision) of the estimate of treatment effect at the primary endpoint vary 
by data variability, correlation between repeated assessments, and proportion of 
dropouts between groups, in addition to overall dropout rate and missing data 
mechanism? 
 Within and across the missing data handling approaches, does the coverage and ii.
width of the confidence interval for the estimate of treatment effect at the primary 
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endpoint vary by data variability, correlation between repeated assessment, and 
proportion of dropouts between groups, in addition to overall dropout rate and missing 
data mechanism? 
 Within and across the missing data handling approaches, does the statistical power to iii.
detect the true treatment effect at the primary endpoint vary by the spread of data, 
correlation between repeated assessment, and proportion of dropouts between 
groups, in addition to overall dropout rate and missing data mechanism? 
It should be noted that simulation results, which are presented in this chapter, were based on 
a trajectory profile (trajectory 1; section 4.3.1.1 in chapter 4) with a treatment effect of −9.0 at 
the primary endpoint (i.e. at fourth visit). The effect of levels of trajectory profile and levels of 
treatment effect will be presented in chapter 6. The trajectory profiles that were considered in 
this thesis represent a situation where reduction in baseline score indicates an improvement 
(e.g. pain score); hence, a negative sign in treatment effect indicates that reduction in score 
was more in the experimental group than in the control group. 
To understand the effect of data variability and correlation between repeated assessments on 
the relative performance of the missing data handling approaches, six unstructured variance-
covariance matrices (WL, WM, WH, SL, SM, and SH) were considered, as detailed in chapter 
4, with combinations of three SD matrices – low (L), moderate (M) and high (H) – and two 
correlation matrices – weak (W) and strong (S). Although the selection of the moderate SD 
ensured an effect size of approximately 0.5 at the endpoint (with a treatment effect of −9.0), 
the classification of SD matrices was purely based on the magnitude of the SDs. However, 
the classification of correlation matrices was based on whether the magnitude of correlation 
was close to zero (i.e. no correlation) or one (i.e. perfect correlation). Sample sizes were 
calculated in order to ensure 90% nominal power in all considered scenarios when there is no 
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missing data. Throughout, results are presented on all six levels of the variance-covariance 
structures. 
As detailed in chapter 4, monotone missing data were generated with pre-specified dropout 
rates with equal and unequal dropout rate between groups – higher in the experimental group 
or higher in the control group – under the four missing data mechanisms: MCAR, MAR-B, 
MAR-L and MNAR. The MAR and MNAR dropout mechanisms were implemented under two 
quite different situations to help ascertain the robustness of the results to extremely 
contrasting situations. In the first situation, dropouts were in the same direction in both groups 
(the corresponding missing data mechanisms are denoted as MAR-B1, MAR-L1 or MNAR-1). 
In this situation, the value of an observation at a time-point that triggered dropout is higher 
than a threshold value corresponding to the  th percentile of observations at that time-point in 
both control and experimental group; where                                . In the 
second situation, dropouts were in opposite directions between the groups (the 
corresponding missing data mechanisms are denoted as MAR-B2, MAR-L2 or MNAR-2). In 
this situation, the value of an observation at a time-point that triggered dropout is higher than 
a threshold value corresponding to the  th percentile of observations at that time-point in the 
control group and lower than an another threshold value corresponding to the  th percentile of 
observations at that time-point in the experimental group; where                       . 
In the following sections, I present the simulation results to address the accuracy, CI 
coverage and width, and statistical power of CCA, LOCF, MMRM and MI under various 
scenarios within each missing data mechanism. Section 5.2 presents the accuracy of the 
missing data handling methods in respect of research question 5.1-i, section 5.3 presents the 
CI coverage and width of the methods in respect of research question 5.1-ii, and section 5.4 
presents the empirical power of the methods in respect of research question 5.1-iii. The 
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results are presented in graphs, and the corresponding tables are listed in appendix 5 (Tables 
3–22). 
5.2 Bias and precision 
In this section, the simulation results are presented in terms of raw bias (i.e. true treatment 
effect minus observed treatment effect) and RMSE under various scenarios within each 
missing data mechanism. A negative bias indicates an underestimation of treatment effect at 
the endpoint, and a positive bias indicates an overestimation of treatment effect at the 
endpoint. RMSE is reported as a measure of overall accuracy of the estimate of treatment 
effect; this measure combines the bias and variance of the estimate. The RMSE for the data 
without missing values ranged from 2.67–2.81 across the six variance-covariance matrices 
irrespective of ANCOVA or MMRM. In the following four subsections, the results are 
presented under each of the four missing data mechanisms. 
5.2.1 Bias and RMSE under MCAR 
Figure 5.1 displays the bias in estimates of treatment effect for each of the missing data 
handling methods under equal and unequal dropout rate between study groups. CCA, MMRM 
and MI gave unbiased estimates of treatment effect irrespective of 10% or 30% dropout rate, 
equal or differential dropout rate between groups, level of data variability and level of 
correlation between repeated assessments. However, LOCF produced biased estimates of 
treatment effect even with 10% dropouts; the bias ranged from −2.4 to 0.6. Further, the level 
of bias increased with an increase in the level of dropout; with 30% dropout rate, the bias 
ranged from −4.5 to 0.6. Since the improvement in baseline score (i.e. reduction) was higher 
in the experimental group, the assumption of no change after dropout has a significant effect 
on the estimate in the experimental group compared to the control group. Therefore, as 
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expected, LOCF led to underestimation of the treatment effect under the scenarios of equal 
or higher dropout rate in the experimental group and overestimation under the scenarios of 
higher dropout rate in the control group. 
Figure 5.2 displays the RMSE of the estimates of treatment effect for each of the missing 
data handling methods under equal and unequal dropout rate between groups. CCA, MMRM 
and MI exhibited similar RMSE in this simulation study irrespective of level of dropout rate, 
equal or differential dropout rate between groups, level of data variability and level of 
correlation between repeated assessments. However, in all these methods, RMSE increased 
with an increase in the level of overall dropout rate. RMSEs under LOCF were not consistent 
across the considered scenarios. LOCF overestimated the RMSE in respect of higher dropout 
rate in the experimental group, and the deviation from its true value was substantial at 30% 
dropout rate. Further, LOCF underestimated the RMSE in respect of higher dropout rate in 
the control group, and the deviation from its true value increased with higher level of overall 
dropout rate. When the dropout rate was 10% and equal between groups, RMSE was similar 
to the corresponding value in data without missing values; however, with 30% dropout rate, it 
was slightly overestimated. 
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5.2.2 Bias and RMSE under MAR dependent on baseline value (MAR-B) 
As noted before, the MAR-B mechanism was simulated under two very contrasting situations: 
(i) dropouts were in the same direction in both groups – participants with a high baseline 
score in each group were randomly dropped out (denoted as MAR-B1); (ii) dropouts were in 
opposite directions between the groups – participants with a high baseline score in the control 
group and those with a low score in the experimental group were randomly dropped out 
(denoted as MAR-B2). This simulation study found that the accuracy (in terms of bias and 
RMSE) of all the methods under MAR-B1 was similar to the situation under MCAR. 
Figure 5.3 displays the bias in estimates of treatment effect for each of the missing data 
handling methods under equal and unequal dropout rate between groups. All approaches 
except LOCF were accurate in estimating the true treatment effect irrespective of level of 
dropout rate, equal or unequal dropout rate between groups, level of data variability, and level 
of correlation between repeated assessments in addition to, importantly, the direction of 
dropouts – whether it was in the same or opposite direction. With LOCF, the bias in estimates 
of treatment effect at the endpoint was substantial in most scenarios. However, the bias was 
not consistent across the scenarios; the absolute degree of bias (whether underestimation or 
overestimation) was dependent on the imbalance in dropout rate between groups. Further, 
the trend was stronger when the dropouts were in opposite directions between the groups 
and the data variability was high. The bias ranged from −2.4 to 1.8 with 10% dropout rate and 
from −5.1 to 3.4 with 30% dropout rate. 
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Figure 5.4 displays the RMSE of the estimates of treatment effect for each of the missing 
data handling methods under equal and unequal dropout rate between groups. With 10% 
dropout rate, RMSE of the estimates under CCA, MMRM and MI were almost 
indistinguishable, but slightly overestimated compared to data without missing values, 
irrespective of equal or unequal dropout rate between groups, direction of dropouts, level of 
data variability, and level of correlation between repeated assessments. With 30% dropout 
rate, RMSE was substantially overestimated in these methods; however, it was almost 
identical for MMRM and MI but very slightly lower than that of CCA. Further, with 30% 
dropout rate, there was a noticeable difference within each of these methods in relation to 
direction of dropouts; higher RMSE was observed when dropouts were in opposite directions 
between groups. As in the case of the bias in treatment effect, RMSE under LOCF deviated 
considerably from the true value, especially, in relation to higher level of overall dropout, 
unequal dropout between groups, direction of dropouts and high level of data variability. 
5.2.3 Bias and RMSE under MAR dependent on last observed value (MAR-L) 
As in the case of MAR-B, the MAR-L mechanism was simulated under two very contrasting 
situations: (i) dropouts were in the same direction in both groups – participants with a high 
last observed score in each group were randomly dropped out (denoted as MAR-L1); (ii) 
dropouts were in opposite directions between the groups – participants with a high last 
observed score in the control group and those with a low last observed score in the 
experimental group were randomly dropped out (denoted as MAR-L2). This simulation study 
found that the accuracy (in terms of bias and RMSE) of all the methods under MAR-L1 was 
similar to the situation under MCAR when dropout was equal between groups. Further, 
accuracy of MMRM and MI under MAR-L1 and MCAR was similar even with differential 
dropout rate between groups. 
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Figure 5.5 displays the bias in estimates of treatment effect for each of the missing data 
handling methods under equal and unequal dropout rate between groups. Under situations 
where dropouts were in the same direction in both groups (i.e. MAR-L1) and equal dropout 
rate between the groups, all but LOCF approaches yielded an unbiased estimate of treatment 
effect irrespective of level of dropout rate, level of data variability and level of correlation 
between repeated assessments. However, with an unequal dropout rate between groups in 
this situation, CCA led to biased estimates – underestimated with higher dropout in the 
control group and overestimated with higher dropout in the experimental group. The bias 
ranged from −0.7 to 0.8 with 10% dropout rate and −2.3 to 2.4 with 30% dropout rate. When 
dropouts were in opposite directions between the groups (i.e. MAR-L2), CCA underestimated 
the treatment effect irrespective of equal or unequal dropout rate between the groups. The 
bias ranged from −1.6 to −0.6 with 10% dropout rate and −4.5 to −1.5 with 30% dropout rate. 
Further, the amount of bias was substantial with high data variability and a high dropout rate. 
For example, in the situation where dropouts were in opposite directions between the groups 
and for equal dropout rate between the groups, CCA underestimated the treatment effect by 
40% when the SD was high and the dropout rate was 30%. The bias under LOCF was worse 
than that under MAR-B. The bias ranged from −3.1 to 4.4 with 10% dropout rate and −7.4 to 
9.1 with 30% dropout rate. 
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Figure 5.6 displays the RMSE of the estimates of treatment effect for each of the missing 
data handling methods under equal and unequal dropout rate between groups. RMSE of the 
estimates with MMRM and MI was similar to that under MAR-B; however, very slightly lower 
RMSE was observed under MAR-L with 30% dropout rate. RMSE under these two methods 
was similar across the levels of data variability, correlation between repeated assessments 
and dropout rate between the groups, but slightly increased in relation to increased dropout 
rate. Unlike the situation in MAR-B, CCA led to a substantial increase in RMSE with 30% 
overall dropout rate and, especially, with dropouts in opposite directions. The inflation in 
RMSE was furthermore associated with greater data variability and level of correlation 
between the repeated assessments. As in the case of the bias in estimate of treatment effect, 
LOCF markedly affected the RMSE even with 10% dropout rate. 
5.2.4 Bias and RMSE under MNAR 
As noted before, the MNAR mechanism was simulated under two very contrasting situations: 
dropouts were in the same direction in both groups – participants with a high score at the time 
of dropping out in each group were dropped out (denoted as MNAR-1); dropouts were in 
opposite directions between the groups – participants with a high score at the time of 
dropping out in the control group and those with a low score in the experimental group were 
dropped (denoted as MNAR-2). This simulation study found that the accuracy (in terms of 
bias and RMSE) of all the methods under MNAR-1 was similar to the situation under MCAR 
when dropout rate was equal between groups. 
Figures 5.7a and 5.7b display the bias in estimates of treatment effect for each of the missing 
data handling methods under equal and unequal dropout rate between groups. Figure 5.7a 
displays the bias in relation to level of dropout rate with a fixed strong correlation and 
moderate SD. It can be seen that all methods displayed an increase in magnitude of the bias 
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in proportion to the level of dropout rate with the exception of MI, MMRM and CCA when 
dropout was equal and in the same direction for the two treatment groups. Level of bias was 
certainly evident when the dropouts were in opposite directions between the groups. With 
10% dropout rate, the bias ranged from −2.9 to 1.0 for CCA, −2.2 to 0.8 for MMRM and MI, 
and −2.6 to 0.4 for LOCF; with 30% dropout rate, it was −6.4 to 3.4, −4.9 to 2.6 and −6.1 to 
−0.4, respectively. Figure 5.7b displays the bias in relation to data variability and correlation 
between repeated assessments with 30% dropout rate. It can be seen that all the approaches 
displayed an increase in magnitude of the bias in relation to the data variability but the 
increase was slightly limited by a strong correlation, with the exception of MI, MMRM and 
CCA when dropout was equal and in the same direction for the two treatment groups. The 
bias became severe with an MNAR-2 mechanism. With a weak correlation and moderate SD, 
the bias ranged from −7.9 to 4.3 for CCA, −7.0 to 3.9 for MMRM and MI, and −7.6 to −1.3 for 
LOCF; with a strong correlation, it was −6.4 to 3.4, −4.9 to 2.6 and −6.1 to −0.4, respectively. 
These findings indicated a possible lower bias with MMRM and MI under strong correlation. 




Figure 5.7: Bias under MNAR – in relation to (a) level of dropout rate (%) with a fixed strong correlation and moderate SD; (b) 
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Figure 5.8: RMSE under MNAR – in relation to (a) level of dropout rate (%) with a fixed strong correlation and moderate SD; 
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Figures 5.8a and 5.8b display the RMSE of the estimates of treatment effect for each of the 
missing data handling methods under equal and unequal dropout rate between groups. 
Figure 5.8a displays the RMSE in relation to level of dropout rate with a fixed strong 
correlation and moderate SD. As in the case of bias, RMSEs were also substantially inflated 
in proportion to the dropout rate, and the issue was more severe when the dropouts were in 
opposite directions between the groups. Figure 5.8b displays the RMSE in relation to data 
variability and correlation between the repeated assessments with 30% dropout rate. As 
expected, RMSEs in all methods were affected by the level of data variability but slightly 
controlled by a strong correlation, with the exception of MI, MMRM and CCA when dropout 
was equal and in the same direction for the two treatment groups. However, the inflation in 
RMSE under MMRM and MI was restricted by the strong correlation between repeated 
assessments compared to CCA. 
5.3 Confidence interval coverage and width 
In this section, the simulation results are presented in terms of coverage and width of 95% CI 
under various scenarios within each missing data mechanism. As Burton et al. (2006) 
suggested the observed coverage that falls inside the interval 93.6%–96.4% is considered to 
be an acceptable coverage of the nominal 95% CI. If the coverage rate is accurate (i.e. close 
to 95%), the probability of a type I error will also be accurate in accordance with the 
designated 5% nominal level (Burton et al., 2006; Collins et al., 2001). Subject to correct 
coverage, confidence interval of an estimate of treatment effect should be narrow, because 
the smaller interval will reduce the probability of a type II error (Burton et al., 2006). The width 
of the CI for data without missing values ranged between 10.68–10.89 across the six 
variance-covariance matrices irrespective of ANCOVA or MMRM. The observed difference in 
the width between the variance-covariance matrices was mainly due to random sample error 
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since different sample sizes had been used to generate the complete data in order to ensure 
90% power. In the following four subsections, the results are presented under each of the 
four missing data mechanisms. 
5.3.1 CI coverage and width under MCAR 
Figure 5.9 displays the CI coverage of each of the missing data handling methods under 
equal and unequal dropout rate between groups. For all approaches other than LOCF, the 
observed coverage of the 95% CI was within the acceptable range (i.e. 93.6%–96.4%) 
irrespective of all considered scenarios. However, even with 10% overall dropout rate, LOCF 
led to over-coverage when there was a higher dropout rate in the control group, and 
otherwise led to under-coverage; the situation was much worse with 30% dropout rate. The 
coverage of LOCF under the different scenarios considered ranged from 90.6%–97.4% with 
10% dropout rate and from 66.0%–97.6% with 30% dropout rate. Further, LOCF showed a 
trend of reduction in coverage in relation to increase in data variability and correlation 
between repeated assessments. 
Figure 5.10 displays the average CI width in each of the missing data handling methods 
under equal and unequal dropout rate between groups. As noted earlier, for data without 
missing values, the width of the 95% CI was approximately 10.8 units irrespective of the data 
characteristics (data variability and correlation between repeated assessments). LOCF was 
the approach with the smallest CI width among the four approaches; however, with a high SD 
the width was narrower than that for the data without missing values – indicating an 
underestimation of the standard error. The width varied by the level of data variability but was 
fairly consistent across different dropout rates, being in the range of 10.8 to 11.7 with 10% 
dropout rate and 10.5 to 11.9 with 30% dropout rate. In all the other approaches, the width 
increased in proportion to the level of dropout rate. 
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The width in CCA and MMRM was unaffected by data variability, correlation and dropout rate 
between the groups; the width in MI was slightly affected by the data variability and the 
correlation (i.e. the width was slightly narrower with a high SD and a strong correlation). With 
10% dropout rate, the width ranged from 11.5–11.8 for CCA, from 11.5–11.6 for MMRM and 
from 11.6–12.0 for MI; with 30% dropout rate, it was 13.0–13.5, 12.5–13.1 and 13.0–13.8, 
respectively. In general, the CI width was slightly narrower with MMRM compared to CCA 
and MI. 
5.3.2 CI coverage and width under MAR-B 
Figure 5.11 displays the CI coverage of each of the missing data handling methods under 
equal and unequal dropout rate between groups. As in the case of MCAR, all but the LOCF 
approach retained the coverage within the acceptable range nearly in all scenarios 
irrespective of level of overall dropout rate, dropout rate between groups, direction of 
dropouts, data variability and correlation between repeated assessments. With 10% dropout 
rate, the observed coverage ranged from 94.0%–96.9% for CCA, from 93.7%–96.4% for 
MMRM and from 94.3%–96.3% for MI; with 30% dropout rate, it was from 93.3%–96.6%, 
93.2%–96.0% and 93.8%–96.6% respectively. However, deviation from the nominal coverage 
was of real concern in LOCF, even with a 10% dropout rate; in most scenarios, LOCF led to 
under-coverage, and in some scenarios it was worse than 60%. The deviation was 
substantially dependent on the data variability, level of overall dropout, dropout rate between 
groups and direction of dropouts. The observed coverage with LOCF ranged from 88.7%–
97.2% with 10% dropout rate and from 55.8%–98.0% with 30% dropout rate. 
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Figure 5.12 displays the average CI width in each of the missing data handling methods 
under equal and unequal dropout rate between groups. When the dropouts were in the same 
direction in both groups (i.e. MAR-B1), the findings were similar to the situation under MCAR. 
From the figure, it can be seen that LOCF was the approach with the narrowest CI width; 
however, it led to a narrower CI compared to data without missing values when the data 
variability was high – indicating an underestimation of the standard error. Though the width 
under LOCF was associated with data variability, it was less affected by the level of dropout 
rate, equal or unequal dropout rate between groups, direction of dropout and correlation 
between repeated assessments. The width ranged from 10.8–11.7 with 10% dropout rate and 
from 10.5–11.8 with 30% dropout rate – which was similar to the situation under MCAR. In all 
the other approaches, the width increased in proportion to the overall dropout rate, and was 
further influenced by direction of dropout rate and data variability when the dropout rate was 
high. It was observed that the data variability had slightly more impact on the width in MI 
compared to MMRM. In addition, MMRM produced a slightly narrower CI compared to CCA 
and MI. With 10% dropout rate, the width ranged from 11.5–12.0 for CCA, from 11.4–11.8 for 
MMRM and from 11.5–12.2 for MI; with 30% dropout rate, it was 12.9–14.8, 12.5–14.2 and 
13.0–15.2, respectively. 
5.3.3 CI coverage and width under MAR-L 
Figure 5.13 displays the CI coverage of each of the missing data handling methods under 
equal and unequal dropout rate between groups. Under the situation where dropouts were in 
the same direction in both groups (i.e. MAR-L1) and the dropout rate was equal between the 
groups, all but the LOCF approaches yielded similar CI coverage – and the observed 
coverage was within the acceptable range – irrespective of level of dropout rate, level of data 
variability and level of correlation between repeated assessments.  
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However, with an unequal dropout rate between groups, CCA led to under-coverage; the loss 
of coverage was noticeable with 30% dropout rate. When dropouts were in opposite 
directions between the groups (i.e. MAR-L2), CCA led to under-coverage irrespective of 
equal or unequal dropout rate between the groups; the loss of coverage was substantial with 
30% dropout rate and further influenced by the data variability. The observed coverage with 
MMRM and MI was within the acceptable range in most scenarios; however, as in MAR-B, MI 
retained very slightly higher coverage than that for MMRM. With 10% dropout rate, the 
observed coverage ranged from 91.7%–95.9% for CCA, from 93.6%–95.9% for MMRM and 
from 93.6%–96.2% for MI; with 30% dropout rate, it was 74.3%–96.3%, 93.4%–96.3% and 
94.0%–97.3%, respectively. The observed coverage under LOCF severely deviated from the 
acceptable range, and was worse than under MAR-B. For different scenarios, it ranged from 
67.2%–97.7% with 10% dropout rate and from 6.9%–99.1% with 30% dropout rate. 
Figure 5.14 displays the average CI width in each of the missing data handling methods 
under equal and unequal dropout rate between groups. When dropouts were in the same 
direction in both groups (i.e. MAR-L1), the findings were similar to the situation under MCAR. 
Unlike the findings under MAR-B, LOCF produced a smaller CI when the dropouts were in 
opposite directions between groups (i.e. MAR-L2) compared to the situation where dropouts 
were in the same direction in both groups; the width was further influenced by the data 
variability. However, the observed width from LOCF was unrelated to the situation where 
equal or unequal dropout rate between the groups, and was less influenced by the overall 
dropout rate compared to other approaches. The width ranged from 10.7–12.7 with 10% 
dropout and from 10.2–13.1 with 30% dropout. For all other approaches, the average 95% CI 
became wider when the overall dropout rate was increased from 10% to 30%. The direction 
of dropouts also had an impact on the width – CCA, MMRM and MI produced a wider CI 
when the dropouts were in opposite directions between groups; however, the impact was 
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lower compared to the situation under MAR-B. In addition, the width with MMRM was slightly 
smaller than for CCA and MI. Further, the width under MI altered notably with greater data 
variability. With 10% dropout rate, the width ranged from 11.5–11.9 for CCA, from 11.5–11.7 
for MMRM and from 11.5–12.3 for MI; with 30% dropout rate, it was 12.9–14.2, 12.5–13.6 
and 12.9–15.1, respectively. 
5.3.4 CI coverage and width under MNAR 
Figures 5.15a and 5.15b display the observed CI coverage of each of the missing data 
handling methods under equal and unequal dropout rate between groups. Figure 5.15a 
displays the coverage in relation to level of dropout rate with a fixed strong correlation and 
moderate SD. It can be seen that all the approaches displayed substantial loss of coverage in 
proportion to increased dropout rate; the problem of loss of coverage was severe when the 
dropouts were in opposite directions between the groups, and this was true even with a 10% 
dropout rate. With 10% dropout, the coverage ranged from 83.5%–95.0% for CCA, from 
87.6%–95.3% for MMRM, from 84.1%–97.0% for LOCF, and from 87.9%–94.8% for MI; with 
30% dropout rate, it was 50.7%–94.7%, 66.9%–94.0%, 35.8%–97.0% and 68.6%–94.5%, 
respectively. Figure 5.15b displays the coverage in relation to data variability and correlation 
between the repeated assessments with 30% dropout. It can be seen that all the approaches 
displayed increasing loss of coverage in relation to greater data variability and weaker 
correlation, with the exception to the situation where dropout was equal and in the same 
direction for the groups. With a weak correlation and moderate SD, the coverage ranged from 
33.5%–95.7% for CCA, from 41.1%–95.6% for MMRM, from 16.2%–95.0% for LOCF, and 
from 44.3%–96.0% for MI. In these two figures, it can be seen that the loss of coverage was 
comparatively lower in all approaches when the dropouts were in the same direction in 
comparison with dropouts in opposite directions between the groups. 
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Figure 5.15: CI coverage under MNAR – in relation to (a) level of dropout rate (%) with a fixed strong correlation and 
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Figure 5.16: Average width of CI under MNAR – in relation to (a) level of dropout rate (%) with a fixed strong correlation and 
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Figures 5.16a and 5.16b display the average CI width in each of the missing data handling 
methods under equal and unequal dropout rate between groups. Figure 5.16a displays the 
width in relation to level of dropout rate with a fixed strong correlation and moderate SD. For 
all but the LOCF approach, the 95% CI became wider in relation to increase in the overall 
dropout rate; however, the width was unaffected by the direction of dropouts and the dropout 
rate between the groups. LOCF produced the narrowest CI; however, it led to 
underestimation of standard error for many scenarios especially under MNAR-2. With 10% 
dropout rate, the width ranged from 11.3–11.4 for CCA, from 11.2–11.3 for MMRM, from 
10.6–11.2 for LOCF, and from 11.4–11.5 for MI; with 30% dropout rate, it was 12.6–13.0, 
12.3–12.6, 10.3–11.5 and 12.7–13.1, respectively. Figure 5.16b displays the width in relation 
to data variability and correlation between repeated assessments with 30% dropout rate. 
Under LOCF with 30% dropout rate, the width was markedly reduced in relation to increase in 
data variability. With a weak correlation and moderate SD, the coverage ranged from 12.8–
13.0 for CCA, from 12.6–12.8 for MMRM, from 10.3–11.5 for LOCF, and from 13.0–13.2 for 
MI – indicating a slightly narrower CI under MMRM compared to MI. 
5.4 Statistical power to detect the true difference 
In this section, the simulation results are presented in terms of statistical power to detect the 
true difference under various scenarios within each missing data mechanism. As noted 
earlier, sample size was calculated in order to ensure 90% power for data without missing 
values in each variance-covariance scenario.14 
                                               
14
 With WL variance-covariance, the power was slightly higher than 90% due to rounding-up the 
required sample size. 
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5.4.1 Statistical power under MCAR 
Figure 5.17 displays the empirical power under MCAR missingness for each of the missing 
data handling methods under equal and unequal dropout rate between groups. In general, 
deviation from the nominal power of 90% was increased with respect to increase in overall 
dropout rate. In LOCF, substantial loss of power was observed when there was equal dropout 
rate between the groups or higher dropout rate in the experimental group; artificial over-
powering was observed with higher dropout in the control group. The loss of power was 
further influenced by level of data variability. In other methods, missing data led to substantial 
loss of power in proportion to overall dropout rate; however, the loss was not greatly affected 
by equal or unequal dropout rate between groups. It can be seen that MMRM had slightly 
greater power compared to CCA and MI. With 10% dropout rate, the empirical power ranged 
from 83.5%–87.8% for CCA, from 84.4%–88.1% for MMRM, from 64.0%–93.3% for LOCF, 
and from 83.3%–87.4%; with 30% dropout rate, it was 73.1%–78.5%, 75.5%–81.1%, 27.9%–
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5.4.2 Statistical power under MAR-B 
Figure 5.18 displays the empirical power under MAR-B missingness for each of the missing 
data handling methods under equal and unequal dropout rate between groups. As in MCAR, 
LOCF led to substantial deviation from the nominal power in relation to overall dropout rate, 
dropout rate between groups and direction of dropout. The level of data variability also had an 
impact on the deviation, especially when the dropouts were in opposite directions between 
the groups. Similarly, CCA, MMRM and MI also led to loss of power in relation to overall 
dropout rate, and the loss was slightly higher with differential dropout rates between the 
groups; but the loss was unaffected by the level of data variability and the correlation 
between repeated assessments. These methods produced markedly greater power under 
MAR-B1 compared to MAR-B2. Further, with 30% dropout rate, these methods had greater 
power under situations where dropout rate was equal between groups compared to unequal 
dropout. Additionally, MMRM had slightly greater power than MI in most scenarios. With 10% 
dropout rate and dropouts in the same direction in both groups, the empirical power ranged 
from 84.3%–88.1% for CCA, from 85.4%–88.8% for MMRM, from 60.4%–95.7% for LOCF, 
and from 83.1%–87.2% for MI; when dropouts were in opposite directions between the 
groups, power was 82.5%–87.4%, 84.1%–87.7%, 73.3%–97.9% and 81.3%–86.4%, 
respectively. With 30% dropout rate and dropouts in the same direction in both groups, the 
power ranged from 71.2%–79.8% for CCA, from 75.4%–81.2% for MMRM, from 25.5%–
96.5% for LOCF, and from 70.7%–79.5% for MI; when dropouts were in opposite directions 
between the groups, power was 64.9%–74.0%, 68.3%–76.6%, 44.3%–99.6% and 64.3%–
74.6%, respectively. 
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5.4.3 Statistical power under MAR-L 
Figure 5.19 displays the empirical power under MAR-L missingness for each of the missing 
data handling methods under equal and unequal dropout rate between groups. Similar to the 
findings under MCAR and MAR-B, power under LOCF was severely affected under MAR-L – 
it was either overpowered or underpowered depending upon the direction and magnitude of 
bias and underestimation of standard error. For example, in the third graph with higher 
dropout rate in the control group, for data with high SD and weak correlation, the observed 
power was close to 100% under LOCF when dropouts were in opposite directions between 
the groups irrespective of whether 10% or 30% dropout rate. In contrast, in the second graph 
where there was higher dropout rate in the experimental group, for data with high SD and 
weak correlation the observed power was as low as 5% under LOCF when dropouts were in 
the same direction in both groups. The deviation was further affected by level of data 
variability and correlation between repeated assessments. Unlike the situations under MCAR 
and MAR-B, CCA was also flawed under MAR-L; this approach led to substantial loss of 
power in most scenarios especially under MAR-L2. In general, for MMRM and MI approaches 
under MAR-L1, the observed power was nearly similar to that under MAR-B1; however, the 
estimate under MAR-L2 was markedly higher than that of under MAR-B2. Further, the power 
of MMRM was noticeably better than that of MI, and was less affected by the direction of 
dropouts. With 10% dropout rate and dropouts in the same direction in both groups, the 
empirical power ranged between 79.4%–90.9% for CCA, 85.0%–88.5% for MMRM, 47.6%–
97.0% for LOCF, and 82.9%–86.9% for MI; when dropouts were in opposite directions 
between the groups, it was 68.4%–80.8%, 84.0%–87.6%, 81.0%–99.9% and 82.2%–86.5% 
respectively. With 30% dropout rate and dropouts in the same direction in both groups, the 
power ranged between 50.0%–91.2% for CCA, 74.6%–80.7% for MMRM, 4.5%–99.6% for
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LOCF, and 70.2%–79.7% for MI; when dropouts were in opposite directions between the 
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5.4.4 Statistical power under MNAR 
Figures 5.20a and 5.20b display the empirical power under MNAR for each of the missing 
data handling methods under equal and unequal dropout rate between groups. Figure 5.20a 
displays the empirical power in relation to level of dropout rate with a fixed strong correlation 
and moderate SD. It can be seen that all methods yielded considerably lower power (than the 
nominal 90% level), as was the case with bias in estimate of treatment effect. Loss of power 
was substantial even with 10% dropout rate under MNAR-2, and this finding does not differ 
greatly in respect of equal or unequal dropout rate between groups. Under MNAR-1, 
observed power for CCA, MMRM and MI was greater than nominal power as the treatment 
effect was overestimated with these approaches when dropout rate was higher in the 
experimental group. Figure 5.20b displays the empirical power in relation to data variability 
and correlation between repeated assessments with 30% dropout rate. It can be seen that all 
methods were severely flawed, and the deviation from the nominal power was markedly 
affected by the level of data variability and the correlation in most scenarios, irrespective of 
equal or unequal dropout rate between groups. Importantly, it can be seen that power was 
mostly lower than 50% for MNAR-2 scenarios across all analytical approaches – and 
extending to less than 30% power when dropout was 30% across methods. 
 
 




Figure 5.20: Statistical power under MNAR – in relation to (a) level of dropout rate (%) with a fixed strong correlation and 





































































































































CCA MMRM LOCF MI CCA MMRM LOCF MI CCA MMRM LOCF MI






































































































H SL SM S
H
CCA MMRM LOCF MI CCA MMRM LOCF MI CCA MMRM LOCF MI








No dropout MNAR-1 MNAR-2
a 
b 
 Chapter 5              150 
5.5 Summary of findings 
Under MCAR, all but LOCF approach yielded an unbiased estimate of treatment effect in all 
considered scenarios, whereas RMSE increased with an increase in the dropout rate. In this 
simulation study, LOCF led to overestimation when dropout rate was higher in the control 
group. Further, larger bias with lower RMSE indicates the underestimation of variability in 
LOCF. Data characteristics such as spread of data and correlation between repeated 
assessments did not affect accuracy of CCA, MMRM or MI when the missing data 
mechanism is MCAR. In addition, all but the LOCF approach retained the targeted CI 
coverage and width; however, the width in MI was slightly affected by the data variability and 
the correlation, and was slightly wider than that of CCA and MMRM. LOCF failed to attain the 
acceptable coverage and leads to underestimation of the width in most scenarios. 
Under MAR dependent on baseline value, all approaches but LOCF yielded an unbiased 
estimate of treatment effect as in the case of MCAR; however, MMRM and MI consistently 
produced the smallest RMSE, and very slightly lower than that of CCA, compared to LOCF. 
This study found that the direction of dropouts and level of dropout rate moderately affected 
the overall accuracy in terms of RMSE, for CCA, MMRM and MI, but particularly in the case 
of LOCF. Importantly, CCA, MMRM and MI could attain the targeted coverage, even with a 
30% dropout rate across all scenarios; MI retained very slightly higher coverage than in 
MMRM. In these approaches, the CI width was increased in proportion to the overall dropout 
rate, and was further influenced by equal or differential dropout rates between groups and 
data variability when the dropout rate was high. It can be found that the data variability had 
slightly more impact on the width in MI compared to that in MMRM. In addition, MMRM 
produced a smaller CI compared to CCA and MI. For LOCF, the situation under MAR is 
worse than for that under MCAR. 
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Under MAR dependent on last observed value, MMRM and MI yielded unbiased estimates of 
treatment effect, and consistently produced lower RMSE compared to CCA and LOCF. This 
study found that the direction of dropouts and level of dropout rate moderately affected the 
overall accuracy, in terms of RMSE, of MMRM and MI, but substantially for CCA and LOCF. 
Further, the bias and RMSE of the estimate under CCA and LOCF were influenced by the 
data variability and the correlation between repeated assessments. Unlike the findings in 
MAR-B, only MMRM and MI could attain the targeted coverage, irrespective of scenario. CCA 
led to under-coverage when the dropouts were in opposite directions between the groups; the 
coverage was markedly reduced in relation to an increase in dropout rate and data variability. 
With LOCF, the coverage varied substantially across the scenarios; it ranged from 67.2%–
97.7% with 10% dropouts and from 6.9%–99.1% with 30% dropouts. It was found that MMRM 
produced a slightly narrower CI compared to CCA and MI, and the impact of direction of 
dropout on the width was slightly lower with MMRM compared to the other approaches. 
Under MNAR, all approaches were substantially flawed; the bias and RMSE markedly 
increased in relation to an increase in overall dropout rate and data variability. However, with 
equal dropout rate between groups, the estimates of treatment effect in CCA, MMRM and MI 
were less adversely affected by the dropout rate when the dropouts were in the same 
direction. Further, both MMRM and MI yielded similar estimates of the treatment effect and 
RMSE in all scenarios; these measures were more appropriate than those given by CCA, 
especially when the correlation was strong. In this simulation under an MNAR mechanism, it 
has been noted that LOCF was the most favourable approach compared to others in few 
circumstances; however, mean change over time had significant effect on LOCF – the effect 
of mean trajectory profile is reported in chapter 6. Since the bias in estimate of treatment 
effect was a major problem with all the approaches, the coverage and power were also 
substantially deviated from the targeted level. 
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Chapter 6: Simulation study: findings 2 
6.1 Introduction 
This chapter presents the results of simulation studies 2, 3 and 4 (detailed in chapter 4) that 
were designed to examine the relative performance of four missing data handling approaches 
– CCA, MMRM, LOCF and MI – when analysing incomplete longitudinal RCT data under the 
four missing data mechanisms: MCAR, MAR-B, MAR-L and MNAR. Analysis of covariance 
(ANCOVA) was used in conjunction with CCA, LOCF and MI. As proposed in the introduction 
chapter, the goal was to answer the following research questions: 
 Within and across the missing data handling approaches, do the accuracy and i.
efficiency of the parameter estimates (i.e. treatment effect at the primary endpoint) 
vary by changes in an average trajectory pattern over a study period and by size of 
the treatment effect at the endpoint, given a fixed variance-covariance matrix under 
the missing data mechanisms? 
 Does considering baseline of an outcome measure as part of an outcome vector in ii.
MMRM analysis have an advantage over the analysis with baseline-as-covariate when 
there are participants without follow-up data? 
 Does an increment in sample size in proportion to an expected dropout rate help to iii.
achieve the desired statistical power when using the missing data handling 
approaches under the missing data mechanisms? 
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6.2 Effect of trajectory pattern and size of treatment effect on inferences from 
the missing data handling approaches 
This study was planned in order to evaluate the effect of mean trajectories with the same 
treatment effect at the primary endpoint (trajectories 1 and 2 with the same treatment effect of 
−9.0), and the effect of mean trajectories with different treatment effects at the endpoint 
(trajectories 1, 3 and 4 with treatment effects of −9.0, 0 [no effect] and −18.0, respectively). 
Trajectory 1 assumed both treatments improved over time. However, the treatment group 
improved more and thus resulted in a treatment benefit over time. In contrast to trajectory 1, 
trajectory 2 assumed that the control group showed better improvement during the initial visit 
(visit 1) than the experimental group but it retained the same treatment effect at the end as in 
trajectory 1. Trajectory 3 assumed both treatments improved equally well, and reflected the 
null hypothesis that there was no difference between treatments at the primary endpoint. 
Trajectory 4 assumed the experimental group improved quickly but then showed little change 
over time; however, there was minor improvement in the control group and a treatment effect 
of −18.0 at the primary endpoint was assumed in favour of the experimental group. This study 
compared bias, RMSE, and width and coverage of 95% CI in respect of the estimate of 
treatment effect from the missing data handling approaches under various dropout scenarios 
for a given SM covariance (strong correlation and moderate SD) matrix, sample size (n = 60 
per group) and 30% dropouts. 
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Figures 6.1–6.4 display the bias, RMSE, and coverage and width of 95% CI respectively. As 
expected, the performance measurements in respect of the estimate of treatment effect from 
CCA, MMRM and MI were similar across the mean trajectories (i.e., independent of the 
trajectory pattern and the size of treatment effect) under the various dropout scenarios. The 
CCA performed well under the missing data mechanisms: MCAR, MAR-B1, MAR-B2, MAR-
L1 (with equal dropout rate between arms) and MNAR-1 (with equal dropout rate between 
arms). In addition to these mechanisms, the MMRM and MI ANCOVA analyses also 
performed well under MAR-L1 (with differential dropout rates between arms) and MAR-L2. 
These results also confirmed the findings in chapter 5. 
By contrast, the performance of LOCF varied considerably across the trajectories, especially 
under a scenario where there was higher dropout rate in the experimental group than in the 
control group. The considerable variation in this scenario was due to the steep reduction in 
outcome score over time in the experimental group compared to the control group for 
trajectories 1 and 2. Despite a high treatment effect at the primary endpoint, LOCF performed 
relatively better with trajectory 4 than with trajectories 1 and 2 because a high treatment effect 
was attained so quickly and remains constant over time. It was clear from these results that 




























































































Figure 6.1: Effect of trajectory pattern and mean difference between groups over time 


























































































































































































































































































































































































































































Trajectory 1 with treatment effect -9.0 Trajectory 2 with treatment effect -9.0
Trajectory 3 with treatment effect 0.0 Trajectory 4 with treatment effect -18.0






















































































Figure 6.2: Effect of trajectory pattern and mean difference between groups over time 



































































































































































































































































































































































































































































Trajectory 1 with treatment effect -9.0 Trajectory 2 with treatment effect -9.0
Trajectory 3 with treatment effect 0.0 Trajectory 4 with treatment effect -18.0






















































































Figure 6.3: Effect of trajectory pattern and mean difference between groups over time 





















































































































































































































































































































































































































































































Trajectory 1 with treatment effect -9.0 Trajectory 2 with treatment effect -9.0
Trajectory 3 with treatment effect 0.0 Trajectory 4 with treatment effect -18.0






















































































Figure 6.4: Effect of trajectory pattern and mean difference between groups over time 

































































































































































































































































































































































































































































































Trajectory 1 with treatment effect -9.0 Trajectory 2 with treatment effect -9.0
Trajectory 3 with treatment effect 0.0 Trajectory 4 with treatment effect -18.0
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6.3 Comparison of two strategies for handling baseline data in an MMRM 
analysis 
This section shows the findings for comparison of two strategies for handling baseline 
observations in a mixed-effects model for repeated measures analysis under various dropout 
scenarios. In the first strategy (denoted as MMRM), the baseline score of a repeated outcome 
measure was included as a covariate in the analysis of post-randomization outcome data in a 
repeated measures analysis model. In order to obtain baseline-adjusted estimates, baseline–
follow-up visit interaction was specified in the analysis model. This model was used in all 
other simulation studies in this thesis. In the second strategy (denoted as constrained 
longitudinal data analysis [cLDA]), the baseline was included together with the post-
randomization outcome measurements in the context of the outcome variable. Although the 
outcome variable in the model includes the baseline measures, a constrained term is added 
to the model to specify that the true baseline means are the same for different treatment 
groups due to randomization, and this analysis provides baseline-adjusted estimate of 
treatment effect. Both strategies were described in chapter 2. A detailed discussion around 
the simulation methodology for this comparison was provided in chapter 4. 
There is subtle contrast between the two strategies in the number of participants that are 
included in the analysis. The analysis with baseline-as-outcome (strategy 2; cLDA) includes 
all participants with either baseline or follow-up outcome data. By contrast, the analysis with 
baseline-as-covariate (strategy 1; MMRM) includes only those participants who provided 
outcome data at baseline and at least one follow-up. Since the simulated datasets in this 
thesis involve early dropouts without any follow-up assessments, those dropouts were 
excluded from the MMRM analysis. Therefore, cLDA was used to evaluate the robustness of 
the analysis results to those exclusions under different missing data mechanisms. All 
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analyses were performed with restricted maximum likelihood instead of maximum likelihood 
estimation, but with and without the Kenward-Roger correction for finite sample. Since there 
is no finite sample correction implemented in conjunction with Stata xtmixed procedure 
(StataCorp, 2011), this correction was performed using an add-on within the SAS proc mixed 
procedure (SAS Institute Inc., 2011). Without the Kenward-Roger correction, SAS and Stata 
produced identical results if the parameter estimation in Stata mixed was set to be based on 
a t-distribution (the customary default option in Stata is that of a standard normal distribution). 
Data simulation was performed with the SM covariance (strong correlation and moderate SD) 
matrix and 30% overall dropout rate – nearly 10% of participants had not completed any 
follow-up – under different missing data mechanisms. 
6.3.1 Effects on overall accuracy 
The overall accuracy – in terms of bias and RMSE – of the estimate of treatment effect was 
identical across the strategies in all the scenarios considered in this simulation. These results 
are provided in appendix 6 (Tables 23 and 24). However, the study found slight differences in 
average SE between these strategies, and this therefore influenced the coverage of the 95% 
CI and statistical power. 
6.3.2 Effects on the coverage of 95% CI 
Figure 6.5 displays the 95% CI coverage for each of the strategies under equal and unequal 
dropout rate between groups. The red and blue solid lines represent the observed coverage 
with MMRM with and without Kenward-Roger correction, respectively. The purple and green 
dashed lines represent the corresponding observed coverage with cLDA. 
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It was found that the MMRM analysis yielded a very similar coverage probability with and 
without Kenward-Roger correction. However, the correction led to a slightly better coverage 
(i.e. coverage closer to 95%) in the cLDA, irrespective of the dropout scenarios considered in 
this study. When comparing the baseline handling strategies, the MMRM analysis yielded 
very slightly better coverage compared to the cLDA, especially when the dropouts were in 
opposite directions between the intervention groups. Under MAR-B2 with equal dropout rate 
between the groups, the observed coverage increased from 92.9% (without Kenward-Roger 
correction) to 94.3% by considering baseline as a covariate rather than an outcome. Under 
MAR-L2, it increased from 93.0% to 94.2%. Therefore, as seen in the figure, the coverage 
with MMRM (i.e. model with baseline-as-covariate) was unlikely to be affected by the 
direction of dropouts in scenarios where the estimate of treatment effect was unbiased – 
similar results were found in chapter 5 (section 5.3). 
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*Coverage was less than 70% 
Figure 6.5: Coverage of 95% CI under various scenarios (MMRM – Mixed model with baseline-as-covariate; cLDA – Mixed 
































































































































MMRM with Kenward-Roger correction cLDA with Kenward-Roger correction
MMRM without Kenward-Roger correction cLDA without Kenward-Roger correction
Acceptable range: Lower Acceptable range: Upper
* * 
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6.3.3 Effects on the observed power 
Figure 6.6 displays the observed statistical power for each of the strategies under equal and 
differential dropout rate between groups. The effect of the Kenward-Roger correction on 
power differed from the effect on coverage. That is, due to the correction, power was 
decreased slightly with cLDA but not that much with MMRM. It appeared that cLDA without 
Kenward-Roger correction (green dashed line) yielded the highest power, and MMRM with 
Kenward-Roger correction (red solid line) yielded the lowest power among the strategies to 
handle baseline data. 
As expected, due to a higher number of subjects included in the analysis, cLDA yielded a 
higher power compared to MMRM, and the power with cLDA was less likely to be affected by 
the direction of dropouts. Specifically, under MCAR and MAR with dropouts in the same 
direction in both groups (i.e. MAR-B1 and MAR-L1), the empirical power was in the range of 
78%–80% across all strategies except cLDA without the correction. Under MAR with dropouts 
in opposite directions between groups (i.e. MAR-B2 and MAR-L2), the power of cLDA with 
the correction was similarly ranged at about 80% as in MAR-B1 and MAR-L1; whereas the 
power of MMRM with/without the correction ranged between 74%–77%. Under MNAR, the 
power comparison was not relevant as all strategies were flawed with substantial bias in the 
estimate of treatment effect. 




*Power was less than 70% 
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6.4 Effect of sample size on power under different missing data mechanisms: 
a comparison of missing data handling approaches 
The effect of missing data on the statistical power of clinical trials has been detailed in 
chapter 5. The simulation studies have established that trials could be artificially 
underpowered/overpowered depending on the magnitude and direction of bias in estimates. It 
was also found that trials are still underpowered even with unbiased estimates of treatment 
effect irrespective of analysis methods or missing data mechanisms. When there is no bias in 
the estimate of treatment effect, the reduction of power was shown to be associated with the 
direction of dropout in addition to the amount of missing data. The reduction was relatively 
larger in situations where dropouts were in opposite directions between study groups 
compared to the situation where dropouts were in the same direction in both groups. 
The current practice in the presence of anticipated missing data is simply to inflate the 
sample size that was calculated assuming no missing data, based on the inverse of one 
minus the anticipated dropout proportion. Further simulation studies were performed here to 
verify how far this current practice in sample size calculation protects against the loss of 
statistical power due to missing data. With a WM15 variance-covariance matrix among the 
repeated measurements, and 10% dropout rate, these studies used two sample sizes: n = 
150 (without inflation for the missing data) – this sample size ensured 90% power to detect 
the true treatment effect at an endpoint in the absence of missing data; and n = 168 (inflated 
for 10% dropouts). These studies were repeated for the 30% dropout scenario with n = 150 
(without inflation for the missing data) and n = 216 (inflated for 30% dropouts). The 
                                               
15
 Weak correlation and moderate SD 
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corresponding scenarios with 80% power were also explored: an unadjusted sample size of 
57 per group was used. The corresponding inflated sample sizes were 63 per group and 81 
per group when adjusted for 10% and 30% dropout rates, respectively. Unlike the studies in 
sections 6.2 and 6.3, this simulation used a weak correlation matrix because the earlier 
simulation studies observed lower power for weak correlation scenario compared to the 
strong correlation. 
6.4.1 When the desired power was 90% in the absence of missing data 
As expected, all approaches but LOCF yielded similar estimates of treatment effect and 
coverage probability across the sample sizes (results not shown), which was equal to the 
estimates found in chapter 5 under corresponding missing data scenarios. Figures 6.7 and 
6.8 display the observed statistical power – when the desired power was 90% in the absence 
of missing data – for each analytical method in relation to the sample sizes under 10% and 
30% dropout scenarios, respectively. The figures are split in order to show results stratified 
according to balance/imbalance in dropout rate between treatment groups: (i) equal dropout 
rate between the groups; (ii) higher dropout rate in the experimental group; and (iii) higher 
dropout rate in the control group. The dashed line indicates the observed power 
corresponding to scenarios where no attrition adjustment to the required sample size was 
made. The solid line indicates the observed power corresponding to scenarios where the 
required sample size was inflated. Table 6.1 shows the observed power for CCA, MMRM and 
MI for inflated sample sizes of 10% and 30% dropout rates. 
 

































































































































































































































































































































































































































































































































































Not inflated for 10% dropouts (n=150) Inflated for 10% dropouts (n=168)



































































































































































































































































































































































































































































































































































Not inflated for 30% dropouts (n=150) Inflated for 30% dropouts (n=216)
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Table 6.1: The observed power (%) with inflated sample size – desired power was 90% 
Mechanism 
10% dropouts (n = 168) 30% dropouts (n = 216) 
CCA MMRM MI CCA MMRM MI 
Equal dropout between groups 
   
MCAR 88.9 89.1 88.7 89.7 90.2 89.7 
MAR-B1 89.7 90.0 89.2 89.5 90.2 89.2 
MAR-B2 88.8 90.0 88.5 85.3 86.7 85.3 
MAR-L1 88.8 89.0 88.6 89.2 90.5 89.3 
MAR-L2 79.7* 89.0 88.5 64.7* 89.2 87.3 
MNAR-1 89.4 89.5 90.0 92.0 92.1 91.6 
MNAR-2 60.2* 64.8* 64.6* 15.1* 22.9* 21.5* 
Higher dropout in the experimental group 
   
MCAR 88.7 88.9 88.3 88.1 89.7 88.5 
MAR-B1 90.3 89.8 89.4 86.8 87.3 86.9 
MAR-B2 89.6 89.9 88.5 84.5 85.7 83.9 
MAR-L1 92.3* 89.3 88.8 95.8* 89.7 87.6 
MAR-L2 80.7* 89.1 88.2 55.3* 85.9 83.2 
MNAR-1 96.8* 96.3* 96.2* 99.7* 99.4* 99.3* 
MNAR-2 59.2* 64.9* 63.3* 8.3* 13.5* 12.4* 
Higher dropout in the control group 
   
MCAR 89.4 89.0 89.0 89.2 89.5 88.5 
MAR-B1 89.3 88.9 87.9 87.4 88.5 87.9 
MAR-B2 88.7 88.8 87.7 82.6 83.2 81.4 
MAR-L1 85.8* 89.4 90.0 75.5* 89.3 88.2 
MAR-L2 81.1* 90.0 88.6 55.7* 86.8 85.0 
MNAR-1 77.9* 79.0* 78.1* 41.3* 50.2* 48.9* 
MNAR-2 58.6* 63.5* 62.0* 8.4* 14.0* 14.0* 
*Estimates of treatment effect were biased 
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As seen in chapter 5 (section 5.4), the bias in the estimate of treatment effect caused 
underestimation or overestimation of the power to detect the true treatment effect and was 
dependent on the direction and size of the bias. In figures 6.7 and 6.8, the observed power 
was slightly higher with MMRM in comparison with CCA and MI in scenarios where the 
estimate of treatment effect was unbiased, and the power of MI was no better than CCA in 
these scenarios. The same observations were made in chapter 5 (section 5.4) in relation to 
the WM covariance matrix. Those studies in chapter 5 further showed that MI could perform 
well in comparison to CCA in terms of the observed power when the baseline-endpoint 
correlation increased. 
As seen in figures 6.7 and 6.8, the observed power in all methods was substantially 
increased in relation to increases in sample size. Therefore, the loss of power due to attrition 
was substantially reduced with the increased sample size in scenarios where the analytical 
methods – CCA, MMRM and MI – provide unbiased estimates of treatment effect (Table 6.1). 
Importantly, in these scenarios, CCA, MMRM and MI could attain the observed power close 
to the nominal level of 90% by using the increased sample size when dropout rate was equal 
and dropouts were in the same direction in both groups, irrespective of level of dropout rate 
(10% or 30%) and dropout mechanism (MCAR, MAR or MNAR). 
With 10% dropout rate and the inflated sample size (n = 168), neither the differential dropout 
rates between the groups or the direction of dropouts prevented the desired power of 90% 
from being attained (Figure 6.7 and Table 6.1). Importantly, in scenarios where the estimate 
of treatment effect was unbiased, the observed power with the inflated sample size was 
higher than 88.7% for CCA, higher than 88.8% for MMRM and higher than 87.7% for MI. The 
lowest power among these methods was observed under an MAR-B2 mechanism. 
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With 30% dropout rate (Figure 6.8 and Table 6.1), the inflated sample size maintained the 
desired power in CCA, MMRM and MI under an MCAR mechanism. Under MAR, the 
observed power in these methods was slightly lower than the desired level for the case of 
differential dropout rate between the groups, but the loss was substantial when dropouts were 
in opposite directions between the groups (MAR-B2 and MAR-L2). With increased sample 
size (n = 216), the observed power among the methods with unbiased estimate of treatment 
effect was as low as: 82.6% for CCA, 83.2% for MMRM, and 81.4% for MI. As in the case of 
a 10% dropout rate, the lowest power for these methods was observed under an MAR-B2 
mechanism. The observed power for MMRM and MI under an MAR-L mechanism was better 
than the corresponding power under MAR-B2, and even with differential dropout scenarios: 
the observed power ranged 85.9%–90.5% for MMRM and 83.2%–89.3% for MI. 
Similar findings were observed when the simulation study was repeated with an SW variance-
covariance (strong correlation and moderate SD) matrix (Appendix 7: table 25). 
6.4.2 When the desired power was 80% in the absence of missing data 
Table 6.2 provides the observed statistical power – when the desired power was 80% in the 
absence of missing data – for CCA, MMRM and MI in relation to the inflated sample sizes 
under 10% and 30% dropout scenarios. Graphical presentations of these results are given in 
appendix 7 (Figures 1 and 2). The findings were similar to the scenarios where the nominal 
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Table 6.2: The observed power (%) with inflated sample size – desired power was 80% 
Mechanism 
10% dropouts (n = 114) 30% dropouts (n = 162) 
CCA MMRM MI CCA MMRM MI 
Equal dropout between groups 
   
MCAR 78.9 79.2 78.0 81.0 82.1 80.0 
MAR-B1 78.8 79.5 78.4 81.0 82.1 80.2 
MAR-B2 77.7 78.8 77.0 75.5 76.6 73.6 
MAR-L1 81.1 80.6 79.5 80.3 81.2 79.4 
MAR-L2 69.0* 80.9 80.0 53.1* 80.6 78.6 
MNAR-1 81.2 81.4 80.0 81.5 82.1 81.1 
MNAR-2 48.1* 54.9* 52.7* 13.2* 18.6* 17.5* 
Higher dropout in the experimental group 
   
MCAR 80.1 80.7 79.8 79.0 80.1 78.5 
MAR-B1 80.0 80.0 78.3 79.2 80.3 77.4 
MAR-B2 78.4 78.6 78.3 72.7 73.9 71.5 
MAR-L1 82.3* 80.1 79.1 89.1* 79.2 77.4 
MAR-L2 68.8* 78.1 76.9 47.5* 78.2 74.1 
MNAR-1 89.3* 88.8* 87.4* 98.8* 97.9* 98.0* 
MNAR-2 48.3* 53.3* 51.7* 8.7* 15.0* 13.6* 
Higher dropout in the control group 
   
MCAR 80.1 80.9 79.3 80.3 81.1 79.9 
MAR-B1 79.3 79.4 78.3 77.4 78.7 76.8 
MAR-B2 77.6 78.6 77.9 74.7 76.9 73.9 
MAR-L1 76.5* 80.0 78.8 65.3* 80.6 79.3 
MAR-L2 69.6* 78.9 78.0 48.0* 81.4 77.3 
MNAR-1 71.8* 73.7* 72.4* 35.6* 42.1* 39.6* 
MNAR-2 48.7* 53.7* 52.3* 8.8* 14.8* 14.5* 
*Estimates of treatment effect were biased 
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With 10% overall dropout rate (Table 6.2), the inflated sample size retained the observed 
power closer to the desired power in those methods considered here when the estimate of 
treatment effect was unbiased. The observed power did not vary greatly with differential 
dropout rate or the direction of dropouts. In scenarios where the estimate of treatment effect 
was unbiased, the observed power with the inflated sample size was higher than 77.6% 
(under MAR-B2 with higher dropout in the control group) for CCA, higher than 78.1% (under 
MAR-L2 with higher dropout in the experimental group) for MMRM, and higher than 76.9% 
(under MAR-L2 with higher dropout in the experimental group) for MI. 
Similar findings were observed when the simulation study was repeated with an SW 
covariance (strong correlation and moderate SD) matrix (Appendix 7: table 26). 
With 30% dropout rate (Table 6.2), the inflated sample size maintained the desired power in 
CCA, MMRM and MI under an MCAR mechanism. Although the estimate of treatment effect 
was unbiased, CCA failed to attain the nominal power with the inflated sample size under 
MAR-B2. The loss was substantial when dropout rate was higher in the experimental group – 
the observed power was 72.7%. In all missing data mechanisms except MAR-B2, where the 
estimate of treatment effect was unbiased, MMRM demonstrated an observed power closer 
to the desired level. In MAR-B2, the observed power with MMRM was as low as 73.9% in the 
scenario with higher dropout rate in the experimental group; however, slightly higher power 
was observed under a scenario with an equal dropout rate between groups (the observed 
power was 76.6%) or higher dropout rate in the control group (the observed power was 
74.7%). MI also demonstrated an observed power closer to the desired level after increasing 
the sample size under scenarios where dropout rate was equal between groups, except for 
MAR-B2 and MNAR-2 missing data mechanisms. The loss of statistical power in MI after 
increasing the sample size was noticeable compared to MMRM in scenarios where 
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differential dropout occurred, and the loss of power was substantial in scenarios where 
dropouts were in opposite directions between the groups. In scenarios where the estimate of 
treatment effect was unbiased, the observed power of MI was considerably lower under 
MAR-B2 (73.6% with equal dropout rate between groups, 71.5% with higher dropout in the 
experimental group, and 73.9% with higher dropout in the control group) than under MAR-L2. 
6.5 Summary of findings 
In the first part of this chapter (section 6.2), I assessed the robustness of the results from 
CCA, MMRM, LOCF and MI to variations in the trajectory profile (trajectory 1) and the 
magnitude of the treatment effect (−9.0 at the primary endpoint) considered in chapter 5 
under various dropout scenarios. For CCA, MMRM and MI, the results were very similar 
across the trajectories and magnitudes of treatment effect when other factors were kept 
constant. However, the performance of LOCF varied considerably across the trajectories, 
especially when dropout rate was higher in the experimental group, where the improvement 
was substantial. It appears that the estimation of treatment effect using the LOCF approach 
was substantially affected by differential improvement over time between intervention groups. 
Hence, evaluation of trajectory profile by dropout patterns may be helpful to assess the 
impact of the LOCF approach. 
In the second part of the chapter (section 6.3), I compared the results from MMRM with 
baseline-as-covariate to an alternative repeated measures analysis model with baseline-as-
outcome. Since the presence of early dropouts is common in pragmatic trials, all simulated 
datasets in this thesis involved some participants without any follow-up measurements. 
Hence, analysis using the model with baseline-as-covariate led to the exclusion of those 
participants from the analysis. It was found that the inclusion of participants without any 
follow-up data (by considering baseline as an outcome) did not make a difference to the 
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estimates of treatment effect. However, with 30% dropouts, the study found a difference in 
the coverage of the 95% CI and the observed power. The model with baseline-as-covariate 
and Kenward-Roger correction showed the highest coverage, and the model with baseline-
as-outcome and without the correction showed the lowest coverage. In contrast, the model 
with baseline-as-outcome and without Kenward-Roger correction showed the highest power, 
and the model with baseline-as-covariate and the correction showed the lowest power. The 
differences were noticeable for the dropout mechanism with differing directions compared 
with the same direction. 
In the final part of this chapter (section 6.4), I evaluated the common practice of inflating 
sample size – by the inverse of one minus the anticipated dropout rate – to retain the desired 
power at a nominal level of 80% or 90% in the presence of dropouts. Overall, the inflation in 
sample size was helpful in protecting against the loss of power due to attrition. When the 
dropout rate was 10%, the methods – CCA, MMRM and MI – could retain the observed 
power very close to the desired level with the increased sample size in dropout scenarios 
where the estimate of treatment effect was unbiased. This was the case even with 30% 
dropouts under MCAR. However, the difference between the observed and desired power 
was noticeable in a few scenarios under MAR, though the estimate of treatment effect was 
unbiased. Importantly, the difference was not noticeable in the same-direction MAR 
mechanisms (MAR-B1 and MAR-L1), and was not substantially lower than 85% (when the 
desired power was 90%) or 75% (when the desired power was 80%) in cases where dropouts 
were in different directions between treatment groups (MAR-B2 and MAR-L2). Among the 
scenarios where the estimate of treatment effect was unbiased, the lowest statistical power 
was observed under MAR-B2. 
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6.6 Overall summary of findings from simulation studies 
Simulation studies in chapters 5 and 6, which examined the relative performance of four 
statistical analysis approaches (CCA, LOCF ANCOVA, MMRM and MI ANCOVA), have 
demonstrated the impact of missing data on the estimation of treatment effect in an RCT. The 
comparison was in respect of various levels of experimental conditions typical of an RCT: 
levels of data variability, levels of correlation between repeated assessments, trajectory 
pattern, levels of overall dropouts, levels of differential dropout rates between groups, and 
direction of dropouts. These evaluations were performed in missing data scenarios where the 
missing data mechanism was known. Results from these simulation studies have shown that 
MMRM and MI yield unbiased estimates of treatment effect under MCAR and MAR-
dependent on baseline or the last observed value, whereas CCA produces biased estimates 
with MAR-dependent on the last observed value. The performance of LOCF was severely 
influenced by the dropouts’ trajectory profile and the timing of dropouts, irrespective of the 
missing data mechanism that was used to generate dropouts. That is, MMRM and MI 
ANCOVA are found to be more robust to bias from missing data compared to CCA and LOCF 
ANCOVA. Under all MNAR data scenarios, except the scenario of equal dropout rates with 
the same direction of dropout, none of the considered approaches performs well in terms of 
controlling bias in estimation of treatment effect; the bias markedly increases in relation to an 
increase in overall dropout rate and data variability. When the estimate of treatment effect 
from a statistical method was unbiased, the simulation studies showed that the coverage of 
95% CI of the estimate was not affected (i.e. performance in respect of coverage closely 
aligned to performance in respect of bias); however, statistical power was substantially 
reduced with higher dropout. In the additional simulation studies, it was found that the 
inflation in sample size in proportion to the amount of dropout was helpful in protecting 
against the loss of power due to attrition. Also, the inclusion of participants without any follow-
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up data (by considering baseline as an outcome with MMRM analysis) did not make a 
difference to the estimates of treatment effect compared to those from the analysis excluding 
such participants. However, the study found a slight difference in the coverage of the 95% CI 
and the observed power due to slightly reduced average SEs with the baseline-as-outcome 
method for scenarios of opposite direction of dropout. 
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Chapter 7: An empirical evaluation of the impact of missing data 
on treatment effect: analysis of TATE and STarT Back trials 
7.1 Introduction 
This chapter presents a re-analysis of two pragmatic clinical trials wherein the trial team 
had taken extra effort to minimize the amount of dropouts by sending reminders to initial 
non-responders and finally limiting data collection to key outcome measures. The present 
work utilizes the additional information from these trials and the earlier simulation study 
findings to assess the impact of missing data on the estimation of treatment effect. The 
next few sections (7.2–7.4) present the background, methodology and assumptions 
behind the present approach. Sections 7.5 and 7.6 present the results from the analysis of 
the two empirical datasets. Section 7.7 discusses the proposed approach and findings, 
and section 7.8 concludes the findings. 
7.2 Background 
Simulation studies in the previous chapters have shown that MMRM and MI yield 
unbiased estimates of treatment effect under MCAR and MAR dependent on baseline or 
the last observed value, whereas CCA produces biased estimates with MAR dependent 
on the last observed value. The performance of LOCF was severely influenced by the 
dropouts’ trajectory profile and the timing of dropouts, irrespective of the missing data 
mechanism that was used to generate dropouts. In summary, the efficiency and accuracy 
of estimates from statistical methods depend on how close the mechanisms generating 
either the data or missing values are to the underlying statistical assumptions of the 
methods used. In practice, the missing data mechanisms are not strictly identifiable from 
incomplete data, so the desired “fit” in terms of assessing whether a method properly 
aligns to the mechanism of missingness is difficult to ascertain. Further, comparison of 
estimates of treatment effect from different methods in an empirical dataset is not 
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sufficient to make a valid conclusion about the unbiasedness of the estimates since the 
‘true’ value is unknown. As seen in the simulation studies under MNAR mechanisms, the 
equality of estimates from these methods may not guarantee accuracy. 
An MMRM or MI-based analysis should be treated as the primary analysis in longitudinal 
RCTs because of the following: (i) MMRM/MI-based analysis provides accurate and 
consistent estimates of treatment effect in relatively larger number of scenarios than 
CCA/LOCF-based analysis and (ii) since the observed outcome is likely to be associated 
with dropouts in a longitudinal RCT, an MAR missing data mechanism might be more 
plausible than an MCAR mechanism. Since it is not possible to guarantee that at least 
some of the missing data are not MNAR, it is important to assess the sensitivity of results 
from an MAR-based analysis to departure from the MAR assumption. The NRC report on 
the prevention and treatment of missing data in clinical trials (National Research Council, 
2010) highlights the need for sensitivity analyses to confirm the primary analysis findings; 
however, the report also acknowledges the lack of guidelines on the selection of 
sensitivity analyses and interpretation of their findings, and lack of software packages16 to 
implement such analyses. Considering the difficulties associated with the sensitivity 
analyses, I propose an approach using the responses obtained after a number of failed 
attempts to verify the ignorability of the missing data that is assumed by the primary 
analysis and hence the unbiasedness of the estimate of treatment effect. 
7.3 Reminder responses as proxies of non-responses 
In an effort to minimize the amount of dropout in pragmatic RCTs, trialists often follow a 
strategy of sending reminders to initial non-responders and re-approaching them for 
minimum data collection (MDC), where data collection is usually limited to the primary 
                                               
16
 PROC MI in SAS/STAT(R) 13.2 (SAS Institute Inc., 2014) has a few options for doing a 
sensitivity analysis based on MI. 
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outcome variable plus perhaps other key outcome measures, if they have still failed to 
respond. The data that are recovered through the reminder strategy would otherwise have 
been missing. That is, one of the key features of the reminder responses is that they are 
data that can be treated as missing while knowing their true value. The simulation studies 
in chapters 5 and 6 showed that the estimate of treatment effect from a statistical method 
is not affected by the amount of dropout when the mechanism behind the missing data 
meets the assumption associated with the statistical method. For example, in MAR data, 
MMRM analysis yielded similar estimates of treatment effect irrespective of a 10% or 30% 
dropout rate; whereas in MNAR data, MMRM analysis yielded dissimilar estimates of 
treatment effect under 10% and 30% dropout rate scenarios. The purpose of this chapter 
is to explore empirically the mechanism behind the reminder responses in specific trial 
data by utilizing the key feature of the reminder data and the simulation findings, and 
thereby to verify the missing data mechanism that is assumed by the primary analysis. 
The following paragraphs explain the approach in detail. 
The present approach considers two data scenarios: (i) one with the actual dataset and (ii) 
another one with a modified dataset, where outcome responses after a certain number of 
reminders are regarded as missing. The comparison of estimates from MAR-based 
analyses between the two data scenarios – actual versus modified datasets – identifies 
the impact of the reminder responses. If the mechanism behind the reminder responses 
meets the statistical assumption with regard to the statistical method applied for the 
estimation of treatment effect, the estimates of treatment effect from the actual and the 
modified datasets are expected to be similar. This conclusion is justified by the simulation 
studies (Chapters 5 and 6) in which it was found that a valid MAR-based estimate of 
treatment effect was not influenced by the amount of missing data that were generated 
under an MCAR or Mar mechanisms. Therefore, similar MAR-based estimates from the 
actual and modified datasets indicate that the mechanism behind the reminder responses 
is potentially ignorable. On the other hand, dissimilar estimates of treatment effect from 
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the actual and the modified datasets based on an MMRM or MI analysis indicate that 
either reminder or actual missing responses are non-ignorable under the MAR-based 
analysis. That is, dissimilar estimates from the datasets do not confirm a particular 
mechanism to either the reminder or actual missing responses. 
In order to extend the finding on reminder responses to the actual missing responses, it is 
required to assume the reminder responses as representative of the actual missing 
responses. The plausibility of the assumption can be increased by defining the reminder 
responses as the responses that are obtained after a number of failed attempts to recover 
the data. If reminder responses are representative of the actual missing responses, then 
the mechanisms generating the reminder responses and the missing responses might be 
similar. Therefore, similar estimates of treatment effect based on an MAR-based analysis 
from the actual and the modified datasets generally indicate an ignorable missing data 
mechanism and the unbiasedness of the estimates obtained from both the datasets, if the 
assumption holds. Correspondingly, dissimilar estimates of treatment effect based on an 
MAR-based analysis from the actual and modified datasets generally indicate a non-
ignorable missing data mechanism, if the assumption holds. In the latter case, the 
estimates of treatment effect from MAR-based analyses of the actual and modified 
datasets are biased, and the difference in estimates between the datasets might be the 
additional bias associated with the reminder responses in the modified dataset where the 
reminder responses are regarded as ‘missing’ for the comparison. 
7.4 Methods 
This study used datasets from two recent RCTs: (i) an RCT that evaluated transcutaneous 
electrical nerve stimulation as an adjunct to primary care management for tennis elbow 
(TATE trial; Chesterton et al., 2009; 2013) and (ii) an RCT that compared stratified 
primary care management for low back pain with current best practice (STarT Back trial; 
Hay et al., 2008; Hill et al., 2011). Both primary and key secondary outcome variables 
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from these trials were included since these variables provide different levels of missing 
data (depending on whether or not the MDC strategy had been employed) and can add to 
the imputation modelling of the MI method. In each trial dataset, initial explorations were 
carried out with respect to the amount and pattern of missing data. Forward logistic 
regression models were used to investigate which factors – such as baseline covariates, 
post-randomization variables and previously observed outcomes – were associated with 
the probability of missingness for outcomes at each follow-up. A significant finding 
counters the possibility of an MCAR mechanism. Further, correlation analysis was used to 
assess association between variables in each datasets. The predictors of missingness for 
an outcome and predictors of the outcome were used for evaluating an MI modelling 
strategy. 
The incomplete empirical datasets were analysed using the four different approaches to 
deal with missing values. In the first approach, a standard ANCOVA (i.e. CCA) was 
employed, wherein a substantial number of participants who failed to provide sufficient 
data were excluded. In order to take account of the exclusion of participants with missing 
values from the ANCOVA model, incomplete datasets were also analysed using the 
approaches of: LOCF ANCOVA, MI ANCOVA and MMRM. MI was implemented in two 
different ways by considering two modelling strategies: restrictive and inclusive. In the 
restrictive imputation model, the imputation phase included only variables considered in 
the subsequent analysis (estimation) model; whereas the inclusive imputation model 
included auxiliary variables that were not part of the subsequent analysis model. The 
simulation studies in this thesis were very restrictive in that they utilized an MI imputation 
model that included only the outcome variable of interest and the treatment indicator (so 
being similar in content to the comparison MMRM model). Both the MMRM and MI-
restrictive imputation analyses yielded similar estimates of treatment effect but slightly 
different SEs. Sequential imputation using chained equations (StataCorp, 2013) with a 
regression procedure was used to impute missing values in the outcome variables. Five-
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hundred imputed datasets were created to reduce sampling variability from the imputation 
process and 50 iterations were used for the burn-in period prior to saving each imputed 
dataset to ensure a chain that converged to a stationary distribution. The MMRM with 
baseline-as-covariate analysis was performed using a restricted maximum likelihood 
estimation procedure. The model included the fixed-effect outcome variables, categorical 
effects of treatment and treatment-by-time interaction, as well as the fixed covariates of 
baseline score, age and sex, and covariates-by-time interactions. An unstructured 
covariance structure was used to model within-subject errors. Since the presence of early 
dropouts was substantial in both the trials, the MMRM analysis was repeated by 
considering baseline-as-outcome to make the analysis truly intention-to-treat and to 
explore the impact of the exclusion of participants with only baseline data. 
The estimates of treatment effect at the final visit (primary endpoint) and its SE for the 
primary and the secondary outcome variables were obtained from these analysis methods 
in each data scenario (i.e., the actual and the modified datasets). The estimates were 
adjusted for age, sex and baseline score. Standardized effect size of treatment effect for 
an outcome was calculated as the estimate of treatment effect divided by the baseline SD 
of the outcome variable. The advantage of using baseline SD as the denominator is that 
the baseline spread is not influenced by dropouts since baseline observations are usually 
available on all randomized subjects. 
The comparison of effect size from CCA with that from MMRM/MI analysis helps to 
assess the impact of the MCAR assumption with respect to the MAR assumption. 
Dissimilar estimates from methods assuming MCAR and MAR mechanisms can be taken 
as an indication against the MCAR mechanism; however, agreement between CCA and 
MMRM/MI analyses cannot be taken as an indication that data are MCAR. As found in the 
simulation studies, it is quite possible for a mechanism to produce non-ignorable 
missingness, yet result in comparable outcomes in these methods. 
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Finally a comparison of estimates from the actual and modified data scenarios was 
performed. Importantly, if the assumption that the reminder responses are representative 
of the actual missing responses holds, the difference in estimates between the two data 
scenarios can inform a preliminary estimate of the potential non-response bias associated 
with an MAR-based analysis of the actual dataset. In order to make the assumption more 
plausible, the reminder responses on the primary outcome were defined as the responses 
obtained through the MDC (i.e. responses retrieved after three failed attempts) in the 
TATE and STarT Back trials. The reminder responses on secondary outcome variables, 
where no MDC strategy was implemented, were defined as the responses obtained after 
the second reminder in the TATE trial; however, no reminder information on secondary 
outcome variables was available in the STarT Back trial. If the assumption holds, similarity 
in estimates between the data scenarios indicates an MCAR or MAR mechanism and 
unbiasedness of the estimates obtained from the actual data, whereas dissimilarity 
indicates an MNAR mechanism and the possibility of bias in the estimate of treatment 
effect from the actual data. 
7.5 The TATE trial 
The TATE trial (Chesterton et al., 2009; 2013) was designed as a pragmatic RCT to 
investigate the effectiveness of transcutaneous electrical nerve stimulation (TENS) as an 
adjunct to primary care management (PCM) for reducing pain intensity in patients with 
tennis elbow. Two hundred and forty-one participants with a first or new clinical diagnosis 
of tennis elbow were randomly allocated to either PCM alone (n = 120) or PCM plus TENS 
(n = 121). The total sample size was calculated to detect a 20% difference in the primary 
outcome between intervention groups with 90% power, 5% two-tailed significance level 
and 15% anticipated loss to follow-up. The primary outcome was the intensity of elbow 
pain, and the secondary outcomes were patient-rated tennis elbow evaluation (PRTEE) 
and the 12-item short-form health survey (SF12). The pain intensity score ranges from 0 
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(no pain) to 10 (worst pain imaginable). The PRTEE score ranges between 0–100, with 
high scores indicating greater pain/limitation. The SF12 provides two summary measures 
– physical component summary (SF12-PCS) and mental component summary (SF12-
MCS), each measured on a 0–100 scale with high scores indicating better general health. 
All the outcomes were self-reported. The outcomes were assessed at baseline prior to 
randomization and were further measured at six weeks, six months, and 12 months after 
randomization by postal questionnaires. Though 6 weeks evaluation was the original 
primary endpoint, the 12 months is regarded as the primary endpoint in this analysis in 
order to ensure two interim visits prior to the primary endpoint. 
At each follow-up if a participant did not return their questionnaire within two weeks after 
the first mail-out a reminder was issued, and subsequently a second reminder two weeks 
later if they had still not responded. Participants who did not respond to the reminder 
letters were telephoned twice: the first call as a reminder and the second one to those 
who did not respond to the previous reminders to collect minimum data (i.e. data on the 
primary outcome). The data that were collected through either the reminders or the MDC 
– the data that would otherwise have been missing – allows trialists to investigate the 
impact of the reminder strategy on the trial's conclusion. The average number of days 
delay in response after the first mail-out at each follow-up visit is provided in table 7.1. For 
the purpose of the re-analysis, participants who responded through the MDC strategy 
were considered as ‘reminder’ responders on the primary outcome (pain intensity); the 
remaining responders were considered as ‘initial’ responders for the primary outcome. For 
the secondary outcomes where there was no MDC, participants who responded to the first 
mail-out or the first reminder were considered as ‘initial’ responders, and participants who 
responded after the second mail reminder were considered as ‘reminder’ responders. This 
classification is based on the assumption that the reminder data are more likely to 
represent the non-responder data when the number of failed attempts (i.e. number of 
reminders) increases. 
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Table 7.1: Responders’ status at follow-up assessments 
Responding through 
Week 6 Month 6 Month 12 
n Mean* n Mean* n Mean* 
First mail-out 93 11.5 109 14.1 103 13.2 
First reminder 41 22.0 23 38.9 28 39.4 
Second reminder
†
 - - 14 56.0 13 55.8 
First telephone call 26 56.4 4 114.8 5 76.8 
Minimum data 
collection 
50 90.9 31 110.0 26 92.7 
* Average number of days delay in response after the first mail-out. 
†
There was no second reminder at week 6. 
 
7.5.1 Descriptive analysis of missing data 
7.5.1.1 Missing data in the TATE trial 
The proportions of missing data for the primary and secondary outcome variables in the 
actual dataset are shown in figure 7.1. The dropout rate was up to 40% (96/241) at the 
final visit for some variables (Figure 7.1b) with differential rates between the two 
intervention groups (46% [55/120] in PCM only and 34% [41/121] in PCM plus TENS). A 
better response rate was achieved for the pain intensity score through the MDC strategy 
(Figure 7.1a). The dropout rate for the pain intensity score at the final visit was 26% (32% 
[38/120] in PCM only and 20% [24/121] in PCM plus TENS). As seen in the figures, a 
substantial number of participants dropped out even prior to the first follow-up at week 6, 
and intermittent missing data (due to missed visits or missed item) were limited to a small 
proportion of participants in all outcome variables. The trial could obtain reasons for 
dropouts in limited instances only. The reasons could have been helpful in guiding 
judgement on the missing data mechanism if it were obtained in full. 
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The numbers displayed on the bars represents the number of participants; the reminder data includes 
the responses recovered after second reminder; *reminder data excludes the responses through MDC 
 
Figure 7.1: Response rate (%) over time on outcome measures – (a) pain intensity, (b) 
PRTEE total score, and (c) SF12 score.  
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In the modified dataset, the amount of missing data at the final visit for the primary 
outcome, where minimally collected responses (retrieved through MDC strategy) were 
designated as missing, was 44% (53/120) in PCM only and 32% (39/121) in PCM plus 
TENS. That is, a difference of 12% in dropout rate between the actual (26%; 62/241) and 
the modified (38%; 92/241) datasets. For the secondary outcome measures where 
reminder responses (retrieved through second and third reminders) were designated as 
missing, it was 56% (67/120) in PCM only and 39% (47/121) in PCM plus TENS. That is, 
a difference of 7% in dropout rate between the actual (40%; 96/241) and modified (47%; 
114/241) datasets. 
7.5.1.2 Dropout pattern and predictors of missingness in the TATE trial 
Knowing the missing data mechanism is important in determining the best way to handle 
the missing data in order to provide the least biased results. Figure 7.2 displays the mean 
score over time by different dropout patterns for the primary and secondary outcome 
variables. The number of participants within each dropout pattern can be determined from 
figure 7.1. Taking figure 7.2a as an example, 20 and 7 participants dropped out before the 
first follow-up assessment from the control and intervention groups, respectively. The 
observed mean baseline scores for these participants are represented with square and 
round dots in figure 7.2a. Another 18 participants (13 from the control group and 5 from 
the experimental group) were lost to follow-up in between week 6 and month 6. The 
group-wise mean score at baseline and week 6 for these participants are represented in 
lines (black lines; solid for PCM plus TENS and dashed for PCM only) ending at week 6. 
Another 17 (5 from the control group and 12 from the experimental group) dropped out 
before the endpoint at month 12. The group-wise mean scores at baseline, week 6 and 
month 6 for these participants are represented in lines (blue lines) ending at month 6. The 
green lines represent the completers. 
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The solid lines represent the estimates from the PCM plus TENS group and dashed lines represent 
the estimates from PCM only group. Red denotes dropouts between baseline and week 6; black 
denotes dropouts between week 6 and month 6; blue denotes dropouts between month 6 and 
month 12; green denotes completers. 
 
Figure 7.2: Observed mean profiles according to intervention groups and time at 
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If mean profiles are similar across different dropout patterns, then the data help support 
the MCAR missingness mechanism; otherwise, if the mean trajectories are dissimilar, this 
would counter MCAR in favour of MAR or MNAR. For the pain intensity score (Figure 
7.2a), the mean profiles for the dropouts at various time-points were notably different from 
those who completed the final follow-up. Further, the observed differences between the 
intervention groups in the last observed values before dropping out were dissimilar across 
the dropout pattern. The differential dropout rate, combined with the trend of improved 
pain intensity score for all subjects in later visits (i.e. over time), would cause LOCF 
analysis to give inaccurate estimates of the treatment effect at the final visit. A similar 
observation could be made with other variables: PRTEE (Figure 7.2b) and SF12-PCS 
(Figure 7.2c). Importantly, in figure 7.2b, the dissimilarity in the observed differences 
across the dropout patterns was noticeable, and hence the estimates of treatment effect 
from CCA and LOCF approaches would be expected to be different. In figure 7.2d, the 
dissimilarity was not noticeable across the dropout patterns except for those who dropped 
out without any follow-up measurements. Due to a significant number of early dropouts, 
the difference in the mean baseline value of SF12-MCS for the early dropouts between 
the intervention groups (50.1 for PCM only and 46.3 for PCM plus TENS) may influence 
the LOCF estimate of treatment effect. 
The odds ratio (OR) from logistic regression models indicated that the intervention group 
was significantly associated with a lower probability for missing response in the primary 
outcome (adjusted OR = 0.44, p = 0.039), where MDC strategy had been applied, at the 
first follow-up (week 6). For the secondary outcomes, where the level of missing data was 
similar across the outcomes and the MDC strategy had not been applied, the intervention 
group (adjusted OR = 0.37, p = 0.001), and increased baseline age (adjusted OR = 0.95, 
p = 0.002) and SF12-MCS (adjusted OR = 0.97, p = 0.049) showed an association with 
the lower level of missingness. 
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At month 6, the intervention group and age at baseline were significant predictors of 
missingness in the primary outcome and the secondary outcomes. The adjusted OR for 
the intervention group was 0.30 (p-value < 0.001) for missingness in the primary outcome, 
and 0.39 (p-value = 0.001) for missingness in the secondary outcomes; for age at 
baseline, the adjusted OR was 0.96 (p = 0.025) and 0.93 (p < 0.001), respectively. The 
intervention group (adjusted OR = 0.10, p = 0.001), baseline pain intensity (adjusted OR = 
1.82, p = 0.017), and week 6 PRTEE (adjusted OR = 1.08, p = 0.006) and SF12-PCS 
(adjusted OR = 1.15, p = 0.033) were found to be significantly associated with the 
additional missing responses at month 6 compared to week 6. The probability of the 
additional missing responses in the secondary outcomes was dependent on baseline data 
on age (adjusted OR = 0.94, p = 0.025), pain intensity (adjusted OR = 1.42, p = 0.043) 
and PRTEE (adjusted OR = 0.93, p = 0.005) and week 6 data on PRTEE (adjusted OR = 
1.03, p = 0.030). 
The intervention group and age were significant predictors of missing response in the 
primary and secondary outcomes at month 12. However, no variables (either baseline or 
previously observed data) were found to be significantly associated with the additional 
missing responses at month 12 compared to month 6. 
In summary, the above associations provide evidence against the MCAR scenario in the 
dataset; however, there is no evidence to favour either an MAR or an MNAR mechanism. 
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Table 7.2: The observed pairwise correlation between variables in the actual dataset 
 
Age Pain score PRTEE SF12-PCS SF12-MCS 
 
w0 w6 m6 m12 w0 w6 m6 m12 w0 w6 m6 m12 w0 w6 m6 m12 
Age 
 








 w0 0.03 1.00                
w6 -0.07 0.40 1.00               
m6 -0.06 0.16 0.37 1.00              






 w0 0.01 0.72 0.34 0.21 0.26 1.00            
w6 -0.13 0.47 0.85 0.37 0.35 0.53 1.00           
m6 -0.03 0.23 0.53 0.85 0.61 0.35 0.60 1.00          








 w0 -0.17 -0.40 -0.17 -0.12 -0.20 -0.46 -0.35 -0.26 -0.32 1.00        
w6 -0.18 -0.24 -0.36 -0.22 -0.14 -0.34 -0.45 -0.38 -0.27 0.62 1.00       
m6 -0.10 -0.08 -0.27 -0.40 -0.23 -0.22 -0.29 -0.49 -0.36 0.46 0.67 1.00      








 w0 0.14 -0.14 -0.17 -0.25 -0.16 -0.23 -0.18 -0.29 -0.14 0.00 0.10 0.26 0.26 1.00    
w6 0.17 -0.08 -0.11 -0.07 0.02 -0.22 -0.29 -0.18 -0.03 0.16 0.08 0.18 0.18 0.63 1.00   
m6 0.06 -0.10 -0.10 -0.10 -0.09 -0.14 -0.14 -0.18 -0.09 0.13 0.13 0.04 0.13 0.50 0.59 1.00 
 
m12 0.05 -0.14 -0.03 -0.04 -0.15 -0.16 -0.17 -0.16 -0.20 0.22 0.09 0.06 0.05 0.56 0.55 0.61 1.00 
Bold values represent the absolute values of the correlations higher than 0.30. 
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Table 7.2 provides the observed pairwise correlation between variables at different 
occasions. Though age was a significant predictor of missingness in outcome variables, it 
did not show a significant correlation with any of the outcome variables at any occasion. 
PRTEE showed the strongest correlation with pain intensity and SF12-PCS; however, 
SF12-MCS showed only weak correlations with any other variables. 
In the next section, both the actual and the modified datasets were analysed using the 
considered statistical methods, and an assessment made of the impact of the reminder 
response on the trial's conclusion from the data with no distinction between the initial and 
reminder data. 
7.5.2 Analysis of the incomplete TATE trial – estimation of treatment effect at 
month 12 
7.5.2.1 Results from the actual dataset 
Table 7.3 provides the estimates of treatment effect, SE and standardized effect size for 
the primary and secondary outcomes at the final visit based on a standard ANCOVA (i.e. 
CCA) and LOCF ANCOVA models. Due to an MDC strategy, the number of participants 
with complete data on the primary outcome (pain intensity) was substantially higher 
compared to the secondary outcome measures. As shown in table 7.3, LOCF produced a 
substantially different estimate of treatment effect in comparison with CCA, particularly for 
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Table 7.3: TATE - ANCOVA results at 12 months follow-up before and after LOCF 


























Pain intensity -0.452 0.302 0.137 -0.220 
 
-0.953 0.304 0.002 -0.464 
PRTEE -3.599 3.057 0.241 -0.203 
 
-8.566 2.841 0.003 -0.483 
SF12-PCS 0.134 1.476 0.928 0.014 
 
1.073 1.089 0.326 0.111 
SF12-MCS 2.214 1.532 0.151 0.202 
 
1.900 1.057 0.073 0.173 
Estimate – estimate of treatment effect for an outcome at month 12 adjusted for age, sex, baseline 
pain intensity, and the corresponding baseline of the outcome; SE – standard error; 
1
Pain intensity 
measured on a 0–10 scale, other outcomes on a 0–100 scale. 
2
Number of subjects included in the 
analysis was 179 for pain intensity, 145 for PRTEE, and 146 for SF12-PCS and MCS. 
3
Number of 
subjects included in the analysis was 241 for all outcomes.
 4
Treatment effect relative to the pooled 
SD of baseline scores. 
 
 
Under the standard ANCOVA analysis, the estimates of treatment effect in both the 
primary and secondary outcomes were statistically non-significant at the primary endpoint. 
However, the estimates of treatment effect of pain intensity (measured on a 0–10 scale) 
and PRTEE (measured on a 0–100 scale) markedly favoured the new intervention when 
missing data were imputed through LOCF approach – the absolute difference in 
standardized effect size between the two analysis methods was 0.244 for pain intensity 
and 0.280 for PRTEE measure. The treatment effect in these two outcome measures 
became statistically significant with LOCF. The estimates of treatment effect in SF12-PCS 
(measured on a 0–100 scale) also increased in favour of the new intervention at the 
primary endpoint under LOCF ANCOVA but retained non-significance. On the other hand, 
the estimate for SF12-MCS (measured on a 0–100 scale) slightly reduced under LOCF 
ANCOVA compared to the standard ANCOVA (though the p-value was also slightly 
lower). LOCF ANCOVA yielded a lower SE compared to the standard ANCOVA in all 
scenarios, except for pain intensity at month 12, in relation to the amount of missing data. 
Table 7.4 presents the treatment effect in the primary and the secondary outcomes at the 
final visit estimated from the actual dataset based on MMRM models. The estimate of 
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treatment effect did not differ by the baseline handling strategies in the MMRM model. 
That is, subjects with only baseline values did not make a difference to the estimate at the 
follow-up visit. However, the SE of the estimate was slightly lower in an MMRM model 
with baseline-as-outcome compared to the baseline-as-covariate strategy. 


























Pain intensity -0.456 0.300 0.129 -0.222 
 
-0.456 0.299 0.127 -0.222 
PRTEE -3.788 2.910 0.193 -0.214 
 
-3.788 2.900 0.191 -0.214 
SF12-PCS -0.193 1.422 0.892 -0.020 
 
-0.193 1.396 0.890 -0.020 
SF12-MCS 2.502 1.505 0.096 0.228 
 
2.503 1.494 0.094 0.229 
Estimate – estimate of treatment effect at month 12 adjusted for fixed covariates (age, sex, 
baseline pain intensity, baseline of outcome variable) and their interaction with time; SE – standard 
error;
 1
Pain intensity measured on a 0–10 scale, other outcomes on a 0–100 scale. 
2
Number of 
subjects included in the analysis was 214 for pain intensity and 182 for other outcomes. 
3
Number 
of subjects included in the analysis was 241 for all outcomes.
 4
Treatment effect relative to the 
pooled SD of baseline scores. 
 
 
For the primary outcome (pain intensity), the estimate of treatment effect and its SE from 
MMRM analysis were very close to that from CCA. For the secondary outcomes (PRTEE, 
SF12-PCS and SF12-MCS), the standardized effect sizes were slightly more in favour of 
the new intervention compared to CCA. In combination with a reduced standard error, this 
resulted in slightly lower p-values for MMRM analysis compared to CCA, but this small 
change was not sufficient to influence statistical significance. 
Table 7.5 presents the MI-based ANCOVA results from the actual dataset. A restrictive 
imputation model included only the variables considered for an MMRM model for an 
outcome variable (i.e. baseline score, age and sex in addition to the outcome variable), 
whereas an inclusive model additionally included variables that were not part of the 
MMRM model for that outcome variable. The estimates of treatment effect from the MI 
ANCOVA with restrictive modelling were comparable to that from MMRM for all outcome 
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variables. However, the SE of the estimate from the MI was higher than that from MMRM, 
but comparable to that from CCA. 


























Pain intensity -0.458 0.305 0.136 -0.223 
 
-0.497 0.306 0.106 -0.242 
PRTEE -3.817 3.038 0.211 -0.215 
 
-3.961 2.771 0.155 -0.223 
SF12-PCS -0.276 1.448 0.849 -0.029 
 
-0.424 1.500 0.778 -0.044 
SF12-MCS 2.411 1.541 0.120 0.220 
 
2.796 1.584 0.080 0.255 
Estimate – estimate of treatment effect at month 12 adjusted for age, sex, baseline pain intensity, 
and corresponding baseline of outcome variable; SE – standard error of the difference; Restrictive 
modelling – imputation models included only those variables considered for the MMRM analysis 
models; Inclusive modelling – imputation model for an outcome included, in addition to the 
variables considered for the MMRM analysis model, other outcome variables as auxiliary variables 
in order to improve the performance of the imputation procedure;
 1
Pain intensity measured on a 0–
10 scale, other outcomes on a 0–100 scale. 
2
Number of subjects included in the analysis was 241 
for all outcomes. 
3
Treatment effect relative to the pooled SD of baseline scores. 
 
 
An inclusive imputation model with MI produced an increased standardized effect size for 
all outcome measures compared to the restrictive modelling based MI. Reduced SE for 
PRTEE was observed with the inclusive imputation modelling; however, there was a very 
slight increase in SE with the other outcome measures. Even though none of the auxiliary 
variables in the inclusive imputation model were found to be a significant predictor of 
missingness in SF12-MCS at month 12 or correlated with SF12-MCS, there was a 
difference of 0.035 in the standardized effect size for SF12-MCS and a difference of 0.043 
in the SE between the two imputation modelling strategies. Results based on various 
inclusive imputation models with MI are reported in appendix 8 (Tables 27–30). The 
results indicate slight inconsistency in the estimate of treatment effect and SE, though 
none that affected statistical decision-making. 
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7.5.2.2 Results from the modified dataset and the impact of reminder or MDC 
responses 
Table 7.6 provides the results from the modified dataset including deviation in the 
standardized effect size and SE from that observed with the actual dataset. As observed 
with the actual dataset, the estimates of treatment effect (and hence the standardized 
effect size) obtained from MMRM and MI with restrictive imputation modelling did not differ 
for any outcome measure in the modified dataset, and the SE was slightly lower for 
MMRM compared to MI. However, this was not the case with CCA versus MMRM or MI – 
both the estimates and SEs differed between the methods. The SE of the estimate from 
all methods increased due to the higher number of missing responses with the modified 
dataset. 
In MAR-based analyses (MMRM and MI), an increased standardized effect size – 
approximately 3% of baseline SD – for pain intensity was observed with the modified data 
compared to the actual data; CCA also yielded a similar increase – approximately 4% of 
baseline SD – with the modified data. Similarly, an increased standardized effect size – 
approximately 5% of baseline SD – for PRTEE was observed with MAR-based analyses 
of the modified data, but little difference with CCA. With MMRM analysis, the standardized 
effect size for SF12-PCS was changed from −0.020 in the actual data to 0.033 in the 
modified data (i.e. approximately 5% of baseline SD). MI also yielded a similar difference; 
but, little difference with CCA. The standardized effect size for SF12-MCS differed 
between the two datasets mostly with MMRM and CCA: the estimate was reduced with 
MMRM while it increased with CCA. Importantly, for any outcome measure in the modified 
dataset, the final statistical conclusion did not change from the inference that was made in 
the actual dataset (p-value > 0.05 for all outcome measures). 
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Deviation in results 
from actual dataset 








Results from MMRM (baseline-as-covariate) 
   
Pain intensity 241 -0.524 0.327 0.109 -0.255 
 
-0.028 0.033 
PRTEE 241 -4.722 2.975 0.112 -0.266 
 
-0.065 0.053 
SF12-PCS 241 0.316 1.576 0.841 0.033 
 
-0.154 -0.053 
SF12-MCS 241 2.172 1.586 0.171 0.198 
 
-0.081 0.030 
Results from MI (restrictive modelling) 
    
Pain intensity 241 -0.528 0.331 0.112 -0.215 
 
-0.026 0.034 
PRTEE 241 -4.723 2.987 0.116 -0.266 
 
0.051 0.051 
SF12-PCS 241 0.397 1.629 0.808 0.041 
 
-0.182 -0.070 
SF12-MCS 241 2.233 1.627 0.173 0.204 
 
-0.087 0.016 
Results from ANCOVA 
      
Pain intensity 149 -0.533 0.336 0.115 -0.260 
 
-0.034 0.039 
PRTEE 127 -3.558 3.162 0.263 -0.201 
 
-0.105 -0.002 
SF12-PCS 128 0.192 1.665 0.908 0.020 
 
-0.189 -0.006 
SF12-MCS 128 2.464 1.616 0.130 0.225 
 
-0.084 -0.023 
n – number of subjects included in the analysis; estimate – estimate of treatment effect at month 
12; SE – standard error;
 1
Pain intensity measured on a 0–10 scale, other outcomes on a 0–100 
scale. 
2
reminder responses were regarded as missing (for pain intensity, the reminder responses 
include responses retrieved through MDC; for other outcomes, reminder responses include 
responses retrieved after second reminder).
 3
Treatment effect relative to the pooled SD of baseline 
scores. 
 
7.5.3 Summary and interpretation of findings 
The estimates of treatment effect and SE with LOCF ANCOVA for pain intensity, PRTEE 
and SF12-PCS were quite different from those of the other imputation methods and CCA 
in the actual dataset. Variance estimates from CCA, MMRM and MI are generally larger 
than LOCF, because LOCF often underestimates standard errors when there is missing 
data. This study has, however, found an example where the LOCF-estimated variance for 
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pain intensity was higher than CCA, MMRM, or MI when the LOCF values were very 
different from the observed values at the final visit. 
In the actual dataset, both the estimate of treatment effect and the SE for the pain 
intensity were similar across the MCAR-based and MAR-based analyses. However, 
based on this finding alone one should not necessarily conclude that the missing data 
mechanism was MCAR. Further, findings from the graphical evaluation of dropout 
patterns and logistic regression based identification of predictors of missingess did not 
support the MCAR assumption. The comparison of estimates from the actual dataset 
(dropout rate at month 12 was 26%) and the modified dataset (dropout rate at month 12 
was 38%) found that treatment effect in pain intensity would have been overestimated by 
3% of baseline pain intensity SD with an MAR-based analysis if an MDC strategy had not 
been implemented. This finding points towards a potential MNAR mechanism associated 
with missing pain intensity scores if the responses that had been retrieved through the 
MDC represent the actual missing data. It implies that the ‘true’ estimate of treatment 
effect (and effect size) might be lower than the observed estimate if the assumption holds; 
however, it was very unlikely that difference in the estimates would influence the statistical 
decision-making due to the small observed effect size. 
For the secondary outcome measures, the amount of missing data differed only by around 
7% between the actual dataset (amount of missing data at month 12 was 40%) and the 
modified dataset (amount of missing data at month 12 was 47%). However, similar to the 
finding on the primary outcome, all the secondary outcome measures showed a difference 
between the two datasets under MMRM analysis. The results from the MMRM analysis of 
the modified dataset showed that the estimate of treatment effect was overestimated by 
5% of baseline SD for PRTEE and SF12-PCS, and underestimated by 3% of baseline SD 
for SF12-MCS, compared to the estimates from the actual dataset. These findings might 
be an indication of potential MNAR mechanisms associated with missing data in those 
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outcome measures if the responses (7%) that had been retrieved through the second and 
third reminders represent the actual missing data (40%). However, the representativeness 
can be criticized because of the large gap in the percentages and a minimal number (one) 
of failed attempts before obtaining the response, compared to the situation in the primary 
outcome. In addition, it was found that the absence of responses that had been retrieved 
through second and third reminders and the absence of minimally collected data had 
contrasting effects on the actual observed estimate of treatment effect in the primary 
outcome; i.e. MMRM analysis overestimated the actual estimate in the absence of 
minimally collected data whereas the similar analysis underestimated the actual estimate 
in the absence of the reminder responses (results are provided in appendix 9 [Table 31]). 
Though the findings on the secondary outcome measures provide an indication of 
potential bias associated with the actual missing responses, it is difficult to make a 
judgement of the direction of bias if it is assumed that minimally collected data might be 
more representative of the actual missing responses. Thus, these results show that it is 
important to investigate the robustness of the findings from an MAR-based analysis 
(MMRM) of these outcome measures in the actual dataset to the possibility of an MNAR 
mechanism behind the missing responses. 
The findings from the TATE trial were generally comparable to the findings from the 
simulation studies. The analysis of the trial dataset confirms that the inclusion of 
participants without any follow-up data in MMRM analysis (by considering baseline as an 
outcome) did not make a difference to the estimates of treatment effect at the endpoint but 
there was a small reduction in SE. As found in the simulation studies, MI ANCOVA by 
restrictive imputation modelling did not add any advantage to the MMRM analysis. The 
estimate of treatment effect from the MI ANCOVA was close to that from the MMRM 
analysis when the number of imputations increased substantially. In this data, I used a 
large number of imputations, which was more than ten-fold of the current recommendation 
(White et al., 2011b), and a large number of iterations in the burn-in period, which was 
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fivefold the default value in Stata (StataCorp, 2013), to obtain a closer value of the 
estimates between the two analysis methods. However, as also found in the simulation 
studies, the SE with MI ANCOVA was still higher than that from the MMRM analysis. 
Further, it was found that the inclusive imputation modelling with MI resulted in a slight 
difference in the estimates of treatment effect and SE compared to restrictive imputation 
modelling with MI or MMRM analysis. The observed difference varied by the number of 
auxiliary variables added into the inclusive imputation model even in situations where the 
auxiliary variable was not associated with an outcome variable. 
7.6 The STarT Back trial 
The STarT Back trial (Hay et al., 2008; Hill et al., 2011) was designed to compare the 
effectiveness of stratified primary care for low back pain with current best practice. 
Participants were randomized to receive either a screening and targeted intervention, 
delivered by trained physiotherapists (intervention group; n = 568), or best current care 
(control group; n = 283). The total sample size (n = 851) was calculated with adjustment 
for 25% loss to follow-up at the primary endpoint (month 12). The primary outcome was 
the Roland Morris Disability Questionnaire (RMDQ), and the secondary outcomes were 
back pain intensity and health-related quality of life (using SF12). The RMDQ score 
ranges between 0–24, with high scores indicating severe disability. Back pain intensity 
was measured on a 0–10 numerical rating scale, with high scores indicating severe pain. 
As previously noted, the SF12 provides two summary measures – physical component 
summary (SF12-PCS) and mental component summary (SF12-MCS), each measured on 
a 0–100 scale, with high scores indicating better general health. The outcomes were 
obtained before randomization, and 4 months and 12 months later by use of postal 
questionnaires. The 12-month evaluation was regarded as the primary endpoint in this 
analysis. 
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In order to increase response rate, a similar reminder strategy was implemented as in the 
TATE trial. Participants who did not respond to the reminders were telephoned for MDC 
on the primary outcome. For the purpose of the re-analysis, participants who responded 
through the MDC strategy were considered as ‘reminder’ responders on the primary 
outcome (RMDQ); the remaining responders were considered as ‘initial’ responders for 
the primary outcome. Since details on reminders were not accessible electronically, this 
analysis did not consider the secondary outcomes, where there was no MDC, to 
investigate the impact of the missing data on the study conclusion. 
7.6.1 Descriptive analysis of missing data 
7.6.1.1 Missing data in the STarT Back trial 
The proportions of missing data for the primary and secondary outcome variables in the 
dataset are shown in figure 7.3. The dropout rate was up to 36% for the secondary 
outcome variables (Figure 7.3b [304/581] and figure 7.3c [307/851]) with nearly equal 
dropout rate between the two treatment groups (38% in the intervention group and 35% in 
the control group) at the final visit. A better response rate was achieved for the primary 
outcome (RMDQ) through the MDC strategy (Figure 7.3a): 10% (82/851) of randomized 
participants responded through this strategy at the final visit. The dropout rate for the 
RMDQ at the final visit was 24% (202/851; 26% in the intervention group and 23% in the 
control group). As seen in the figures, a substantial number of participants dropped out 
even before the first follow-up assessment at month 4. The trial team could obtain the 
reason for dropouts in limited instances only. Obtaining reasons would have been helpful 
in making a judgement on the missing data mechanism.  
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7.6.1.2 Dropout pattern and missing data mechanism in the STarT Back trial 
Knowing the missing data mechanism is important in determining the best way to handle 
the missing data in order to provide the least biased results. Figure 7.4 displays the 
observed mean score over time by different dropout patterns for the primary and 
secondary outcome variables. The number of participants within each dropout pattern can 
be determined from figure 7.3. Taking figure 7.3a as an example, 41 and 61 participants 
dropped out before the first follow-up assessment from the control and intervention 
groups, respectively. The observed mean baseline scores for these participants are 
represented with square and round dots in figure 7.4a.  
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The number displayed on the bar indicates the number of responses 
 
Figure 7.3: Response rate (%) over time on outcome variables – (a) RMDQ, (b) back 
pain intensity, and (c) SF12 (PCS & MCS) 
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The solid lines represent the estimates from the intervention group and dashed lines represent the 
estimates from the control group. Red denotes dropouts between baseline and month 4; black 
denotes dropouts between month 4 and month 12; green denotes completers 
 
 Figure 7.4: Observed mean profile according to intervention groups and the time at 
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Another 100 participants (33 from the control group and 67 from the experimental group) 
dropped out after the first follow-up assessment; hence, no outcome measurements on 
these participants were obtained at the final follow-up. The group-wise mean score at 
baseline and month 4 for these participants were represented in lines ending at month 4. 
Generally, those participants who dropped out immediately after baseline assessment 
displayed the worst score at baseline on all the outcome variables. In figure 7.4a, mean 
RMDQ score at month 4 in the intervention group appeared to be higher among those 
patients who did not provide data at month 12 than those who completed the assessment 
at month 12. Further, pain intensity score at month 4 in the control group appeared to 
differ between those patients who did and did not provide data at month 12 (Figure 7.4b). 
Logistic regression models that were used to identify the possible observed predictors of 
missingness revealed that age (adjusted OR = 0.94, p < 0.001) and back pain intensity 
(adjusted OR = 1.12, p = 0.050) at baseline were significant predictors of missingness in 
the primary outcome, where MDC strategy had been employed, at month 4. For the 
secondary outcomes, where MDC strategy had not been employed, only age (adjusted 
OR = 0.95, p < 0.001) showed a significant association with missingness; the baseline 
back pain intensity measure was not a significant predictor for missingness (adjusted OR 
= 1.10, p = 0.058). 
At month 12, age (adjusted OR = 0.95, p < 0.001) was the only significant predictor of the 
missing response in the primary outcome; whereas age (adjusted OR = 0.94, p < 0.001) 
and baseline SF12-PCS (adjusted OR = 0.98, p = 0.026) were significant predictors of the 
missing response in the secondary outcomes. When the missing response was restricted 
to dropouts after month 4, age (adjusted OR = 0.97, p = 0.001) was still associated with 
the additional dropouts with respect to the primary outcome. However, for the additional 
dropouts with respect to the secondary outcomes, SF12-MCS at month 4 (adjusted OR = 
0.98, p-value = 0.028) was a predictor in addition to these baseline variables: age 
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(adjusted OR = 0.96, p < 0.001), RMDQ (adjusted OR = 0.95, p = 0.037), and SF12-PCS 
(adjusted OR = 0.97, p = 0.021). 
Table 7.7 provides the observed pairwise correlations between variables at different 
occasions. Though age was a significant predictor of missingness in outcome variables, it 
showed little correlation with any of the outcome variables. A moderate level of correlation 
between the outcome variables, except between SF12-PCS and SF12-MCS, was 
observed on most occasions. 
 Chapter 7                     208 
Table 7.7: The observed pairwise correlation between variables 
  
Age RMDQ Pain score SF12-PCS SF12-MCS 
 
m0 m4 m12 m0 m4 m12 m0 m4 m12 m0 m4 m12 
Age   1.00 
 





 m0 0.11 1.00            
m4 0.11 0.51 1.00 
 
         









m0 0.15 0.62 0.39 0.40 1.00 
        
m4 0.09 0.35 0.75 0.61 0.46 1.00 
       
m12 0.15 0.39 0.61 0.82 0.45 0.66 1.00 









m0 -0.20 -0.66 -0.45 -0.43 -0.52 -0.33 -0.35 1.00 
     
m4 -0.25 -0.48 -0.74 -0.67 -0.42 -0.67 -0.58 0.58 1.00 
    
m12 -0.28 -0.47 -0.66 -0.77 -0.43 -0.59 -0.70 0.57 0.76 1.00 









m0 0.09 -0.44 -0.31 -0.29 -0.32 -0.23 -0.25 0.10 0.22 0.18 1.00 
  
m4 0.04 -0.27 -0.40 -0.29 -0.20 -0.31 -0.24 0.10 0.15 0.16 0.56 1.00 
 
m12 0.06 -0.29 -0.37 -0.40 -0.21 -0.31 -0.36 0.09 0.24 0.18 0.55 0.65 1.00 
m0 - baseline, m4 - month 4 and m12 - month12; Bold values represent the absolute values of the correlations higher than 0.30. 
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7.6.2 Analysis of STarT Back trial data – estimation of the treatment effect at 
month 12 
7.6.2.1 Results from the actual dataset 
Table 7.8 provides the estimates of treatment effect, SE and standardized effect size for 
the primary and secondary outcomes at the final visit based on a standard ANCOVA (i.e. 
CCA) and LOCF ANCOVA models. Due to the MDC strategy, the number of participants 
with complete data on the primary outcome (RMDQ) was substantially higher compared to 
the secondary outcome measures. Further, a few subjects were excluded from both 
models for secondary outcomes due to missing baseline data. 























RMDQ -0.964 0.421 0.022 -0.170 
 
-1.010 0.373 0.007 -0.178 
Pain intensity -0.067 0.216 0.757 -0.031 
 
-0.200 0.167 0.231 -0.092 
SF12-PCS 1.811 0.835 0.030 0.173 
 
1.963 0.634 0.002 0.188 
SF12-MCS 0.983 0.791 0.215 0.083 
 
0.787 0.601 0.191 0.067 
Estimate – estimate of treatment effect at month 12 adjusted for age, sex, baseline RMDQ and 
corresponding baseline of the outcome; SE – standard error of the estimate; 
1
RMDQ measured on 
a 0–24 scale, pain intensity on a 0–10 scale and other variables on a 0–100 scale. 
2
Number of 
subjects included in the analysis was 649 for RMDQ, 541 for secondary outcomes. 
3
Number of 
subjects included in the analysis was 851 for RMDQ, 842 for PRTEE, and 847 for SF12-PCS and 
MCS. 
4
Treatment effect relative to the pooled SD of baseline scores. 
 
 
Unlike in the TATE trial, the difference in standardized effect size between LOCF 
ANCOVA and CCA was not substantial in most cases – the largest difference of 0.061 
between the two methods was observed for pain intensity. The SE of the estimate of 
treatment effect was noticeably lower with LOCF ANCOVA compared to CCA in all 
outcome measures – the largest difference in SEs between the two methods was 
observed for pain intensity: 0.049 at month 12. However, these deviations in the estimates 
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and its SE did not affect the overall statistical conclusions for any of the outcome 
variables. 
Table 7.9 presents the treatment effect in the primary and the secondary outcomes at the 
final visit based on MMRM models. As found in the TATE trial, the MMRM estimates of 
treatment effect (and hence the standardized effect size) for RMDQ were the same 
irrespective of baseline scores as a covariate or an outcome. However, a difference was 
observed for the other variables – pain intensity, SF12-PCS and SF12-MCS – due to 
missing baseline scores for some participants who responded at later visits. A model with 
baseline-as-covariate led to the exclusion of the subjects with missing baseline score. The 
largest difference in the effect size (0.028) was observed between the two baseline 
handling strategies for pain intensity. Further, the SE of the estimate of treatment effect 
was slightly lower for the model with baseline-as-outcome for those variables. Therefore, 
the model with baseline-as-outcome was considered for the remaining analysis in 
following sections. 


























RMDQ -0.855 0.414 0.039 -0.151 
 
-0.855 0.413 0.039 -0.151 
Pain intensity -0.091 0.209 0.663 -0.042 
 
-0.151 0.208 0.468 -0.070 
SF12-PCS 1.873 0.804 0.020 0.179 
 
1.881 0.802 0.019 0.180 
SF12-MCS 0.920 0.777 0.236 0.078 
 
1.042 0.775 0.179 0.088 
Estimate – estimate of treatment effect at month 12 adjusted for fixed covariates (age, sex, 
baseline RMDQ for secondary outcomes) and their interaction with time; SE – standard error of the 
estimate; 
1
RMDQ measured on a 0–24 scale, pain intensity on a 0–10 scale and other variables on 
a 0–100 scale.
 2
Number of subjects included in the analysis was 749 for RMDQ, 665 for PRTEE, 
and 666 for SF12-PCS and MCS outcomes. 
3
Number of subjects included in the analysis was 851 
for RMDQ, 850 for PRTEE, and 851 for SF12-PCS and MCS. 
4
Treatment effect relative to the 
pooled SD of baseline scores. 
 
For the primary outcome measure (RMDQ), a difference of 0.019 in the standardized 
effect size between MMRM model and CCA was observed. For pain intensity, it was 0.039 
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at the endpoint. Whereas for the other remaining secondary outcomes (SF12-PCS and 
SF12-MCS), the difference in effect size between the two methods was negligible. A 
marginal reduction in SE with MMRM compared to CCA was found for all the outcome 
measures. 
Table 7.10 presents MI ANCOVA results from the actual dataset. The standardized effect 
size was generally similar between restrictive and inclusive imputation modelling 
strategies for all of the outcome measures – the largest difference (0.012) was observed 
for RMDQ. The SE was also comparable between the two strategies. In addition, the 
effect size and SE of the estimate of treatment effect were comparable between MMRM 
with baseline-as-outcome and MI with restrictive imputation modelling. 






















RMDQ -0.855 0.414 0.040 -0.151 
 
-0.926 0.417 0.027 -0.163 
Pain intensity -0.158 0.211 0.456 -0.073 
 
-0.164 0.204 0.421 -0.076 
SF12-PCS 1.874 0.791 0.018 0.179 
 
1.807 0.795 0.023 0.173 
SF12-MCS 1.037 0.764 0.175 0.088 
 
1.073 0.792 0.176 0.091 
estimate – estimate of treatment effect at month 12 adjusted for age, sex, baseline RMDQ, and 
corresponding baseline; SE – standard error of the difference; Restrictive modelling – imputation 
models included only the variables considered for the MMRM analysis models; Inclusive modelling 
– imputation model for an outcome included, in addition to the variables considered for the MMRM 
analysis model, other outcome variables as auxiliary variables in order to improve the performance 
of the imputation procedure; 
1
RMDQ measured on a 0–24 scale, pain intensity on a 0–10 scale and 
other variables on a 0–100 scale.
 2
Number of subjects included in the analysis was 851 for all 
outcome variables. 
3
Treatment effect relative to the pooled SD of baseline scores. 
 
Similar to the MMRM results, only small differences in the effect size between MI-
restrictive imputation modelling and CCA were found for the outcome variables RMDQ, 
SF12-PCS and SF12-MCS. For pain intensity, the estimate of treatment effect at month 
12 was slightly higher under MI-restrictive imputation modelling, with a difference in effect 
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size of 0.042. A small reduction in SE with MI compared to CCA was also found for all the 
outcome measures. 
7.6.2.2 Results from the modified dataset and the impact of responses through 
MDC 
Table 7.11 presents what would have been the estimates for the primary outcome 
(RMDQ) if the MDC strategy had not been employed. This table provides the results from 
the modified dataset, and shows the standardized effect size and deviation in SE from that 
observed with the actual dataset. It was found that the standardized effect size obtained 
from CCA, MMRM and MI with restrictive imputation modelling did not differ in the 
modified dataset, but the SE of the estimate of treatment effect was slightly lower for 
MMRM compared to MI and CCA. 
Table 7.11: Results from the modified dataset – RMDQ1 
Results based on 
Modified dataset 
 
Deviation in results 
from actual dataset 

















 851 -0.807 0.445 0.070 -0.142 
 
0.030 0.008 
ANCOVA 567 -0.818 0.449 0.069 -0.144 
 
0.028 0.026 
n – number of subjects included in the analysis; Estimate – estimate of treatment effect at month 
12; SE – standard error; 
1
RMDQ measured on a 0–24 scale; 
2




Treatment effect relative to the pooled SD of baseline scores. 
 
The difference in standardized effect size between the actual and modified datasets was 
trivial for RMDQ score with either the MMRM or MI; however, a larger difference of 0.026 
was observed with CCA. The SE of the estimate from all methods increased due to a 
higher number of missing responses with the modified dataset. Though the estimates 
showed little difference, the p-values were non-significant for the modified dataset. So the 
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higher SE values would impact on acceptance/rejection of the null hypothesis, and hence 
the interpretation of findings. 
7.6.3 Summary and interpretation of findings 
Unlike in the TATE trial, single imputation of missing responses using LOCF did not make 
substantial difference to the estimates from CCA of the STarT Back trial data; however, 
LOCF underestimated SEs compared to the other approaches. 
In the actual dataset, both the estimate of treatment effect and SE for the RMDQ were 
somewhat similar across MCAR-based and MAR-based analyses. Further, the initial 
exploration of the dropout pattern and predictors of missingness provided evidence 
against the MCAR scenario in the dataset. However, these findings alone were not 
sufficient to reject or accept the possibility of MNAR mechanism. The comparison of 
estimates from the actual dataset (dropout rate at month 12 was 24%) and the modified 
dataset (dropout rate at month 12 was 34%) found that the RMDQ responses (from 10% 
of randomized participants) that had been obtained through MDC did not affect the 
estimate of treatment effect under an MAR-based analysis. That is, the minimally 
collected responses were potentially ignorable under the MAR-based analysis. Thus, the 
finding favours a potential ignorable mechanism associated with missing RMDQ 
responses if the responses that had been retrieved through MDC represent the actual 
missing data. Therefore, it might be appropriate to conclude that the estimate of treatment 
effect (and effect size) for the primary outcome under a MAR-based analysis was 
potentially unbiased. 
In the analysis of the STarT Back trial dataset, as observed with TATE trial, it was found 
that subjects with only baseline data did not make a difference to the estimate of 
treatment effect at follow-up and there was little reduction in SE by considering the 
baseline as an outcome with an MMRM analysis. However, implementation of a baseline-
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as-covariate model excludes subjects with missing baseline data even though the 
subjects responded at later visits. This MMRM model yielded a lower estimate of 
treatment effect and slightly higher SE for the secondary outcomes compared to the 
model with baseline-as outcome. It was further found that MI ANCOVA by restrictive 
imputation modelling showed similar results to the MMRM analysis with baseline-as-
outcome. In particular, the estimate of treatment effect from the MI ANCOVA was close to 
that from the MMRM analysis when the number of imputations was increased 
substantially. In these data, I again used a large number of imputations, which was more 
than twenty-fold of the current recommendation (White et al., 2011b), and a large number 
of iterations in the burn-in period, which was fivefold the default value in Stata (StataCorp, 
2013), to obtain more accurate estimates of mean difference and SE. MI ANCOVA 
displayed a slightly higher SE than that from MMRM in the modified dataset where the 
amount of missing data increased to 33% from 24% in the actual dataset. Further, it was 
found that the inclusive imputation modelling with MI did not make any noticeable 
difference to the estimates from restrictive imputation modelling with MI or MMRM 
analysis even though auxiliary variables showed a moderate level of correlation with 
outcome variables and association with missingness in these variables. 
7.7 Discussion 
As noted in chapter 2, any analysis of incomplete data requires unverifiable assumptions 
about the nature of the missing data, and the validity of inferences from these analyses 
depends on the correctness of these assumptions. Since it is not possible to verify the 
correctness of the missing data assumption with certainty based on observed data alone, 
it has been recommended that one performs sensitivity analyses to assess the robustness 
of inferences from the primary analysis to a range of alternative plausible missing data 
assumptions (Food and Drug Administration, 2008; European Medicines Agency, 2010; 
National Research Council, 2010). Despite this recommendation, sensitivity analyses are 
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rarely used or reported in practice. The systematic review in chapter 3 found that 
sensitivity analyses are infrequently and inappropriately used, and insufficiently reported. 
Even though a fifth (18/86) of trials with missing outcome values at the primary endpoint 
report having carried out a sensitivity analysis, very few trials (6/18) presented the results 
of their sensitivity analysis. Either exclusion of subjects with missing data or a single 
imputation method was the designated sensitivity analysis. Importantly, none of them 
considered the violation of the MAR assumption. This might be due to the lack of 
guidance in the literature on how to actually do one. The NRC report on the prevention 
and treatment of missing data in clinical trial (National Research Council, 2010) admits 
that there is no established guideline or method in this matter as this is an active area of 
research. This chapter proposed an approach that makes use of the reminder data (i.e. 
data that is recovered after number of failed attempts) to assess the influence of missing 
data on the estimation of treatment effect, and set out to demonstrate this assessment 
procedure through the empirical evaluation of two incomplete pragmatic trial datasets. 
This analysis takes a position in between the primary analysis and a detailed sensitivity 
analysis, and allows a decision to be taken on whether to move ahead with the detailed 
sensitivity analysis that makes stringent assumptions about missing data. 
As pointed out in the background chapter, although some methods (Little, 1988; Diggle, 
1989; Ridout, 1991; Fairclough, 2002) have been proposed for the identification of the 
missing data mechanism, their purpose is generally to detect violations of MCAR 
assumption by identifying dependence on observed data. Fielding et al. (2009) performed 
an investigation of missing data mechanisms in a few empirical trial datasets using these 
previous methods. Similar to the observations from the initial exploration of missing data 
mechanism in the TATE and STarT Back trials, Fielding et al.’s (2009) investigation found 
only a distorted view of the mechanism among their datasets. That is, the conclusion 
about the missing data mechanism was not consistent across the different methods of 
assessment in their study. The proposed approach in this thesis does not rely heavily on 
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this kind of initial exploration to investigate the missing data mechanism and to identify the 
appropriateness of an MAR-based analysis to deal with the missing data. 
In accordance with good clinical practice (International Conference on Harmonisation, 
1998) and to avoid outcome reporting bias (Dwan et al., 2008), it has been recommended 
in clinical trials to specify the statistical analysis plan in advance, and it is not advisable to 
undertake any kind of sensitivity analyses post-hoc. Researchers should pre-specify their 
plan for handling any potential missing data, to avoid performing several approaches and 
reporting favourable results. However, it is very challenging to comment on a plausible 
missing data mechanism and specify a sensitivity analysis to missingess assumptions in 
advance, with little relevant information in hand. Therefore, it is advisable to consider an 
MAR-based analysis as the primary analysis method. In this instance, the proposed 
approach can be used to assess whether a sensitivity analysis to an MNAR assumption 
should be carried out. 
Fielding et al. (2010) introduced an alternative approach to identify which method would 
be most suitable to deal with missing outcome data in an RCT by utilizing responses later 
recovered by reminders. A selection of missing data methods were applied to a subset of 
the actual dataset where individuals with actual missing response at the primary endpoint 
were excluded. The analyses were repeated for the new reduced dataset but the 
responses obtained through reminders were regarded as missing. The ‘best’ method that 
introduced least bias (i.e. difference in estimates between the two new datasets) to the 
estimation of treatment effect was then suggested as the analysis method most 
appropriate for the actual dataset. Unless the amount of missing data is minimal, the best 
method in the new reduced dataset may not be best in the actual dataset because of the 
exclusion of individuals with actual missing data at the primary endpoint, irrespective of 
availability of data at an earlier time-point. 
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Fielding et al. (2012) presented a similar comparison of estimates of treatment effect 
between the actual data and modified data (reminder responses were regarded as 
missing) to that provided in the present study. However, the purpose of these 
comparisons was quite different. In their evaluation, the authors assumed an MAR 
missing data mechanism that had been assessed in Fielding et al. (2009) and reviewed a 
number of possible analysis methods (Fielding et al., 2010) using the actual data, and 
also with the modified data for comparison. The authors did not make use of the findings 
to validate or invalidate the findings from the actual data; instead, they focused on the 
difference in the estimate if the reminder strategy had not been implemented. Although 
missing data in the actual and modified data were ‘identified’ as MAR, MAR-based 
analyses – linear mixed-effects model and predictive mean match MI model – resulted in 
quite different estimates between the actual and modified datasets. They concluded that 
“this suggests that ignoring the reminder responses, under-estimates the treatment 
difference and introduces a bias to the results”. This conclusion has ultimately brought into 
question their approaches to investigating the missing data mechanism. Under the newly 
proposed approach, the difference in estimates from the actual and modified data 
indicates non-ignorability of non-responses in the actual dataset if the reminder responses 
were representative of non-responses in the actual data. 
The newly proposed approach mainly relies on three assumptions: (i) non-responders to 
the first mail-outs are reminded a number of times before employing an MDC strategy, (ii) 
data collected via reminder or MDC strategy is treated on an equal footing to that obtained 
via first mail-out, and (iii) responses that have been retrieved after a number of failed 
attempts are likely to represent the actual missing responses when the number of failed 
attempts increases. In pragmatic trials, trialists often follow a strategy of sending a number 
of reminders to initial non-responders and re-approaching them for minimum data 
collection, where data collection is usually limited to key outcome measures, if they still 
have failed to respond. The third assumption becomes more plausible with the minimally 
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collected responses on an outcome compared to the earlier reminder responses. For 
example, a subgroup with poor health or disability – common characteristics of 
participants in a musculoskeletal trial – is highly unlikely to respond to usual mail-outs. 
The size of a questionnaire and number of repetition (i.e. number of follow-ups) – which 
usually requires extra effort to complete and return – can de-motivate such participants 
from responding to the mail-outs; however, these non-responders are possible more likely 
to respond to a minimum data collection request because they are usually contacted by 
telephone and it demands only minimal effort on their part. In this example, it is very 
unlikely to obtain similar estimates from the actual and modified datasets if the third 
assumption does not hold because a similarity in estimates indicates ignorable MDC 
responses and MDC responders are unlikely to be better (in terms of improvement in 
outcome) than non-responders. 
The down side of the present approach is that either the reminder or actual missing 
responses could be non-ignorable when the estimates of treatment effects from the actual 
and modified datasets are dissimilar and the third assumption does not hold. That is, the 
dissimilarity of estimates does not confirm the non-ignorability of the actual missing data if 
the assumption does not hold. Therefore, further sensitivity analysis may be required to 
assess the impact of departures from an MAR assumption specified with the primary 
analysis when dissimilarity in estimate of treatment effect between the actual and modified 
dataset is observed. 
Reporting bias – for example, reporting of outcome status at 15 months rather than at the 
endpoint of 12 months – due to longer follow-up of late responders is a potential limitation 
of the implementation of reminders and/or minimal data collection approach for reducing 
the amount of missing data. In addition, the key assumption regarding the 
representativeness of reminder or MDC responses to the actual missing responses may 
not be valid if the “true” treatment effect is different at the time of the reminder / MDC 
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response than at first mail out (due to the reporting bias among late responders). Hence it 
is important that there is limited influence of time/delay on marginal treatment effect 
differences in consideration of the proposed approach as a suitable method of evaluating 
the likely missingness mechanism. In the case of TATE trial, those in the MDC responded 
a median of 3 months after those who responded to the first mail out at the 12 month 
follow-up. The observed difference in estimates of treatment effect between the actual and 
modified datasets indicated the possibility of non-ignorability of the MDC responses, and 
therefore implied non-ignorability in respect of the missing data. However, the noticeably 
delayed MDC responses may threaten the validity of the key assumption and the 
conclusion of non-ignorability of the actual missing responses at the time point of 
relevance based on the proposed approach unless trialists can ensure lack of reporting 
bias due to delayed MDC responses.  
7.8 Conclusion 
In this chapter, I have presented a simple technique to perform a sensitivity analysis to 
assess the impact of missing data on the primary conclusion using responses 
subsequently recovered via reminder or MDC. This chapter used two recent pragmatic 
RCTs to demonstrate this technique. In the TATE trial, this approach showed that an 
MAR-based analysis is unlikely to yield unbiased estimates of treatment effect for the 
primary and secondary outcomes (i.e. non-responses were non-ignorable under the MAR-
based analysis). Therefore, further sensitivity analyses were required under a range of 
plausible MNAR assumptions. However, in the STarT Back trial, this approach showed 
that an MAR-based analysis is unlikely to yield a biased estimate of treatment effect for 
the primary outcome. In addition, it was found that estimates from MMRM and MI with 
restrictive imputation modelling were quite similar; however, MI with inclusive imputation 
modelling resulted in slightly different estimates for some outcome variables and the 
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estimates further varied by inclusion of additional auxiliary variables within the inclusive 
imputation model.  
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Chapter 8: Summary, discussion and conclusions 
8.1 Introduction 
Randomized clinical trials play a vital role in assessing the efficacy and effectiveness of 
new interventions compared to a standard or control intervention. Randomization in a 
clinical trial is intended to generate comparable groups of patients in terms of known and, 
more importantly, unknown factors that could be associated with the outcome of interest 
at the onset of the trial. When some outcome measurements are missing, the principal 
advantage of randomization is threatened, treatment comparisons are potentially biased, 
and the trial becomes inefficient to detect the treatment effect. Hence, proper treatment of 
missing data is necessary for a valid analysis; however, it is important to note that none 
can ‘cure’ the problem of missing data.  
An ITT analysis works well to preserve the benefits of randomization, which is intended to 
ensure that differences in outcome observed between treatment groups are solely the 
result of the treatments (Montori & Guyatt, 2001; Heritier et al., 2003), and to reduce the 
risk of selection bias (Altman, 2009; Fleming, 2011). The ITT principle states that an 
analysis should be performed by including all study participants in the groups to which 
they were randomized, regardless of any departures from the original assigned group 
(Chan et al., 2013). However, the presence of missing data in a trial creates many 
challenges to implementation of an ITT analysis strategy. White et al. (2012) point out 
that, for the estimation of treatment effect in clinical trials with missing data, statistical 
methods that include all randomized participants may sometimes be less valid than 
methods that do not include all randomized participants, depending on the assumptions 
made about the missing data. Hence, the researchers state that including all randomized 
individuals in an analysis of an outcome with missing data is not enough; one should 
consider an appropriate method to handle the missing data. Further, White et al. (2012) 
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suggested a framework for an ITT analysis strategy, and this strategy should include a 
design that is intended to minimize missing data by following up all randomized 
individuals, an analysis based on a plausible assumption about the missing data, and 
sensitivity analyses that aim to explore the robustness of the results to a range of 
alternative plausible assumptions regarding missingness. 
8.2 Summary of findings 
This thesis consists of three main parts. First, a systematic review has been performed to 
examine practices relating to methods to handle missing data in published trials in 
musculoskeletal conditions. Second, a simulation study has been performed to compare 
the performance of various methods for handling missing data in a longitudinal clinical trial 
with missing continuous outcome data in a number of scenarios. Finally, an approach has 
been proposed to investigate the ignorability of the missing data mechanism, and thus to 
verify the unbiasedness of the estimate of treatment effect from an MAR-based analysis. 
8.2.1 Summary of systematic review 
The systematic review of RCTs published during January 2010 to December 2011 in five 
major musculoskeletal journals, which was detailed in chapter 3, identified deficiencies in 
current practices in relation to dealing with missing outcome data. Many of the reviewed 
trials failed to obtain outcome data on all randomized participants and/or include all 
participants in the primary analysis. Almost 95% (86/91) of trials in this review reported 
dropouts – a high proportion (60%) of trials had more than 10% dropouts and 31% had 
more than 20%. The high proportion of trials with a significant number of dropouts is of 
concern. 
It was not clear from the reviewed publications whether trialists took careful steps to 
improve response rate in the trial design and data collection stages. Given that no method 
can cure the problem of missing data, one should consider ways to try to prevent missing 
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data during the design and conduct of RCTs. For example, considering sending reminders 
to encourage participants to respond and limiting data collection to essential variables of 
interest. Limiting missing data helps to reduce the need to make unverifiable assumptions 
about the missing data and thus minimizes problems in inferential analyses, especially 
those problems that flow from misspecification of missing data assumptions in the 
analyses. The NRC report (National Research Council, 2010) devoted a section of the 
design aspects of a trial to prevent missing data, and added three recommendations 
regarding this point (detailed in chapter 3, section 3.6.3). 
The present review suggested that published trials continue to use either deletion of cases 
with missing data or single imputation as the primary approach to dealing with missing 
data. Nearly 60% (44/75) of reviewed longitudinal trials with missing outcome data used a 
kind of single imputation to replace missing values – last observation carried forward 
(LOCF) was the most frequently used single imputation method. Nearly a quarter (18/75) 
of reviewed trials excluded dropouts who had completed at least one follow-up 
assessment from the primary analysis. Analyses based on either multiple imputation (MI) 
or full-information maximum likelihood (FIML) were limited to a small proportion (8/75) of 
longitudinal trials with missing data. 
The review also found that sensitivity analyses are infrequently and inappropriately used, 
and insufficiently reported. The sensitivity analyses were performed in trials with relatively 
high proportions of missing data (median 24%; IQR 17%, 33%) but were limited to a low 
proportion (18/86) of trials with missing data. Furthermore, either exclusion of subjects 
with missing data (i.e. listwise deletion) or a single imputation method was the designated 
sensitivity analysis. Very few trials (6/18; 33%) presented the results of their sensitivity 
analysis, while the others just reported that a sensitivity analysis had been performed and 
indicated that the findings from the primary analysis were supported by those of the 
sensitivity analysis. In the present era of the internet, authors have opportunities to publish 
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sufficient details through online supplements if there is space restriction in the main body 
of reports. 
8.2.2 Summary of simulation study 
To address the limitations with the previous simulation studies, which were detailed in 
chapter 2, and in order to provide a broader and practically more accessible picture of the 
impact of missing outcome data on estimation of treatment effect in an RCT, a 
comprehensive simulation study has been used to examine the relative performance of 
four statistical analysis approaches – CCA, LOCF ANCOVA, MMRM and MI ANCOVA – 
on a number of possible and credible clinical trial scenarios. The scenarios included 
various levels of missingness properties (i.e. overall dropout rate, dropout rate between 
groups, dropout mechanism and the direction of dropouts) along with different levels of 
data characteristics (i.e. correlation between repeated measurements and data variability, 
the size of treatment effect, mean trajectory and sample size). The study methodology 
was specified in detail in chapter 4: incomplete data were generated with pre-specified 
dropout rates (equal and differential dropout rates between groups) under different 
missing data mechanisms: MCAR, MAR-B, MAR-L and MNAR. The MAR and MNAR 
dropout mechanisms were implemented under two contrasting scenarios. In the first 
scenario, dropouts were in the same direction in both study groups (MAR-B1, MAR-L1 
and MNAR-1) – dropouts were a random sub-sample of subjects who did poorly in both 
study groups. Results from an opposite scenario, wherein dropouts were a random sub-
sample of subjects who did well in both study groups, are provided in appendix 4; as 
expected results were the same as in the first scenario but differed in respect of the 
direction of bias. In the second scenario, dropouts were in opposite directions between 
study groups (MAR-B2, MAR-L2 and MNAR-2) – dropouts were a random sub-sample of 
subjects who did poorly in the control group and those who did well in the experimental 
group. Results from an opposite scenario wherein dropouts were a random sub-sample of 
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subjects who did well in the control group and those who did poorly in the experimental 
group are provided in appendix 4; as expected, results were the same as in the second 
scenario but differed in respect of the direction of bias. For any analysis of incomplete 
data in practice, it is necessary to make assumptions, which are often unverifiable in the 
incomplete data, about the missingness. It is crucial, therefore, to assess the performance 
of methods to deal with missing data in relation to a variety of contrasting scenarios in 
order to understand the robustness of the results under the different missing data handling 
approaches to variation and possible extreme situations in the missing data mechanism 
and criteria for dropout, and to aid interpretation of findings from an incomplete dataset. 
Table 8.1 presents a summary of key simulation results that were reported in chapter 5 in 
which the study assessed the relative performance of the missing data methods with 
respect to bias, CI coverage and statistical power in relation to the estimation of treatment 
effect.  
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Table 8.1: Summary of simulation results* 
Method Acceptability
1
 Missing data mechanism 



















CCA Acceptable MCAR; MAR-B1; MAR-B2; 
MAR-L1 (with equal dropout 
rate between arms); MNAR-







Unacceptable MAR-L1 (with differential 
dropout rate between arms); 
MAR-L2; MNAR-1 (with 
differential dropout rate 











MMRM Acceptable MCAR; MAR-B1; MAR-B2; 
MAR-L1; MAR-L2; MNAR-1 







Unacceptable MNAR-1 (with differential 







MI Acceptable MCAR; MAR-B1; MAR-B2; 
MAR-L1; MAR-L2; MNAR-1 







Unacceptable MNAR-1 (with differential 
dropout rate between arms); 
MNAR-2 
0.041–0.205 0.138–0.462   73.8–94.6 12.3–92.8   44.0–96.5 4.4–99.5 
*126 scenarios with 10% and 30% dropout rate; 
†
effect size standardized for baseline data variability; 
‡
the bias in standardized effect size ranged 
0.001–0.011 with no missing data; 
1
a method is considered as acceptable if the standardized effect size did not vary by dropout rate.
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In the simulation study, LOCF yielded biased estimates of treatment effect in most 
scenarios irrespective of missing data mechanisms, and there was no consistency in the 
magnitude of bias across the considered scenarios. For example, LOCF overestimated 
the treatment effect for scenarios of higher dropout rate in the control group under MCAR 
and MAR mechanisms, but underestimated the treatment effect in the same scenario 
under an MNAR mechanism. Furthermore, the bias varied by dropout rates, the direction 
of dropout, the timing of dropout, data variability, and the level of correlation between 
repeated measurements. Even with 10% dropout rate and an MCAR mechanism, the 
magnitude of the bias exceeded 23% of baseline SD for a scenario in which there was 
higher dropout rate in the experimental group. With LOCF, the statistical power in some 
scenarios was close to 100% due to overestimation of treatment effect and 
underestimation of SE. 
In the present simulation study, CCA yielded unbiased estimates of treatment effect for 
scenarios of equal dropout rate and the same direction of dropouts in both treatment 
groups, irrespective of missing data mechanism. Furthermore, the analysis also produced 
unbiased estimates of treatment effect under MCAR and MAR-B (MAR dependent on the 
baseline), irrespective of other scenarios. In all these scenarios, CCA maintained the CI 
coverage at an acceptable level, but not the statistical power. The loss of statistical power 
with 10% dropout rate was 2%–7% for MCAR, 2%–6% for MAR-B1 (same direction of 
dropout), and 3%–8% for MAR-B2 (opposite direction of dropout) depending on various 
levels of data variability and correlation between the baseline and the final endpoint. The 
effect of differential dropout rate and differential direction of dropouts on statistical power 
were not noticeable at 10% dropout level but were so somewhat at 30% dropout level. A 
CCA estimate of treatment effect was biased under MAR-L and MNAR mechanisms, 
except in the scenario of equal dropout rate and same direction of dropouts in both 
groups. With 10% dropout rate, the bias was up to 13% of baseline SD under MAR-L and 
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27% of baseline SD under MNAR mechanism depending on other considered factors. 
Correspondingly, the CI coverage and power were also affected under the MAR-L and 
MNAR mechanisms. 
MMRM and MI-based analyses produced unbiased estimates of treatment effect in all 
scenarios in which CCA yielded unbiased estimates. These analyses also produced 
unbiased estimates under MAR-L. In all these scenarios, CI coverage was maintained but 
statistical power was not. Both methods yielded similar estimates of treatment effect in all 
scenarios. However, a slightly lower coverage (maximum difference of 1% for 10% 
dropout rate) and higher statistical power (maximum difference of 3% for 10% dropout 
rate) was observed with MMRM compared to MI, especially under scenarios of differential 
dropout rate and opposite direction of dropouts. Furthermore, the difference slightly 
increased when the dropout rate was increased from 10% to 30%. Importantly, the loss of 
power in these methods was not substantially different from CCA in scenarios in which the 
estimate of treatment effect was unbiased. Estimates of treatment effect from MMRM and 
MI-based analyses were biased under the MNAR mechanism, except in the scenario of 
equal dropout rate and same direction of dropouts in both groups. With 10% dropout rate, 
the bias was up to 12% of baseline SD under MNAR-1 and 20% of baseline SD under 
MNAR-2, depending on other considered factors. Correspondingly, the CI coverage and 
power were also affected under the MNAR mechanisms. 
8.2.3 Summary of empirical evaluation 
Chapter 7 presented re-analyses of two pragmatic RCTs – TATE and STarT Back trials – 
that included a reminder process for non-responders. The dropout rate in respect of the 
primary outcome at the final visit was 26% for the TATE and 24% for the STarT Back. 
Both trial datasets had been previously analysed using MI with an inclusive imputation 
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modelling strategy (i.e. a strategy that included all variables17 in a dataset in the 
imputation model). The present study re-analysed these datasets using standard 
ANCOVA, LOCF ANCOVA, MMRM and MI ANCOVA (with restrictive imputation 
modelling strategy). In the TATE trial, it was found that all but LOCF-based analyses of 
the primary outcome yielded a similar standardized effect size, which was equivalent to 
the estimate from the original analysis. The LOCF-based analysis led to double the 
estimate. In the STarT Back trial, the estimates of treatment effect were not consistent 
across the analysis methods – CCA and LOCF slightly overestimated the treatment effect 
compared to the estimates from MMRM and MI. Additionally, the estimates from all these 
methods were slightly lower than the estimate reported from the original analysis but the 
p-values remained less than 0.05 in all the analyses. It was observed that the estimates of 
treatment effect from MI varied by use of inclusive imputation modelling strategies with 
different number and types of auxiliary variables. 
A comparison of MMRM estimates of treatment effect from the actual and modified 
(responses from minimal data collection (MDC) were regarded as missing) datasets found 
a difference between these estimates in the TATE trial but not in the STarT Back trial. 
This finding implies that the MDC responses had an impact on the estimate of treatment 
effect in the TATE trial, and these additional responses should not be ignored from the 
estimation. If it can be assumed that the MDC responses were representative of the non-
responses, the MMRM estimate of treatment effect from the TATE trial was more likely to 
be biased. Therefore, further sensitivity analyses to assess the robustness of the estimate 
of treatment effect were required in the TATE trial under a range of plausible MNAR 
assumptions. Judging from the change in direction of effect, an analysis addressing 
                                               
17
 Although the original dataset involved a substantial number of variables, the re-analysis used 
only six variables (a primary outcome variable, three secondary outcome variables, and two 
additional baseline variables (age and sex)). 
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MNAR with missing data mimicking MDC responses would result in a narrowing in the 
effect estimate between treatment arms (the same conclusion would likely hold).  By 
contrast, the MMRM estimate of treatment effect from the STarT Back trial was fairly 
consistent between actual and restricted datasets – so the original MAR evaluation is 
unlikely to be biased if the assumption holds that late responders typify non-responders. 
8.3 Discussion of the findings 
8.3.1 The performance of incomplete data analysis methods for the estimation of 
treatment effect in RCTs 
8.3.1.1 Analysis using last observation carried forward 
The present simulation study showed that LOCF ANCOVA is very unlikely to give an 
unbiased estimate of treatment effect. This study further found that LOCF does not yield a 
better estimate of treatment effect – in terms of bias – compared to CCA, MMRM or MI 
ANCOVA when the missing data mechanism is MCAR or MAR. Since values imputed with 
LOCF are treated as ‘true’ observations and do not add any sort of component of 
uncertainty in the estimation, this approach generally underestimates the SE of the 
treatment effect as evident in the simulation study. The biased estimates of treatment 
effect and SE introduce artificial inflation or deflation of CI coverage and statistical power, 
depending on the direction and magnitude of the bias. The findings clearly contradict the 
statement that LOCF-based analysis relies on an MCAR assumption (Mallinckrodt et al., 
2001a; Mallinckrodt et al., 2008; Fielding et al., 2010; Bredemeier, 2012) – this 
assumption is, therefore, unwarranted. 
In the simulation under an MNAR mechanism, LOCF was more favourable compared to 
other missing data approaches in a few circumstances. Lower bias for LOCF was 
observed when there was higher dropout rate in the control group in the presence of a 
greater improvement in outcome in the intervention group. Further, the simulation study 
 Chapter 8             231 
(Chapter 6) that assessed the robustness of the findings to variations in trajectory profile 
found that the performance of LOCF varied considerably across the scenarios, especially 
when dropout rate was higher in the intervention group with substantial improvement in 
outcome. It appears that differential improvement in outcome between treatment groups 
and the timing of dropout substantially affect the estimation of treatment effect using 
LOCF-based analysis. Hence, an evaluation of trajectory profile by dropout patterns may 
be helpful in assessing the impact of the LOCF approach. 
One argument in favour of LOCF is that an LOCF-based analysis does not bias the 
treatment effect in favour of a new intervention against a control intervention (Streiner, 
2008; Navarro-Sarabia et al., 2011). Results from previous simulation studies by Baron et 
al. (2008) and Olsen et al. (2012) seem to support this argument. Their work on an MNAR 
mechanism showed that LOCF led to an underestimation of treatment effect with reduced 
(and hence, conservative) statistical power for all considered scenarios. Their finding 
might be true with a trajectory profile that had been used for their simulation studies. 
However, as found in the present simulation study, this may not always be true, since 
overestimation of treatment effect is evident when there are more or earlier dropouts in 
the control group than in the intervention group and the rate of improvement on an 
outcome in the intervention group is higher than in the control group. In a previous study 
(Mallinckrodt et al., 2001a), the authors reported that LOCF-based analysis overestimated 
the true effect in treatment versus ineffective placebo comparisons and underestimated 
the true treatment effect in treatment versus effective placebo comparisons. The present 
study identified that the direction of bias with LOCF can also be influenced by many other 
factors, such as the timing of dropout, direction of dropout, and differential dropout rate 
between treatment groups. In the TATE trial (Chapter 8, section 7.3), the estimates of 
treatment effect in the primary (pain intensity) and the secondary (PRTEE) outcomes from 
LOCF ANCOVA were higher than those of CCA, MMRM and MI ANCOVA. It seems the 
magnitude of the bias in estimate of treatment effect from an LOCF-based analysis is 
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quite unpredictable in any scenario. Some researchers may use LOCF to maintain the 
sample size. This ultimately underestimates the SE of treatment effect in most situations, 
and therefore ends up with an unacceptable CI coverage. 
In summary, the use of LOCF-based analysis as the primary analysis in an RCT should 
be avoided. A very recent search of PubMed for of “("LOCF"[All Fields] OR "last 
observation carried forward"[All Fields]) AND (clinical trial[ptyp] AND ("2014/01/01"[PDAT] 
: "2014/09/30"[PDAT]))” resulted in 15 hits. Even though the lower number is promising, it 
cannot be concluded that LOCF-based analysis has been completely discarded. 
8.3.1.2 Analysis of covariance without imputation of missing values (Complete-
case analysis) 
A standard ANCOVA yields an unbiased estimate of treatment effect under MCAR or 
MAR dependent on the baseline (MAR-B) – which is sometimes referred to as covariate-
dependent MAR – irrespective of dropout rate, direction of dropout, data variability and 
correlation between repeated assessments. So, a standard ANCOVA analysis ensures an 
unbiased estimation of treatment effect if the missingness in outcome is truly associated 
with the covariates in the ANCOVA model. In addition, CCA retains the targeted CI 
coverage to an acceptable level in all these scenarios. However, the width of CI increases 
with decreases in the number of complete cases, and the width further varies by the 
direction of dropout (whether dropouts are in the same direction in both groups or not) – a 
slightly wider CI is obtained for scenarios whereby dropout is in the opposite direction 
between treatment groups. The changes in CI width directly translate to loss of statistical 
power. 
Many authors in the systematic review highlighted an equality in dropout rate between 
treatment groups. The general view appeared to be that equal dropout rate between 
groups would not lead to a biased estimate of treatment effect. This is true with CCA if the 
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MCAR or MAR-B assumption is satisfied. In addition, this is also true for MAR dependent 
on the last observed values (MAR-L) – also referred to as outcome-dependent MAR – and 
MNAR data if dropouts are in the same direction in both groups. That is, in all situations 
where dropout rates are equal between the groups and dropouts are in the same 
direction, CCA produces unbiased estimates of treatment effect with an acceptable CI 
coverage irrespective of missing data mechanism. Bell et al. (2013) reported a similar 
conclusion based on a simulation study with a 30% dropout rate. In the present study, 
‘same direction’ means dropouts performed either well in both groups or worse in both 
groups, and ‘opposite direction’ means dropouts in one group performed well and 
dropouts in the other group did worse. Intuitively, the reality is that missingness is unlikely 
to be completely skewed between treatment groups (i.e. entirely in opposite direction) and 
is likely to be somewhere in between. Thus, the findings serve to caution against a 
conclusion of unbiasedness just because of equal dropout rate between treatment groups 
– unless it can be justified in some way that dropout in the same direction is the most 
plausible explanation for missingness. 
For all MAR-L and MNAR scenarios except the scenario of equal dropout rate with the 
same direction of dropout, CCA analysis gives biased estimates of treatment effect. In the 
present simulation study, it was observed that the bias ranged from 2% to 27% of baseline 
SD (Table 8.1) for scenarios of a 10% dropout rate and 8% to 53% of baseline SD for 
scenarios of a 30% dropout rate. As expected, bias in estimate of treatment effect from 
CCA is severe for MNAR scenarios with opposite direction of dropout, and is greater than 
for MAR-L missingness. In particular, even with 10% dropout rate this analysis method 
can lead to substantially biased estimates of treatment effect. In the present study, the 
treatment effect was underestimated in most MAR-L and MNAR scenarios, especially for 
scenarios with opposite direction of dropout, since individuals with favourable responses 
in the intervention group and individuals with unfavourable responses in the control group 
 Chapter 8             234 
were regarded as the dropouts for the scenario with the opposite direction of dropout. In 
general, the bias adversely affects the desired CI coverage and statistical power. 
Although a CCA produces less biased estimates of treatment effect in many scenarios 
compared to a LOCF-based analysis, the CCA does not consider the availability of 
outcome responses at interim visits. In many situations in clinical trials, these interim 
measurements have some level of influence on participants’ decision to continue a trial 
(Prakash et al., 2008). By ignoring these interim measurements CCA is omitting available 
and potentially informative data in respect of the treatment effect and thus leads to biased 
estimation of treatment effect. Therefore, CCA should be disregarded in favour of a more 
efficient analysis method that can effectively utilize the additional available data, 
irrespective of the amount of missing data. 
8.3.1.3 Mixed-effects model for repeated measures and MI-based analysis of 
covariance 
The estimate of treatment effect at the final time-point from MMRM is based on the FIML 
approach and is implicitly adjusted for the outcome observed at the previous time-points 
and their correlation with the final time-point (Davis, 2014). By contrast, MI requires 
explicit imputation of missing values and involves multiple random draws from the 
posterior predictive distribution of the missing data under a posited Bayesian model, 
instead of a single set of FIML estimates of parameters (Ratitch, 2014). 
In the present simulation study, MMRM and MI ANCOVA are found to be more robust to 
bias from missing data compared to CCA and LOCF ANCOVA. That is, MMRM and MI-
based analyses produce valid estimates of treatment effect for MCAR, covariate-
dependent MAR and outcome-dependent MAR (MAR-L) scenarios, irrespective of dropout 
rate and direction of dropout. Previous studies (Lane, 2008; DeSouza et al., 2009; 
Siddiqui et al., 2009; Siddiqui, 2011; Bell et al., 2013) that evaluated a number of dropout 
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scenarios under an MAR dropout mechanism also confirmed that MMRM performed well 
– in terms of controlling bias – compared to LOCF and CCA. However, the present study 
finding on MI ANCOVA contradicts the results from a previous study by Siddiqui (2011), 
who reported a biased estimate of treatment effect in relation to a scenario of outcome-
dependent MAR. In addition, the present simulation study shows that both methods yield 
unbiased estimates of treatment effect in the MNAR situation whereby dropout is equal 
and in the same direction between treatment groups. This result (in the context of MMRM) 
agrees with previous work by Bell et al. (2013). 
Siddiqui (2011) also reported MI-based analysis as being a conservative approach with 
type 1 error rate of 1% and a high SE (compared to MMRM) in an MAR scenario of 
differential dropout rate. However, the present study countered his finding by virtue of the 
fact that both methods (MMRM and MI ANCOVA) attain the accepted level of CI coverage 
(i.e. 93.6%–96.4%) for all MCAR and MAR data scenarios, irrespective of dropout rate. A 
slight difference in CI coverage and width between these methods was observed in the 
present study. This difference was most noticeable for scenarios with opposite direction of 
dropout – MI retained very slightly higher CI coverage and width than MMRM. The present 
study also found that data variability had a slightly greater impact on the width in respect 
of MI-based analysis compared to MMRM. In this simulation, only a limited number of 
imputations – a number equivalent to percentage of dropouts – was used as 
recommended by White et al. (2011b). However, it is noted that a substantial number of 
imputations are required to minimize the variability due to randomness associated with MI 
(Rubin, 1987; Graham et al., 2007). 
In the empirical evaluation of the TATE and STarT Back trials, it was found that a large 
number of imputations need to be used with MI to minimize the difference in estimate of 
treatment effect between MI and MMRM analyses. In the TATE dataset, a large number of 
imputations, which was more than ten-fold of the current recommendation (White et al., 
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2011b), was used to obtain a closer estimate from the two analysis methods. Similarly, in 
the STarT Back data, the number of imputations used in MI was more than twenty-fold of 
the current recommendation (White et al., 2011b). However, the SE with MI ANCOVA was 
still slightly higher than that from the MMRM analysis. This confirms the finding from 
previous studies (Collins et al., 2001; Schafer & Graham, 2002; Barnes et al., 2008) that 
FIML-based methods, in general, produce slightly smaller SEs than MI-based methods 
unless the number of imputation is substantially high. 
Under all MNAR data scenarios, except the scenario of equal dropout rates with the same 
direction of dropout, none of the considered approaches performs well in terms of 
controlling bias in estimation of treatment effect; the bias markedly increases in relation to 
an increase in overall dropout rate and data variability. Further, both MMRM and MI yield 
similar estimates of the treatment effect and RMSE in all scenarios. In the present 
simulation study, it was observed that the bias ranged from 4% to 21% of baseline SD 
(Table 8.1) for the scenarios with 10% dropout rate and 14% to 46% of baseline SD for 
scenarios with 30% dropout rate. It was further found in the present study that the bias is 
severe for scenarios of ‘opposite direction’ of dropout compared to ‘same direction’ of 
dropout when the missing data mechanism is MNAR. Moreover, the bias can be 
substantial with only a 10% dropout rate. However, estimates are slightly more 
appropriate than those given by CCA in some instances, especially for scenarios of strong 
correlation between repeated follow-ups. Further, the bias adversely affects the desired CI 
coverage and statistical power. Previous studies by Mallinckrodt et al. (2001b; 2001a; 
2004), in which data were simulated under an MNAR mechanism and a high overall 
dropout rate, showed only a negligible bias in MMRM estimates of treatment effect. 
Another simulation study by Barnes et al. (2008) also showed that MMRM and MI retained 
an acceptable level of CI coverage under similar scenarios of MNAR mechanisms. 
However, the present study provides a clear warning against the use of MMRM or MI-
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based analyses when an MNAR missing data mechanism is suspected. Lane (2008) also 
showed some scenarios in which MMRM can be severely flawed. 
The present study is partially comparable to the previous simulation study by Olsen et al. 
(2012), in which they compared CCA, MMRM and MI ANCOVA for the analysis of a 
continuous outcome variable in MNAR scenarios of an approximately 30% overall dropout 
rate. For an equal dropout rate scenario, the previous study reported valid (with 
no/negligible bias) estimates of treatment effect from these three methods. However, the 
present study identified, in line with Bell et al. (2013), that the implication of validity cannot 
be generalized to all equal dropout scenarios, and that the only possible scenario for an 
unbiased estimate under an MNAR mechanism is the scenario of equal dropout rate with 
‘same direction’ of dropout. For a differential dropout rate scenario, Olsen et al. (2012) 
reported biased estimates from these analysis methods, but lower bias with MMRM 
compared to CCA and MI ANCOVA. The present study also confirms the possibility of 
bias from these methods for the same scenario, but does not confirm the superiority of 
MMRM over MI ANCOVA in terms of bias. The previous study also reported that CCA 
yielded a high type 1 error rate in a scenario of differential dropout rate and acceptable 
level of type 1 error rate in a scenario of equal dropout rate. The present comprehensive 
simulation study (with 546 scenarios in chapter 5 and 6) concluded that all methods retain 
the acceptable CI coverage (which can be directly translated to acceptable type 1 error 
rate) when the estimate of treatment effect is unbiased. 
8.3.2  Choice between MMRM and MI-based analyses in an RCT 
There are a number of practical difficulties associated with MI implementation. One 
disadvantage with MI is the inconsistent estimates due to random draws; a high number of 
imputations are required to reduce the variability due to randomness (Graham et al., 
2007). Depending on the number of imputations and the model specifications to impute 
missing values, more computing time might be required. Since only a limited number of 
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variables were involved in the simulation study (i.e. an outcome variable and treatment 
indicator), the implementation of MI was as simple as the MMRM model. However, in 
practice where an analysis model involves a number of covariates and interactions, it is 
quite difficult to specify an imputation model in MI since the imputation model should be 
congenial (Molenberghs & Kenward, 2007). That is, the imputation model should at least 
include all the variables, interactions and transformations (e.g. non-linear terms) that are 
also intended for use in the analysis model. In the simulation study, a ‘restrictive’ 
imputation model (i.e. the model included only those variables that used for the MMRM 
model) was used. From the simulation and empirical evaluation of MMRM and MI 
ANCOVA, it is clear that both methods yield similar estimates of treatment effect and SE if 
the number of imputations is substantially high. That is, as Rubin (1987) showed, an 
infinite number of imputations are required to make MI ANCOVA as efficient as MMRM. 
However, with the recommended (White et al., 2011b) number of imputations, it is 
possible to get sufficient efficiency for MI, and the difference in SE between the two 
methods is very unlikely to influence statistical decision-making. In summary, there is no 
advantage of using MI with restrictive imputation as opposed to MMRM unless covariates 
have missing values. 
Further, it is possible to incorporate auxiliary variables that are not part of a subsequent 
analysis model into the imputation model in order to make MAR more plausible and, 
therefore, to increase efficiency and reduce bias (Collins et al., 2001; Spratt et al., 2010) – 
this is referred to as an inclusive modelling strategy (Collins et al., 2001). This strategy is 
generally implemented in two ways: (i) include all auxiliary variables into the imputation 
model or (ii) include variables that are selected based on data considerations. Collins et 
al. (2001) performed a simulation study in which they compared the restrictive and 
inclusive imputation modelling strategies to assess the influence of auxiliary variables on 
the estimation of population mean and regression parameters in a linear regression model 
on an outcome variable with missing values. Referring to Collins et al.’s (2001) work, the 
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advantage of auxiliary variables is considerable in estimation of treatment effect only if 
those variables are strongly associated with missingness in the outcome and highly 
correlated with the observed outcome. Further, the inclusion of too many ‘junk’ variables 
(variables that are not associated with either missingness or the observed outcome) may 
increase bias in estimation of treatment effect and decrease precision (Collins et al., 2001; 
Hardt et al., 2012). Spratt et al. (2010) conducted an empirical evaluation of inclusive 
imputation models using a longitudinal observational dataset. In that dataset, the outcome 
variable (wheeze at age 81 months) and two of three prognostic variables were subject to 
missing data. They reported that inclusion of only those auxiliary variables that were 
predictive of variables having missing data increased odds ratio and reduced SE. 
However, the inclusion of only those variables associated with missingness did not make 
a difference to the OR and SE. The impact of ‘junk’ variables was not reported in their 
study. Enders (2010) suggested selecting auxiliary variables that have correlations greater 
than ±0.4 with variables with missing data. In line with Collins et al.’s (2001) work, White 
at al. (2011b) pointed out that one should include variables that are associated with the 
missing data mechanism and/or correlated with the variables having missing 
observations. However, Thoemmes and Rose (2014) argue that there are auxiliary 
variables that can induce bias in estimation using MI irrespective of the association 
between the auxiliary and outcome variables. In general, there is no consensus on the 
selection of the auxiliary variables. Importantly, if researchers consider the inclusion of 
auxiliary variables that are selected based on data considerations as suggested by White 
at al. (2011b), the analyses of primary and secondary outcome variables in an RCT data 
may require separate imputation models, costing considerable effort and time. Therefore, 
further research is necessary to develop guidance on selecting auxiliary variables in MI for 
the analyses of longitudinal RCTs where there are several baseline, secondary outcome 
and primary outcome variables, and where both primary and secondary outcomes have 
missing responses. 
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As noted, the present simulation study did not address the inclusive MI modelling strategy. 
However, comparisons of restrictive and inclusive imputation modelling with MI were 
performed on a range of outcome variables from the TATE and STarT Back trial datasets. 
In the TATE trial, it was found that the inclusive imputation modelling with MI resulted in 
slightly different estimates of treatment effect and SE from restrictive imputation modelling 
with MI or MMRM analysis. The observed difference varied by the number and type of 
auxiliary variables added into the inclusive imputation model even if the auxiliary variables 
were not associated with an outcome variable and its missing indicator. For example 
(appendix 8), the effect size for the secondary outcome PRTEE was −0.215 based on MI 
with restrictive imputation modelling strategy. The inclusion of pain intensity (for which 
additional observations were available due to the MDC strategy) as an auxiliary variable in 
the imputation model led to a reduced effect size of −0.193; whereas the inclusion of SF 
12-PCS led to an increased effect size of −0.261. The inclusion of both auxiliary variables 
in the restrictive imputation model for PRTEE yielded an effect size of −0.212. In the TATE 
trial dataset, pain intensity showed a strong correlation with the PRTEE but not the SF 12-
PCS. In the STarT Back trial, it was found that the inclusive imputation modelling with MI 
did not make any noticeable difference18 to the estimates from restrictive imputation 
modelling with MI or MMRM analysis even though included auxiliary variables showed a 
moderate level of correlation with outcome variables and moderate association with 
missingness in the outcome variables. These findings make a strong case for further 
research on selection of auxiliary variables in missing data problems. 
                                               
18
 However, inclusion of all variables in the original dataset (where the number of variables is 
substantially greater than that in the dataset used for the re-analysis) showed a difference in 
estimate from the original analysis published. 
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In summary, unless a researcher is more comfortable with MI than with mixed models, it is 
better to utilize an MMRM model as the primary analysis method. However, MI with an 
inclusive modelling strategy can be an ideal starting point for a sensitivity analysis. 
8.3.3 Strategy for handling baseline values with MMRM analysis 
In chapter 6, comparisons of the results from MMRM with baseline-as-covariate to an 
alternative model with baseline-as-outcome were reported. Since the presence of early 
dropouts is common in pragmatic trials, all simulated datasets in this thesis involved some 
participants without any follow-up measurements. Hence, analysis using MMRM with 
baseline-as-covariate led to the exclusion of those participants from the analysis. In the 
present simulation study, it was found that the inclusion of participants without any follow-
up data (by considering baseline as an outcome) did not make a difference to the 
estimates of treatment effect. However, with a 30% dropout rate (nearly 10% were early 
dropouts), the study found a slight difference in the coverage of the 95% CI and the 
observed power due to slightly reduced average SEs for scenarios of opposite direction of 
dropout. The model with baseline-as-covariate and Kenward-Roger correction for a finite 
sample showed the highest coverage but the lowest statistical power, whereas the model 
with baseline-as-outcome and without the correction showed the lowest coverage but the 
highest power. Since it was found that the difference is only a concern for some extreme 
scenarios of dropout, the choice of baseline handling strategy is unlikely to influence the 
CI coverage or statistical power when baseline is fully observed. Thus, the findings of the 
present study do not concur with previous work by Lui et al. (2009) in which the authors 
found that retaining baseline as a covariate could result in greater loss of efficiency 
compared to the other approach and hence favoured the model with baseline-as-outcome. 
The analysis of the TATE and STarT Back trial datasets (Chapter 7) also confirmed that 
the inclusion of participants without any follow-up data in MMRM analysis (by considering 
baseline as an outcome) does not make a difference to the estimates of treatment effect 
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at the endpoint, but there was a small reduction in SE. Overall, the present study supports 
Kenward et al.’s (2010) disagreement with Lui et al.’s (2009) conclusion. Since both the 
strategies do not take into account early dropouts in the estimation of treatment effect, it is 
consequently important to ensure that these early dropouts do not have any adverse 
impact on the benefit achieved through randomization. 
In a setting with missing baseline data, the implementation of MMRM with baseline-as-
covariate excludes individuals with missing baseline data. In the STarT Back trial it was 
observed that this MMRM model yielded a lower estimate of treatment effect and slightly 
higher SE for the secondary outcomes compared to the model with baseline-as-outcome. 
However, it is also possible to retain the same power using MMRM with baseline-as-
covariate without the risk of bias using supplementary methods i.e. mean imputation or 
missing indicator method (White & Thompson, 2005). 
8.3.4 The benefits of sample size inflation to the effect of attrition on statistical 
power 
The effect of missing data on the statistical power to detect the true treatment effect in a 
clinical trial has been detailed in chapter 5 and 6. The present simulation study has 
established that trials could be artificially underpowered/overpowered depending on the 
magnitude and direction of bias in estimates. It was also found that trials are 
underpowered even with unbiased estimates of treatment effect irrespective of analysis 
methods or missing data mechanisms. When there is no bias in the estimate of treatment 
effect, the reduction in power is shown to be associated with the direction of dropout, the 
amount of missing data, data variability and correlation between repeated measurements. 
The reduction is relatively larger in scenarios of ‘opposite direction’ of dropouts between 
study groups compared to the scenarios of ‘same direction’ of dropouts in both groups.  
 Chapter 8             243 
Though previous simulation studies (Mallinckrodt et al., 2001a; Baron et al., 2008; Lane, 
2008; DeSouza et al., 2009; Siddiqui, 2011; Olsen et al., 2012) have shown the effect on 
power of the presence of missing data in a few scenarios, these studies were generally 
not sufficient to extend their inference into real practice. This is mainly because these 
simulation studies used unrealistic sample sizes that yielded substantially higher or lower 
power in the absence of missing data than the routinely desired power of 80% or 90% in 
real clinical trial scenarios. Unlike the previous studies, the present study in chapter 5 
used sample sizes that were calculated in order to ensure 90% power for data without 
missing values and the effects of missing data were explored in contrasting scenarios for 
the purpose of generalizability. 
In the literature, discussion about the loss of efficiency in terms of power is generally 
limited to the methods that lead to listwise deletion of cases with missing values. Thus, 
researchers may be less concerned over the possible effect of missing data on the 
desired power, particularly when the planned analysis is other than CCA. For example, in 
a recently published statistical analysis plan for a trial (Johnsen et al., 2014), the authors 
reported that an MI-based approach will be used as the primary analysis, and they 
claimed that their previous experience supports the MAR assumption. The authors 
reported the sample size calculation in detail, but they failed to comment on loss in power 
due to an expected attrition in their calculation. However, they had targeted a 90% 
statistical power in the sample size calculation. The consideration of a high power might 
be because of expected dropouts but the report did not detail any such explanation. The 
systematic review in chapter 3 also found that many of the reviewed trials did not consider 
the attrition effect on statistical power in their sample size calculation. In the systematic 
review, it was found that 21% of trials (19/91) failed to report a formal sample size 
calculation, contrary to CONSORT recommendations (Moher et al., 2010). Furthermore, 
many of the trials (44/72) that reported a sample size calculation did not address the 
adjustment for anticipated dropout rate. This indicates a need to promote the importance 
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of adjustment for attrition in sample size calculations in order to retain sufficient statistical 
power to detect a true treatment effect. Importantly, the present simulation study shows 
that none of the considered methods is immune to loss of power due to dropouts. 
An extract of simulation results regarding observed statistical power under the WM19 
variance-covariance scenario is provided in table 8.2. The sample size of 75 per group 
(columns two and four) was calculated to detect the true difference of −9.0 with 90% 
power in the absence of missing data. These columns provide the range of statistical 
power for each analysis method among the scenarios of unbiased estimates of treatment 
effect. For example, the observed power ranged from 84.1% to 87.7% for CCA when the 
dropout rate was 10% and the estimates were unbiased. It can be seen that all three 
methods almost equally underestimated the nominal power (even with 30% dropout rate). 
As noted earlier, the slightly lower power with MI ANCOVA can be improved by 
considering a substantially larger number of imputations. The lower limits of the results 
(i.e. larger underestimation of power) in each method were associated with scenarios for 
opposite direction of dropout with differential rate of dropout, and in contrast the upper 
limits of the results were associated with scenarios of same direction of dropout with equal 
dropout rate between groups. As was seen, the amount of missing data and the direction 
of dropout are the two major factors that contribute to the underestimation of power (due 
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 Weak correlation with moderate SD 
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Table 8.2: Statistical power for analysis methods (among the scenarios in which the 
methods yielded unbiased estimates of treatment effect) 
Analysis  
method 
10% dropout rate 
 










CCA 84.1%–87.7% 88.7%–90.3% 
 
66.0%–78.9% 82.6%–92.0% 
MMRM 84.6%–87.6% 88.8%–90.0% 
 
68.3%–79.8% 83.2%–92.1% 
MI ANCOVA 83.1%–87.5% 87.7%–90.0% 
 
65.8%–77.5% 81.4%–91.6% 
Percentages are range of power among the scenarios in which the methods yield unbiased 
estimate of treatment effect; 
1
sample size calculated to detect the true difference of −9.0 with 90% 
power in the absence of missing data; 
2
adjusted for 10% dropout rate; 
3




In chapter 6, an additional simulation study was performed to evaluate the common 
practice of inflating sample size – by the inverse of one minus the anticipated dropout rate 
– for the purpose of retaining the desired power at a nominal level of 80% or 90% in the 
presence of dropouts. Overall, the inflation in sample size was helpful in protecting against 
the loss of power due to attrition. For example, columns three and five in table 8.2 provide 
the range of observed statistical power (desired power was 90%) for each analysis 
method among the scenarios of unbiased estimates of treatment effect with increased 
sample size for dropout rate of 10% and 30%, respectively. In the case of 10% dropout 
rate, the methods – CCA, MMRM and MI – could retain the observed power very close to 
the desired level with the increased sample size in dropout scenarios of unbiased 
estimate of treatment effect. In the case of 30% dropout rate, these methods could also 
retain the observed power to the desired level with the increased sample size in many of 
the scenarios of unbiased estimate of treatment effect – especially in scenarios of MCAR, 
MAR with the same direction of dropout, and MNAR with the same direction of dropout 
and equal dropout rate. In scenarios of MAR with opposite direction of dropout, the 
increased sample for 30% dropout rate was not sufficient to reach the desired level of 
statistical power; however the observed power was not substantially lower than 85% when 
the desired power was 90% or 75% when the desired power was 80% in these scenarios 
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based on MMRM analysis. As noted earlier, CCA and MI yielded a slightly larger loss of 
power under these scenarios, and the power of MI can be improved by considering a 
substantially large number of imputations. Considering that the scenarios of opposite 
direction of dropout were extreme cases and bearing in mind the limitations of previously 
proposed approaches (Lu et al., 2008; 2009), which were detailed in chapter 2, the naïve 
approach of sample size inflation might be sufficient in order to account for expected 
attrition effect and provide an acceptable statistical power conditional on parameters that 
are less likely to adversely affect the probability of rejecting the null. 
8.3.5 Reminder data to investigate the appropriateness of MAR-based analyses 
From the simulation work, it was clear that the validity of approaches to handling missing 
data depend on the missing data mechanism. That is, to understand the potential impact 
of, and how best to deal with, missing data, it is important to consider the mechanism 
leading to the missingness. As pointed out in the background chapter, although some 
methods (Little, 1988; Diggle, 1989; Ridout, 1991; Fairclough, 2002) have been proposed 
for the identification of the missing data mechanism, their purpose is generally to detect 
violations of the MCAR assumption by identifying dependence on observed data. Fielding 
et al. (2009) performed an investigation of missing data mechanisms on a number of 
empirical trial datasets using these methods and found that different approaches yielded 
different conclusions on the mechanism among their datasets (detailed in chapter 7, 
discussion section). As there is no effective way to identify the underlying missing data 
mechanism with certainty and no best single analysis method under an MNAR 
mechanism, a primary analysis based on an MAR assumption is often reasonable 
(National Research Council, 2010; Mallinckrodt, 2013). Since the validity of inferences 
from this analysis depends on the correctness of the MAR assumption, it is critical to 
assess the robustness of inferences from the primary analysis to departures from MAR 
assumptions (Food and Drug Administration, 2008; European Medicines Agency, 2010; 
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National Research Council, 2010). However, due to lack of consensus on sensitivity 
analysis methods to assess the robustness of results from primary analysis of an RCT 
and how to draw inferences from these analyses, sensitivity analyses are often performed 
inappropriately and largely unreported (Morris et al., 2014). A simple approach has been 
proposed in chapter 7 to ensure the ignorability that is assumed with the primary analysis 
and thus to verify the unbiasedness of the estimate of treatment effect from the primary 
analysis if the possibility of bias from other (otherwise non-observable) sources has 
already been considered. A more detailed discussion was provided in chapter 7. 
The proposed approach makes use of the responses subsequently recovered via 
reminder or MDC to assess the validity of the inferences from the MAR-based primary 
analysis. In the TATE trial, this approach showed that an MAR-based analysis was 
unlikely to yield unbiased estimates of treatment effect for the primary and secondary 
outcomes (i.e. non-responses were non-ignorable under the MAR-based analysis). 
Therefore, further sensitivity analyses were required under a range of plausible MNAR 
assumptions. However, in the STarT Back trial, this approach showed that an MAR-based 
analysis was unlikely to yield a biased estimate of treatment effect for the primary 
outcome (hence, non-responses were ignorable under MAR). 
In summary, this analysis takes a position in between the primary analysis and a detailed 
sensitivity analysis, and allows a decision to be taken on whether to move ahead with the 
detailed sensitivity analysis that makes stringent assumptions about missing data. 
Guidance under the proposed approach is based on the assumption that reminder 
responses share the same (or at least similar) mechanism underlying missingness as the 
true non-responders/missing data. 
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8.4 Limitations and generalizability 
The present systematic review was restricted to trials published in speciality journals 
relating to musculoskeletal/pain disorders. The selected journals were high-impact factor 
journals, which should bias the results towards a better methodology and reporting; 
hence, it is expected that the systematic review findings around appropriate use of 
methodology for ITT analysis and proper handling of missing data will be overstated rather 
than understated. Thus, the finding in this review that the minority of RCTs are performing 
a full ITT analysis (as per recommendation) is likely to be conservative, particularly in 
respect of publications within speciality journals in the area of musculoskeletal clinical 
trials. Further, the systematic review of trials published in 2010 and 2011 does not 
necessarily reflect the impact of recent regulatory guidelines on the prevention and 
handling of missing data (European Medicines Agency, 2010; National Research Council, 
2010) and thus the quality of practice in 2014. However, the systematic review provides a 
strong indication that inappropriate practices in dealing with missing data still exist and 
that little progress has been made in reducing the large proportion of trials that are 
inappropriately analysed compared to the similar previous reviews in this area that 
evaluated trials published in 2001 and 2002 (Wood et al., 2004; Gravel et al., 2007). 
Furthermore, the present review can be the reference for a future systematic review that 
could assess the impact of the regulatory guidelines on the quality of practice with regard 
to the treatment of missing data. 
Though the focus of the thesis is on musculoskeletal trials, the simulation study findings 
can be generalized to any parallel-group trials with serial multiple outcome measurements 
with a continuous outcome variable that is assumed to be normally distributed. The clinical 
trial scenarios considered are likely to reflect some of the most common scenarios 
encountered across the spectrum of real-life pragmatic clinical trials where data is 
collected at set intervals and missing data is commonplace. The simulation study does 
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have limitations and does not reflect the full range of possible scenarios in RCTs. The 
findings of the study are limited in interpretation to RCTs with normally distributed 
outcomes and they should not be generalized to RCTs in which the outcome is non-
normal; for example, those that involve substantial skew, a binary outcome or in which 
time-to-event is the primary outcome. For selecting trajectories, the present simulation 
study did not consider a common scenario of a short-term treatment effect that 
disappears. However, the simulation study did show that the shape of trajectories does 
not influence bias in either the ANCOVA or the MMRM estimate of difference in treatment 
effects between groups at a given time point unless missing responses were imputed 
using LOCF. Further, this study may not reflect all reasons for missing data and thus all 
patterns of missing data that could occur in real situations. However, in order to overcome 
this limitation to some extent, the simulation study has considered contrasting scenarios 
(e.g. 10% versus 30% overall dropout rates, equal versus differential dropout rates 
between groups, same versus opposite direction of dropouts) in generating missing data. 
This study considered missing data due to dropouts but not due to missed visits or 
missing item(s). However, the statistical methods that have been considered in this study 
are generalizable to non-monotone missing data as well. Another limitation is that the 
study did not consider other methods, such as weighted generalized estimating equations 
(wGEE; Mallinckrodt, 2013), for handling of missing data. The wGEE approach involves 
weighting observations by the inverse probability of dropout, and the validity of this 
approach depends on the correct specification of the dropout model (Mallinckrodt, 2013). 
The illustration of the proposed approach to consideration of reminder data has only been 
performed on two musculoskeletal related, parallel-group trials where outcome 
measurements were assumed to be normally distributed and estimate was the difference 
in treatment effects between groups at a given time point. The effect sizes in these trials 
were also particularly small, which may limit the interpretation of difference in effect size 
between the original and the modified datasets. Therefore, this approach needs to be 
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evaluated in other trial contexts, including trials with different effect sizes and other types 
of design, and trials in other clinical areas. Further, the proposed approach that was used 
to confirm the ignorability of missing data mechanism using responses obtained after a 
number of reminders depends heavily on the assumption that the reminder responses are 
representatives of missing responses. In fact this assumption cannot be verified, as the 
data required to do so are missing. Collection and comparison of reasons for delayed 
responses and non-responses may help inform the justification for this assumption. Such 
a comparison was not performed in the present study because the reasons for delayed 
response and largely for non-response were not available for the TATE and STarT Back 
trials. 
8.5 Implications for practice 
The simulation study findings can act as a guide to the selection of the most appropriate 
statistical approach for dealing with missing data in clinical trials. Further, this study could 
address the conflicting findings from the previous studies. Importantly, this study found 
that equal dropout rate guarantees an unbiased estimate of treatment effect from CCA, 
MMRM or MI only for scenarios of the same direction of dropout in both treatment groups. 
Contrary to the findings from many of the previous studies, the present simulation study 
shows the non-conservative nature (i.e. bias in estimate favours the new treatment) of the 
LOCF imputation approach. This study further showed that MMRM and MI yield similar 
results if they are implemented appropriately. This finding indicates that one should not 
devalue MI on the basis of a finding by Siddiqui (2011) in which the author reported that 
MI was severely impaired by a very low type 1 error rate (i.e. MI was too conservative to 
reject a true null hypothesis). The previous study finding was highlighted as the drawback 
of MI over MMRM in a recent report (Gewandter et al., 2014); however, the claim is 
unwarranted. The present study also favours an MMRM over MI with a restrictive 
imputation modelling strategy considering the ease with which MMRM can be 
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implemented – a substantially high number of imputations are required with the MI to 
obtain an estimate that is equivalent to MMRM. The advantage of an MI-inclusive 
modelling strategy is that an imputation model can include auxiliary variables that may 
predict missing values; especially for the secondary variables when MDC is limited to the 
primary outcome variable, the ‘additional information’ on the primary outcome variable 
may help to improve the estimation of treatment effect on the secondary variables. 
However, the evaluation of the empirical datasets suggests that MI with an inclusive 
imputation modelling strategy may be a reasonable consideration for a sensitivity analysis 
because of the difficulty associated with the selection of the ‘best’ model to impute missing 
data. Further, this study encourages the use of the proposed reminder approach to check 
the ignorability that is assumed with MMRM analysis and thus to confirm the 
unbiasedness of the estimate of treatment effect from the MMRM analysis. 
Given the findings of this study, the following are recommended for future statistical 
analysis of a normally-distributed incomplete continuous outcome in a longitudinal 
randomized clinical trial: 
i. Minimize the amount of missing data: the best way to deal with missing data is 
to avoid them. Trialists should anticipate potential missing data problems. The 
study protocol should address this issue and show necessary steps taken in 
the design and conduct of the trial to limit the impact of missing data. In 
pragmatic trials, it is often possible to use reminders to encourage participants 
to respond. 
ii. Perform a priori sample size calculation and ensure it is adjusted for 
anticipated loss to follow-ups. In this thesis, it has been showed that the naïve 
approach of inflating the sample size directly proportional to anticipated loss to 
follow-up is generally acceptable to retain sufficient power to detect the true 
difference if the missing data analysis method is appropriate. 
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iii. All randomized participants should be accounted for in reporting the trial results 
irrespective of whether or not the participants are lost to follow-up. In the 
systematic review, it was found that the use of partial intention-to-treat analysis 
is quite common. Any planned exclusion of randomized participants from the 
analysis should be pre-specified in the study protocol with justification for such 
exclusions. 
iv. Statistical methods to deal with missing data – the primary analysis and 
sensitivity analyses – should be pre-specified in the study protocol, and the 
assumptions required for such analyses should also be stated clearly. 
v. LOCF-based analysis should not be regarded as the primary analysis. The 
analysis provides biased estimates with underestimated SEs in most 
situations; the estimate of treatment effect is not conservative in many 
situations. 
vi. CCA should also not be performed as the primary analysis because MAR-
based analyses – such as MMRM and MI-based analysis – can efficiently 
handle missing data more appropriately and in a greater number of situations 
than CCA, and retain sufficient CI coverage and statistical power. Missing data 
have been shown in many cases to at least follow an MAR mechanism, and 
therefore CCA is inadequate for analysing such datasets. 
vii. Equal dropout rate between treatment groups does not guarantee an unbiased 
estimate of treatment effect (notably as dropout may not be in the same 
direction in both treatment groups). 
viii. An MAR-based analysis might be ideal as the primary analysis because 
MNAR-based analyses require stringent assumptions about missing data. 
Unless a researcher is more comfortable with MI than with mixed models or 
covariates having missing observations, it is better to adopt an MMRM model 
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as the primary analysis. However, MI with an inclusive modelling strategy can 
be performed as a sensitivity analysis. 
ix. It is advisable to perform the proposed approach (as outlined in chapter 7), 
which uses reminder responses to check the ignorability that is assumed with 
MMRM analysis and thus to confirm, or not, the unbiasedness of the estimate 
of treatment effect from the MMRM analysis. 
x. If the proposed approach does not favour the ignorability of the missing data 
mechanism and the unbiasedness of the estimate of treatment effect, well-
structured sensitivity analyses (Mallinckrodt et al., 2013; Ratitch et al., 2013) 
that include statistical models that incorporate plausible departure from the 
ignorability of the missing data mechanism should be included as part of the 
statistical analysis plan. 
8.6 Future work 
Further additional research is required to address the limitations of the present work. 
i. A further systematic review is required, considering the present review as a 
reference, to assess the implication of recent research and regulatory 
guidelines with regard to missing data in clinical trials. 
ii. The present simulation study did not consider the availability of multiple 
outcome measures, covariates and auxiliary variables. Therefore, this study 
did not explore the advantages of MI with inclusive imputation modelling 
strategies. Since the validity of MI involves the correctness of the imputation 
model, guidelines on selection of auxiliary variables into an imputation model 
are required. 
iii. The rationale underlying the proposed approach is that the responses that 
have been retrieved after a number of failed attempts are likely to represent the 
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actual missing responses when the number of failed attempts increases. It 
would be interesting to investigate the plausibility of this assumption by utilizing 
reasons for delayed responses and non-responses. 
iv. If the proposed approach does not support the ignorability of the missing data 
mechanism and the unbiasedness of the estimate of treatment effect, further 
investigation is needed on how to make best use of the reminder responses 
within modelling strategies that appropriately take into account departure from 
the ignorability of the missing data mechanism. 
8.7 Conclusion 
Given that no method can completely overcome the problem of missing data, trialists 
should consider ways to prevent missing data during the design and conduct of RCTs. In 
a pragmatic setting, it is quite often possible to consider sending reminders to encourage 
participants to respond and, as a final attempt, to limit the data collection to essential 
variables of interest, in order to maximize response to the primary endpoint. 
A Monte Carlo simulation study was conducted to compare four methods for dealing with 
missing longitudinal normal continuous outcome data in clinical trials. On the basis of this, 
LOCF ANCOVA is very unlikely to give an unbiased estimate of treatment effect. 
Differential improvement in outcome between treatment groups and timing of dropout 
substantially affect the estimation of treatment effect using LOCF-based analysis. Hence, 
the use of LOCF-based analysis as the primary analysis in an RCT should be avoided.  
Although CCA can produce an unbiased estimate of treatment effect in many scenarios, 
the analysis does not consider the availability of outcome responses at interim visits. In 
many situations in clinical trials, these interim measurements have some level of influence 
on participants’ decision to continue a trial. Therefore, CCA should be disregarded in 
favour of more efficient analysis methods such as MMRM and MI-based analysis that can 
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effectively utilize the additional available data. MMRM and MI with a restrictive imputation 
modelling strategy yield similar results when they are implemented in a similar manner. In 
an MMRM model, baseline can be considered either as covariate or as outcome. Both 
strategies are acceptable if baseline data are complete, otherwise a model that includes 
baseline as an outcome is preferable. 
The proposed reminder approach can be used to assess the robustness of the MAR 
assumption by checking expected consistency in MMRM estimates. If the results deviate, 
then analyses incorporating a range of plausible MNAR assumptions are advisable, at 
least as sensitivity tests for the evaluation of treatment effect. 
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Appendix 2: Systematic review - data extraction form 
A. Basic details 
1. Serial Number: 
2. Author: 
3. Year of publication: 
4. Journal Name: 
5. Disease category being studied: 
6. Number of groups compared: 
7. Primary objective: 
8. Primary outcome – variable type [1-numerical (discrete/continuous); 2-categorical 
(nominal/ordinal)] 
a. As measured : 
b. As analysed : 
9. Design of trial (1- cluster RCT; 2 – other): 
10. Multicentre trial? (1 – yes; 0 - no): 
11. Number of follow-up visit (1 – 1 follow-up; 2 – 2 or more follow-up): 
12. Sample size 
a. Calculated sample size: 
b. Adjustment for attrition in sample size calculation (1 – yes; 0 – no): 
c. Number of subjects randomized: 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Total 
       
 
13. Number of participants completed the trial (at the primary endpoint) 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Total 
       
 
14. Reported analysis strategy:  
B. Analysis strategy (primary analysis) 
1. Size of the trial (Number of participants in the analysis): 
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Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Total 
       
 
2. Handling of ineligible subjects (Subsequent ineligible subjects - based on 
inclusion or exclusion criteria) 
a. Presence of ineligible subjects (1 – yes; 0 – no): 
b. If yes in (a), how the subjects were handled (1 -excluded; 2 – withdrawal; 
3 – included; 99 –not clear): [withdrawal (treated as missing data) can be 
either patient’s or clinician’s decision] 
c. If excluded, how many subjects 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Total 
       
 
3. Handling of major treatment protocol violations 
3.1. Presence of treatment crossover  
a. Treatment crossover (1 – yes; 0 – no): 
b.  If yes, analysed as (1 – excluded; 2 – randomized; 3 - treated; 99- not 
clear): 
c. If excluded, how many subjects 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Total 
       
  
3.2. Major treatment protocol violation (other than treatment crossover & ineligible 
inclusion) [for e.g., subjects may not have followed the treatment procedure 
properly or may have taken other medication along with assigned treatment, etc.] 
a. Whether major protocol violations were reported? (1 – yes; 0 – no): 
b. If yes in (a), how the subjects were handled (1 – excluded; 2 – withdrawal; 
3 – included; 99 –not clear): 
c. If excluded, how many subjects 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Total 
       
 
4. Handling of missing data 
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4.1. Subjects were randomized, but not started the treatment [or discontinued before 
start of the treatment] 
a. Subjects with that condition (1 –present; 2 – Absent): 
b. If present, how many subjects 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Total 
       
 
c. If present, how the subjects were handled (1 – excluded; 2 – included; 99 
–not clear): 
d. If included, method of analysing missing data:  
4.2. Treatment was started, but no post-baseline measurements were available 
[Treatment was started, but discontinued prior to the post-baseline measurement] 
a. Subjects with that condition (1 –present; 2 – Absent): 
b. If present, how many subjects 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Total 
       
 
c. If present, how the subjects were handled (1 – excluded; 2 – included; 99 
–not clear): 
d. If included, method of handling missing data:  
 
4.3. Missing at primary endpoint (excluding subjects with the above conditions 4.1 & 
4.2) [Post-baseline measurements were available, but discontinued prior to the 
primary endpoint] 
a. Missing data (1 –present; 2 – Absent): 
b. If present, how many subjects 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Total 
       
 
c. If present, how the subjects were handled (1 – excluded; 2 – included; 99 
–not clear): 
d. If included, method of handling missing data:  
 
5. Reason for missing data ( in situations 4.2 & 4.3) 
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a. Major reason for patient withdrawal: 
 (1 – Adverse event; 2 – inefficacy; 3- lost to follow-up; 4- other; 99- not clear) 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Total 
       
 
6. Analysis method (Hypothesis testing) 
a. Analysis method: 
 
7. Sensitivity analysis (with alternative assumptions made about missing data) 
a. Whether sensitivity analysis was performed ( 1 – yes; 0 – no): 
b. If yes in (a), analysis result was presented (1 –yes; 0 – no): 
c. If yes in (a), handling of subjects with missing data (1 – excluded; 2 – 
included; 99 –not clear): 
d. If included, method of handling missing data: 
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Appendix 3: Stata syntax for data simulation and analyses 
/*Smulation program (sim_dropout) to generate based on 30% MCAR missing data under different 
scenarios in ANCOVA, MMRM(reml), LOCF, & MI. */ 
 
clear 
capture program drop sim_dropout_30 
program define sim_dropout_30, rclass 
version 12.0 
syntax , TRAJectory(integer) cs(integer) obs(integer) 
 
//Correlation structure (positive semi-definite): strong - 1: weak - 0 
if `cs'==0 { 
matrix input Corr = (1, 0.45, 0.39, 0.30\0.45, 1.0, 0.41, 0.34\0.39, 0.41, 1.0, 0.40\0.30, 0.34, 0.40, 
1.0) 
} 
if `cs'==1 { 
matrix input Corr = (1.0, 0.75, 0.63, 0.54\0.75, 1.0,0.71, 0.59\0.63, 0.71, 1.0, 0.66\0.54, 0.59, 0.66, 
1.0) 
} 
//std deviation: low(=1), medium (=2), high(=3) 
if `sd'==1 { 
matrix input SD = (10.2, 10.7, 11.4, 12.2) 
} 
if `sd'==2 { 
matrix input SD = (14.1, 14.6, 16.9, 17.7) 
} 
if `sd'==3 { 
matrix input SD = (24.5, 25, 25.7, 26.5) 
} 
local no=`obs'/2 
set obs `no' 
 //under trajectory 1: 
 if `trajectory'==1 { 
matrix input Mean1 = (53, 50, 46, 40) /*Mean for group 0*/ 
matrix input Mean2 = (53, 50, 46, 40) /*Mean for group 1*/ 
drawnorm y01 y11 y21 y31, means(Mean1) sds(SD) corr(Corr) 
drawnorm y02 y12 y22 y32, means(Mean2) sds(SD) corr(Corr) 
 } 
 //under trajectory 2: 
 if `trajectory'==2 { 
matrix input Mean1 = (53, 50, 53, 48) /*Mean for group 0*/ 
matrix input Mean2 = (53, 31, 28, 30) /*Mean for group 1*/ 
drawnorm y01 y11 y21 y31, means(Mean1) sds(SD) corr(Corr) 
drawnorm y02 y12 y22 y32, means(Mean2) sds(SD) corr(Corr) 
 } 
 //under trajectory 3: main one 
 if `trajectory'==3 { 
matrix input Mean1 = (53, 50, 46, 40) /*Mean for group 0*/ 
matrix input Mean2 = (53, 47, 41, 31) /*Mean for group 1*/ 
drawnorm y01 y11 y21 y31, means(Mean1) sds(SD) corr(Corr) 
drawnorm y02 y12 y22 y32, means(Mean2) sds(SD) corr(Corr) 
 } 
 //under trajectory 4: 
 if `trajectory'==4 { 
matrix input Mean1 = (53, 45, 48, 32) /*Mean for group 0*/ 
matrix input Mean2 = (53, 51, 43, 23) /*Mean for group 1*/ 
drawnorm y01 y11 y21 y31, means(Mean1) sds(SD) corr(Corr) 
 Appendices              286 
drawnorm y02 y12 y22 y32, means(Mean2) sds(SD) corr(Corr) 
 } 
 







Generating missing datasets based on 21 dropout pattern (the final dataset will be a combination of 
22 datasets);  dr - dropout rate,  dm - dropout mechanism,  dp - direction of dropout 
**********************************************************************************************************/ 
//generating baseline variable for each datasets 
gen baseline=y0 
foreach dr in 30 { 
foreach dm in 01 02 04 06 08 10 12 {  
foreach dp in 01 02 03 { 






Dropout pattern 01: (MCAR 01; Dropout rate 30%; Dropout direction 01 - equal dropout between 
groups) 
Cumulative dropout rate: visit 0 - 0%/0%; visit 1 - 10%/10%; visit 2 - 20%/20%; visit 3 - 30%/30% 
**************************************************************************************************************/ 






//generate 10% dropouts at visit 1 in control group  
gen rand=runiform() if group==0 /*create a new variable to randomly order the outcome values at 
visit 1*/ 
_pctile rand if group==0, nq(100) 
scalar cutoff=r(r90) 
replace y0130011=. if rand >=cutoff & rand<.& group==0 /*10% obns were randomly deleted at 
visit 1*/ 
replace y0130012=. if y0130011==. & group==0 /* corresponding obns were deleted at visit 2*/ 
replace y0130013=. if y0130011==. & group==0 /* corresponding obns were deleted at visit 3*/ 
drop rand /*dropped the new variable*/ 
 
//generate additional 10% dropouts at visit 2 in control group  
gen rand=runiform() if y0130012!=.& group==0 /*create a new variable to randomly order the 
remaining outcome values at visit 2*/ 
_pctile rand if y0130012!=.& group==0 , nq(90) 
scalar cutoff=r(r80) 
replace y0130012=. if rand >=cutoff & rand<.& group==0 /*10% observations were randomly 
deleted at visit 2*/ 
replace y0130013=. if y0130012==.& group==0 /* corresponding obns were deleted at visit 3*/ 
drop rand /*dropped the new variable*/ 
 
//generate additional 10% dropouts at visit 3 in control group  
gen rand=runiform() if y0130013!=.& group==0 /*create a new variable to randomly order the 
remaining outcome values at visit 3*/ 
_pctile rand if y0130013!=.& group==0 , nq(80) 
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scalar cutoff=r(r70) 
replace y0130013=. if rand >=cutoff & rand<.& group==0 /*10% observations were randomly 
deleted at visit 3*/ 
drop rand /*dropped the new variable*/ 
 
**group 1** 
 //generate 10% dropouts at visit 1 in experimental group 
gen rand=runiform() if group==1 
_pctile rand if group==1, nq(100) 
scalar cutoff=r(r90) 
replace y0130011=. if rand >=cutoff & rand<.& group==1 
replace y0130012=. if y0130011==. & group==1 
replace y0130013=. if y0130011==. & group==1 
drop rand 
//generate additional 10% dropouts at visit 2 in experimental group 
gen rand=runiform() if y0130012!=.& group==1 
_pctile rand if y0130012!=.& group==1 , nq(90) 
scalar cutoff=r(r80) 
replace y0130012=. if rand >=cutoff & rand<.& group==1 
replace y0130013=. if y0130012==.& group==1 
drop rand 
//generate additional 10% dropouts at visit 3 in experimental group 
gen rand=runiform() if y0130013!=.& group==1 
_pctile rand if y0130013!=.& group==1 , nq(80) 
scalar cutoff=r(r70) 




Dropout pattern 02: (MCAR 01; Dropout rate 30%; Dropout direction 02 - higher dropout in 
experimental group) 
Cumulative dropout rate: visit 0 - 0%/0%; visit 1 - 5%/10%; visit 2 - 15%/25%; visit 3 - 20%/40% 
**********************************************************************************************************/ 





gen rand=runiform() if group==0 
_pctile rand if group==0, nq(100) 
scalar cutoff=r(r95) 
replace y0130021=. if rand >=cutoff & rand<.& group==0 
replace y0130022=. if y0130021==. & group==0 
replace y0130023=. if y0130021==. & group==0 
drop rand 
gen rand=runiform() if y0130022!=.& group==0 
_pctile rand if y0130022!=.& group==0 , nq(95) 
scalar cutoff=r(r85) 
replace y0130022=. if rand >=cutoff & rand<.& group==0 
replace y0130023=. if y0130022==.& group==0 
drop rand 
gen rand=runiform() if y0130023!=.& group==0 
_pctile rand if y0130023!=.& group==0 , nq(85) 
scalar cutoff=r(r80) 
replace y0130023=. if rand >=cutoff & rand<.& group==0 
drop rand 
**group 1** 
gen rand=runiform() if group==1 
_pctile rand if group==1, nq(100) 
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scalar cutoff=r(r90) 
replace y0130021=. if rand >=cutoff & rand<.& group==1 
replace y0130022=. if y0130021==. & group==1 
replace y0130023=. if y0130021==. & group==1 
drop rand 
gen rand=runiform() if y0130022!=.& group==1 
_pctile rand if y0130022!=.& group==1 , nq(90) 
scalar cutoff=r(r75) 
replace y0130022=. if rand >=cutoff & rand<.& group==1 
replace y0130023=. if y0130022==.& group==1 
drop rand 
gen rand=runiform() if y0130023!=.& group==1 
_pctile rand if y0130023!=.& group==1 , nq(75) 
scalar cutoff=r(r60) 




Dropout pattern 03: (MCAR 01; Dropout rate 30%; Dropout direction 03 - high dropout in control 
group) 
Cumulative dropout rate: visit 0 - 0%/0%; visit 1 - 10%/5%; visit 2 - 25%/15%; visit 3 - 40%/20%  
**********************************************************************************************************/ 





gen rand=runiform() if group==0 
_pctile rand if group==0, nq(100) 
scalar cutoff=r(r90) 
replace y0130031=. if rand >=cutoff & rand<.& group==0 
replace y0130032=. if y0130031==. & group==0 
replace y0130033=. if y0130031==. & group==0 
drop rand 
gen rand=runiform() if y0130032!=.& group==0 
_pctile rand if y0130032!=.& group==0 , nq(90) 
scalar cutoff=r(r75) 
replace y0130032=. if rand >=cutoff & rand<.& group==0 
replace y0130033=. if y0130032==.& group==0 
drop rand 
gen rand=runiform() if y0130033!=.& group==0 
_pctile rand if y0130033!=.& group==0 , nq(75) 
scalar cutoff=r(r60) 
replace y0130033=. if rand >=cutoff & rand<.& group==0 
drop rand 
**group 1** 
gen rand=runiform() if group==1 
_pctile rand if group==1, nq(100) 
scalar cutoff=r(r95) 
replace y0130031=. if rand >=cutoff & rand<.& group==1 
replace y0130032=. if y0130031==. & group==1 
replace y0130033=. if y0130031==. & group==1 
drop rand 
gen rand=runiform() if y0130032!=.& group==1 
_pctile rand if y0130032!=.& group==1 , nq(95) 
scalar cutoff=r(r85) 
replace y0130032=. if rand >=cutoff & rand<.& group==1 
replace y0130033=. if y0130032==.& group==1 
drop rand 
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gen rand=runiform() if y0130033!=.& group==1 
_pctile rand if y0130033!=.& group==1 , nq(85) 
scalar cutoff=r(r80) 




Dropout pattern 04: (MAR 2 - dropout depends on baseline values; Dropout rate 30%; Dropout 
direction 01 - equal dropout between groups)* 
Deletion restricted to subjects with high baseline score in both groups ( i.e., above p50 of y0) 
cumulative dropout rate: visit 0 - 0%/0%; visit 1 - 10%/10%; visit 2 - 20%/20%; visit 3 - 30%/30% 
***************************************************************************************************************/ 





_pctile y0 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==0 /*randomly order the baseline values that are above 
50th percentile*/ 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r40) 
replace y0230011=. if rand >=cutoff & rand<. & group==0 /*randomly delete 10% values among the 
outcome at visit 1 where the corresponding baseline values are above 50th percentile of y0*/ 
replace y0230012=. if y0230011==. 
replace y0230013=. if y0230011==. 
drop rand 
gen rand=runiform() if y0230012!=. & y0>=p50 & group==0 /*randomly order the baseline values 
that are above 50th percentile if the values at subsequent visits are not missing */ 
_pctile rand if y0230012!=. & rand<. & group==0 , nq(40) 
scalar cutoff=r(r30) 
replace y0230012=. if rand >=cutoff & rand<.& group==0 
replace y0230013=. if y0230012==. 
drop rand 
gen rand=runiform() if y0230013!=. & y0>=p50 & group==0 
_pctile rand if y0230013!=. & rand<. & group==0, nq(30) 
scalar cutoff=r(r20) 




_pctile y0 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r40) 
replace y0230011=. if rand >=cutoff & rand<. & group==1 
replace y0230012=. if y0230011==. 
replace y0230013=. if y0230011==. 
drop rand 
gen rand=runiform() if y0230012!=. & y0>=p50 & group==1 
_pctile rand if y0230012!=. & rand<. & group==1 , nq(40) 
scalar cutoff=r(r30) 
replace y0230012=. if rand >=cutoff & rand<.& group==1 
replace y0230013=. if y0230012==. 
drop rand 
gen rand=runiform() if y0230013!=. & y0>=p50 & group==1 
_pctile rand if y0230013!=. & rand<. & group==1, nq(30) 
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scalar cutoff=r(r20) 




Dropout pattern 05: (MAR 2 - dropout depends on baseline values; Dropout rate 30%; Dropout 
direction 02 - higher dropout in group 1) 
Deletion restricted to subjects with high baseline score in both groups ( i.e., above p50 of y0) 
Cumulative dropout rate: visit 0 - 0%/0%; visit 1 - 5%/10%; visit 2 - 15%/25%; visit 3 - 20%/40%  
***************************************************************************************************************/ 





_pctile y0 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r45) 
replace y0230021=. if rand >=cutoff & rand<. & group==0 
replace y0230022=. if y0230021==. 
replace y0230023=. if y0230021==. 
drop rand 
gen rand=runiform() if y0230022!=. & y0>=p50 & group==0 
_pctile rand if y0230022!=. & rand<. & group==0 , nq(45) 
scalar cutoff=r(r35) 
replace y0230022=. if rand >=cutoff & rand<.& group==0 
replace y0230023=. if y0230022==. 
drop rand 
gen rand=runiform() if y0230023!=. & y0>=p50 & group==0 
_pctile rand if y0230023!=. & rand<. & group==0, nq(35) 
scalar cutoff=r(r30) 




_pctile y0 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r40) 
replace y0230021=. if rand >=cutoff & rand<. & group==1 
replace y0230022=. if y0230021==. 
replace y0230023=. if y0230021==. 
drop rand 
gen rand=runiform() if y0230022!=. & y0>=p50 & group==1 
_pctile rand if y0230022!=. & rand<. & group==1 , nq(40) 
scalar cutoff=r(r25) 
replace y0230022=. if rand >=cutoff & rand<.& group==1 
replace y0230023=. if y0230022==. 
drop rand 
gen rand=runiform() if y0230023!=. & y0>=p50 & group==1 
_pctile rand if y0230023!=. & rand<. & group==1, nq(25) 
scalar cutoff=r(r10) 
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Dropout pattern 06: (MAR 2 - dropout depends on baseline values; Dropout rate 30%; Dropout 
direction 03 - higher dropout in group 0) 
Deletion restricted to subjects with high baseline score in both groups ( i.e., above p50 of y0) 
Cumulative dropout rate: visit 0 - 0%/0%; visit 1 - 10%/5%; visit 2 - 25%/15%; visit 3 - 40%/20%  
**************************************************************************************************************/ 





_pctile y0 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r40) 
replace y0230031=. if rand >=cutoff & rand<. & group==0 
replace y0230032=. if y0230031==. 
replace y0230033=. if y0230031==. 
drop rand 
gen rand=runiform() if y0230032!=. & y0>=p50 & group==0 
_pctile rand if y0230032!=. & rand<. & group==0 , nq(40) 
scalar cutoff=r(r25) 
replace y0230032=. if rand >=cutoff & rand<.& group==0 
replace y0230033=. if y0230032==. 
drop rand 
gen rand=runiform() if y0230033!=. & y0>=p50 & group==0 
_pctile rand if y0230033!=. & rand<. & group==0, nq(25) 
scalar cutoff=r(r10) 




_pctile y0 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r45) 
replace y0230031=. if rand >=cutoff & rand<. & group==1 
replace y0230032=. if y0230031==. 
replace y0230033=. if y0230031==. 
drop rand 
gen rand=runiform() if y0230032!=. & y0>=p50 & group==1 
_pctile rand if y0230032!=. & rand<. & group==1 , nq(45) 
scalar cutoff=r(r35) 
replace y0230032=. if rand >=cutoff & rand<.& group==1 
replace y0230033=. if y0230032==. 
drop rand 
gen rand=runiform() if y0230033!=. & y0>=p50 & group==1 
_pctile rand if y0230033!=. & rand<. & group==1, nq(35) 
scalar cutoff=r(r30) 




Dropout pattern 07: (MAR 4 - dropout depends on baseline values; Dropout rate 30%; Dropout 
direction 01 - equal dropout between groups) 
Deletion restricted to subjects with high baseline score in control group and subjects with low 
baseline score in experimental group 
Cumulative dropout rate: visit 0 - 0%/0%; visit 1 - 10%/10%; visit 2 - 20%/20%; visit 3 - 30%/30% 






_pctile y0 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r40) 
replace y0430011=. if rand >=cutoff & rand<. & group==0 
replace y0430012=. if y0430011==. 
replace y0430013=. if y0430011==. 
drop rand 
gen rand=runiform() if y0430012!=. & y0>=p50 & group==0 
_pctile rand if y0430012!=. & rand<. & group==0 , nq(40) 
scalar cutoff=r(r30) 
replace y0430012=. if rand >=cutoff & rand<.& group==0 
replace y0430013=. if y0430012==. 
drop rand 
gen rand=runiform() if y0430013!=. & y0>=p50 & group==0 
_pctile rand if y0430013!=. & rand<. & group==0, nq(30) 
scalar cutoff=r(r20) 




_pctile y0 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0<=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r40) 
replace y0430011=. if rand >=cutoff & rand<. & group==1 
replace y0430012=. if y0430011==. 
replace y0430013=. if y0430011==. 
drop rand 
gen rand=runiform() if y0430012!=. & y0<=p50 & group==1 
_pctile rand if y0430012!=. & rand<. & group==1 , nq(40) 
scalar cutoff=r(r30) 
replace y0430012=. if rand >=cutoff & rand<.& group==1 
replace y0430013=. if y0430012==. 
drop rand 
gen rand=runiform() if y0430013!=. & y0<=p50 & group==1 
_pctile rand if y0430013!=. & rand<. & group==1, nq(30) 
scalar cutoff=r(r20) 




Dropout pattern 08: (MAR 4 - dropout depends on baseline values; Dropout rate 30%; Dropout 
direction 02 - higher dropout rate in group 1) 
Deletion restricted to subjects with high baseline score in control group and subjects with low 
baseline score in experimental group 
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_pctile y0 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r45) 
replace y0430021=. if rand >=cutoff & rand<. & group==0 
replace y0430022=. if y0430021==. 
replace y0430023=. if y0430021==. 
drop rand 
gen rand=runiform() if y0430022!=. & y0>=p50 & group==0 
_pctile rand if y0430022!=. & rand<. & group==0 , nq(45) 
scalar cutoff=r(r35) 
replace y0430022=. if rand >=cutoff & rand<.& group==0 
replace y0430023=. if y0430022==. 
drop rand 
gen rand=runiform() if y0430023!=. & y0>=p50 & group==0 
_pctile rand if y0430023!=. & rand<. & group==0, nq(35) 
scalar cutoff=r(r30) 




_pctile y0 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0<=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r40) 
replace y0430021=. if rand >=cutoff & rand<. & group==1 
replace y0430022=. if y0430021==. 
replace y0430023=. if y0430021==. 
drop rand 
gen rand=runiform() if y0430022!=. & y0<=p50 & group==1 
_pctile rand if y0430022!=. & rand<. & group==1 , nq(40) 
scalar cutoff=r(r25) 
replace y0430022=. if rand >=cutoff & rand<.& group==1 
replace y0430023=. if y0430022==. 
drop rand 
gen rand=runiform() if y0430023!=. & y0<=p50 & group==1 
_pctile rand if y0430023!=. & rand<. & group==1, nq(25) 
scalar cutoff=r(r10) 




Dropout pattern 09: (MAR 4 - dropout depends on baseline values; Dropout rate 30%; Dropout 
direction 03 - higher dropout rate in group 0) 
Deletion restricted to subjects with high baseline score in control group and subjects with low 
baseline score in experimental group 






_pctile y0 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r40) 
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replace y0430031=. if rand >=cutoff & rand<. & group==0 
replace y0430032=. if y0430031==. 
replace y0430033=. if y0430031==. 
drop rand 
gen rand=runiform() if y0430032!=. & y0>=p50 & group==0 
_pctile rand if y0430032!=. & rand<. & group==0 , nq(40) 
scalar cutoff=r(r25) 
replace y0430032=. if rand >=cutoff & rand<.& group==0 
replace y0430033=. if y0430032==. 
drop rand 
gen rand=runiform() if y0430033!=. & y0>=p50 & group==0 
_pctile rand if y0430033!=. & rand<. & group==0, nq(25) 
scalar cutoff=r(r10) 
replace y0430033=. if rand >=cutoff & rand<. & group==0 
drop rand 
**group 1** 
_pctile y0 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0<=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r45) 
replace y0430031=. if rand >=cutoff & rand<. & group==1 
replace y0430032=. if y0430031==. 
replace y0430033=. if y0430031==. 
drop rand 
gen rand=runiform() if y0430032!=. & y0<=p50 & group==1 
_pctile rand if y0430032!=. & rand<. & group==1 , nq(45) 
scalar cutoff=r(r35) 
replace y0430032=. if rand >=cutoff & rand<.& group==1 
replace y0430033=. if y0430032==. 
drop rand 
gen rand=runiform() if y0430033!=. & y0<=p50 & group==1 
_pctile rand if y0430033!=. & rand<. & group==1, nq(35) 
scalar cutoff=r(r30) 




Dropout pattern 10: (MAR 06 - dropout depends on last observed values; Dropout rate 30%; 
Dropout direction 01 - equal dropout between groups) 
Deletion restricted to subjects with high last follow-up score in both groups ( i.e., above p50 of last 
follow-up visit) 






_pctile y0 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r40) 
replace y0630011=. if rand >=cutoff & rand<. & group==0 
replace y0630012=. if y0630011==. 
replace y0630013=. if y0630011==. 
drop rand 
 
_pctile y0630011 if group==0, nq(90) 
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scalar p50=r(r50) 
gen rand=runiform() if y0630012!=. & y0630011>=p50 & group==0 
_pctile rand if y0630012!=. & rand<. & group==0 , nq(40) 
scalar cutoff=r(r30) 
replace y0630012=. if rand >=cutoff & rand<.& group==0 
replace y0630013=. if y0630012==. 
drop rand 
 
_pctile y0630012 if group==0, nq(80) 
scalar p50=r(r50) 
gen rand=runiform() if y0630013!=. & y0630012>=p50 & group==0 
_pctile rand if y0630013!=. & rand<. & group==0, nq(30) 
scalar cutoff=r(r20) 




_pctile y0 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r40) 
replace y0630011=. if rand >=cutoff & rand<. & group==1 
replace y0630012=. if y0630011==. 
replace y0630013=. if y0630011==. 
drop rand 
 
_pctile y0630011 if group==1, nq(90) 
scalar p50=r(r50) 
gen rand=runiform() if y0630012!=. & y0630011>=p50 & group==1 
_pctile rand if y0630012!=. & rand<. & group==1 , nq(40) 
scalar cutoff=r(r30) 
replace y0630012=. if rand >=cutoff & rand<.& group==1 
replace y0630013=. if y0630012==. 
drop rand 
 
_pctile y0630012 if group==1, nq(80) 
scalar p50=r(r50) 
gen rand=runiform() if y0630013!=. & y0630012>=p50 & group==1 
_pctile rand if y0630013!=. & rand<. & group==1, nq(30) 
scalar cutoff=r(r20) 




Dropout pattern 11: (MAR 06 - dropout depends on last observed values; Dropout rate 30%; 
Dropout direction 02 - higher dropout in group 1) 
Deletion restricted to subjects with high last follow-up score in both groups ( i.e., above p50 of last 
follow-up visit) 






_pctile y0 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
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scalar cutoff=r(r45) 
replace y0630021=. if rand >=cutoff & rand<. & group==0 
replace y0630022=. if y0630021==. 
replace y0630023=. if y0630021==. 
drop rand 
_pctile y0630021 if group==0, nq(95) 
scalar p50=r(r50) 
gen rand=runiform() if y0630022!=. & y0630021>=p50 & group==0 
_pctile rand if y0630022!=. & rand<. & group==0 , nq(45) 
scalar cutoff=r(r35) 
replace y0630022=. if rand >=cutoff & rand<.& group==0 
replace y0630023=. if y0630022==. 
drop rand 
_pctile y0630022 if group==0, nq(85) 
scalar p50=r(r50) 
gen rand=runiform() if y0630023!=. & y0630022>=p50 & group==0 
_pctile rand if y0630023!=. & rand<. & group==0, nq(35) 
scalar cutoff=r(r30) 




_pctile y0 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r40) 
replace y0630021=. if rand >=cutoff & rand<. & group==1 
replace y0630022=. if y0630021==. 
replace y0630023=. if y0630021==. 
drop rand 
_pctile y0630021 if group==1, nq(90) 
scalar p50=r(r50) 
gen rand=runiform() if y0630022!=. & y0630021>=p50 & group==1 
_pctile rand if y0630022!=. & rand<. & group==1 , nq(40) 
scalar cutoff=r(r25) 
replace y0630022=. if rand >=cutoff & rand<.& group==1 
replace y0630023=. if y0630022==. 
drop rand 
_pctile y0630022 if group==1, nq(75) 
scalar p50=r(r50) 
gen rand=runiform() if y0630023!=. & y0630022>=p50 & group==1 
_pctile rand if y0630023!=. & rand<. & group==1, nq(25) 
scalar cutoff=r(r10) 




Dropout pattern 12: (MAR 06 - dropout depends on last observed values; Dropout rate 30%; 
Dropout direction 03 - higher dropout in group 0) 
Deletion restricted to subjects with high last follow-up score in both groups ( i.e., above p50 of last 
follow-up visit) 







 Appendices              297 
_pctile y0 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r40) 
replace y0630031=. if rand >=cutoff & rand<. & group==0 
replace y0630032=. if y0630031==. 
replace y0630033=. if y0630031==. 
drop rand 
_pctile y0630031 if group==0, nq(90) 
scalar p50=r(r50) 
gen rand=runiform() if y0630032!=. & y0630031>=p50 & group==0 
_pctile rand if y0630032!=. & rand<. & group==0 , nq(40) 
scalar cutoff=r(r25) 
replace y0630032=. if rand >=cutoff & rand<.& group==0 
replace y0630033=. if y0630032==. 
drop rand 
_pctile y0630032 if group==0, nq(75) 
scalar p50=r(r50) 
gen rand=runiform() if y0630033!=. & y0630032>=p50 & group==0 
_pctile rand if y0630033!=. & rand<. & group==0, nq(25) 
scalar cutoff=r(r10) 




_pctile y0 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r45) 
replace y0630031=. if rand >=cutoff & rand<. & group==1 
replace y0630032=. if y0630031==. 
replace y0630033=. if y0630031==. 
drop rand 
_pctile y0630031 if group==1, nq(95) 
scalar p50=r(r50) 
gen rand=runiform() if y0630032!=. & y0630031>=p50 & group==1 
_pctile rand if y0630032!=. & rand<. & group==1 , nq(45) 
scalar cutoff=r(r35) 
replace y0630032=. if rand >=cutoff & rand<.& group==1 
replace y0630033=. if y0630032==. 
drop rand 
_pctile y0630032 if group==1, nq(85) 
scalar p50=r(r50) 
gen rand=runiform() if y0630033!=. & y0630032>=p50 & group==1 
_pctile rand if y0630033!=. & rand<. & group==1, nq(35) 
scalar cutoff=r(r30) 




Dropout pattern 13: (MAR 08 - dropout depends on last observed values; Dropout rate 30%; 
Dropout direction 01 - equal dropout between groups) 
Deletion restricted to subjects with high last follow-up score in control group and low score in 
experimental group 
Cumulative dropout rate: visit 0 - 0%/0%; visit 1 - 10%/10%; visit 2 - 20%/20%; visit 3 - 30%/30%*/ 
***************************************************************************************************************/ 
gen y0830011=y1 





_pctile y0 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r40) 
replace y0830011=. if rand >=cutoff & rand<. & group==0 
replace y0830012=. if y0830011==. 
replace y0830013=. if y0830011==. 
drop rand 
_pctile y0830011 if group==0, nq(90) 
scalar p50=r(r50) 
gen rand=runiform() if y0830012!=. & y0830011>=p50 & group==0 
_pctile rand if y0830012!=. & rand<. & group==0 , nq(40) 
scalar cutoff=r(r30) 
replace y0830012=. if rand >=cutoff & rand<.& group==0 
replace y0830013=. if y0830012==. 
drop rand 
_pctile y0830012 if group==0, nq(80) 
scalar p50=r(r50) 
gen rand=runiform() if y0830013!=. & y0830012>=p50 & group==0 
_pctile rand if y0830013!=. & rand<. & group==0, nq(30) 
scalar cutoff=r(r20) 




_pctile y0 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0<=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r40) 
replace y0830011=. if rand >=cutoff & rand<. & group==1 
replace y0830012=. if y0830011==. 
replace y0830013=. if y0830011==. 
drop rand 
_pctile y0830011 if group==1, nq(90) 
scalar p50=r(r40) 
gen rand=runiform() if y0830012!=. & y0830011<=p50 & group==1 
_pctile rand if y0830012!=. & rand<. & group==1 , nq(40) 
scalar cutoff=r(r30) 
replace y0830012=. if rand >=cutoff & rand<.& group==1 
replace y0830013=. if y0830012==. 
drop rand 
_pctile y0830012 if group==1, nq(80) 
scalar p50=r(r30) 
gen rand=runiform() if y0830013!=. & y0830012<=p50 & group==1 
_pctile rand if y0830013!=. & rand<. & group==1, nq(30) 
scalar cutoff=r(r20) 




*Dropout pattern 14: (MAR 08 - dropout depends on last observed values; Dropout rate 30%; 
Dropout direction 02 - higher dropout in group 1) 
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Deletion restricted to subjects with high last follow-up score in control group and low score in 
experimental group 







_pctile y0 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r45) 
replace y0830021=. if rand >=cutoff & rand<. & group==0 
replace y0830022=. if y0830021==. 
replace y0830023=. if y0830021==. 
drop rand 
_pctile y0830021 if group==0, nq(95) 
scalar p50=r(r50) 
gen rand=runiform() if y0830022!=. & y0830021>=p50 & group==0 
_pctile rand if y0830022!=. & rand<. & group==0 , nq(45) 
scalar cutoff=r(r35) 
replace y0830022=. if rand >=cutoff & rand<.& group==0 
replace y0830023=. if y0830022==. 
drop rand 
_pctile y0830022 if group==0, nq(85) 
scalar p50=r(r50) 
gen rand=runiform() if y0830023!=. & y0830022>=p50 & group==0 
_pctile rand if y0830023!=. & rand<. & group==0, nq(35) 
scalar cutoff=r(r30) 




_pctile y0 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0<=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r40) 
replace y0830021=. if rand >=cutoff & rand<. & group==1 
replace y0830022=. if y0830021==. 
replace y0830023=. if y0830021==. 
drop rand 
_pctile y0830021 if group==1, nq(90) 
scalar p50=r(r40) 
gen rand=runiform() if y0830022!=. & y0830021<=p50 & group==1 
_pctile rand if y0830022!=. & rand<. & group==1 , nq(40) 
scalar cutoff=r(r25) 
replace y0830022=. if rand >=cutoff & rand<.& group==1 
replace y0830023=. if y0830022==. 
drop rand 
_pctile y0830022 if group==1, nq(75) 
scalar p50=r(r25) 
gen rand=runiform() if y0830023!=. & y0830022<=p50 & group==1 
_pctile rand if y0830023!=. & rand<. & group==1, nq(25) 
scalar cutoff=r(r10) 
replace y0830023=. if rand >=cutoff & rand<. & group==1 
drop rand 
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/********************************************************************************************************** 
Dropout pattern 15: (MAR 08 - dropout depends on last observed values; Dropout rate 30%; 
Dropout direction 03 - higher dropout in group 0) 
Deletion restricted to subjects with high last follow-up score in control group and low score in 
experimental group 







_pctile y0 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r40) 
replace y0830031=. if rand >=cutoff & rand<. & group==0 
replace y0830032=. if y0830031==. 
replace y0830033=. if y0830031==. 
drop rand 
_pctile y0830031 if group==0, nq(90) 
scalar p50=r(r50) 
gen rand=runiform() if y0830032!=. & y0830031>=p50 & group==0 
_pctile rand if y0830032!=. & rand<. & group==0 , nq(40) 
scalar cutoff=r(r25) 
replace y0830032=. if rand >=cutoff & rand<.& group==0 
replace y0830033=. if y0830032==. 
drop rand 
_pctile y0830032 if group==0, nq(75) 
scalar p50=r(r50) 
gen rand=runiform() if y0830033!=. & y0830032>=p50 & group==0 
_pctile rand if y0830033!=. & rand<. & group==0, nq(25) 
scalar cutoff=r(r10) 




_pctile y0 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y0<=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r45) 
replace y0830031=. if rand >=cutoff & rand<. & group==1 
replace y0830032=. if y0830031==. 
replace y0830033=. if y0830031==. 
drop rand 
_pctile y0830031 if group==1, nq(95) 
scalar p50=r(r45) 
gen rand=runiform() if y0830032!=. & y0830031<=p50 & group==1 
_pctile rand if y0830032!=. & rand<. & group==1 , nq(45) 
scalar cutoff=r(r35) 
replace y0830032=. if rand >=cutoff & rand<.& group==1 
replace y0830033=. if y0830032==. 
drop rand 
 
_pctile y0830032 if group==1, nq(85) 
scalar p50=r(r35) 
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gen rand=runiform() if y0830033!=. & y0830032<=p50 & group==1 
_pctile rand if y0830033!=. & rand<. & group==1, nq(35) 
scalar cutoff=r(r30) 




Dropout pattern 16: (MNAR 10 - dropout depends on last observed values; Dropout rate 30%; 
Dropout direction 01 - equal dropout between groups) 
Deletion restricted to subjects with high score in each group 







_pctile y1030011 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y1030011>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r40) 
replace y1030011=. if rand >=cutoff & rand<. & group==0 
replace y1030012=. if y1030011==. 
replace y1030013=. if y1030011==. 
drop rand 
_pctile y1030012 if group==0, nq(90) 
scalar p50=r(r50) 
gen rand=runiform() if y1030012!=. & y1030012>=p50 & group==0 
_pctile rand if y1030012!=. & rand<. & group==0 , nq(40) 
scalar cutoff=r(r30) 
replace y1030012=. if rand >=cutoff & rand<.& group==0 
replace y1030013=. if y1030012==. 
drop rand 
_pctile y1030013 if group==0, nq(80) 
scalar p50=r(r50) 
gen rand=runiform() if y1030013!=. & y1030013>=p50 & group==0 
_pctile rand if y1030013!=. & rand<. & group==0, nq(30) 
scalar cutoff=r(r20) 




_pctile y1030011 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y1030011>=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r40) 
replace y1030011=. if rand >=cutoff & rand<. & group==1 
replace y1030012=. if y1030011==. 
replace y1030013=. if y1030011==. 
drop rand 
_pctile y1030012 if group==1, nq(90) 
scalar p50=r(r50) 
gen rand=runiform() if y1030012!=. & y1030012>=p50 & group==1 
_pctile rand if y1030012!=. & rand<. & group==1 , nq(40) 
scalar cutoff=r(r30) 
replace y1030012=. if rand >=cutoff & rand<.& group==1 
replace y1030013=. if y1030012==. 
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drop rand 
_pctile y1030013 if group==1, nq(80) 
scalar p50=r(r50) 
gen rand=runiform() if y1030013!=. & y1030013>=p50 & group==1 
_pctile rand if y1030013!=. & rand<. & group==1, nq(30) 
scalar cutoff=r(r20) 




Dropout pattern 17: (MNAR 10 - dropout depends on last observed values; Dropout rate 30%; 
Dropout direction 02 - higher dropout in group 1) 
Deletion restricted to subjects with high score in each group 







_pctile y1030021 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y1030021>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r45) 
replace y1030021=. if rand >=cutoff & rand<. & group==0 
replace y1030022=. if y1030021==. 
replace y1030023=. if y1030021==. 
drop rand 
_pctile y1030022 if group==0, nq(95) 
scalar p50=r(r50) 
gen rand=runiform() if y1030022!=. & y1030022>=p50 & group==0 
_pctile rand if y1030022!=. & rand<. & group==0 , nq(45) 
scalar cutoff=r(r35) 
replace y1030022=. if rand >=cutoff & rand<.& group==0 
replace y1030023=. if y1030022==. 
drop rand 
_pctile y1030023 if group==0, nq(85) 
scalar p50=r(r50) 
gen rand=runiform() if y1030023!=. & y1030023>=p50 & group==0 
_pctile rand if y1030023!=. & rand<. & group==0, nq(35) 
scalar cutoff=r(r30) 




_pctile y1030021 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y1030021>=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r40) 
replace y1030021=. if rand >=cutoff & rand<. & group==1 
replace y1030022=. if y1030021==. 
replace y1030023=. if y1030021==. 
drop rand 
_pctile y1030022 if group==1, nq(90) 
scalar p50=r(r50) 
gen rand=runiform() if y1030022!=. & y1030022>=p50 & group==1 
_pctile rand if y1030022!=. & rand<. & group==1 , nq(40) 
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scalar cutoff=r(r25) 
replace y1030022=. if rand >=cutoff & rand<.& group==1 
replace y1030023=. if y1030022==. 
drop rand 
_pctile y1030023 if group==1, nq(75) 
scalar p50=r(r50) 
gen rand=runiform() if y1030023!=. & y1030023>=p50 & group==1 
_pctile rand if y1030023!=. & rand<. & group==1, nq(25) 
scalar cutoff=r(r10) 




Dropout pattern 18: (MNAR 10 - dropout depends on last observed values; Dropout rate 30%; 
Dropout direction 03 - higher dropout in group 0) 
Deletion restricted to subjects with high score in each group 







_pctile y1030031 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y1030031>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r40) 
replace y1030031=. if rand >=cutoff & rand<. & group==0 
replace y1030032=. if y1030031==. 
replace y1030033=. if y1030031==. 
drop rand 
_pctile y1030032 if group==0, nq(90) 
scalar p50=r(r50) 
gen rand=runiform() if y1030032!=. & y1030032>=p50 & group==0 
_pctile rand if y1030032!=. & rand<. & group==0 , nq(40) 
scalar cutoff=r(r25) 
replace y1030032=. if rand >=cutoff & rand<.& group==0 
replace y1030033=. if y1030032==. 
drop rand 
_pctile y1030033 if group==0, nq(75) 
scalar p50=r(r50) 
gen rand=runiform() if y1030033!=. & y1030033>=p50 & group==0 
_pctile rand if y1030033!=. & rand<. & group==0, nq(25) 
scalar cutoff=r(r10) 




_pctile y1030031 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y1030031>=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r45) 
replace y1030031=. if rand >=cutoff & rand<. & group==1 
replace y1030032=. if y1030031==. 
replace y1030033=. if y1030031==. 
drop rand 
_pctile y1030032 if group==1, nq(95) 
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scalar p50=r(r50) 
gen rand=runiform() if y1030032!=. & y1030032>=p50 & group==1 
_pctile rand if y1030032!=. & rand<. & group==1 , nq(45) 
scalar cutoff=r(r35) 
replace y1030032=. if rand >=cutoff & rand<.& group==1 
replace y1030033=. if y1030032==. 
drop rand 
_pctile y1030033 if group==1, nq(85) 
scalar p50=r(r50) 
gen rand=runiform() if y1030033!=. & y1030033>=p50 & group==1 
_pctile rand if y1030033!=. & rand<. & group==1, nq(35) 
scalar cutoff=r(r30) 




*Dropout pattern 19: (MNAR 12 - dropout depends on last observed values; Dropout rate 30%; 
Dropout direction 01 - equal dropout between groups)* 
Deletion restricted to subjects with high score in control group and low score in experimental group 







_pctile y1230011 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y1230011>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r40) 
replace y1230011=. if rand >=cutoff & rand<. & group==0 
replace y1230012=. if y1230011==. 
replace y1230013=. if y1230011==. 
drop rand 
_pctile y1230012 if group==0, nq(90) 
scalar p50=r(r50) 
gen rand=runiform() if y1230012!=. & y1230012>=p50 & group==0 
_pctile rand if y1230012!=. & rand<. & group==0 , nq(40) 
scalar cutoff=r(r30) 
replace y1230012=. if rand >=cutoff & rand<.& group==0 
replace y1230013=. if y1230012==. 
drop rand 
_pctile y1230013 if group==0, nq(80) 
scalar p50=r(r50) 
gen rand=runiform() if y1230013!=. & y1230013>=p50 & group==0 
_pctile rand if y1230013!=. & rand<. & group==0, nq(30) 
scalar cutoff=r(r20) 




_pctile y1230011 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y1230011<=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r40) 
replace y1230011=. if rand >=cutoff & rand<. & group==1 
replace y1230012=. if y1230011==. 
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replace y1230013=. if y1230011==. 
drop rand 
_pctile y1230012 if group==1, nq(90) 
scalar p50=r(r40) 
gen rand=runiform() if y1230012!=. & y1230012<=p50 & group==1 
_pctile rand if y1230012!=. & rand<. & group==1 , nq(40) 
scalar cutoff=r(r30) 
replace y1230012=. if rand >=cutoff & rand<.& group==1 
replace y1230013=. if y1230012==. 
drop rand 
_pctile y1230013 if group==1, nq(80) 
scalar p50=r(r30) 
gen rand=runiform() if y1230013!=. & y1230013<=p50 & group==1 
_pctile rand if y1230013!=. & rand<. & group==1, nq(30) 
scalar cutoff=r(r20) 




Dropout pattern 20: (MNAR 12 - dropout depends on last observed values; Dropout rate 30%; 
Dropout direction 02 - higher dropout in group 1)* 
Deletion restricted to subjects with high score in control group and low score in experimental group 






_pctile y1230021 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y1230021>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r45) 
replace y1230021=. if rand >=cutoff & rand<. & group==0 
replace y1230022=. if y1230021==. 
replace y1230023=. if y1230021==. 
drop rand 
_pctile y1230022 if group==0, nq(95) 
scalar p50=r(r50) 
gen rand=runiform() if y1230022!=. & y1230022>=p50 & group==0 
_pctile rand if y1230022!=. & rand<. & group==0 , nq(45) 
scalar cutoff=r(r35) 
replace y1230022=. if rand >=cutoff & rand<.& group==0 
replace y1230023=. if y1230022==. 
drop rand 
_pctile y1230023 if group==0, nq(85) 
scalar p50=r(r50) 
gen rand=runiform() if y1230023!=. & y1230023>=p50 & group==0 
_pctile rand if y1230023!=. & rand<. & group==0, nq(35) 
scalar cutoff=r(r30) 




_pctile y1230021 if group==1, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y1230021<=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r40) 
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replace y1230021=. if rand >=cutoff & rand<. & group==1 
replace y1230022=. if y1230021==. 
replace y1230023=. if y1230021==. 
drop rand 
_pctile y1230022 if group==1, nq(90) 
scalar p50=r(r40) 
gen rand=runiform() if y1230022!=. & y1230022<=p50 & group==1 
_pctile rand if y1230022!=. & rand<. & group==1 , nq(40) 
scalar cutoff=r(r25) 
replace y1230022=. if rand >=cutoff & rand<.& group==1 
replace y1230023=. if y1230022==. 
drop rand 
_pctile y1230023 if group==1, nq(75) 
scalar p50=r(r25) 
gen rand=runiform() if y1230023!=. & y1230023<=p50 & group==1 
_pctile rand if y1230023!=. & rand<. & group==1, nq(25) 
scalar cutoff=r(r10) 




*Dropout pattern 21: (MNAR 12 - dropout depends on last observed values; Dropout rate 30%; 
Dropout direction 03 - higher dropout in group 0)* 
Deletion restricted to subjects with high score in control group and low score in experimental group 







_pctile y1230031 if group==0, nq(100) 
scalar p50=r(r50) 
gen rand=runiform() if y1230031>=p50 & group==0 
_pctile rand if rand<. & group==0 , nq(50) 
scalar cutoff=r(r40) 
replace y1230031=. if rand >=cutoff & rand<. & group==0 
replace y1230032=. if y1230031==. 
replace y1230033=. if y1230031==. 
drop rand 
_pctile y1230032 if group==0, nq(90) 
scalar p50=r(r50) 
gen rand=runiform() if y1230032!=. & y1230032>=p50 & group==0 
_pctile rand if y1230032!=. & rand<. & group==0 , nq(40) 
scalar cutoff=r(r25) 
replace y1230032=. if rand >=cutoff & rand<.& group==0 
replace y1230033=. if y1230032==. 
drop rand 
_pctile y1230033 if group==0, nq(75) 
scalar p50=r(r50) 
gen rand=runiform() if y1230033!=. & y1230033>=p50 & group==0 
_pctile rand if y1230033!=. & rand<. & group==0, nq(25) 
scalar cutoff=r(r10) 




_pctile y1230031 if group==1, nq(100) 
scalar p50=r(r50) 
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gen rand=runiform() if y1230031<=p50 & group==1 
_pctile rand if rand<. & group==1 , nq(50) 
scalar cutoff=r(r45) 
replace y1230031=. if rand >=cutoff & rand<. & group==1 
replace y1230032=. if y1230031==. 
replace y1230033=. if y1230031==. 
drop rand 
_pctile y1230032 if group==1, nq(95) 
scalar p50=r(r45) 
gen rand=runiform() if y1230032!=. & y1230032<=p50 & group==1 
_pctile rand if y1230032!=. & rand<. & group==1 , nq(45) 
scalar cutoff=r(r35) 
replace y1230032=. if rand >=cutoff & rand<.& group==1 
replace y1230033=. if y1230032==. 
drop rand 
_pctile y1230033 if group==1, nq(85) 
scalar p50=r(r35) 
gen rand=runiform() if y1230033!=. & y1230033<=p50 & group==1 
_pctile rand if y1230033!=. & rand<. & group==1, nq(35) 
scalar cutoff=r(r30) 









/*ANALYSIS: No dropout*/ 
keep id group baseline y0 y1 y2 y3 
****ANCOVA 
regress y3 i.group y0 
return scalar at3=_b[1.group] 
 return scalar ase3=_se[1.group] 
 return scalar adf3= e(df_r) 
 return scalar ap3=(2*ttail(e(df_r), abs(_b[1.group]/_se[1.group]))) /* 'ttail' returns the 
reverse cumulative (upper tail or survivor) Student's t-distribution; it returns the probability T > t.*/ 
****MMRM 




*xtmixed y i.time i.rand1 i.rand2 i.rand3 || id:, reml nocons res(uns, t(time)) /*MMRM - baseline as 
an outcome*/ 
xtmixed y i.time##c.baseline i.rand1 i.rand2 i.rand3 if time>0 || id:, reml nocons res(uns, t(time)) 
/*MMRM - baseline as an covariate*/ 
 return scalar bt3=_b[1.rand3] 
 return scalar se3=_se[1.rand3] 
 return scalar df3= e(N) 
 return scalar p3=(2*normal(-abs(_b[1.rand3]/_se[1.rand3]))) 
foreach dr in 30 { 
foreach dm in 01 02 04 06 08 10 12 {     
/*ANALYSIS without IMPUTATION*/ 
use `missdata', clear 
keep id group baseline y0 y1 y2 y3 y`dm'`dr'010 y`dm'`dr'011 y`dm'`dr'012 y`dm'`dr'013  
y`dm'`dr'020 y`dm'`dr'021 y`dm'`dr'022 y`dm'`dr'023 y`dm'`dr'030 y`dm'`dr'031 y`dm'`dr'032 
y`dm'`dr'033 
****ANCOVA without IMPUTATION 
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foreach dp in  01 02 03 { 
  regress y`dm'`dr'`dp'3 i.group y0 
 return scalar at`dm'`dr'`dp'3=_b[1.group] 
 return scalar ase`dm'`dr'`dp'3=_se[1.group] 
 return scalar adf`dm'`dr'`dp'3= e(df_r) 
 return scalar ap`dm'`dr'`dp'3= (2*ttail(e(df_r), abs(_b[1.group]/_se[1.group]))) 
} 
   
****MMRM without IMPUTATION 
 reshape long y y`dm'`dr'01 y`dm'`dr'02 y`dm'`dr'03, i(id) j(time)     
 gen rand1=group*(time==1) 
 gen rand2=group*(time==2) 
 gen rand3=group*(time==3) 
 foreach dp in  01 02 03 { 
 *xtmixed y`dm'`dr'`dp' i.time i.rand1 i.rand2 i.rand3 || id:, reml nocons res(uns, t(time)) 
/*MMRM - baseline as an outcome*/ 
 xtmixed y`dm'`dr'`dp' i.time##c.baseline i.rand1 i.rand2 i.rand3 if time>0 || id:, reml nocons 
res(uns, t(time)) /*MMRM - baseline as an covariate*/ 
 return scalar bt`dm'`dr'`dp'3=_b[1.rand3] 
 return scalar se`dm'`dr'`dp'3=_se[1.rand3] 
 return scalar df`dm'`dr'`dp'3= e(N) 
 return scalar p`dm'`dr'`dp'3=(2*normal(-abs(_b[1.rand3]/_se[1.rand3]))) 
 }  
/*ANALYSIS with LOCF */ 
use `missdata', clear 
keep id group baseline y0 y1 y2 y3 y`dm'`dr'010 y`dm'`dr'011 y`dm'`dr'012 y`dm'`dr'013  
y`dm'`dr'020 y`dm'`dr'021 y`dm'`dr'022 y`dm'`dr'023 y`dm'`dr'030 y`dm'`dr'031 y`dm'`dr'032 
y`dm'`dr'033 
/*Imputing with LOCF*/ 
foreach dp in  01 02 03 { 
replace y`dm'`dr'`dp'1=y0 if y`dm'`dr'`dp'1==. 
replace y`dm'`dr'`dp'2=y`dm'`dr'`dp'1 if y`dm'`dr'`dp'2==. 
replace y`dm'`dr'`dp'3=y`dm'`dr'`dp'2 if y`dm'`dr'`dp'3==. 
} 
****LOCF ANCOVA 
foreach dp in  01 02 03 { 
regress y`dm'`dr'`dp'3 i.group y0 
return scalar l_at`dm'`dr'`dp'3=_b[1.group] 
return scalar l_ase`dm'`dr'`dp'3=_se[1.group] 
return scalar l_adf`dm'`dr'`dp'3= e(df_r) 
return scalar l_ap`dm'`dr'`dp'3= (2*ttail(e(df_r), abs(_b[1.group]/_se[1.group]))) 
} 
//ANALYSIS with MI */ 
 tempname A B C 
foreach dp in 01 02 03 { 
use `missdata', clear 
keep id group baseline y`dm'`dr'`dp'0 y`dm'`dr'`dp'1 y`dm'`dr'`dp'2 y`dm'`dr'`dp'3 
mi set flong 
mi reg imp y`dm'`dr'`dp'1 y`dm'`dr'`dp'2 y`dm'`dr'`dp'3 
mi impute monotone (reg) y`dm'`dr'`dp'1 y`dm'`dr'`dp'2 y`dm'`dr'`dp'3 = baseline group, add(`dr') 
/*MI ANCOVA*/ 
mi estimate: reg y`dm'`dr'`dp'3 baseline i.group 
matrix A = e(b_mi) 
matrix B = e(V_mi) 
matrix C = e(df_mi) 
return scalar m_at`dm'`dr'`dp'3=A[1,3] 
return scalar m_ase`dm'`dr'`dp'3=sqrt(B[3,3]) 
return scalar m_adf`dm'`dr'`dp'3=C[1,3] 
return scalar m_ap`dm'`dr'`dp'3=(2*ttail( C[1,3], abs(A[1,3]/sqrt(B[3,3])))) 
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Appendix 4: Simulation results (tables 1 and 2) 
Tables 1 and 2 presents the simulation results for scenarios contrasting to the missing 
data mechanisms used in the main text. In these tables, the ‘same direction of dropouts’ 
was defined such that dropouts were subjects who did well in both study groups and the 
‘opposite direction of dropouts’ was defined such that dropouts were subjects who did well 
in the control group and those who did poorly in the experimental group. 
Table 1: Bias and RMSE (in bracket) 
Mechanism 
30% dropouts 
CCA MMRM LOCF MI 
No dropout 0.09 (2.68) 0.09 (2.68) 
  
Equal dropout between groups 
  
MAR-B1 0.09 (3.18) 0.10 (3.13) -1.80 (3.08) 0.11 (3.15) 
MAR-B2 0.0 (3.43) 0.02 (3.36) -2.93 (3.87) 0.02 (3.38) 
MAR-L1 0.04 (3.18) 0.01 (3.14) -1.91 (3.12) 0.03 (3.15) 
MAR-L2 2.56 (4.16) 0.10 (3.25) -4.21 (4.88) 0.11 (3.28) 
MNAR-1 0.12 (3.06) 0.15 (3.01) -1.76 (2.97) 0.15 (3.04) 
MNAR-2 5.57 (6.42) 4.28 (5.33) -0.10 (2.44) 4.28 (5.33) 
Higher dropout in the experimental group 
MAR-B1 0.01 (3.28) 0.05 (3.18) -3.77 (4.52) 0.05 (3.20) 
MAR-B2 0.16 (3.49) 0.12 (3.42) -5.05 (5.67) 0.12 (3.43) 
MAR-L1 -1.46 (3.58) 0.05 (3.23) -3.19 (4.07) 0.04 (3.24) 
MAR-L2 3.09 (4.59) 0.16 (3.37) -6.45 (6.92) 0.16 (3.40) 
MNAR-1 -3.23 (4.46) -2.44 (3.93) -5.02 (5.61) -2.44 (3.94) 
MNAR-2 6.43 (7.19) 4.92 (5.88) -2.15 (3.29) 4.90 (5.87) 
Higher dropout in the control group 
  
MAR-B1 0.02 (3.29) 0.0 (3.19) 0.24 (2.52) -0.01 (3.19) 
MAR-B2 0.17 (3.65) 0.17 (3.50) -0.35 (2.56) 0.18 (3.53) 
MAR-L1 1.62 (3.62) 0.08 (3.17) -0.37 (2.49) 0.09 (3.18) 
MAR-L2 2.98 (4.50) 0.06 (3.31) -1.85 (3.09) 0.06 (3.33) 
MNAR-1 3.41 (4.63) 2.60 (4.02) 1.53 (2.85) 2.60 (4.03) 
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Table 2: Coverage of 95% CI and statistical power (in bracket) 
Mechanism 
30% dropouts 
CCA MMRM LOCF MI 
No dropout 95.9 (91.5) 95.9 (91.5) 
  
Equal dropout between groups 
  
MAR-B1 96.2 (78.9) 95.8 (80.9) 91.8 (78.7) 96.0 (78.6) 
MAR-B2 95.8 (72.7) 95.7 (75.2) 83.6 (60.8) 96.1 (73.0) 
MAR-L1 95.0 (78.8) 95.2 (79.5) 88.8 (82.2) 95.9 (78.8) 
MAR-L2 88.9 (93.0) 94.9 (79.8) 71.9 (37.9) 94.8 (75.9) 
MNAR-1 95.6 (81.7) 95.8 (83.9) 89.8 (82.8) 95.9 (82.0) 
MNAR-2 61.7 (99.2) 73.7 (98.4) 96.7 (91.6) 74.9 (98.0) 
Higher dropout in the experimental group 
MAR-B1 96.2 (76.1) 96.2 (79.5) 72.1 (50.3) 96.9 (77.2) 
MAR-B2 95.5 (73.1) 95.2 (74.3) 56.0 (28.2) 95.4 (72.1) 
MAR-L1 93.0 (62.8) 94.9 (79.7) 75.7 (63.9) 95.1 (77.7) 
MAR-L2 86.2 (94.6) 94.7 (77.7) 38.3 (10.5) 95.7 (75.0) 
MNAR-1 84.5 (43.9) 87.9 (54.9) 47.9 (35.3) 88.9 (52.5) 
MNAR-2 50.5 (99.7) 66.0 (98.8) 91.4 (68.9) 68.0 (98.6) 
Higher dropout in the control group 
  
MAR-B1 95.0 (76.8) 94.9 (79.6) 96.1 (94.9) 95.8 (76.1) 
MAR-B2 94.9 (73.1) 94.9 (77.5) 96.8 (90.2) 94.8 (74.7) 
MAR-L1 93.4 (88.8) 95.8 (81.1) 94.5 (93.3) 96.4 (78.3) 
MAR-L2 87.1 (92.6) 94.3 (78.3) 91.7 (76.3) 95.3 (75.0) 
MNAR-1 82.7 (97.6) 86.7 (96.6) 91.5 (98.7) 88.1 (95.7) 
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Appendix 5: Simulation results (tables 3–22) 
Tables 3–22 present the simulation results, which presented graphically in chapter 5, in 
tabular form. 










WL 0.04 0.05 −0.74 0.06 
WM −0.03 −0.04 −0.69 −0.05 
WH −0.01 −0.01 −0.62 0.01 
SL −0.10 −0.14 −1.09 −0.13 
SM −0.06 −0.05 −0.85 −0.05 
SH 0.07 0.11 −0.54 0.13 
HE 
WL 0.11 0.11 −2.00 0.09 
WM −0.05 −0.05 −1.46 −0.04 
WH −0.05 −0.04 −1.55 −0.04 
SL −0.11 −0.12 −2.36 −0.12 
SM −0.06 −0.07 −1.67 −0.08 
SH 0.11 0.10 −1.62 0.10 
HC 
WL 0.22 0.20 0.61 0.20 
WM −0.04 −0.03 0.03 −0.04 
WH 0.03 0.03 0.23 0.04 
SL −0.11 −0.11 0.24 −0.11 
SM −0.06 −0.06 −0.10 −0.04 
SH 0.08 0.09 0.41 0.10 
30% 
EQ 
WL 0.08 0.12 −1.92 0.12 
WM 0.02 0.04 −2.00 0.03 
WH −0.11 −0.09 −1.98 −0.09 
SL −0.01 −0.07 −1.97 −0.08 
SM −0.01 0.02 −1.89 0.03 
SH 0.13 0.19 −1.75 0.20 
HE 
WL −0.05 −0.02 −4.52 −0.01 
WM −0.02 −0.04 −4.36 −0.05 
WH −0.19 −0.18 −4.24 −0.18 
SL −0.13 −0.15 −4.39 −0.16 
SM 0.04 0.01 −4.17 −0.01 
SH 0.12 0.15 −4.05 0.14 
HC 
WL 0.12 0.10 0.59 0.10 
WM −0.01 −0.02 0.38 −0.02 
WH 0.02 0.03 0.43 0.01 
SL −0.06 −0.09 0.20 −0.09 
SM −0.03 −0.05 0.45 −0.04 
SH 0.10 0.09 0.49 0.11 
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WL 2.89 2.87 2.73 2.89 
WM 2.91 2.90 2.76 2.93 
WH 2.83 2.82 2.71 2.85 
SL 2.96 2.91 2.79 2.92 
SM 2.96 2.94 2.81 2.96 
SH 3.02 2.99 2.80 3.00 
HE 
WL 2.90 2.87 3.27 2.90 
WM 2.98 2.98 3.11 2.99 
WH 2.89 2.88 3.11 2.90 
SL 2.91 2.85 3.46 2.88 
SM 2.93 2.90 3.10 2.91 
SH 3.01 2.97 3.17 3.00 
HC 
WL 2.86 2.85 2.72 2.87 
WM 3.00 2.99 2.74 3.02 
WH 2.92 2.91 2.70 2.93 
SL 2.94 2.91 2.59 2.95 
SM 2.96 2.92 2.65 2.95 
SH 2.95 2.94 2.75 2.96 
30% 
EQ 
WL 3.36 3.34 3.22 3.37 
WM 3.37 3.35 3.30 3.35 
WH 3.28 3.23 3.28 3.22 
SL 3.27 3.18 3.16 3.21 
SM 3.25 3.22 3.15 3.23 
SH 3.28 3.21 3.09 3.23 
HE 
WL 3.33 3.27 5.16 3.28 
WM 3.37 3.34 5.06 3.35 
WH 3.29 3.29 4.99 3.30 
SL 3.45 3.36 5.06 3.37 
SM 3.28 3.24 4.88 3.26 
SH 3.39 3.29 4.80 3.31 
HC 
WL 3.43 3.35 2.60 3.38 
WM 3.40 3.35 2.58 3.38 
WH 3.24 3.21 2.60 3.22 
SL 3.42 3.30 2.49 3.35 
SM 3.24 3.19 2.56 3.20 
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WL 0.16 0.16 0.14 0.12 −0.70 −0.10 0.16 0.12 
WM 0.04 0.02 0.04 0.04 −0.62 0.14 0.04 0.04 
WH −0.03 −0.03 −0.02 −0.03 −0.63 0.74 −0.01 −0.04 
SL −0.10 −0.06 −0.10 −0.07 −0.86 −0.37 −0.13 −0.07 
SM −0.04 −0.04 −0.03 −0.03 −0.82 −0.21 −0.05 −0.04 
SH 0.11 0.11 0.08 0.10 −0.57 0.66 0.09 0.10 
HE 
WL 0.11 0.08 0.11 0.09 −2.24 −1.23 0.10 0.11 
WM −0.01 −0.07 0.00 −0.06 −2.06 −0.73 0.00 −0.07 
WH −0.01 0.01 −0.01 0.01 −2.06 0.15 −0.01 0.03 
SL −0.03 −0.13 −0.03 −0.11 −2.43 −1.68 −0.02 −0.11 
SM −0.02 −0.10 −0.01 −0.12 −1.77 −1.01 −0.01 −0.11 
SH 0.09 0.13 0.11 0.12 −2.06 −0.25 0.11 0.12 
HC 
WL 0.17 0.15 0.16 0.14 0.84 1.33 0.17 0.12 
WM 0.02 −0.02 0.01 0.00 0.54 1.22 0.02 −0.01 
WH 0.00 −0.03 0.01 −0.02 0.70 1.89 0.01 0.00 
SL −0.13 −0.08 −0.12 −0.10 0.51 0.90 −0.12 −0.11 
SM −0.07 −0.04 −0.06 −0.03 0.06 0.60 −0.06 −0.02 
SH 0.12 0.07 0.10 0.08 0.89 1.77 0.10 0.09 
30% 
EQ 
WL 0.09 0.12 0.07 0.13 −1.96 −0.57 0.06 0.14 
WM 0.04 −0.16 0.04 −0.16 −2.01 −0.30 0.04 −0.15 
WH 0.04 0.06 0.03 0.06 −1.90 1.65 0.03 0.05 
SL −0.06 −0.11 −0.08 −0.12 −1.91 −1.11 −0.09 −0.11 
SM 0.01 −0.03 −0.01 0.01 −1.93 −0.80 −0.02 0.02 
SH 0.08 0.16 0.05 0.16 −1.85 0.85 0.06 0.16 
HE 
WL 0.13 0.06 0.13 0.02 −4.76 −3.32 0.12 0.01 
WM 0.02 −0.25 0.02 −0.20 −4.78 −2.81 0.00 −0.20 
WH −0.01 −0.18 0.01 −0.14 −5.08 −1.17 0.01 −0.13 
SL −0.01 −0.10 0.00 −0.15 −4.44 −3.52 0.00 −0.16 
SM −0.01 −0.05 −0.06 −0.04 −4.55 −3.20 −0.05 −0.04 
SH 0.03 0.15 0.02 0.15 −4.86 −1.65 0.03 0.15 
HC 
WL 0.12 0.09 0.14 0.12 1.05 1.83 0.11 0.11 
WM −0.06 −0.05 −0.05 −0.01 0.90 1.94 −0.05 0.00 
WH −0.09 −0.13 −0.08 −0.14 1.26 3.38 −0.08 −0.12 
SL −0.15 −0.09 −0.13 −0.09 0.48 1.07 −0.14 −0.10 
SM 0.05 0.07 0.05 0.11 0.84 1.49 0.06 0.12 
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WL 2.84 2.87 2.84 2.87 2.75 2.64 2.88 2.89 
WM 2.90 2.92 2.90 2.89 2.79 2.64 2.91 2.91 
WH 2.85 2.90 2.84 2.88 2.73 2.73 2.85 2.89 
SL 2.89 2.90 2.87 2.86 2.78 2.57 2.88 2.87 
SM 2.94 3.02 2.90 2.96 2.78 2.66 2.93 2.97 
SH 2.97 3.01 2.95 2.97 2.81 2.79 2.95 2.98 
HE 
WL 2.85 2.95 2.83 2.91 3.43 2.87 2.83 2.94 
WM 2.96 3.07 2.96 3.05 3.42 2.82 2.99 3.06 
WH 2.86 2.92 2.86 2.90 3.37 2.65 2.88 2.95 
SL 2.93 2.96 2.91 2.92 3.61 3.07 2.93 2.96 
SM 2.97 3.04 2.95 3.00 3.21 2.85 2.96 3.02 
SH 2.98 3.02 2.95 2.99 3.45 2.72 2.97 3.02 
HC 
WL 2.84 2.86 2.83 2.86 2.75 2.94 2.84 2.90 
WM 2.92 3.01 2.92 3.00 2.74 2.95 2.95 3.03 
WH 2.91 2.94 2.88 2.93 2.72 3.29 2.90 2.92 
SL 2.95 3.02 2.90 2.99 2.66 2.74 2.92 2.99 
SM 2.97 3.02 2.94 2.98 2.70 2.72 2.96 3.01 
SH 2.97 2.96 2.93 2.94 2.82 3.22 2.94 2.96 
30% 
EQ 
WL 3.28 3.62 3.25 3.56 3.23 2.64 3.25 3.61 
WM 3.30 3.60 3.28 3.56 3.27 2.53 3.30 3.55 
WH 3.20 3.47 3.16 3.40 3.14 3.02 3.19 3.42 
SL 3.19 3.38 3.11 3.27 3.18 2.67 3.11 3.28 
SM 3.29 3.56 3.22 3.45 3.24 2.65 3.23 3.46 
SH 3.31 3.67 3.25 3.52 3.17 2.67 3.27 3.54 
HE 
WL 3.36 3.59 3.32 3.55 5.41 4.17 3.35 3.59 
WM 3.31 3.81 3.28 3.75 5.43 3.83 3.30 3.75 
WH 3.45 3.58 3.38 3.54 5.68 2.91 3.40 3.55 
SL 3.44 3.73 3.34 3.58 5.15 4.30 3.37 3.60 
SM 3.36 3.61 3.27 3.51 5.22 4.08 3.31 3.55 
SH 3.38 3.74 3.33 3.60 5.53 3.08 3.33 3.63 
HC 
WL 3.32 3.53 3.31 3.46 2.84 3.12 3.33 3.47 
WM 3.35 3.55 3.30 3.49 2.70 3.15 3.33 3.51 
WH 3.32 3.62 3.29 3.58 2.86 4.29 3.31 3.59 
SL 3.43 3.81 3.30 3.62 2.62 2.68 3.32 3.64 
SM 3.33 3.52 3.26 3.38 2.73 2.91 3.26 3.38 
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MAR-L1 MAR-L2 MAR-L1 MAR-L2 MAR-L1 MAR-L2 MAR-L1 MAR-L2 
10% 
EQ 
WL 0.08 −0.71 0.08 0.14 −0.71 1.35 0.08 0.14 
WM 0.00 −0.99 0.01 −0.06 −0.62 1.60 0.01 −0.04 
WH −0.13 −1.56 −0.13 −0.09 −0.76 3.33 −0.13 −0.09 
SL −0.10 −1.29 −0.09 −0.10 −1.00 0.28 −0.11 −0.10 
SM 0.00 −1.27 0.00 0.00 −0.81 0.60 −0.01 0.01 
SH 0.16 −1.64 0.14 0.11 −0.54 1.91 0.15 0.11 
HE 
WL 0.49 −0.64 0.08 0.17 −2.85 0.09 0.08 0.17 
WM 0.42 −1.11 −0.06 −0.05 −3.02 0.72 −0.06 −0.05 
WH 0.59 −1.48 −0.07 −0.02 −3.12 2.62 −0.07 −0.01 
SL 0.27 −0.99 −0.09 −0.08 −2.68 −1.11 −0.08 −0.09 
SM 0.40 −1.33 −0.04 −0.08 −2.04 −0.23 −0.03 −0.08 
SH 0.84 −1.43 0.11 0.12 −2.54 0.83 0.11 0.11 
HC 
WL −0.27 −0.64 0.13 0.16 1.39 2.62 0.12 0.16 
WM −0.50 −1.08 −0.02 −0.01 1.37 3.02 −0.03 −0.01 
WH −0.73 −1.54 −0.08 −0.06 1.66 4.35 −0.08 −0.05 
SL −0.40 −0.98 −0.04 −0.12 0.74 1.43 −0.03 −0.11 
SM −0.45 −1.33 0.00 −0.08 0.34 1.34 0.01 −0.08 
SH −0.63 −1.42 0.08 0.13 1.33 2.88 0.09 0.15 
30% 
EQ 
WL 0.19 −1.50 0.18 0.21 −1.93 1.66 0.19 0.21 
WM 0.00 −2.51 0.01 −0.06 −2.05 2.92 0.01 −0.07 
WH −0.11 −3.61 −0.10 −0.12 −1.98 6.44 −0.09 −0.14 
SL −0.09 −1.81 −0.09 −0.16 −1.92 −0.21 −0.07 −0.17 
SM 0.00 −2.59 −0.02 −0.11 −1.92 0.41 −0.02 −0.11 
SH 0.14 −3.62 0.11 0.09 −1.80 2.93 0.11 0.09 
HE 
WL 1.26 −1.94 0.20 0.09 −5.72 −0.76 0.22 0.09 
WM 1.39 −2.96 −0.09 −0.01 −6.44 0.64 −0.09 −0.02 
WH 2.05 −4.36 −0.07 −0.11 −7.39 4.43 −0.07 −0.09 
SL 0.94 −2.50 −0.09 −0.03 −4.49 −1.92 −0.06 0.00 
SM 1.47 −2.93 −0.08 0.01 −5.16 −1.74 −0.08 0.01 
SH 2.40 −4.50 0.08 0.17 −5.70 0.93 0.10 0.17 
HC 
WL −1.05 −1.91 −0.03 0.13 1.91 4.32 −0.04 0.13 
WM −1.48 −2.93 0.00 −0.01 2.41 5.59 −0.01 0.02 
WH −2.30 −4.36 −0.15 −0.12 3.48 9.07 −0.16 −0.14 
SL −1.15 −2.57 −0.16 −0.22 0.15 1.65 −0.17 −0.21 
SM −1.53 −2.86 0.00 0.07 1.40 2.88 0.01 0.06 
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MAR-L1 MAR-L2 MAR-L1 MAR-L2 MAR-L1 MAR-L2 MAR-L1 MAR-L2 
10% 
EQ 
WL 2.82 2.98 2.82 2.89 2.67 2.92 2.83 2.90 
WM 2.90 3.09 2.89 2.93 2.72 3.11 2.89 2.95 
WH 2.87 3.31 2.86 2.92 2.73 4.26 2.90 2.93 
SL 2.92 3.24 2.91 2.94 2.79 2.54 2.94 2.98 
SM 2.88 3.26 2.87 3.00 2.75 2.74 2.91 3.01 
SH 3.01 3.42 2.97 3.00 2.78 3.34 2.99 3.03 
HE 
WL 2.89 3.00 2.84 2.93 3.82 2.59 2.86 2.98 
WM 2.98 3.16 2.95 2.96 4.02 2.74 2.97 2.97 
WH 2.96 3.23 2.89 2.87 4.10 3.70 2.91 2.89 
SL 2.92 3.14 2.89 2.94 3.73 2.78 2.90 2.96 
SM 3.00 3.27 2.98 2.95 3.40 2.62 2.97 2.95 
SH 3.13 3.28 3.00 2.95 3.76 2.81 3.00 2.96 
HC 
WL 2.89 2.92 2.86 2.86 2.93 3.65 2.88 2.88 
WM 2.98 3.12 2.93 2.93 2.95 4.00 2.93 2.95 
WH 2.99 3.24 2.89 2.86 3.11 5.07 2.93 2.90 
SL 2.94 3.08 2.90 2.91 2.68 2.91 2.91 2.93 
SM 3.03 3.33 2.99 3.05 2.73 3.03 3.00 3.06 
SH 3.05 3.32 2.96 3.01 3.01 3.96 2.97 3.03 
30% 
EQ 
WL 3.25 3.80 3.24 3.52 3.14 3.02 3.25 3.55 
WM 3.21 4.11 3.20 3.30 3.19 3.79 3.22 3.32 
WH 3.22 4.95 3.20 3.43 3.15 6.92 3.21 3.42 
SL 3.22 3.76 3.19 3.27 3.19 2.41 3.22 3.28 
SM 3.33 4.30 3.30 3.42 3.22 2.52 3.31 3.45 
SH 3.35 4.99 3.31 3.42 3.16 3.86 3.34 3.43 
HE 
WL 3.51 3.98 3.31 3.51 6.24 2.59 3.35 3.53 
WM 3.73 4.58 3.45 3.60 6.91 2.62 3.48 3.61 
WH 3.90 5.56 3.31 3.52 7.80 5.11 3.32 3.55 
SL 3.45 4.25 3.28 3.47 5.16 3.08 3.32 3.49 
SM 3.63 4.59 3.29 3.50 5.75 3.04 3.31 3.53 
SH 4.22 5.67 3.44 3.42 6.28 2.67 3.46 3.45 
HC 
WL 3.45 3.87 3.29 3.40 3.17 4.96 3.32 3.41 
WM 3.64 4.51 3.30 3.48 3.46 6.14 3.32 3.51 
WH 4.03 5.50 3.31 3.38 4.29 9.40 3.34 3.40 
SL 3.59 4.36 3.41 3.52 2.54 2.92 3.43 3.53 
SM 3.64 4.42 3.29 3.36 2.92 3.80 3.31 3.37 
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Table 9(A): Bias under MNAR in relation to dropout rate 
variance-
covariance 
Dropout rate CCA MMRM LOCF MI 
 between 
groups 
% MNAR-1 MNAR-2 MNAR-1 MNAR-2 MNAR-1 MNAR-2 MNAR-1 MNAR-2 
SM 
EQ 
10% 0.00 −2.77 −0.01 −2.11 −0.81 −1.79 0.00 −2.13 
20% 0.06 −4.70 0.04 −3.56 −1.22 −2.91 0.03 −3.56 
30% 0.03 −5.56 0.05 −4.23 −1.84 −3.62 0.06 −4.24 
40% 0.19 −8.17 0.15 −6.20 −2.18 −4.78 0.16 −6.20 
50% 0.07 −9.41 0.04 −6.94 −2.75 −5.31 0.05 −6.94 
HE 
10% 0.99 −2.84 0.76 −2.20 −1.20 −2.62 0.77 −2.19 
20% 1.72 −4.90 1.33 −3.76 −2.20 −4.38 1.32 −3.74 
30% 3.41 −6.42 2.62 −4.92 −3.10 −6.11 2.61 −4.92 
40% 3.80 −8.12 2.91 −6.17 −3.83 −7.00 2.90 −6.17 
50% 4.51 −10.16 3.39 −7.59 −4.16 −7.40 3.41 −7.59 
HC 
10% −0.93 −2.85 −0.72 −2.21 −0.39 −1.07 −0.71 −2.22 
20% −1.70 −4.90 −1.28 −3.77 −0.43 −1.61 −1.29 −3.78 
30% −3.24 −6.26 −2.43 −4.73 −0.42 −1.37 −2.43 −4.74 
40% −3.72 −8.15 −2.82 −6.16 −1.03 −2.37 −2.84 −6.17 
50% −4.62 −10.18 −3.49 −7.62 −1.71 −3.33 −3.49 −7.61 








MNAR-1 MNAR-2 MNAR-1 MNAR-2 MNAR-1 MNAR-2 MNAR-1 MNAR-2 
30% 
EQ 
WL 0.14 −4.69 0.14 −4.11 −1.97 −3.92 0.14 −4.08 
WM −0.04 −6.90 −0.04 −6.06 −2.06 −4.98 −0.03 −6.07 
WH −0.01 −9.79 −0.01 −8.58 −1.91 −5.63 −0.02 −8.59 
SL −0.15 −3.86 −0.20 −2.93 −2.03 −2.98 −0.20 −2.94 
SM −0.20 −5.68 −0.20 −4.34 −2.08 −3.67 −0.18 −4.35 
SH 0.07 −8.37 0.04 −6.36 −1.88 −3.62 0.04 −6.37 
HE 
WL 3.18 −5.26 2.81 −4.59 −3.22 −6.46 2.81 −4.60 
WM 4.35 −7.86 3.86 −6.88 −2.71 −7.61 3.85 −6.87 
WH 6.21 −11.46 5.49 −10.05 −1.79 −8.46 5.48 −10.04 
SL 2.16 −5.24 1.62 −3.97 −3.34 −5.34 1.64 −3.96 
SM 3.25 −6.45 2.45 −4.89 −3.23 −6.12 2.44 −4.91 
SH 5.11 −9.94 3.93 −7.49 −2.70 −6.23 3.93 −7.48 
HC 
WL −2.92 −5.40 −2.54 −4.71 −0.53 −1.52 −2.53 −4.71 
WM −4.44 −7.95 −3.94 −6.98 −1.26 −2.76 −3.92 −6.98 
WH −6.35 −11.39 −5.58 −9.94 −1.98 −3.71 −5.57 −9.95 
SL −2.31 −5.18 −1.75 −3.91 −0.89 −1.65 −1.74 −3.90 
SM −3.29 −6.41 −2.45 −4.85 −0.46 −1.45 −2.44 −4.84 
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Table 10(A): RMSE under MNAR in relation to dropout rate 
variance-
covariance 






















10% 2.93 4.02 2.92 3.60 2.79 3.20 2.91 3.62 
20% 3.05 5.59 3.02 4.69 2.88 3.87 3.04 4.70 
30% 3.25 6.40 3.24 5.32 3.17 4.39 3.24 5.32 
40% 3.38 8.85 3.34 7.08 3.32 5.35 3.35 7.10 
50% 3.60 10.19 3.55 7.97 3.68 5.84 3.54 7.97 
HE 
10% 3.06 4.05 2.98 3.65 2.89 3.71 3.00 3.65 
20% 3.53 5.77 3.36 4.84 3.46 5.06 3.37 4.85 
30% 4.69 7.21 4.14 5.93 4.02 6.62 4.15 5.92 
40% 5.11 8.82 4.49 7.10 4.57 7.41 4.50 7.11 
50% 5.89 10.90 5.02 8.54 4.79 7.75 5.05 8.56 
HC 
10% 3.05 4.07 2.98 3.66 2.66 2.84 3.00 3.69 
20% 3.51 5.80 3.30 4.87 2.61 3.00 3.31 4.89 
30% 4.57 7.09 4.05 5.77 2.60 2.87 4.06 5.79 
40% 5.17 8.88 4.54 7.10 2.73 3.35 4.56 7.12 
50% 5.91 10.94 5.06 8.62 2.94 4.10 5.07 8.63 


























WL 3.11 5.70 3.14 5.23 3.23 4.68 3.16 5.21 
WM 3.17 7.62 3.20 6.87 3.29 5.59 3.21 6.89 
WH 3.22 10.26 3.21 9.13 3.23 6.17 3.23 9.14 
SL 3.21 5.01 3.21 4.34 3.29 3.86 3.23 4.34 
SM 3.17 6.56 3.19 5.44 3.29 4.44 3.21 5.46 
SH 3.23 9.01 3.18 7.18 3.15 4.47 3.20 7.20 
HE 
WL 4.43 6.19 4.19 5.63 4.06 6.94 4.20 5.66 
WM 5.41 8.48 5.02 7.58 3.73 8.01 5.02 7.58 
WH 6.97 11.91 6.34 10.56 3.17 8.86 6.34 10.55 
SL 3.89 6.20 3.66 5.16 4.21 5.87 3.68 5.19 
SM 4.59 7.22 4.04 5.85 4.05 6.60 4.04 5.88 
SH 6.10 10.46 5.11 8.17 3.73 6.74 5.10 8.17 
HC 
WL 4.27 6.28 4.03 5.69 2.59 2.94 4.03 5.70 
WM 5.50 8.55 5.11 7.65 2.86 3.67 5.10 7.66 
WH 7.06 11.80 6.39 10.41 3.20 4.51 6.39 10.43 
SL 4.00 6.15 3.68 5.11 2.64 2.88 3.69 5.12 
SM 4.55 7.19 3.98 5.82 2.56 2.90 3.99 5.82 
SH 5.92 10.46 4.97 8.17 2.74 3.07 4.98 8.17 
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WL 96.0% 95.5% 96.5% 95.7% 
WM 95.2% 95.3% 94.9% 94.8% 
WH 96.4% 96.4% 95.8% 95.8% 
SL 94.7% 94.9% 96.0% 95.6% 
SM 94.3% 94.4% 93.7% 94.1% 
SH 94.5% 94.5% 94.6% 94.0% 
HE 
WL 95.2% 95.1% 92.5% 95.6% 
WM 94.5% 94.5% 92.1% 95.1% 
WH 95.7% 95.9% 93.2% 95.9% 
SL 94.8% 95.2% 90.6% 95.6% 
SM 95.4% 95.1% 92.3% 96.3% 
SH 94.7% 95.2% 90.8% 95.0% 
HC 
WL 95.5% 95.5% 95.2% 96.2% 
WM 94.5% 94.0% 96.0% 94.7% 
WH 94.8% 94.8% 95.5% 94.6% 
SL 94.6% 94.7% 97.4% 95.2% 
SM 94.3% 94.8% 96.0% 95.3% 
SH 94.8% 94.3% 94.8% 94.7% 
30% 
EQ 
WL 95.2% 94.6% 92.0% 95.6% 
WM 96.1% 95.5% 90.3% 96.0% 
WH 94.7% 94.9% 90.2% 95.5% 
SL 94.5% 94.8% 93.9% 95.2% 
SM 94.9% 94.7% 92.0% 95.5% 
SH 95.8% 95.1% 91.5% 95.2% 
HE 
WL 94.7% 94.9% 69.4% 95.9% 
WM 95.6% 94.7% 66.3% 95.0% 
WH 95.4% 95.8% 66.0% 95.4% 
SL 95.1% 94.1% 71.8% 95.1% 
SM 94.9% 94.0% 69.3% 94.8% 
SH 94.6% 94.1% 67.4% 94.8% 
HC 
WL 94.0% 93.7% 97.0% 94.7% 
WM 94.3% 95.6% 96.6% 95.5% 
WH 96.4% 96.3% 95.9% 96.0% 
SL 94.3% 94.2% 97.6% 95.4% 
SM 96.4% 95.7% 96.3% 96.0% 
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WL 11.67 11.56 11.36 11.84 
WM 11.52 11.46 10.98 11.61 
WH 11.50 11.45 10.85 11.56 
SL 11.77 11.55 11.46 11.96 
SM 11.58 11.45 10.91 11.63 
SH 11.58 11.47 10.82 11.57 
HE 
WL 11.69 11.58 11.50 11.88 
WM 11.58 11.51 11.01 11.65 
WH 11.53 11.48 10.85 11.58 
SL 11.68 11.50 11.66 11.87 
SM 11.63 11.49 10.97 11.69 
SH 11.57 11.47 10.85 11.59 
HC 
WL 11.69 11.59 11.27 11.91 
WM 11.58 11.52 10.95 11.66 
WH 11.53 11.48 10.82 11.59 
SL 11.69 11.50 11.33 11.86 
SM 11.63 11.49 10.88 11.66 
SH 11.58 11.48 10.79 11.61 
30% 
EQ 
WL 13.25 12.96 11.82 13.64 
WM 13.28 13.05 10.97 13.42 
WH 13.03 12.86 10.68 13.07 
SL 12.97 12.53 11.94 13.22 
SM 13.00 12.65 10.90 13.00 
SH 13.07 12.76 10.57 12.96 
HE 
WL 13.47 13.13 11.84 13.81 
WM 13.35 13.11 11.02 13.47 
WH 13.22 13.02 10.73 13.26 
SL 13.45 12.86 11.91 13.67 
SM 13.11 12.70 10.91 13.08 
SH 13.29 12.91 10.62 13.14 
HC 
WL 13.46 13.11 11.62 13.84 
WM 13.34 13.10 10.88 13.49 
WH 13.20 13.01 10.69 13.21 
SL 13.46 12.87 11.68 13.69 
SM 13.10 12.71 10.77 13.09 
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MAR-B1 MAR-B2 MAR-B1 MAR-B2 MAR-B1 MAR-B2 MAR-B1 MAR-B2 
10% 
EQ 
WL 95.1 95.4 94.8 95.1 96.2 96.3 95.4 96.0 
WM 95.0 95.1 94.9 95.0 95.4 96.5 94.6 95.5 
WH 95.6 96.9 95.6 96.4 95.1 95.0 95.5 96.3 
SL 94.7 94.6 94.9 94.3 95.5 96.6 95.3 95.1 
SM 94.6 94.9 95.1 95.6 95.1 95.7 95.2 95.1 
SH 95.0 94.0 94.7 93.7 94.7 94.6 95.1 94.5 
HE 
WL 95.6 95.0 95.1 95.1 91.3 94.9 95.6 95.4 
WM 95.3 94.6 95.4 94.3 89.7 94.6 95.5 94.6 
WH 96.0 95.0 95.8 95.1 89.4 95.6 95.6 94.7 
SL 94.7 95.1 94.8 94.8 88.7 93.1 95.3 95.5 
SM 94.0 94.9 93.9 94.1 91.8 94.8 94.3 94.8 
SH 94.5 94.6 93.9 94.4 89.0 95.2 94.6 94.6 
HC 
WL 95.3 95.5 95.1 95.3 95.6 93.2 95.6 95.8 
WM 95.2 94.2 94.9 94.9 96.2 92.9 95.4 94.6 
WH 95.3 95.0 95.2 94.9 94.9 89.6 95.0 95.8 
SL 95.0 94.5 94.9 94.4 97.2 96.0 95.7 95.5 
SM 95.0 95.1 94.6 95.3 96.1 95.1 95.0 95.1 
SH 95.3 95.0 95.1 95.4 94.2 91.2 95.2 95.2 
30% 
EQ 
WL 94.6 95.1 94.8 95.1 93.9 98.0 95.4 96.0 
WM 95.5 95.8 94.7 94.9 91.0 97.5 95.0 95.4 
WH 95.1 95.6 95.3 95.2 91.1 92.1 95.3 95.7 
SL 95.0 95.8 94.5 95.2 92.5 97.6 96.0 95.4 
SM 95.5 93.3 95.4 94.4 91.8 95.8 95.7 94.4 
SH 94.5 94.0 94.5 94.7 91.6 95.9 95.0 94.7 
HE 
WL 95.4 94.8 94.7 95.1 66.4 83.9 96.1 96.4 
WM 95.6 93.8 95.1 93.5 60.1 84.1 95.9 94.5 
WH 94.2 95.1 94.6 94.5 55.8 92.3 94.7 94.7 
SL 95.2 94.6 95.1 93.2 68.7 82.5 95.8 95.4 
SM 94.1 94.7 94.8 94.1 63.8 80.4 94.9 95.3 
SH 94.9 94.7 94.2 94.4 57.7 91.1 94.8 94.5 
HC 
WL 95.1 96.6 95.2 95.8 95.4 92.9 95.7 96.5 
WM 95.4 94.8 95.3 95.5 96.1 91.5 95.7 95.3 
WH 95.5 93.4 95.1 93.5 94.5 77.8 95.3 93.8 
SL 94.8 94.8 94.6 94.1 96.4 96.8 95.8 95.4 
SM 94.9 94.8 94.5 96.0 94.5 94.1 95.1 96.6 
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MAR-B1 MAR-B2 MAR-B1 MAR-B2 MAR-B1 MAR-B2 MAR-B1 MAR-B2 
10% 
EQ 
WL 11.64 11.86 11.53 11.73 11.50 11.29 11.82 12.08 
WM 11.53 11.64 11.46 11.56 11.14 10.96 11.61 11.73 
WH 11.50 11.62 11.45 11.55 11.00 10.84 11.55 11.68 
SL 11.54 11.73 11.39 11.54 11.54 11.36 11.72 11.96 
SM 11.62 11.81 11.47 11.63 11.00 10.87 11.65 11.86 
SH 11.54 11.67 11.45 11.55 10.97 10.82 11.54 11.67 
HE 
WL 11.73 11.89 11.62 11.76 11.73 11.28 11.92 12.13 
WM 11.65 11.78 11.58 11.70 11.25 10.92 11.75 11.90 
WH 11.56 11.66 11.50 11.59 11.06 10.80 11.61 11.73 
SL 11.72 11.96 11.53 11.71 11.71 11.42 11.89 12.20 
SM 11.64 11.83 11.50 11.65 11.05 10.88 11.69 11.88 
SH 11.60 11.72 11.50 11.60 11.02 10.77 11.63 11.74 
HC 
WL 11.73 11.89 11.62 11.76 11.50 11.30 11.97 12.09 
WM 11.65 11.79 11.58 11.71 11.13 10.97 11.77 11.88 
WH 11.55 11.65 11.49 11.59 11.00 10.85 11.60 11.71 
SL 11.73 11.97 11.53 11.73 11.49 11.35 11.93 12.22 
SM 11.64 11.84 11.51 11.66 10.98 10.88 11.68 11.85 
SH 11.60 11.72 11.50 11.59 10.95 10.81 11.60 11.74 
30% 
EQ 
WL 13.29 14.33 12.99 13.90 11.84 11.72 13.67 14.81 
WM 13.25 14.27 13.03 13.94 11.03 10.87 13.41 14.41 
WH 13.05 13.89 12.88 13.64 10.82 10.59 13.07 13.89 
SL 12.92 13.73 12.49 13.13 11.81 11.81 13.18 14.02 
SM 12.98 13.81 12.63 13.29 10.87 10.84 12.96 13.75 
SH 13.05 13.89 12.74 13.43 10.67 10.50 12.92 13.68 
HE 
WL 13.70 14.68 13.32 14.17 11.73 11.57 14.15 15.20 
WM 13.53 14.43 13.26 14.07 11.00 10.85 13.65 14.55 
WH 13.42 14.20 13.20 13.90 10.82 10.59 13.43 14.24 
SL 13.72 14.80 13.07 13.92 11.60 11.68 13.94 15.10 
SM 13.29 14.08 12.85 13.48 10.83 10.78 13.25 13.99 
SH 13.46 14.33 13.05 13.75 10.65 10.48 13.31 14.04 
HC 
WL 13.71 14.71 13.32 14.21 11.55 11.56 14.08 15.21 
WM 13.56 14.40 13.29 14.04 10.93 10.85 13.72 14.57 
WH 13.41 14.20 13.19 13.90 10.79 10.62 13.43 14.20 
SL 13.69 14.80 13.05 13.91 11.51 11.64 13.94 15.06 
SM 13.35 14.06 12.89 13.46 10.75 10.74 13.29 13.96 





 Appendices              324 



























WL 95.7 94.7 95.4 95.8 97.6 94.2 96.0 96.0 
WM 94.5 93.0 94.6 95.4 96.5 92.2 95.1 96.0 
WH 95.9 92.0 95.7 95.1 96.6 78.4 95.5 95.9 
SL 95.0 92.5 94.9 95.1 97.1 96.8 95.1 95.4 
SM 95.6 92.8 95.3 94.6 96.6 95.7 95.5 94.6 
SH 94.6 91.7 94.5 94.1 95.8 90.0 94.7 94.3 
HE 
WL 95.0 93.6 95.1 95.1 92.0 96.6 95.7 95.7 
WM 94.8 93.9 95.0 94.2 86.0 95.1 95.5 95.1 
WH 94.7 92.1 95.6 95.9 83.2 85.4 95.6 96.0 
SL 94.6 92.8 94.6 94.3 90.5 95.7 94.9 94.8 
SM 94.6 92.8 95.4 94.8 90.9 96.1 95.5 95.1 
SH 93.8 92.4 94.3 94.5 87.2 93.7 94.5 95.0 
HC 
WL 95.2 95.4 95.2 94.9 96.2 88.4 95.3 95.7 
WM 94.3 93.8 95.4 95.4 94.5 83.5 95.3 95.5 
WH 95.4 92.2 95.7 95.8 93.4 67.2 96.2 95.9 
SL 95.8 94.9 94.9 95.2 97.7 95.0 95.6 95.7 
SM 93.8 91.8 94.1 94.9 96.0 92.9 94.2 94.9 
SH 93.1 92.5 94.9 93.6 93.9 83.6 94.9 93.6 
30% 
EQ 
WL 96.3 93.3 95.9 94.3 96.5 93.7 96.4 95.7 
WM 95.8 89.2 95.8 96.3 93.4 83.6 96.0 97.3 
WH 96.2 81.9 95.6 93.7 92.7 30.6 95.3 94.5 
SL 95.2 91.1 94.7 94.7 95.7 98.5 95.1 95.6 
SM 94.2 86.5 94.0 93.4 93.2 97.1 94.9 94.0 
SH 95.2 80.9 94.7 94.7 92.2 81.7 94.9 94.8 
HE 
WL 94.5 92.8 94.8 95.7 62.1 97.4 95.4 96.8 
WM 92.7 85.9 94.2 93.4 42.5 95.1 94.8 94.8 
WH 91.2 75.5 94.4 93.6 25.6 62.5 95.3 94.7 
SL 93.9 90.4 94.1 94.3 76.2 92.9 95.8 96.6 
SM 93.5 85.9 94.9 94.0 60.8 91.5 95.3 94.5 
SH 88.4 74.8 94.3 95.0 48.9 94.9 94.3 95.6 
HC 
WL 93.9 90.9 95.3 94.7 95.9 71.9 96.1 96.2 
WM 94.0 86.1 95.1 95.0 91.5 48.1 95.9 96.3 
WH 90.6 76.2 95.3 93.9 81.6 6.9 95.2 95.0 
SL 93.4 89.9 93.7 93.6 99.1 95.1 95.2 95.7 
SM 92.4 86.5 94.5 94.3 94.7 84.8 95.2 95.3 
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MAR-L1 MAR-L2 MAR-L1 MAR-L2 MAR-L1 MAR-L2 MAR-L1 MAR-L2 
10% 
EQ 
WL 11.64 11.67 11.58 11.60 12.53 11.27 11.87 12.02 
WM 11.51 11.53 11.48 11.50 11.74 11.02 11.61 11.71 
WH 11.47 11.49 11.45 11.46 11.51 10.94 11.53 11.63 
SL 11.71 11.88 11.56 11.68 12.44 11.31 11.98 12.28 
SM 11.56 11.68 11.47 11.57 11.53 10.87 11.67 11.81 
SH 11.54 11.62 11.48 11.55 11.37 10.86 11.61 11.71 
HE 
WL 11.65 11.73 11.59 11.66 12.67 11.06 11.92 12.04 
WM 11.67 11.70 11.63 11.66 11.91 10.83 11.83 11.91 
WH 11.50 11.54 11.48 11.51 11.54 10.81 11.59 11.66 
SL 11.64 11.77 11.51 11.63 12.50 11.22 11.85 12.08 
SM 11.58 11.69 11.50 11.60 11.59 10.80 11.68 11.84 
SH 11.55 11.61 11.50 11.54 11.40 10.71 11.61 11.70 
HC 
WL 11.65 11.72 11.58 11.65 12.28 11.58 11.91 12.02 
WM 11.66 11.72 11.62 11.67 11.71 11.18 11.80 11.92 
WH 11.50 11.54 11.48 11.51 11.45 11.07 11.59 11.67 
SL 11.65 11.78 11.51 11.62 12.11 11.49 11.88 12.09 
SM 11.58 11.67 11.50 11.58 11.45 10.98 11.68 11.83 
SH 11.55 11.62 11.49 11.55 11.26 10.96 11.62 11.71 
30% 
EQ 
WL 13.27 13.55 13.03 13.27 13.05 11.46 13.73 14.35 
WM 13.21 13.47 13.04 13.28 11.87 10.69 13.41 13.98 
WH 13.00 13.21 12.88 13.08 11.38 10.47 13.10 13.55 
SL 12.83 13.30 12.48 12.86 12.72 11.63 13.16 13.78 
SM 12.88 13.33 12.61 12.98 11.56 10.70 12.97 13.54 
SH 12.97 13.45 12.74 13.13 11.16 10.40 12.93 13.50 
HE 
WL 13.48 13.73 13.21 13.43 13.13 11.10 14.08 14.67 
WM 13.41 13.64 13.23 13.44 11.96 10.47 13.71 14.27 
WH 13.24 13.42 13.10 13.27 11.47 10.32 13.43 13.87 
SL 13.52 14.18 13.02 13.57 12.82 11.30 13.98 15.09 
SM 13.07 13.51 12.76 13.12 11.63 10.48 13.21 13.80 
SH 13.28 13.72 12.99 13.36 11.23 10.22 13.29 13.92 
HC 
WL 13.44 13.69 13.18 13.40 12.78 11.56 14.07 14.72 
WM 13.43 13.62 13.25 13.42 11.76 10.84 13.71 14.27 
WH 13.21 13.43 13.08 13.27 11.35 10.65 13.40 13.89 
SL 13.55 14.13 13.03 13.51 12.64 11.67 14.00 14.98 
SM 13.09 13.51 12.77 13.12 11.40 10.82 13.19 13.80 
SH 13.28 13.73 13.00 13.36 11.11 10.52 13.31 13.96 
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Table 17(A): Coverage (%) under MNAR in relation to dropout rate 
variance-
covariance 





















10 95.0 85.3 95.3 87.9 95.4 89.9 94.7 88.3 
20 94.4 66.8 94.5 76.9 94.9 82.1 94.6 79.0 
30 94.7 61.0 94.0 73.1 92.8 75.5 94.5 75.0 
40 96.4 37.8 95.2 55.6 92.5 58.4 96.2 58.4 
50 96.2 36.7 95.8 54.4 87.8 48.8 96.8 59.3 
HE 
10 93.6 83.5 93.6 87.7 94.6 84.1 94.0 87.9 
20 90.7 65.6 91.8 76.1 89.3 63.9 92.4 77.7 
30 81.3 50.7 87.0 66.9 84.5 35.8 87.8 68.6 
40 79.5 41.1 84.5 57.8 77.5 21.8 87.4 61.2 
50 80.8 30.7 85.9 51.1 76.1 15.5 87.5 56.3 
HC 
10 93.9 83.6 94.5 87.6 97.0 93.6 94.8 88.1 
20 91.1 63.8 92.3 76.0 96.9 92.7 92.8 75.7 
30 82.7 52.5 87.4 69.0 97.0 93.6 88.1 71.5 
40 81.0 39.0 85.3 57.7 96.4 88.9 86.5 61.3 
50 80.7 31.0 84.7 49.2 95.0 79.4 87.6 56.0 








MNAR-1 MNAR-2 MNAR-1 MNAR-2 MNAR-1 MNAR-2 MNAR-1 MNAR-2 
30 
EQ 
WL 95.9 71.7 94.9 75.8 94.9 75.6 95.5 78.9 
WM 95.7 44.1 95.6 54.1 91.8 56.4 96.0 56.6 
WH 95.1 13.6 94.6 23.0 91.2 40.6 95.3 25.3 
SL 95.0 78.0 93.9 83.7 95.2 86.9 95.4 86.1 
SM 95.2 59.6 95.0 72.7 91.6 74.4 94.5 74.3 
SH 94.5 28.8 94.2 49.4 91.0 73.1 94.5 51.4 
HE 
WL 84.6 65.7 85.5 71.2 88.8 36.8 87.3 73.1 
WM 74.7 33.6 77.3 43.4 86.7 16.2 78.7 46.5 
WH 49.8 6.0 59.8 12.0 91.8 11.1 60.2 13.2 
SL 89.6 66.3 89.8 76.2 87.4 55.8 92.0 79.4 
SM 82.1 48.4 87.3 65.8 84.4 33.5 88.2 68.9 
SH 65.9 15.5 75.9 35.3 86.8 31.7 76.3 38.8 
HC 
WL 85.8 61.9 87.2 68.4 98.2 94.3 89.5 73.8 
WM 71.7 33.5 76.0 41.1 95.0 86.7 78.5 44.3 
WH 48.7 5.7 59.0 11.4 91.1 74.1 60.0 12.3 
SL 90.0 68.5 91.3 77.3 98.3 95.9 92.8 81.1 
SM 83.2 50.0 87.1 67.0 97.1 93.9 88.5 70.7 
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Table 18(A): Average width of CI under MNAR in relation to dropout rate 
variance-
covariance 
Dropout rate CCA MMRM LOCF MI 
 between 
groups 
% MNAR-1 MNAR-2 MNAR-1 MNAR-2 MNAR-1 MNAR-2 MNAR-1 MNAR-2 
SM 
EQ 
10% 11.37 11.43 11.25 11.30 11.17 10.67 11.46 11.51 
20% 11.85 12.04 11.64 11.78 11.32 10.63 11.88 12.13 
30% 12.63 12.92 12.34 12.57 11.39 10.61 12.67 13.01 
40% 13.70 14.18 13.11 13.49 11.46 10.55 13.61 14.13 
50% 15.42 16.08 14.43 14.94 11.41 10.46 15.17 16.04 
HE 
10% 11.35 11.42 11.24 11.30 11.23 10.61 11.43 11.50 
20% 11.92 12.12 11.71 11.87 11.40 10.48 11.97 12.21 
30% 12.70 12.96 12.35 12.57 11.48 10.26 12.70 13.01 
40% 13.82 14.32 13.28 13.67 11.48 10.17 13.86 14.36 
50% 15.64 16.27 14.65 15.14 11.44 10.12 15.51 16.27 
HC 
10% 11.35 11.44 11.24 11.32 11.08 10.76 11.44 11.54 
20% 11.94 12.13 11.72 11.87 11.20 10.73 11.99 12.20 
30% 12.70 12.96 12.36 12.57 11.21 10.74 12.75 13.08 
40% 13.87 14.33 13.31 13.69 11.26 10.72 13.92 14.41 
50% 15.67 16.27 14.67 15.12 11.32 10.66 15.56 16.29 
























No dropout   10.80   10.80           
30% 
EQ 
WL 12.82 12.94 12.55 12.66 12.49 11.48 13.22 13.40 
WM 12.82 12.96 12.63 12.76 11.39 10.68 13.00 13.20 
WH 12.63 12.72 12.49 12.57 10.96 10.43 12.69 12.79 
SL 12.53 12.95 12.16 12.52 12.58 11.62 12.83 13.33 
SM 12.62 12.91 12.32 12.56 11.39 10.63 12.65 13.00 
SH 12.70 12.98 12.45 12.67 11.01 10.33 12.64 12.92 
HE 
WL 12.87 12.95 12.58 12.64 12.61 10.96 13.27 13.44 
WM 12.85 12.95 12.64 12.73 11.48 10.35 13.04 13.17 
WH 12.68 12.72 12.51 12.55 11.02 10.21 12.71 12.83 
SL 13.07 13.47 12.54 12.88 12.76 11.11 13.41 14.02 
SM 12.65 12.94 12.31 12.54 11.48 10.25 12.68 13.03 
SH 12.85 13.15 12.53 12.79 11.09 10.10 12.78 13.12 
HC 
WL 12.82 12.88 12.53 12.57 12.17 11.56 13.29 13.39 
WM 12.82 12.95 12.61 12.73 11.23 10.82 13.00 13.17 
WH 12.64 12.74 12.48 12.56 10.87 10.56 12.69 12.81 
SL 13.09 13.52 12.56 12.91 12.50 11.74 13.50 14.03 
SM 12.69 12.97 12.34 12.58 11.22 10.79 12.73 13.06 
SH 12.85 13.14 12.53 12.78 10.92 10.49 12.77 13.10 
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WL 86.4 87.1 83.8 85.0 
WM 85.4 86.5 85.5 85.6 
WH 87.3 87.5 86.1 86.0 
SL 84.6 85.3 79.3 83.9 
SM 84.8 85.6 83.6 84.4 
SH 85.5 86.2 87.5 86.5 
HE 
WL 87.4 88.1 68.9 87.1 
WM 85.6 85.8 77.3 85.0 
WH 86.3 86.4 76.5 86.2 
SL 84.2 85.2 64.0 84.6 
SM 85.6 86.3 76.0 85.3 
SH 85.4 86.2 75.6 86.0 
HC 
WL 87.2 87.7 93.3 87.4 
WM 84.9 85.1 88.9 84.3 
WH 87.8 87.5 92.2 86.8 
SL 83.5 84.4 90.9 83.3 
SM 85.0 85.7 90.3 85.0 
SH 85.9 86.5 92.5 85.4 
30 
EQ 
WL 77.3 78.9 68.5 76.5 
WM 75.7 76.2 72.2 75.0 
WH 76.8 78.3 73.8 77.6 
SL 77.0 79.5 66.9 75.0 
SM 77.7 80.0 74.1 78.2 
SH 77.9 81.1 78.0 79.8 
HE 
WL 73.6 76.1 27.9 72.7 
WM 75.3 76.0 37.0 75.0 
WH 74.6 75.8 39.0 74.9 
SL 73.6 75.5 29.7 71.3 
SM 78.5 79.9 40.2 77.7 
SH 77.4 79.4 44.9 78.2 
HC 
WL 75.7 77.2 93.3 72.7 
WM 74.3 76.6 94.3 73.8 
WH 75.6 78.0 94.2 76.2 
SL 73.1 76.7 90.4 72.3 
SM 76.1 77.6 95.3 76.4 
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MAR-B1 MAR-B2 MAR-B1 MAR-B2 MAR-B1 MAR-B2 MAR-B1 MAR-B2 
10 
EQ 
WL 88.1 87.2 88.8 87.7 84.4 89.7 87.2 85.1 
WM 87.1 86.0 86.9 85.8 83.5 90.8 86.5 86.2 
WH 87.4 85.0 87.6 85.4 86.1 95.4 86.5 84.5 
SL 84.3 85.2 85.6 86.4 80.7 86.8 83.9 84.0 
SM 85.9 84.4 86.3 85.7 84.6 89.7 86.1 84.6 
SH 86.7 85.9 86.4 86.9 85.5 94.1 86.7 86.0 
HE 
WL 87.0 84.9 87.6 86.0 64.0 80.2 86.1 85.4 
WM 85.2 84.1 86.0 84.6 68.6 84.1 84.7 84.1 
WH 87.2 85.9 87.1 86.6 70.6 91.7 86.9 86.4 
SL 85.1 83.0 86.0 84.1 60.4 73.3 84.4 81.3 
SM 86.1 83.4 87.1 84.3 74.6 83.0 86.6 83.2 
SH 86.5 85.4 87.1 86.0 70.1 88.3 87.1 85.6 
HC 
WL 87.7 87.4 87.7 87.6 93.7 96.4 86.9 86.1 
WM 86.6 84.2 86.4 84.6 92.8 96.9 86.3 84.1 
WH 85.9 86.4 86.8 85.8 94.3 97.6 86.2 85.5 
SL 84.3 82.5 85.4 84.1 91.6 94.2 83.1 81.5 
SM 85.9 84.1 86.1 85.3 90.2 94.4 85.3 84.3 
SH 85.9 84.9 86.8 85.3 95.7 97.9 85.6 84.7 
30 
EQ 
WL 78.4 70.5 79.0 72.0 65.9 82.3 76.1 67.9 
WM 76.9 68.2 78.1 69.9 70.7 90.4 76.0 67.1 
WH 79.8 72.9 81.1 74.8 75.0 98.2 79.5 73.3 
SL 78.9 72.3 81.2 76.2 67.1 78.0 77.4 72.1 
SM 77.8 74.0 78.9 76.3 73.4 86.0 77.4 73.6 
SH 79.3 73.2 80.0 75.8 77.0 96.7 78.4 74.6 
HE 
WL 74.6 67.4 76.9 70.3 25.5 49.1 72.8 64.7 
WM 74.5 66.0 76.5 68.3 29.9 62.3 74.0 65.8 
WH 74.6 69.2 76.6 69.9 27.2 83.6 74.5 68.8 
SL 73.2 65.7 77.2 70.5 32.5 44.3 72.7 64.3 
SM 75.7 70.0 77.1 73.6 35.3 56.7 75.5 69.9 
SH 76.4 69.4 77.6 73.5 32.0 78.6 76.9 71.7 
HC 
WL 75.4 68.8 76.6 70.7 94.6 97.8 72.6 66.0 
WM 74.1 69.4 75.4 71.7 96.4 98.1 73.1 68.6 
WH 74.7 69.7 75.6 70.8 96.4 99.4 75.1 70.3 
SL 71.2 64.9 76.7 70.1 92.1 96.1 70.7 64.3 
SM 76.8 72.7 79.8 76.6 95.9 97.8 77.7 73.7 
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MAR-L1 MAR-L2 MAR-L1 MAR-L2 MAR-L1 MAR-L2 MAR-L1 MAR-L2 
10 
EQ 
WL 87.6 80.0 88.4 87.2 79.3 96.7 86.9 85.6 
WM 86.3 77.9 86.6 86.1 83.0 96.3 85.9 85.5 
WH 86.3 71.8 86.8 85.8 82.6 99.5 85.6 84.2 
SL 84.4 72.6 85.0 84.0 75.5 91.0 82.9 82.2 
SM 86.6 74.5 87.2 85.7 82.7 93.7 86.2 84.8 
SH 86.2 68.4 86.6 86.8 83.9 97.1 86.2 85.4 
HE 
WL 90.9 80.8 87.6 87.3 47.6 91.1 86.0 85.3 
WM 88.0 76.1 85.0 85.2 50.6 94.8 83.1 84.3 
WH 89.9 73.4 85.2 86.5 53.7 98.8 84.7 85.6 
SL 87.5 76.3 85.8 85.0 52.2 81.0 84.5 83.2 
SM 88.6 72.9 85.2 85.4 66.1 89.9 84.5 84.9 
SH 90.6 72.5 86.8 87.6 60.8 94.2 86.3 86.5 
HC 
WL 84.7 80.7 88.5 87.5 95.4 98.5 86.7 86.2 
WM 80.4 75.3 85.8 85.7 96.7 99.4 85.3 84.4 
WH 79.4 72.1 85.4 86.1 97.0 99.9 84.9 85.4 
SL 82.3 75.6 86.2 85.2 91.6 96.1 84.3 82.7 
SM 82.8 72.2 86.9 84.2 91.3 96.1 85.8 82.8 
SH 81.1 73.2 86.4 86.4 96.0 99.2 85.9 85.9 
30 
EQ 
WL 78.4 58.6 80.0 78.7 59.8 97.2 75.9 72.2 
WM 77.2 48.2 78.3 75.7 66.1 99.6 77.5 70.8 
WH 77.2 34.4 77.7 76.9 69.4 100.0 77.0 73.9 
SL 77.6 57.5 79.8 77.5 61.7 87.8 76.7 72.9 
SM 77.9 45.7 79.8 75.5 69.3 94.9 77.8 73.5 
SH 78.6 34.7 80.7 76.9 74.6 99.6 79.7 75.5 
HE 
WL 86.1 52.8 78.5 75.3 9.2 85.0 73.9 68.1 
WM 85.6 41.3 74.6 74.2 9.5 95.0 71.9 69.9 
WH 90.6 26.4 77.0 74.6 4.5 99.9 74.5 71.1 
SL 82.4 44.2 77.3 73.5 23.8 72.8 71.7 67.5 
SM 87.3 43.7 76.1 74.4 21.3 78.7 73.9 71.1 
SH 91.2 25.6 77.4 76.9 18.5 97.3 75.2 74.1 
HC 
WL 64.0 54.8 77.1 76.6 96.3 99.7 71.7 70.2 
WM 58.7 41.9 76.5 74.2 98.8 99.9 73.8 70.0 
WH 50.0 25.7 75.5 75.8 99.6 100.0 73.7 71.9 
SL 62.4 43.3 75.1 71.9 85.8 97.2 70.2 64.7 
SM 60.4 42.8 79.5 77.7 95.9 99.6 76.6 73.9 
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Table 22(A): Power (%) under MNAR in relation to dropout rate 
variance-
covariance 






















10 86.7 56.8 87.1 66.9 82.9 76.5 86.2 66.3 
20 84.3 29.2 84.8 44.3 79.2 63.0 83.8 42.2 
30 80.4 17.9 81.4 32.1 70.4 51.6 80.2 31.0 
40 74.9 4.7 77.9 12.6 66.7 33.2 75.3 11.0 
50 64.8 4.7 69.2 8.8 58.5 26.4 65.0 7.1 
HE 
10 92.4 56.4 91.7 67.3 79.4 66.9 91.2 66.1 
20 93.2 27.5 91.6 41.2 66.0 41.0 90.8 40.1 
30 96.6 11.7 94.6 27.3 52.7 18.7 94.2 25.6 
40 95.7 4.3 93.3 12.5 41.3 10.7 92.7 11.0 
50 92.2 5.5 90.4 6.7 35.3 6.6 87.9 5.0 
HC 
10 79.8 57.1 82.0 66.1 87.1 83.2 81.0 64.0 
20 67.2 26.8 73.9 42.1 86.7 77.9 72.6 39.4 
30 42.4 13.5 56.4 27.4 86.3 81.1 53.3 24.8 
40 32.2 5.9 44.5 12.8 82.5 71.9 41.6 12.0 
50 17.8 5.6 31.4 7.0 74.9 55.0 26.6 5.0 








MNAR-1 MNAR-2 MNAR-1 MNAR-2 MNAR-1 MNAR-2 MNAR-1 MNAR-2 
30 
EQ 
WL 79.8 25.5 81.1 32.1 61.9 38.9 77.8 28.4 
WM 78.9 10.1 79.8 14.6 68.2 28.6 77.5 13.9 
WH 80.6 4.9 80.4 5.6 73.8 22.5 79.3 5.2 
SL 76.4 35.1 78.9 49.9 61.2 53.7 75.9 45.1 
SM 78.9 17.0 80.8 31.4 67.9 51.1 79.3 29.4 
SH 79.6 5.3 81.3 13.4 75.3 54.7 79.8 12.7 
HE 
WL 96.2 20.6 95.6 27.9 41.1 12.5 94.5 25.0 
WM 98.1 6.4 97.6 10.0 58.2 6.0 97.0 8.9 
WH 99.7 12.1 99.5 6.7 74.5 6.0 99.5 5.6 
SL 91.3 18.8 89.1 34.0 40.9 21.7 87.1 28.6 
SM 96.7 12.2 94.8 24.9 51.9 19.4 94.0 22.8 
SH 98.3 5.6 98.0 7.4 60.3 18.7 97.7 7.7 
HC 
WL 45.8 19.1 52.0 27.2 82.4 74.9 47.3 23.1 
WM 29.6 5.2 34.7 8.7 80.3 63.8 33.2 8.1 
WH 12.6 10.2 18.6 4.6 74.7 50.8 17.3 4.4 
SL 51.9 19.8 61.6 34.2 76.7 73.7 56.4 28.5 
SM 41.4 12.3 55.5 25.5 87.8 79.7 52.2 24.3 
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Appendix 6: MMRM versus cLDA (tables 23 and 24) 
Table 23: Effects of baseline handling strategies in a repeated measurement 
analysis model on overall accuracy 
Patterns under 










MMRM cLDA MMRM cLDA MMRM cLDA MMRM cLDA 



























MCAR 0.005 0.005 0.005 0.005 2.549 2.549 2.549 2.549 
MAR-B1 0.015 0.015 0.015 0.015 2.520 2.520 2.520 2.520 
MAR-B2 0.113 0.113 0.113 0.113 2.601 2.601 2.601 2.601 
MAR-L1 -0.029 -0.029 -0.029 -0.029 2.514 2.514 2.514 2.514 
MAR-L2 -0.038 -0.038 -0.038 -0.038 2.611 2.611 2.611 2.611 
MNAR-1 -0.137 -0.137 -0.137 -0.137 2.496 2.496 2.496 2.496 

































MCAR -0.047 -0.047 -0.047 -0.047 2.546 2.546 2.546 2.546 
MAR-B1 -0.073 -0.073 -0.073 -0.073 2.564 2.564 2.564 2.564 
MAR-B2 -0.028 -0.028 -0.028 -0.028 2.638 2.638 2.638 2.638 
MAR-L1 -0.017 -0.017 -0.017 -0.017 2.579 2.579 2.579 2.579 
MAR-L2 -0.113 -0.113 -0.113 -0.113 2.621 2.621 2.621 2.621 
MNAR-1 -2.522 -2.522 -2.522 -2.522 3.552 3.552 3.552 3.552 





























MCAR -0.006 -0.006 -0.006 -0.006 2.550 2.550 2.550 2.550 
MAR-B1 -0.028 -0.028 -0.028 -0.028 2.559 2.559 2.559 2.559 
MAR-B2 0.083 0.083 0.083 0.083 2.619 2.619 2.619 2.619 
MAR-L1 0.126 0.126 0.126 0.126 2.559 2.559 2.559 2.559 
MAR-L2 -0.014 -0.014 -0.014 -0.014 2.599 2.599 2.599 2.599 
MNAR-1 2.539 2.539 2.539 2.539 3.574 3.574 3.574 3.574 
MNAR-2 4.871 4.871 4.871 4.871 5.499 5.499 5.499 5.499 
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Table 24: Effects of baseline handling strategies in a repeated measurement 
analysis model on coverage and power 
Patterns under 
30% dropout rate 









MMRM cLDA MMRM cLDA MMRM cLDA MMRM cLDA 



























MCAR 94.3% 94.3% 94.1% 93.7% 78.9% 78.8% 79.1% 80.0% 
MAR-B1 95.6% 95.6% 95.6% 95.4% 78.4% 78.1% 78.7% 79.5% 
MAR-B2 94.6% 93.2% 94.3% 92.9% 75.3% 78.0% 75.5% 79.1% 
MAR-L1 95.0% 95.0% 94.9% 94.6% 80.3% 79.8% 80.5% 81.4% 
MAR-L2 94.3% 93.3% 94.2% 93.0% 76.6% 78.4% 77.0% 79.5% 
MNAR-1 94.8% 94.8% 94.6% 94.2% 82.3% 82.4% 82.6% 83.5% 

































MCAR 95.1% 95.0% 94.9% 94.4% 79.2% 78.9% 79.5% 80.2% 
MAR-B1 95.5% 95.2% 95.4% 94.7% 77.3% 77.5% 77.7% 79.1% 
MAR-B2 94.7% 93.2% 94.6% 92.4% 74.8% 79.0% 75.6% 80.3% 
MAR-L1 94.3% 94.2% 94.2% 93.9% 77.5% 77.4% 78.0% 78.7% 
MAR-L2 94.7% 93.9% 94.6% 93.2% 76.2% 78.2% 76.8% 79.4% 
MNAR-1 87.6% 87.4% 87.2% 86.7% 95.2% 95.3% 95.6% 95.8% 





























MCAR 95.0% 94.8% 94.8% 94.4% 79.3% 79.2% 79.5% 80.1% 
MAR-B1 94.3% 94.3% 94.3% 93.8% 79.3% 79.4% 79.6% 80.7% 
MAR-B2 94.9% 93.8% 94.8% 93.2% 73.6% 77.5% 74.2% 78.2% 
MAR-L1 94.1% 93.9% 93.9% 93.4% 77.0% 77.4% 77.9% 78.9% 
MAR-L2 94.9% 94.1% 94.5% 93.1% 76.7% 78.1% 77.0% 78.7% 
MNAR-1 86.9% 86.7% 86.9% 86.4% 53.8% 53.7% 54.2% 54.9% 





 Appendices              334 
Appendix 7: Effect of sample size on statistical power (tables 25 and 26; figures 1 
and 2) 
Table 25: The observed power (%) with inflated sample size – (the desired power 
was 90% under a strong correlation matrix) 
Mechanism 
10% dropouts (n = 132) 30% dropouts (n = 168) 
CCA MMRM MI CCA MMRM MI 
Equal dropout between groups 
MCAR 88.8 89.3 88.0 88.6 90.3 89.5 
MAR-B1 89.4 89.8 89.2 89.9 91.7 90.4 
MAR-B2 89.0 89.8 88.4 84.1 89.0 86.4 
MAR-L1 89.3 89.2 88.9 90.4 92.1 90.8 
MAR-L2 78.0 89.0 88.4 55.9 88.3 86.4 
MNAR-1 90.4 90.7 89.1 92.0 93.1 91.9 
MNAR-2 62.3 70.9 69.8 17.7 34.8 32.7 
Higher dropout in the experimental group 
MCAR 89.2 89.8 89.3 88.1 90.2 89.0 
MAR-B1 89.3 90.0 89.3 88.9 90.7 90.1 
MAR-B2 87.7 88.6 88.2 84.2 88.1 86.4 
MAR-L1 92.8 90.0 89.3 96.2 89.3 87.8 
MAR-L2 76.7 89.8 88.7 49.9 87.7 85.6 
MNAR-1 95.6 95.5 95.5 99.7 98.4 98.2 
MNAR-2 59.4 67.6 67.5 13.1 28.0 26.5 
Higher dropout in the control group 
MCAR 89.7 90.6 89.0 87.4 89.4 88.7 
MAR-B1 88.6 89.4 88.0 88.9 90.8 90.0 
MAR-B2 89.1 89.6 88.3 84.1 85.6 84.5 
MAR-L1 85.2 89.2 88.4 74.6 91.1 89.6 
MAR-L2 77.5 89.9 89.5 51.5 88.7 86.3 
MNAR-1 79.3 83.0 82.4 54.2 68.6 65.9 
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Figure 1: Statistical power under different sample sizes (10% dropouts and 80% 

































































































































































































































































































































































































































































































































































Not inflated for 10% dropouts (n=114) Inflated for 10% dropouts (n=126)
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Figure 2: Statistical power under different sample sizes (30% dropouts and 80% 

































































































































































































































































































































































































































































































































































Not inflated for 30% dropouts (n=114) Inflated for 30% dropouts (n=162)
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Table 26: The observed power (%) with inflated sample size – (the desired power 
was 80% under a strong correlation matrix) 
Mechanism 
10% dropouts (n = 98) 30% dropouts (n = 126) 
CCA MMRM MI CCA MMRM MI 
Equal dropout between groups 
MCAR 81.8 81.8 81.2 76.0 79.3 77.2 
MAR-B1 81.0 81.9 81.5 79.0 80.9 78.9 
MAR-B2 79.6 80.0 79.6 72.7 76.2 72.9 
MAR-L1 81.1 81.2 80.8 78.0 79.5 78.4 
MAR-L2 71.6 80.5 79.7 41.4 75.5 71.5 
MNAR-1 82.4 82.9 82.1 81.1 83.1 80.9 
MNAR-2 58.5 65.2 63.7 11.6 26.0 23.7 
Higher dropout in the experimental group 
MCAR 79.6 81.6 80.2 77.6 79.9 77.4 
MAR-B1 81.0 80.8 80.4 76.9 78.9 77.2 
MAR-B2 81.2 81.5 81.2 70.7 73.5 71.7 
MAR-L1 83.7 80.7 79.8 88.7 79.3 75.5 
MAR-L2 72.6 81.7 80.7 39.0 75.3 71.4 
MNAR-1 89.1 87.9 86.9 97.3 96.2 95.5 
MNAR-2 58.4 65.9 64.3 6.8 18.9 17.0 
Higher dropout in the control group 
MCAR 81.8 81.3 80.4 76.2 80.3 78.1 
MAR-B1 80.2 81.5 80.4 75.9 78.9 76.5 
MAR-B2 79.5 81.3 80.2 72.9 75.4 71.5 
MAR-L1 76.9 82.2 81.3 61.1 80.2 76.8 
MAR-L2 71.1 82.1 81.4 38.1 76.7 72.7 
MNAR-1 71.8 74.9 74.7 40.8 52.5 49.8 
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 Appendix 8: TATE trial: MI-inclusive imputation models (tables 27–30) 
Table 27: Inclusive model for pain intensity at month 12 
model b3 se3 p3 Effect size 
1 -0.458 0.305 0.136 -0.223 
2 -0.459 0.302 0.130 -0.223 
3 -0.449 0.306 0.143 -0.219 
4 -0.456 0.306 0.138 -0.222 
5 -0.489 0.308 0.114 -0.238 
6 -0.489 0.309 0.115 -0.238 
7 -0.462 0.302 0.128 -0.225 
8 -0.497 0.306 0.106 -0.242 
model 
1 mi impute chained (regress) w6_pain m6_pain m12_pain = b_pain group1  Age Sex, add(500) 
burnin(50) 
2 mi impute chained (regress) w6_pain m6_pain m12_pain w6_PRTEE_tot m6_PRTEE_tot 
m12_PRTEE_tot = b_PRTEE_tot b_pain group1  Age Sex, add(500) burnin(50) 
3 mi impute chained (regress) w6_pain m6_pain m12_pain w6_SF_PCS m6_SF_PCS 
m12_SF_PCS = b_SF_PCS b_pain group1  Age Sex, add(500) burnin(50) 
4 mi impute chained (regress) w6_pain m6_pain m12_pain w6_SF_MCS m6_SF_MCS 
m12_SF_MCS = b_SF_MCS b_pain group1  Age Sex, add(500) burnin(50) 
5 mi impute chained (regress) w6_pain m6_pain m12_pain w6_PRTEE_tot m6_PRTEE_tot 
m12_PRTEE_tot w6_SF_PCS m6_SF_PCS m12_SF_PCS = b_SF_PCS b_PRTEE_tot 
b_pain group1  Age Sex, add(500) burnin(50) 
6 mi impute chained (regress) w6_pain m6_pain m12_pain w6_PRTEE_tot m6_PRTEE_tot 
m12_PRTEE_tot w6_SF_MCS m6_SF_MCS m12_SF_MCS= b_SF_MCS b_PRTEE_tot 
b_pain group1  Age Sex, add(500) burnin(50) 
7 mi impute chained (regress) w6_pain m6_pain m12_pain w6_SF_MCS m6_SF_MCS 
m12_SF_MCS w6_SF_PCS m6_SF_PCS m12_SF_PCS = b_SF_PCS b_SF_MCS b_pain 
group1  Age Sex, add(500) burnin(50) 
8 mi impute chained (regress) w6_pain m6_pain m12_pain w6_PRTEE_tot m6_PRTEE_tot 
m12_PRTEE_tot w6_SF_PCS m6_SF_PCS m12_SF_PCS w6_SF_MCS m6_SF_MCS 





 Appendices              339 
Table 28: Inclusive model for PRTEE at month 12 
model b3 se3 p3 Effect size 
1 -3.817 3.038 0.211 -0.215 
2 -3.427 2.742 0.213 -0.193 
3 -4.620 2.991 0.125 -0.261 
4 -3.891 2.961 0.191 -0.219 
5 -3.760 2.822 0.185 -0.212 
6 -3.573 2.836 0.210 -0.202 
7 -4.707 2.979 0.116 -0.265 
8 -3.980 2.769 0.153 -0.224 
model 
1 mi impute chained (regress) w6_PRTEE_tot m6_PRTEE_tot m12_PRTEE_tot = 
b_PRTEE_tot b_pain group1  Age Sex, add(500) burnin(50) 
2 mi impute chained (regress) w6_PRTEE_tot m6_PRTEE_tot m12_PRTEE_tot w6_pain 
m6_pain m12_pain = b_pain b_PRTEE_tot group1  Age Sex, add(500) burnin(50) 
3 mi impute chained (regress) w6_PRTEE_tot m6_PRTEE_tot m12_PRTEE_tot w6_SF_PCS 
m6_SF_PCS m12_SF_PCS = b_pain b_SF_PCS b_PRTEE_tot group1  Age Sex, add(500) 
burnin(50) 
4 mi impute chained (regress) w6_PRTEE_tot m6_PRTEE_tot m12_PRTEE_tot w6_SF_MCS 
m6_SF_MCS m12_SF_MCS = b_pain b_SF_MCS b_PRTEE_tot group1  Age Sex, add(500) 
burnin(50) 
5 mi impute chained (regress) w6_PRTEE_tot m6_PRTEE_tot m12_PRTEE_tot w6_pain 
m6_pain m12_pain w6_SF_PCS m6_SF_PCS m12_SF_PCS = b_SF_PCS b_pain 
b_PRTEE_tot group1  Age Sex, add(500) burnin(50) 
6 mi impute chained (regress) w6_PRTEE_tot m6_PRTEE_tot m12_PRTEE_tot w6_pain 
m6_pain m12_pain w6_SF_MCS m6_SF_MCS m12_SF_MCS= b_SF_MCS b_pain 
b_PRTEE_tot group1  Age Sex, add(500) burnin(50) 
7 mi impute chained (regress) w6_PRTEE_tot m6_PRTEE_tot m12_PRTEE_tot w6_SF_MCS 
m6_SF_MCS m12_SF_MCS w6_SF_PCS m6_SF_PCS m12_SF_PCS = b_pain b_SF_PCS 
b_SF_MCS b_PRTEE_tot group1  Age Sex, add(500) burnin(50) 
8 mi impute chained (regress) w6_PRTEE_tot m6_PRTEE_tot m12_PRTEE_tot w6_pain 
m6_pain m12_pain w6_SF_PCS m6_SF_PCS m12_SF_PCS w6_SF_MCS m6_SF_MCS 





 Appendices              340 
Table 29: Inclusive model for SF12-MCS at month 12 
model b3 se3 p3 Effect size 
1 2.411 1.541 0.120 0.250 
2 2.396 1.552 0.125 0.249 
3 2.602 1.509 0.087 0.270 
4 2.575 1.603 0.111 0.267 
5 2.567 1.585 0.108 0.266 
6 2.486 1.577 0.117 0.258 
7 2.882 1.550 0.065 0.299 
8 2.812 1.634 0.088 0.292 
model 
1 mi impute chained (regress) w6_SF_MCS m6_SF_MCS m12_SF_MCS = b_SF_MCS b_pain 
group1  Age Sex, add(500) burnin(50) 
2 mi impute chained (regress) w6_SF_MCS m6_SF_MCS m12_SF_MCS w6_pain m6_pain 
m12_pain = b_pain b_SF_MCS group1  Age Sex, add(500) burnin(50) 
3 mi impute chained (regress) w6_SF_MCS m6_SF_MCS m12_SF_MCS w6_SF_PCS 
m6_SF_PCS m12_SF_PCS = b_pain b_SF_PCS b_SF_MCS group1  Age Sex, add(500) 
burnin(50) 
4 mi impute chained (regress) w6_SF_MCS m6_SF_MCS m12_SF_MCS w6_PRTEE_tot 
m6_PRTEE_tot m12_PRTEE_tot = b_pain b_PRTEE_tot b_SF_MCS group1  Age Sex, 
add(500) burnin(50) 
5 mi impute chained (regress) w6_SF_MCS m6_SF_MCS m12_SF_MCS w6_pain m6_pain 
m12_pain w6_SF_PCS m6_SF_PCS m12_SF_PCS = b_SF_PCS b_pain b_SF_MCS group1  
Age Sex, add(500) burnin(50) 
6 mi impute chained (regress) w6_SF_MCS m6_SF_MCS m12_SF_MCS w6_pain m6_pain 
m12_pain w6_PRTEE_tot m6_PRTEE_tot m12_PRTEE_tot= b_PRTEE_tot b_pain 
b_SF_MCS group1  Age Sex, add(500) burnin(50) 
7 mi impute chained (regress) w6_SF_MCS m6_SF_MCS m12_SF_MCS w6_PRTEE_tot 
m6_PRTEE_tot m12_PRTEE_tot w6_SF_PCS m6_SF_PCS m12_SF_PCS = b_pain 
b_SF_PCS b_PRTEE_tot b_SF_MCS group1  Age Sex, add(500) burnin(50) 
8 mi impute chained (regress) w6_SF_MCS m6_SF_MCS m12_SF_MCS w6_pain m6_pain 
m12_pain w6_SF_PCS m6_SF_PCS m12_SF_PCS w6_PRTEE_tot m6_PRTEE_tot 
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Table 30: Inclusive model for SF12-PCS at month 12 
model b3 se3 p3 Effect size 
1 -0.276 1.448 0.849 -0.025 
2 0.025 1.451 0.987 0.002 
3 -0.380 1.421 0.790 -0.035 
4 -0.373 1.509 0.805 -0.034 
5 -0.138 1.484 0.926 -0.013 
6 -0.333 1.472 0.821 -0.030 
7 -0.491 1.456 0.737 -0.045 
8 -0.421 1.501 0.779 -0.038 
model 
1 mi impute chained (regress) w6_SF_PCS m6_SF_PCS m12_SF_PCS = b_SF_PCS b_pain 
group1  Age Sex, add(500) burnin(50) 
2 mi impute chained (regress) w6_SF_PCS m6_SF_PCS m12_SF_PCS w6_pain m6_pain 
m12_pain = b_pain b_SF_PCS group1  Age Sex, add(500) burnin(50) 
3 mi impute chained (regress) w6_SF_PCS m6_SF_PCS m12_SF_PCS w6_SF_MCS 
m6_SF_MCS m12_SF_MCS = b_pain b_SF_MCS b_SF_PCS group1  Age Sex, add(500) 
burnin(50) 
4 mi impute chained (regress) w6_SF_PCS m6_SF_PCS m12_SF_PCS w6_PRTEE_tot 
m6_PRTEE_tot m12_PRTEE_tot = b_pain b_PRTEE_tot b_SF_PCS group1  Age Sex, 
add(500) burnin(50) 
5 mi impute chained (regress) w6_SF_PCS m6_SF_PCS m12_SF_PCS w6_pain m6_pain 
m12_pain w6_SF_MCS m6_SF_MCS m12_SF_MCS = b_SF_MCS b_pain b_SF_PCS group1  
Age Sex, add(500) burnin(50) 
6 mi impute chained (regress) w6_SF_PCS m6_SF_PCS m12_SF_PCS w6_pain m6_pain 
m12_pain w6_PRTEE_tot m6_PRTEE_tot m12_PRTEE_tot= b_PRTEE_tot b_pain 
b_SF_PCS group1  Age Sex, add(500) burnin(50) 
7 mi impute chained (regress) w6_SF_PCS m6_SF_PCS m12_SF_PCS w6_PRTEE_tot 
m6_PRTEE_tot m12_PRTEE_tot w6_SF_MCS m6_SF_MCS m12_SF_MCS = b_pain 
b_SF_MCS b_PRTEE_tot b_SF_PCS group1  Age Sex, add(500) burnin(50) 
8 mi impute chained (regress) w6_SF_PCS m6_SF_PCS m12_SF_PCS w6_pain m6_pain 
m12_pain w6_SF_MCS m6_SF_MCS m12_SF_MCS w6_PRTEE_tot m6_PRTEE_tot 
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Appendix 9: TATE results (MMRM analysis of pain intensity score) 
Table 31: MMRM estimate of treatment effect from different datasets that were 









Deviation in effect 






























54% −0.445 0.329 −0.217 −0.005 
 
 
 
